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ABSTRACT
A physiologic model using anatomical organ and tissue compartments was deve-
loped for simulating glucose metabolism anJ its regulation by insulin and g'lu-
cagan in normal (nondiabetic) man. Mass balance equations were written to
account for blood f1 ow, exchange betwee.1 compartments, and metabo1i c processes
causing addition or removal of glucose, insulin, and glucagon, yielding
simultaneous diffe,·ential equations which were solved numerically. Physio-
logic parameters were selected to represent a 70 kg adult male. Metaboiic
processes were quantified from clinical data in the literature. Model predic-
tions of plasma concentratiQn5~ hepatic glucose output, and muscle glucose
uptake agreed well (±10%) with clinical data for a wide variety of glucose and
insulin inputs using a single set of model parameters, The model's unique
design gave better physiologic correspondence and accuracy than prior models.
The model pancrea~ was removed from the normal modei to create a "controlled"
Type I (insulin-dependent) diabetic model. becau$e this model represented the
idealized end state apparently achievable with improved therapies, it was em-
ployed for subsequent insulin therapy design and assessment. An "uncontrolled"
Type I diabetic model incorporating the reversible diabetes-related abnor-
malities secondary to pancreatic dysfunction (insulin resistance, insulin
antibody binding, and impaired glucose cQunterregulation) was demonstrated to
yield good predictions of response data for typical Type I diabetics.
Internal ~Ddel Control (IMC) was employed to design an optimal glucose-
controlled (closed-loop) insulin delivery system using the controlled Type I
diabetic model to predict in vivo response. Optimal Ir,,1C analysis yielded a
mathematically simple control system that provided for blood glucose regula-
tion comparable to that resulting from normal pancreatic response in the non-
diabetic. Analysis was exteudefj to explore the quality of IMC blood glucose
, ~ontrol "achievable in the presence of the following glucose sensor measurement
nonidealities: sensor dead time~ sensor response time, variation in the
sampling interval used for digital control, and introduction of systematic
measurement error. Measurament noise and its filtering were also investi-
gated. Results demonstrated that IMC control loop compensation methods pro-
vided a powerful approach to realizing effective blood glucose control in the
presence of glucose sensor measurement nonidealities.
Thesis Supervisor: Dr. Clark K. Colton
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I. INTRODUCTION
Considering all causes of death by disease, diabetes mellitus is
responsible for the third largest toll of life, after cardiovascular
disease and cancer (Ganda, 1983). In the United States, diabetes mellitus
affects 5% of the population, and the number of diabetics ;s increasing at
a rate of nbout 6% per year, or double the population growth rate
(Crofford, 1975). In general, diabetes mellitus ;s caused by an insuf-
ficiency of insulin relative to the requirements of the tissues for this
hormone, the major manifestation of which is an excessive level of glucose
in the circulati~n. Since the discovery of insulin in 1921, the overt
symptoms of diabetes have been controllable and the risk of death by diabe-
tic coma substantially reduced. The traditional therap~es, such as insulin
injectio~. and dietary management, however, have proven inadequate in pre-
venting the chronic complications, including kidney disease, bllndness, and
various cardiovascular and nervous system disorders, that are responsible
for the severe morbidity and mortality associated with diabetes today
(Matas et al., 1976). The life expectancy of the diabetic is currently
about one-third less than that of the general population (Crofford, 1975)~
and the total health costs due to diabetic morbidity alone have been esti-
mated at over $15 billion a year in the United States (National Diabetes
Advisory Board, 1981).
In normal (nondiabetic) man, glucose metabolism is controlled by pre~
cise minute-to-minute pancreatic insulin response to changes in circulating
glucose levels, resulting in the regulation of blood glucose concentration
within a narrow range of about 80-120 mg/dl during the daily transitions
between the fed and fasted metabolic states (Service et al., 1970). In
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contrast, such precise control is not realized in the diabetic Sl~ce con-
ventional therapy, typically consisting of a single daily inject'ion c;
intermediate-acting insulin, only provides a gross compensation for diabe-
tic insulin deficiency by simply maintaining relatively constant in vivo
insulin levels over the course of a 24 h day (Soeldner et al., 1973); as a
result, blood glucose concentration varies over a characteristic range of
about 100-300 mg/dl in the diabetic on conventional injection therapy
(Service et al., 1970). Increasing clinical evidence suggests that the
inability to maintain blood glucose within normal physiologic ranges by
conventional means of treatment may contribute to the development of the
chronic complications associated with diabetes (National Diabetes Data
Group, 1979). Thus, a great deal of effort is being directed toward deve-
lopment of new diabetic therapies that could provide for better glycemic
control through more physiologic patterning of i~sulin delivery (Soeldner,
1981).
Because of the analogy to the physiologic control offered by the nor-
mal pancreas, treatment of diabetes by glucose-controlled insulin delivery
will probably represent the ultimate approach to effective therapy.
Potentially implantable devices for glucose-controlled insulin delivery are
currently under development (Soeldner, 1981), but inherent in potential
designs will be Jarious factors, such as lag times and measurement noni-
dealities, that will tend to degrade performance. Considering the precise
minute-to-minute regulation of blood glucose resulting frGm normal
pancreatic insulin response, serious questions arise concerning tolerable
performance limits ~r improved therapy systems. Although the efficacies
of new therapies will ultimately be established by clinical studies, animal
and human experimentation is extremely expensive and must be limited in
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scope for ethical reasons. An altern~tive and complementary approach
involves use of physiologic modeis of glucose metabolism (Figure 1) to pre-
dict the theoretical responses of a diabetic to a wide variation of insulin
input specifications; a physiologic model of glucose metabolism can thus be
used as a powerful tool for designing and assessing the effectiveness of
potential therapy systems.
The potential usefulness of glucose metabolism models has fostered the
appearance of numerous formulations in the lit~rature. Upon review,
however, all of the literature models of glucose metabolism were found sub-
ject to one or more of the following drawbacks: 1) selection of model
design resulting in poor correspondence between important physiology and
its mathematical modeling, 2) lack of direct quantification of metabolic
processes within respective models, 3) insufficient testing of model per-
formance to establish general predictive capacity over a wide range of
inputs, and 4) errors in mathematical documentation resulting in no~func­
tional equation systems.
Because of problems associated with the existing literature models,
the first thesis objective was to develop a new model for the distribution
and metabolism of glucose and its regulation by insulin and glucagon in
normal man. Using the model of glucose metabolism in normal man as a foun-
dation, the second thesis objective was to develop a model of glucose meta-
bolism in the insulin-dependent diabetic suitable for insulin therapy
assessment. Finally, employing the model of glucose metabolism in the
insulin-dependent diabetic, the third thesis objective was to design an
optimal scheme fur glucose-controlled insulin delivery and to assess how
the presence of glucose sensor measurement limitations affect the quality
of achievable blood glucose control.
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II~ MODELING OF GLUCOSE METABOLISM IN NORMAL MAN
A) General Overview
Model formulations vary in form and detail as primarily Getermined by
their intended purpose. The recent tr~nd in modeling g1ucose metabolism
has been toward development of explanatory physiological system models. An
explanatory model (Finkelstein and Carson, 1979) provide3 a descriptiun of
the ways in which different feat~re,s of system structure and behavior
depend upon each other. Models of this type are extr1emely useful, as they
can promote insight and understanding, be used for hypothesis testing, and
may possibly define quantitative interact~ons which are normally inac-
c€ssible to measurement. An explanatory model, if valid, must describe not
only those specific features of structure and detail which entered into its
formulation, but also correctly predict all relevant system behavior over a
general spectrum of inputs.
The present modeling effort has been directed toward development of an
explanatory physiologic model of glucose metabolism in the human body. In
general, development uf explanatory mathematical representations requires
independent knowledge of the component unit metabolic processes involved.
This is because complex physiologic systems generally encompass a number of
nonlinear processes, and conventional identification and parameter estima-
tion techniques neither guarantee structural nor parametric uniqueness
(Carson and Finkelstein, 1973). Thus, models which are valid explanatory
r~presentations, and which must tharefore mirror structurally and para-
metrically the component regulatory processes, generally require indepen-
dent validation of the functional aspects of these component processes.
With respect to modeling glucose metabolism~ experimental techniques
12
which provide a means of independently varying and maintaining glucose and
insulin levels in vivo (known as clamping) have recently been develaped.
Such procedures have been coupled with measuring arterial-venous glucose
and insulin concentration differences across organ and tissue regions of
the body; results of such stud";es have given a direct measure of tissue and
organ responses to local changes in glucose and insulin concentrations over
a wide spectrum of conditions. Within the ldst few years, a wealth of
experimental data of this type has appeared in the literature, thus pro-
viding a unique opportunity to formulate and validate component metabolic
processes of the model on t~e whole organ and tissue level. It was decided
to structure the present model using J tissue and organ compartmen-
talization approach such that one-to-one correspondence was maintained bet-
ween quantifiable Teatures of the glucose metabolic processes and their
mathematical representations in the model.
The model has been formulated by techniques similar to those origi-
nally developed for simulating drug distribution (Tearell, 1937; Bischoff
and Brown~ 1966; Dedrick, 1973; Himmelstein and Lutz, lS79). For this phy-
siologic modeling approach, the body is divided into a number of physiolo-
gic compartments that represent the capillary beds of various organs and
tissues" A general representat';on for such a ~ompartment (Figure 2) inclu-
des three well-mixed spaces throughout which the solute concentration ;s
assumed tc be uniform. The capillary blood space is fed by arterial blood
inflow and drained by venous biood outflow. The interstitial fluid space
may exchange mass with the capil'iary blood spact:~ by diffusion of solute
through the capillary ~all. The intracellular space may exchange mass with
the interstitial fluid space through transport of solute across the cell
membrane. For the purpose of modeling glucose metabolism, however, at most
13
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only two spaces are requit~ed to represent any given physiologic compart-
men t • In some cases (see Figure 2), the capillary wall permeability is
sufficiently high that rapid equilibration uccurs between the capillary
blood and interstitial fluid spaces, in which case the~e tW0 spaces may be
combined into a sin~11e space of uni7'orm concentration. Likewise"solute
transport across tha cell menbrane is sufficiently rapid in some cases that
the interstitial and intracellular spaces may be combined into a single
spac~ uf uniform concentration. Another pGssibility is that both the
capillary wa11 and cell membrane permeabilities are' high such that all
fluid spaces may be combined into a single space of uniform concentration.
For regions in which no extravascular solute exchange occurs, the extra-
vascular fluid spaces may be excluded from the formulation. Finally, when
the rate of solut~ transport across the cell membrane is not limited by a
significqnt buildup of solute within the intracellular fluid, the intra-
cellular fluid space may be omitted.
Mass balances are written for each physiologic compartment. As an
example, illustrated in Figure 3 is a typical physiologic compartment with
capillary wall re~lstance and negligible intracellular solute accumulation
limitations. Toe mass balances for this compartment may be written
Capillary Blood
deBo
VB---at = QB (CBi - CBa ) + PA (C I - GBa ) - r RBC ( 1)
accumulation . convection diffusion metabolic
sink
Interstitial Fl uid
del
VI~ = PA (G Ba - GI ) - rr
accumulation convection metabolic
sink
15
(2)
PA
CAPILLARY BLOOD
CBo",VB
INTERSTITIAL FLUID
C1~VI
Fig. 3 Schematic representation of a typical phy~1olog1c compartment
~1th capillary wall resistance and no 1ntr!:ellular solute
limitations.
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where~ VB = capillary blood volume
VT - interstitial fluid volume
1.
QS = volumetric blood flow r-ate
PA = permeability-area product
CBi = arterial blood solute concentration
CBo = capillary blood (and venous) solute concentration
Cr = interstitial flyid solute concentration
rRBC = rate of red blood cell uptake of solute
rT ~ rate of tissue cellular removal of solute through the cell
m~mbrane
Since the capll1ary blood space is represented by a well-mixed volume, the
rate of mass accumulation in the capillary blood is equal to the capillary
blood volume multiplied by the time rate of change of the solute con-
centration in the capillary blood. This rate of mass accumulation is the
net add.itive resultant of contributions by convection, diffusion, and any
metabolic sources or sinks which add or remove mass from the capillary
blood space. An example of a metabolic sink for capillary blood solute is
the rate of red bleod cell uptake. A similar mass balance is written for
the interstitial fluid space, ~xcept in this case there is no convective
contribution. Thus, the rate of mass accumulation is the result of contri-
butions from diffusion and any metabolic sources and sinks which add or
remove mass from the interstitial fluid, an example being the rate of
tissue cellular removal of solute across the cell' membrane.
The permeability-area product which characterize5 diffusive resistance
of the capillary walls is oft~n expressed in terms of an alternate para-
meter, the transcapillary diffusion tirne T, as
VI
PA =-
T
(3)
Tha transcapil1ary diffusion time may be interpreted as the cha~acterist;c
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time for diffusion between two well-mixed regions of uniform concentration.
This may be illustrated as follows (Figure 4); for diffusion
dee 11
--- =---(C6 - C1)dt TO.
Imposing a step change in capillary blood solute concentration at time
equals zero
(4)
C(O)
CSo = {C( lIll) t,Ot>O (5)
the resulting interstial fluid solute concentration as a function of time
may be written
CI(t) = (C(lIll) - C(O)][l - exp(- -1-)] + C(O)
T
Thus, when time is equal to the transcapillary diffusion time
C1(T) = [C(~) - C(O)](O.63) + e(O)
(6)
(7)
Therefore, the transcapil1ary diffusion time represents trie time required
for interstitial solute concentration to reflect 63~ of a capillary blood
solut~ step change. In addition,
C1(O.69T) = [C(~) - C(O)](O.SO) + C(O)
Thus, the transcapil1ary diffusion time multiplied by 0.69 ;s the time
required for intersti~ial fluid solute concentration to reflect 50% of a
capillary blood solute concentration step change.
(8)
Physical parameters such as blood flow rates and distribution volumes
\'fare selected !(J ,-epresent a normal 70 kg adult male. Hormonal regulation
by insulin. and glucagon were included in the model formulation. The base-
line initial conditions were defined as basal postabsorptive metabolism.
The model is a p~ysiologically structured explanatory representation of the
18
Fig. 4 Interstitial fluid solute concentration in response to a step
change in capillary blood solute concentration.
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glucose regulatory system and is used for generating predictions of
respon~e to a wide spectrum of glucose and lnsulin inputs. Because of the
basis of parameter selection, model simulations predict mean response of a
70 kg male population.
With respect to limitations of the model, a few comments are in order.
First, hormona1 effects of epinephrlne (adrenalin), cortisol, and growth
hormone have been neglected. In a recent review, Gerich et al. (1981) have
shown that the normal daily variations of these agents are unlikely to
cause quantitative effects on giucose regulation; these potent insulin
antagonistic hormones, however, can induce hyperglycemia (stimulation of
liver glucose output and inducement of peripheral insulin resistance) at
levels associated with various diseased states, stress, and trauma.
Second, physiology related to changes in amino acid and free fatty acid
substrate levels has not been considered. ~11owing ingestion of a mixed
meal, ~ostpranrlial variations in the circulating levels of th~se substrates
could interact with the glucose regulatory system by altering pancreatic
hormonal secretion and influencing hepatic metabolism. During glucose
loading alone. however, effect of these substrate level variations are
generally assumed to be second order with respect to glucose regulation.
Third, initial conditions for the model reflect normal basal postabsorptive
metabolism, and changes in fuel utilization associated with prolonQed
fasting and starvation (Cahill and Soeldner, 1969), such as hepatic glyco-
gen depletion and displacement of brain glucose utilization, have not been
incorporated into the model formulation. Finally, the physiologic modeling
approach employed here uses fixed parameters representative of a 70 kg man
to predict average responses to a wide variety of inputse This may be
distinguished from the modeling efforts of Bergman et al. (1982) in which
20
individual responses to an intravenous glucose tolerance test are used to
fit model parameters, thus providing diagnostic information about the insu-
lin (Bergman et al., 1979) and beta cell (Toffolo et al., 1980j sen-
sitivities of the individual.
A general overview of the model will now be presented. Detailed
discussion of parameter selection and unit metabolic process formulation
will be deferred until later in the text.
A schematic representation of the glucose model is shown in Figure 5.
The body has been divided into six physiologic compartments: 1) brain,
which represents the central nervous system; 2) heart and lungs, which
represents the rapidly mixing vascular volumes of the heart, lungs, and
arteries; 3) periphery, which includes skeletal muscle and adipose tissue;
4) gut; 5) liver; and 6) kidney. Arrows connecting the physiologic com-
partments represent the direction of blood flow. This physiologic compart-
mentalization is similar to that employed by liran et ale (1975) and gives
the minimal set of physiologic compartments required to isolate the unit
metabolic processes on the organ and tissue level. The heart and lungs
compartment serves to close the circulatory loop, representing simply the
blood volume of the cardiopulmonary system and the major arteries; the
small contribution of arteriovenous blood flow through capillaries of these
tissues has been lumped into the periphery. For reasons which will be
discussed later', blood contained in the major veins has been di5tributed on
the basis of relative regional ~lood flow rates among the remaining organ
and tissue blood volume spaces.
The physiologic processes that lead to metabolic sources and sinks in
. the glucose model are summarized in Table 1. In general t these physiologic
processes occur at a constant rate or at a rate which is mediated in a
21
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Fig. 5 Schematic representat10n of the glucose model.
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TABLE 1. Summary of physiologic processes leading to metabolic sources and sinks in the glu~ose model.
N
W
Physiologic Process
Sink!)
Red Blood Cell Uptake
Bra;n Uptake
Gut Uptake
Peripheral Uptake
Urir.arl' Excretion
Hepatic: Uptake
Sources
Hepatic Production
Rate is Function of
Constant
Constant
Constant
Peripheral Interstit1a~ Glucose
Peripheral Interstitial Insulin
Kidney Plasma Glucose
Liver Glucose
Liver Insulin (fi'f'lst-order' response time)
Liver Glucose
Liver Insulin (fir:st-order response time)
Plasma Glucagon (f~rst-order response time)
Process is
Linear
Nonlinear
Nonlinear
Nonlinear
Nonlinear
Nonlinear
Nonlinear
Nonlinear
nonlinear manner by relevant local changes in glucose, insulin, and gluca-
gon concentrations. As indicated, hormonal effects of insulin and glucagon
on hepatic glucose metabolism were formulated to include the time depen-
dence associated with their mediatory action.
The mass balance equatlons for the glucose model are give~ in Table 2.
The mathematical nomenclature is defineci in Table ,2 and corresponds to the
symbols used in the glucose model schematic of Figure 5. In general,
sUbscripts distinguish physiologic compartments and, if required, a second
sUbscript is included to indicate fluid spaces within compartments.
Superscripts indicate respective models (glucose, insulin, or glucagon) and
are used to distinguish those variables for which different numerical
values are employed for the different models. Mass balances for the glu-
cose model result i~ a set of 8 simultaneous ordinary differential
equations which are nonlinear as a result of the metabolic source and sink
rates. In addition, it is through those metabolic rates which depend on
insulin and glucagon concentrations that the glucose model is coupled to
the insulin and glucagon models, respectively. The mass unit of rnilligrams
was employed for glucose modeling since glucose concentrations are
generally expressed in these terms. Mathematical equations for the metabo-
lic rates of glucose addition and removal are summarized in Section II.S.
These rate formulations, as well as selection of physiologic parameter
values, will be discussed in detail in the body of the text.
A schematic diagram of the insulin model is presented in Figure 6.
The body was divided into the same physiologic compartments described for
the glucose model. Differences arise, however, with respect to extravascu-
lar fluid space access in the brain and liver compartments. Studies have
shown (Davson and Spaziani, 1959; Mahon et al., 1962) that the blood-brain
24
TABLE ~. Glucose model mass balance equations~
BRAIN:
G dGBV G VBI (GBV - GBI ) (9)V -- = QB(GH - GBV ) ---BV dt TB
dGB1 V
VBf dt- = .J!.! (G Gal) - rBGU (10)T BV
B
HEART AND LUNGS:
G dGH G G G G G (11)V - = QBGBV + QLGL + QKGK + QpG pv- QHGH - r RBCUH dt
GUT:
G dGG G (12)VG- = QG(GH - GG) - r GGUdt
LIVER:
G dGL G G G (13)VL - = QAGH + QGGG - QLGl + f HGP- f HGUdt
KIDNEY:
G dGK G (14)VK- = QK (GH - GK) - r KGEdt
PERIPHERY:
G dGp~V' G VpI Gpl ) (15)v -- = Qp (GH - Gpv ) - - (Gpv-PV dt
rG
dGpI VpI
P
V -- = - (G pv- Gpl ) - r pGU (16)PI dt
rGp
Variables:
G = glucose concentration (mg/dl)
Q = \'ascular blood water flow rate (dl/min)
r =metabolic source or sink rate (mg/min)
T =transcap11lary diffusion time (min)
V=volume (dl)
t = time (min)
First Subscript: Physiologic Comparmant
8 := brain
G = gut
H = heart and lungs
L • liver
P = periphery
(A = he~atic artery)
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Second SUbscript: Physiologic
SUbcompartment (if required)
J = interstitial fluid space
V = vascular blood water space
Metabolic Rate Subscripts:
BGU = brain glucose uptake
GGU = gut glucose utilization
HGP = hepatic glucose production
HGU = hepatic glucose uptake
KGE = kidney glucose excretion
PGU ~ peripheral giucose uptake
RBCU= red blood cell glucose uptake
Superscri~!:
G = glucos~ model
~IBRAIN
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Fig. 6 Schematic representation of the insulin model.
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barrier capillary structure is impermeable to insulin passage into
cerebrospinal fluid; thus, the brain interstitial fluid space (cerebro-
spinal fluid) has been omitted from the insulin formulation. Also, unlike
the case for glucose, the liver cell melobrane is not freely permeable to
insulin and the intracellular fluid volume has thus been omitted as insulin
is degraded via binding to cell membrane receptors.
Physiologic processes leading to metabolic sources and sinks for insu-
lin are summarized in Table 3. Since pancreatic insulin ;s released into
the portal vein which perfuses the liver, and $ince separate compartments
have not been included in the model for vessel blood volumes, pancreatic
insulin release appears as a source term in the liver insulin compartment.
A separate compartmental model for pancreatic insulin release is used to
predict insulin release t-dtes; the pancreas model, which is an adaptation
of that developed by Landahl and Grodsky (1982), relates insulin relea~-;
rate to arterial (heart and lung compartment) glucose concentration via a
system of three simultaneous nonlinear ordinary differential equations.
Mass balance equations and mathematical nomenclature for the insulin
model are given in Table 4. Mass balances for the insulin formulation
result in a set of 7 simultaneous ordinary differential equations which are
linear except for the liver (Equation 20) where the rate of p~ncreatic
insulin release as an insulin source term is computed from an additional
set of three nonlinear ordinary ciifferential equations which constitute the
model pancreas formulation (a nonlinear coupling to the glucose model).
For insulin modeling, the mass unit of milliunits of insulin was selected
as this choice is convenient for expressing insulin concentrations.
Mathematical equations for calcuiating metabolic rates of insulin addition
and removal are summarized in Section II.S. Details of the model of
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TABLE 3. SUmmdry of physiologic processes leading to metabolic sources and sinks in the insulin
model.
Physiologic Process Rate is Function of Process is
Sinks
Liver Clearance Liver Insulin Linear
I( i dney Clearance Kidney Insulin Linear
Peripheral Clearance Peripheral Interstitial Insulin Linear
Sour~es
Pancreatic Insulin Release Heart and Lung Glucose Nonlinear
(time dependent)
TABLE 4. Insuli" model mass balance equations.
BRAIN:
I dI B I (17)V - = QS(XH - IS)B dt
HEART AND LUNGS:
I dI H I I I I I (18)V - = QSIS + QLI L + QKI K+ Qpl pV- QHI HH dt
GUT: I dIG I (19)V -- = QG{I H - IG)G dt
LIVER:
I d IL I I I (20)VL - = QAI H + QGI G - QLI L + rpIR~ r LICdt
KIDNEY:
-I dI K I (21)V -= QK (I H - IK) - r KICK dt
I dI pV I VPERIPHERY: V -- = Qp (IH - I pV ) - ...!! (I - I pl ) (22)PV dt 1 PV
dI pX V
Tp
V -- = --.!:! (I - I pl ) - r pIC (23)PI dt I PVTp
Variables:
I = insulin concentration (mU/dl)
Q = vascular plasma flow rate (l/min)
r =-metabolic soprce or sink rate (mU/min)
T = transcapl1lary diffusion time (min)
V= volume (1)
t =time (min)
!!rst Subscri~: Physiologic Compartment
B = brain
G =gut
H = h~art and lungs
L := liver
p :L periphery
(A ~ hepatic artery)
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Second Subscript: Physiologic
Subcompartment (if required)
I = interstitial fluid space
V = vascular plasma space
Metabolic Rate SUbscripts:
KIC = kidney insulin clearance
LIe = liver insulin clearance
PIC = peripheral insulin clearance
PIR = pancreatic instill" release
Superscript:
I = insulin model
pancreatic insulin release, selection of physiologic parameter values, and
metabolic rate for-mulations are included later in the text.
The glucagon model is presented in Figure 7. Here» a simple one-
compartment formulation was employed, representing the whole-body fluid
distribution volume for glucagon. As summarized in Table 5, glucagon is
cleared from the body at a rate which is a linear function of its plasma
level, and glucagon is released from the pancreas as a nonlinear function
of arterial glucose and insulin concentrations. The glucagon model mass
balance equation is given by
(24)
where: r = glucagon concentration (pg/ml)
Vr = glucagon distribution volume (ml)
r prR = pancreatic glucagon release rate (pg/min)
rprC = plasma glucagon clearance rate (pg/min)
t = time (min)
Details of the metabolic rate formulations are included in the text and
summarized in Section II.S.
With respect to modeling of the various metabolic processe)t a major
consideration in formulating mathematical representations concerns
selecting an appropriate level at which to scrutinize these biologic~l pro-
cesses. At the molecular level, typical enzyme reactions involved, in glu-
case metabolism are very complex. For example, reactions associated with
phosphofructokinase, an enzyme in the pathway of glycolysis, would require
at least a system of 15 nonlinear differential equations for an accurate
representatic~ (Finkelstein and Carson, 1979). Even if sufficient infor-
mation were available, incorporation of enzymatic reactions into a complete
system model of glucose metabolism is obviously not feasible. Acknowledg-
30
Fig. 7
Pancreati c
Glucagon Release
(rprR )
Plasma Clearance
(rprc )
SChematic diagram of glucagon model.
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TABLE 5. Summary of physiologic processes leading to metabolic sources and s1nks in the glucagon
model.
Physiologic Process Rate is Function of Prncess is
Sinks
Plasma Clearance Plasma Glucagon L;near
Sources
Pancreatic Glucagon Release Heart and Lung Glucose Nonlinear
Heart and Lung Insulin Nonlinear
ing the importance of being able to quantify the component metabolic pro-
cesses which add or remove mass from the system, available data in the
literature strongly supported characterizing these metabolic processes on
the whole-organ or tissue level. This may be considered a grey box
approach. rormulations for organ and tissue responses were quantified
directly from experimental data compiled from the literature. Considera-
tion of underlying mechanisms, at least in a qualitative sense, however,
was often important for insuring proper interpretation.
The general approach employed for the modeling of physiologic pro-
cesses was as follows. Metabolic rates causing addition or removal of mass
were assigned methematical equations of the general form
rIG
r = M(r,t) M(I,t) M(G) rbasal
where r = metabolic rate of mass addition or removal (mass/time)
Mr = multiplicative effect of glucagon (dimensionless)
M1 = multiplicative effect of insulin (dimensionless)
MG = multiplicative effect of glucose (dimensionless)
rbasal = basal metabolic rate (mass/time)
(25)
This method of representing regulatory effects in terms of separable
multiplicatives functions is commonly utilized in the modeling of biologi-
cal processes (Carson et al., 1983). As indicated in Equation 25, the hor-
monal effects of glucagon and insulin could in general incorporate time
dependence. The form of the above equation is particularly suited to
correlating experimental data. Normalizing with ~espect to the basal rate
yielns
rN(rtItGtt) = r = MrMIMG (26)
rbasal
Since hyperbolic tangent functions have been found to be readily suitable
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for representing the sigmoidal nonlinearities commonly observed in biologi-
cal data correlation, the rate multiplier functions were generaliy given
the mathematical form
Mi(i) = A + B tanh[C(i-D)] (27)
wh,ere the i th multipl ier function was fit to cl inical data by adjustment
of the four constants A, Bt C and D. In cases where sufficient data was
ava 'j 1abl e for the metabol ic process bei ng model ed t experimental data for
normalized rates was compliled from the literature over a wide variation in
the relevant local concentrations of glucose, insulin, and glucagon, and
least 5qtia~eS techniques were employed to fit the multiplier functions to
the data. For some processes~ however, c~~~ssive scatter in the data
required assuming appropriate srlapes of curves. Finally, for metabolic
processes that were time dependent, the above procedures were applied to
fitting initial value or steady state rate data, and the time dependence
was incorporated via first order response time dynamics in the rate
multiplier functions. Use of these methods to model metabolic rates will
be further detailed in the text with respect to quantification of each
respective physiologic process.
A problem which was often encountered in attempting to correlate
experimental data was that results in the literature were not always
reported directly in terms of variable of interest in the model. For
example, rates of organ glucose uptake were generally reported as a func-
tion of arterial glucose concentration, whereas the local organ ~lucose
concentration is actually reflected by the venous effluent concentration.
I~ such' cases, variables of interest were estimated from reported values by
sim~ly using steady state mass balance relationships as employed 'in the
model formulation.
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B) Di stri buti on and Flow Pat"ameters for a 70 kg Man
Estimated distribution volumes and blood flow rates for an avey'age 70
kg man are summarized in Ta~le 6. Organ massses (total wet masses
including contained blood) were compiled from Altman and Dittmer (1974).
Values for regional blood flow rates and total cardiac output w~re repre-
sentative of those found in the literature (Specto~, 1956; Mapleson~ 1963;
Bischoff and Brown, 1966; Mountcastle, 1974; Tiran et al., 1975; Guyton,
1976), where the peripheral blood flow rate was taken as the difference
between total cardiac output and the sum of the blood flow rates to the
remaining tissues.
Anatomic volumes were estimated using methods described by Bischoff
and Brown (1966). A 70 kg man has a total blood volume of about 5.60 1
(Gibson and Evans, 1937) which is roughly distributed as shown in Table 7.
The total capillary (plus arteriole and venule) blood volume is about 0.56
1. This was distributed among the tissue regions by assuming that the
ratio of capillary blood volumes between the i th and jth organs is given by
(Bischoff and Brown, 1966)
1
Vc· M. -3 QB·
_1 = ( 1) ( '_)
Vc· If:- ll;B·J J J
(28)
where Vc is capillary blood volume and r~ and QB r-epresent organ mass and
blood flow rate, respectively. Equation 28 was based on the postulate that
capillary flow rates are about the same in every body region and that the
average capillary length is related to the total size of the region
(Bischoff and Brown, 1966). Capillary blood volumes calculated in this
manner are presented in Table 8.
In order to reduc~ computing costs, capillary blood volumes were not
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TABLE 6. Estt-.ted distribution volumes a~d blood flow rates for In ~verlge 71kg .an.
Orgln or Tissue Massd Blood F1 ow Ratee Blood Equilibration Interstitial Fluid Intracellular Fluid
(kg) (l/.1n) Yolunte (1) YollM1e (1) Volume (1)
Brltn 1.35 O.?O 0.41 0.45 8.60
Heart And Lungs I (5.20) 1.64 I I
Liver 1.85 1.50 0.90 0.60 1.15
Gut 1.60 (1.20) 0.71 0.52 1.01
Kidney 0.32 1.20 0.68 0.09 O~18
Periphery 29.84b 1.80 1.26 6.74 19.65
(Hepatic Artery]
-
(0.30)
- - -
TOTAL 34.96b 5.20 5.60 8.40c 22.05
ITissue (Extravascular) spices of the heart and lungs have been lu-ped into periphery
bBased on total fluid volume (see Table 9)
cConnect1ve tissue fluid volume of 3.15 1 assumed inaccessible Ind thus excluded fra. volume (see text)
drotal ~t .ass including contained blood
eEntries in parenthesis represent bran.:h flows or branch flow s..attons and thus do nDt contribute to the
tota1 blood f1 ow rate SUIIIRIt t on va1ue
TABLE 7. Total blood ~olume distribution.
Capillaries. Arterioles, and Venules
Heart. Lungs. Ind Arteries
Vefns
TOT~.L
IGuyton. 1976; Bischoff. and Brown, 1966
bG1bson and EVins. 1937
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, Blood Volume·
10
30
60
leu
Vol LIMe (1)
0.56
1.64
3.40
5.60b
w
(X)
TABLE 8. Regional d~str1but1on of blood volume.
Venous Equilibration Capillary Blood Equilibration
Organ or Tissue , Blood Flow VoltAme (1) VolU\le (1) Volume (1)
Brain 10.9 0.. 370 0.040 0.41
Heart and lungs
- - -
1.64
Liver 23.4 0.800 0.100 0.90
Gut 18.8 0.635 0.075 0.71
Kidney 18.8 0.635 0.045 Oe68
Periphery 28.1 0.960 0.300 1.26
TOTAL 100.0 3.400 0.560 5.60
directly employed in modeling. Instead, regional blood volumes were repre-
sented in terms of blood equilibration volumes (Table 8). At any given
time, the majority of blood is contained in the venous vessels (see Table
7). For modeling, it was assumed that a certain fraction of the venous
pool is essentially in equilibrium with the capillary blood of the region
from which it fiows (Mapleson, 1963). Thus, venous equilibration volumes
were computed by distributing the total venous volume among the body
regions on the basis of their respective fractional blood flows. Regional
blood equilibration volumes were then obtained by summing the respective
venous equilibration and capillary blood volumes. These calculations are
summarized in Table 8. Blood contained in the arterial vessels was "Jrnped
with cardiopulmonary blood volume of 1.64 1 (see Tables 7 and 8). The
alternative t~ using regional bl~od equilibration volumes would be to use
the actual capillary blood volumes with additional blood volume compart-
ments inserted into the circulatory loop to account for the venous vessel
blood volumes. There are two major disadvantages to this alternative: 1)
addition of venous blood volume compartments increases the number of mas~
balance differential equations to be solved, and 2) since the capillary
blood volumes are about an order of magnitude smaller than respective blood
equilibration volumes, their use in model formulation would increase com-
puting time by roughly a factor of ten.
Interstitial and intracellular fluid volumes were estimated using the
approximate whole-body fiuid distribution volumes tabulated in Table 9.
These values are representati~e of estimates reported in the literature
from results of various in vivo tracer dilution studies. In general, total
body fiuid volume is measured using a small tracer such as 020' extracellu-
lar fluid volume is determined by measuring distribution of saccharides
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TABLE 9. Approximate bo~ fluid distrfbution of 70kg man.
Volume (1)
Extracellular Fluid 14.91
Blood Pl 151ft. 3.36b
Iftterstitill-~ph 8.401
Dense Connective Tissue, cartilage 3.151
Intracellular Fluid 25.09
Blood tells 2.24b
E.lttravascullr 22.85
TOTAL 40.00c
I£delman Ind Leibman, 1959~Based on total blood volume of 5.60 1 and hematocrit of 0.40
Guyton. 1976
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such as inulin which are excluded from cells, and intracellular fluid
volume is taken as the difference between these volumes (for review see
Edelman and Leibman, 1959). For modeling, it was assumed that the ratio of
interstitial fluid to cellular fluid volume is the same for all body
regions (Bischoff and Brown, 1966) since more detailed information is not
available. Thus, from Table 9,
Vinterstitial
Vintracellular
=
8.40 + 3.15
22.85
= 0.51 (29)
Using this expression, and noting that for each body region
Vtotal = Vcapillary + Vinterstitial + Vintracellular (30)
where total volume is approximated by equating with total organ or tissue
mass, the interstitial and intracellular fluid volumes were approximated
for each body region, and these values are given in Table 6. It has been
reported (Edelman and Leibman, 1959) that a portion of the extravascular
extracellular fluid volume, associated with the deep connective tissues and
cartilage, is relatively inaccessible to normal solute penetration; whereas
insulin equilibrates within about 6 h with an extravascular fluid volume of
8.401, an additional fluid volume of about 3.15 1 apparently equilibrates
much more slowly (see Table 9). For modeling, the peripheral interstitial
fluid volume calculated from Equations 29 and 30 was corrected to account
for this inaccessible region such that the interstitial fluid volumes of
Table 6 sum to 8.40 1. Although intracellular volumes calculated for
regions other than the liver were not utilized for glucose homeostasis
modeling, these values have been included in Table 6 for completeness.
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C) Glucose Distribution in the Blood
In blood, glucose is distributed in plasma water and erJ!throcyte
intracellular water. Masma protein displacement represents about 7 to 7.5
percent of plasma vo1ume (Harper et al., 1979). Under isotonic conditions,
the water content of normal red cells is approximately 71 volume percent
(Harris, 1965); the displacement volume in red cells is primarily attri-
buted to the 1arge intracelllll ar hemogl obi n content. Based on the above
relationships and a normal hematocrit of 0.40, the distribution volume for
glucose equals 84.2% of whole blood volume with a ratio of intracellular
glucose concentration to plasma glucose concentration of 0.76. This ratio
is in good agreement with the average value of 0.73 reported by Clauvel et
al. (1965) for blood samples for 46 normal subjects.
Jt can be further calculated that under equilibrium conditions about
33.7% of the glucose in whole blood is inside erythrocytes; thus, it is
important to consider the rate at which gluuse equilibrates across the red
cell membrane. Measurements in human erythocytes have indicated that red
cell permeability to glucose is relatively insensitive to insulin
(Wilbrandt, 1961; Zipper and Mawe, 1972). Glucose is transported across
the erythrocyte membrane by facilitated rather than simple diffusion
(Widdas, 1954; Britton, 1964; Widdas, 1968). Although all aspects of the
facilitated diffusion process are not fully understood, it has been exper;-
mentally verified that rates of glucose diffusion across red cell membranes
can be accurately predicted using the carrier system model of Widdas
(1954):
dGcw G= K [ pw
dt Gpw + •
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(31)
where: Gcw = Glucose concentration in RBC water (mg/dl RBC water)
Gpw = Glucose concentration in plasma water (mg/dl plasma water)
K= T~ansfer con~tant (mg/dl RBe water-s)
~ = Half-saturation concentration (mg/dl system water)
For human erythrocytes, Sen and ~iddas (1962) have reported values of Kand
~ measured at 37°~ and pH 7.4 as 1.06 isotonic units/min and 72 mg/dl t
respectively. Since these measurements were made in 342 mill i-osmolar
saline solutions, and assuming a red blood cell water content of 71 volume
percent, the value of Kconverted to the units used herein equals 153.2
mg/dl RBe water-s.
The Widdas model was used to simulate red blood cell water glucose
concentration response to step changes in plasma water glucose con-
centration between 100 and 200 mg/dl (Fi gure 8). Red blood cell water gl u-
cose equilibrated within lbout 20 s follow~ng the 100 mg/dl step increase
in plasma water glucose concentration, and equilibr~ted within about 15 s
following the step decrease; the lorqer response time required for glucose
entry into the red blood cell results from intracelluiar glucose accumula-
tion (Zipper and Mawe, 1972). For the purpose of modeling glucose dynamics
and distribution in the human body, the most extremt' change in plasma glu-
cose occurs dur; ng the i nfus i on peri ad of an intra verl,ous gl ucose to 1erance
test when plasma glucose concentration may rise at a rate of 100 mg/dl per
minute. Sinca the 100 mg/dl step change equilibration time is only about
20 s, it is safe to assume that red blood cell water glucose is essentially
equilibrated with plasma water glucose even during the rapid dynamics of an
intravenous glucose infusion.
For the glucose model) it was assumed that glucose equilibration
exists across the red cell membrane, and thus glucose ;s uniformly distri-
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Fig. 8 Prediction of Widdas model (1954) for RBe water glucose con-
centration response to step changes in plasma water glucose
concentration between 100 and 200 mg/dl.
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buted throughout the entire water volume in whole blood. Since the water
content of whole blood is roughly 84 volume percent, the blood volumes and
flow rates as estimated for a 70 kg man (Table 6) were reduced by 16% for
glucose modeling. The resulting vascular par'ameter values as incorporated
into the glucose model are included in Table 10. Using whole blood water
content as the volume basis for modeling vascular distribution of glucose,
the vascular glucose concentrations in the glucose model mass balance
equations represent whole blood water glucose concentrations. Thus, in
order to compare model predictions with clinical data, the following con-
versions are required: 1) plasma glucose concentration is 92.5% of whole
blood water glucose concentration, and 2) blood glucose concentration is
84% of whole blood water glucose concentration.
Although protein displacement of water 'in whole blood is significant
(about 16%), protein displacement is only about 2% in interstitial fluids
(Pitts,1963). This small correction for glucose distribution in the
interstitial fluid volumes has bee;1 neglected.
D) Kidney Glucose Excretion
In the kidney, the rate of glucose excretion is equal to its rate of
glomerular filtration m1nus its rate of tubular reabsorption (Pitts, 1974;
Vander, 1975; Robinson, 1967). Presented in Figure 9 is experimental data
for the rates of glucose filtration, reabsorption, and excretion as func-
tions of kidney plasma glucose concentration in humans (Brad, 1973).
Clucose is transported against a concentration gradient by the epithelial
cell layer of the kidney tubules; thus, glucose is not normally excreted
into the urine but is reabsorbed from the glomeru1ar filtrate back into the
blood. The maximum tubular reabsorption rate for glucose, however, ;s
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TABLE 10. Vascular volumes and flow r~tes used in glucose model.(based on whole blood water)
Vascular Flow Ratea Vascular Equilibration
Organ or Tissue (1/m1n) Volume (1)
Brain 0.59 0.35
Heart and Lungs (4.37) 1.38
Liver 1.26 0.76
Gut (1.01) 0.60
Kidney 1.01 0.57
Periphery 1.. 51 1.04
(Hepatic Artery) (0.25)
-
TOTAL 4.37 4.70
aEntrfes in parentheses represent redundant flows and are thus excluded in
total sum value
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Experimental data for the mean rates of glucose filtration,
reabsorption, and excretion as a function of kidney plasma glu-
cose concentration in 8 no~al subjects.
(Adapted from Brod, 1973.)
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approximately 361 mg/min, and any amount in excesss of this loau is
excreted rather than reabsorbed. The maximum reabsorption rate ;s
approached somewhat gradually, along a curve (see Figure 9); this behavior
probably results from a gradual saturation of the glucose "carrier" asso-
eiated with the active transport mechanism of glucose reabsorption.
The data in Figu~e 9 was used to quantify the rate of kidney glucose
excretion:
. 71 + 71 tanh[O.Oll(G K-460)]
r KGE(mg/ml n}= {
-330 + 0.872 GK
o ( GK< 460 mg/dl
GK ;. 460 mg/dl
(32)
where GK represents whole blood water glucose concentration. The kidney
excretion data of Figure 9 has been replotted and compared with the model
function fit of Equation 32 in Figure 10.
E) Red Blood Ce11 Upta ke
Red blood cells derive energy from anaerobic glycolysis of intracellu-
lar glucose to lactate. As with other glycolytic tissues, glucose utiliza-
tion is re~atively insensitive to changes in glucose and insulin
concentration (Bishop and Surgenor, 1964). The rate of glucose consumption
by human erythrocytes has been measured by a number of investigators. A
summary of their results is presented in Table 11. Also included in the
table are extrapolations of total red blood cell uptake for an average 70
kg man based on these results. The rate of human leukocyte glucose con-
sumption has been measured at 7.24 ~g/106 cells.h (Guest et al., 1953).
Although this rate is much greater per cell than that observed for erythro-
cytes, the density of leukocytes is only about 1.5 x lOs cel1s/ml whole
blood (Guest et al., 1953); thus, assuming a total blood volume of 5600 ml
for an average 70 kg man, white cell glucose uptake only tota'is about 0.1
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TABLE 11. Literlture values for the rate of rbc glucose uptake and extrapolat.ed total rbc glucose uptake
for a 70 kg -an based on these values.
Reference Rate of ABC Glucose Uptake
Estimated Rate of ABC Glucose
Uptake for 70 kg Man' (~!~in)
Guest et 11. 1953 0.019 "9/106 cells/h 8,9 tt
Murphy. 1960 2.10 "g/.l blood/.in* 9.4
Ul I DeLoecker Ind Prankerdp 1961 2.05 ~l/.l cells/h 13.80
Jacob and Janal, 1964;
Janol, 1965 360 ~g/.l cel1s/h 13.4
Brewer et al •• 1970 0.80 %.12 Mg/ 9 hemoglob1n/h 11.9 tft
* Hematocrit s 0.50 in cellular suspensions of this experiment
AssUMing: t Total Blood Volume • 5600 .1; Hematocrit ~ 0.40
tt 5 x 109 RBe/.l whole blood
ttt 16 9 hemoglobin/loo ~1 whole blood
mg/min.
Red blood cell uptake of glucose was assigned a constant rate of 10
mg/min in the glucose model. Although an exacting approach would require
uniform volumetric distritbution of red cell uptake throughout all of the
vascular compartments of the glucose model, it has been assumed for simpli-
city that the" total red blood cell uptake can be assigned to the large
vascular volume of the heart and lungs with little error. Red cell uptake
is a relatively small metabolic sink for glucose in the model, never
accounting ~r more than about 5% of the total rate of glucose uptake.
F) Erain Glucose Uptake
Under normal conditions, the brain derives its entire fuel requirement
from glucose. Of the glucose consumed, about 8% is glycolized to lactic
and pyruvic acid, and 92% is oxydized to C02 (Gottstein et al., 1963). The
brain contains only 0.1 weight percent glycogen (Fenn and Rahn, 1965) and
thus must rely on a minute-to-minute supply of glucose from the blood.
Estimates of cerebral glucose consumption in man have been obtained by
measuring cerebral blood flow together with arterial and jugular glucose
concentrations. In a review, Sokolov (1960) has reported that normal adult
brain glucose metabolism figures in the literature range from 4.9 to 6.2
mg/lOO 9 brain~min. In a study of 45 subjects having no known brain
disease, Gottstein et al. (1963) reported a mean cerebral glucose consump-
tion of 5.3 my/IOO 9 brain-min.
The rate of glucose entry into cerebral tissue is not affected by
insulin (Sokolov, 1960; Crone, 1965). In addition, brain glucose uptake
remains constant with respect to changes in blood glucose concentration
except in the case of severe hypoglycemia. Experiments on dogs by Himwich
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and Fazikas (1937) indicated that cerebral glucose and oxygen uptake
remained essentially unchanged over a blood glucose range of 25 to 245
mg/dl, but that both glucose and oxygen consumption dropped significantly
when blood glucose was reduced from 25 to 7 mg/dl. Intravenous injection
of glucose during hypoglycemia restored normal brain metabolism. Cerebral
metabolism in humans during hypoglycemia has been studied during treatment
of schizophrenia by insulin shock (Kety et al., 1948; Porta et al., 1964).
During insulin-induced hypoglycema in schizophrenic patients, ~ty et ale
(1948) reported that when arterial glucose fell from 74 to 19 mg/dl, glu-
cose and oxygen metabolism decreased from normal values. At a mean
arterial glucose concentration of 8 mg/dl, deep coma developed, and glucose
metabolism decreased furth~r. Since brain cells are relatively permeable
to glucose, brain hexokinase is the rate-limiting factor in glucose metabo-
lism (Fromm, 1981). When circulating glucose levels fall below a critical
level, usually accepted to be about 40 to 50 mg/dl in humans, glucose
uptake begins to decrease because of an inadequate gradient for normal
rates of facilitated transport of glucose across the blood-brain barrier
(Cahill, 1981).
Another case in which brain glucose uptake may change is during star-
vation. Partial oxidation of fatty acids in the liver provides circulating
ketone bodies, namely acetoacetate and s-hydroxybutyrate. During a pro-
longed fast, the vascular concentration of these water-soluble fuels rises
due to diminuation of their utilization by peripheral tissues. These cir-
culating concentrations become sufficient to provide a gradient for
transport across the blood-brain barrier. Ketone body utiliZe ion thus
displaces about two-thirds of the cerebral gl~cose requirement. This adap-
tation in man ;s important to survival because it conserves body protein by
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reducing the amount of glucose re~ired from hepatic gluconeogenesis
(Cahill and Owen, 1968; Cahill and Soeldner, 1969).
For the glucose model, brain glucose uptake was assumed to occur at a
constant rate of 5.3 mg/IOO 9 brain-min. Assuming the brain of a normal
lO-kg adult has an average mas~ of 1350 g (Altman and Dittmer, 1974), the
total rate of brain glucose uptake was estimated to equal about 70 mg/min.
G) Peri phera1 Gl ucose Upta ke
1) Pathways of Glucose Metabolism in Muscle and Adipose Tissue
The peripheral compartment represents the lumped contributions of ske-
letal muscle and adipose tissue to glucose metabolism. In these tissues,
the rate of glucose transport across the cell membrane is enhanced by insu-
lin and is most likely the rate-limiting step for all subsequent intra-
cellular glucose ~etabolism (Levine et al., 1950).
In muscle tissue, the main pathways for glucose meatbolism are
~llustrated in Figure 11. Und2r basal conditions, resting muscle derives
the major portion of its energy from oxidation of circulating fatty acids
and ketone bodies. The balance of energy is obtained from uptake of plasma
glucose which undergoes aerobic glycolysis and oxidation to carbon dioxide
via the citric acid cycle. During exercise, the capacity of these oxida-
tive pathways to supply energy becomes limited due to lack of tissue oxygen
availability; NADH produced by the citric acid cycle accumulates as its
rate of usag~ for ATP production becomes limited by oxygen availability,
and thus the available NADH is instead 11tilized in the conversion of
pyrurate to lactate. Under these conditions, the primary source of energy
is thus derived from the anaerobic conversion of glucose 6-phosphate to
lactate. Since glucose transport across the muscle cell membrane does not
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increase as a direct result of exercise, glucose 6-phosphate is provided by
the breakdown of muscle glycogen stores.
The major pathways for glucose metabolism in adipose tissue are shown
in Figure 12. Upon entry into the adipose cell, glucose is irreversibly
phosphorylated by hexokinase enzyme. The subsequent conversion of glucose
6-phosphate to fructose 6-phosphate may occur either directly, or
indirectly via the hexose monophospate shunt; this alternate pathway is
important because it provides fat cells with the NADPH required for the
synthesis of long-chain fatty acids. The main pathways for fructose
6-phosphate metabolism are oxidation to carbon dioxide via the citric acid
cycle and incorporation of the skeletal carbons into triglyceride, either
in the glycerol moiety via glycerol 3-phosphate, or in the fatty acids via
lipogenesis. Under normal conditions, the major source of energy for adi-
pose tissue is derived from oxidation of fatty acids.
2) Glucose Disposal in Peripheral Tissues
When circulating levels of glucose and insulin increase, such as in
the postprandial state, glucose uptake in peripheral tissues increases. In
view of the above discussion, glucose entering muscle may be oxidized to
carbon dioxide, converted to lactate, or stored as glJcogen, whereas glu-
cose taken up by adipose tissue may be oxidized to carbon dioxide or incor-
porated into triglyceride. The relative contributions of these different
pathways are important to consider in interpreting the role of peripheral
tissues in uJerall glucose tolerance.
The capacity of adipose cells to convert glucose to triglyceride has
been extensively investigated in rat (Mehlman and Hanson, 1971), which can
incorporate large quantities of glucose carbon into fatty acids (Jeanrenaud
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and Renold, 1959). Mounting evidence would suggest, however, that the rat
is a poor experimental lilodel for studying the regulation of human lipid
uletabolism (Shrago et al., 1971). In contrast to the rat, it has been
reported that the ability of human adipose cells to synthesize fatty acids
(Sjastrmn, 1973; Patel et al., 1975) and glycerol (Bjcrrntorp et al, 1968)
from glucose is extremely limited, and that certain key enzymes in the
lipogenic pathway are present at negligible levels (Shrago et al., 1971).
Based on a comprehensive review of data obtained from in vitro and in vivo
studies of human adipose tissue metabolism, Bjcrrntorp and Sjo~trom (1978)
have concluded that conversion to triglyceride is a quantitatively insigni-
ficant route for glucose di~posal, totaling at most 1-2 g/day in nonobese
subjects.
With respect to the importance of anaerobic glycolysis in muscle,
Jackson et al .(1973), Aoki et ale (1382), and Radziuk and Inculet (1983)
have reported no significant increase in measured lactate production across
human forearm during a 100g OGTT in normal subjects. Similar re~ults have
been obtained from lactate balance measurements across human leg (DeFronzQ
et al., 1981a) and forearm (Rabinowitz and Zierler, 1962) during insulin-
induced stimulation of peripheral glucose uptake and across human forearm
during intravenous glucose (Radziuk and Inculet, 1983). In addition, Aoki
et al. (1983) have recently made extremely precise measur;~ent:; of carbon
dioxide production across human forearm using volumetric bloOd gas analysis
methods (Peters and Van Slyke, 1932) to elucidate the importance of glucose
oxidation. During a 100g OGTT in normal subjects, mean carbon dioxide pro-
duction did n~t rise above a maximum value of 7.3 ± 1.1 ~ol/100 ml
forearm-min, representing an insignificant increase from the basal value of
6.2 ± 1.1.
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Glycogen storage in human skeletal muscle has been studied in relation
to exercise physiology by a number of investigators (Morgan et al., 1971;
Hultman et ale, 1971; BergstrOln et al., 1967). Using needle biopsy studies
on 228 normal subjects, Hultma~ et al. (1970) have reported a mean resting
muscle glycogen content of 13.9 g/kg wet muscle (range 9.2 - 24.9). In
non-exercised muscle, fasting over a period of 10 days only results in
about a 30% reduction in muscle glycogen content (Hultman et al., 1971).
Heavy exercise combined with a carbohydrate-rich diet, however~ can elevate
glycogen levels significantly above normal (Morgan et al., 1971),
increasing muscle content by 200% within a period of several days (Hultman
et al., 1971). Assuming skeletal muscle constitutes 40 percent of total
body weight (Andres et al., 1956; Heymsfield et al., 1982; Yki-Jarvinen and
Koivisto, 1983), the normal muscle glycogen stores of a 70 kg man would
average about 400 g, increasing to a kilogram or more with exercise and
carbohydrate availability. Thus, skeletal muscle has a large blJffering
potential for storage of glucose. Larner et al. (1981) have demonstrated
that both insul in and glucose 6-phosphate stimulate activation of glycoge~l
synthetase, a key enzyme in the regulation of muscle glycogenesis (see
Figure II) ..
The above results would suggest two important conclusions. First,
glucose storage as muscle glycogen represents the only quantitatively
significant metabolic pathway for insulin-mediated glucose uptake by
peripheral tissues. Second, adipose tissue does not significantly contri-
bute to the disposal of glucose in nonobese humans. This general interpre-
tation of peripheral glucose metabolism is further supported by the recent
studies of Finebereg and Schneider (1982) in which glucose uptake was
simultaneously measured across both superficial (mainly adipose tissue) and
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deep (mainly muscle, with a small amount of intramuscular adipose tissue)
beds in the human forearm. During insulin perfusion, no significant
increase in superficial tissue uptake was observed, whereas deep tissue
uptake increased significantly. In studies relating insulin sensitivity to
body composition, Yki-Ja~vien and ~ivisto (1983) have recently reported
that the rate of glucose metabolism in normal man is directly related to
muscle mass and inversely proportional to adiposity.
3) Basal Metabolism of Peripheral Tissues
Studies of human forearm glucose metabolism provide a basis for
modeling peripheral glucose uptake. Forearm uptake is determined experi-
mentally by msasuring arterial-venous differences in glucose concentration
coupled with forearm blood flow. Values for the basal rate of forearm
uptake calculated from data in the literature are presented in Table 12.
ftlso included in the table are total rates of basal peripheral glucose
uptake for a 70 kg man. These values were extrapolated from the forearm
data using following assumptions: 1) muscle and adipose account for
respectively 89 and 11 percent of basal forearm uptake (Jackson et al.,
1973); 2) in nonobese subjects muscle and adipose tissues constitute
respectively 64 and 8 percent of total forearm volume (Cooper et al.,
1955); 3) a normal 70 kg man has a total muscle mass of 30 kg and a total
adipose tissue mass of 10 kg (Dole, 1965; Yki-Jarvinen and ~ivistc, 1983;
Anyan, 1978). The values from Table 12 yield a mean ± sd basal rate of
peripheral glucose uptake of 47.7 ± 27 mg/min. The wide range of values
(22.7 - 88.8 mg/min) and large scatter are attributed to the uncertainty in
determining forearm blood flow and the difficulty in measuring small
arterial-venous concentration differences. Additional uncertainty ;s
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TABLE 12. Basal forea~ glucose uptake rates cOMPiled fra. the 11teratur~ and estimated total rates of basal
peripheral (.uscle and adipose) glucose uptake based on these values.
Reference Subjects Basal Rate of GlucoseUptaket (_g/dl forearm/min)
Est1.ated Basal R~te of
Peripheral Glucose for
70 kg mantt (_g/m1n)
Rabinowitz and Z1erler, 1962 5 .047* 26.1
Pozefsky et al., 1969 16 .083* 46.0
Razto et .1., 1972 9 .139 77.1
0\
I
Jackson et al., 1979 25 .044 24.40
Kalant et .1., 1979 7 .048 26.6
Fineberg and ~hneider, 1982 17 .16* 88.8
Aok1 et .1., 1983 5 .072 39.9
* Assuming Ra~io of Deep Venous to SUperficial Venous Blood Fl~w Equals 4:1
(Cooper et al., 1962)
t Gluco~e Uptake Calculated as Product of Forea~ Blood Flow and Artertal-
Venous Difference in Glucose Concen~rat~on
tt See text for assumptions
introduced in extrapolation of forearm to whole-body values. Under steady
state basal conditions, however, the rate of liver glucose production must
balance the rate of glucose uptake by the remaining tissues of the body.
In order to close this balance on the basis of available data for the rate
of basal liver glucose production, a basal peripheral glucose uptake rate
of 35 mg/min was used for the glucose model. Although this value falls
below the mean extrapolated rate of 47.7 mg/mir, it is well within the
standard deviation of th~ available data. Additional discussion of closing
the basal ~lucose uptake and production balance will be deferred to the
section of the text on basal liver glu~ose metabolism~
4) Mediation of Peripheral Glucose Uptake
The rate of glucose uptake by peripheral tissues is mediated by
changes in the interstitial insulin and glucose concentrations that bathe
these tissue cells. For modeling, it was ~ssumed that these effects are
multiplicative, and the rate of peripheral glucose uptake was is expressed
(33)
or, normalizing with respect to basal uptake
(34)
where basal state values are denoted by superscript B and normalization of
values through division by basal values is indicated by superscript N.
Compiled in Table 13 ar2 data of forearm studies of glucose uptake
taken from the literature. Normalized uptake rates were computed directly
from reported steady state and basal values. Since interstitial fluid
measurements of glucose and insulin concentration were not available, these
quantities required estimation from reported arterial and venous con-
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TABLE 13. Pertpheral glucose uptlke.r.tes blsed on foreana glucose studtes fro. the literlturp..
Nonlal tled Nonultzed No.....ltze~
BI~ll Steady Peripheral Artertal Pll5111 Peripheral Arterial P1ISilI Pertllheral
Forei"' Forel,. Glucose Insultn COne. Intersti ttl' Glucose Cone. InterstitialGlucose Glucose Uptake hlll/l) Insulin (lig/dl ) Glucose
Uptlke Uptake Rat~ [b] Cone., [c] Cone. [e]
Rite Rate
SUb- (Mg'_tn/ (1I9/_tn/ H N HReference jects di forelnl) dl forea... r pGU tlSI' ~teld1 IpI 8151' Steady GpI
Rezto et 11., 1972 9 0.139 0.181 1.3 10 30 3.0 86 86 0.9
Jlckson et 11., 1973 25 0.044 0.55 12.5 10 72[f] 7.2 85 150[f] 1.4
Kallnt et 11., 1979 4 0.034 0.041 1.2 & 8 1.0 106 206 1.3
4 0.041 0.155 3.8 7 17 2.4 170 264 1.5
6 0.045 0.321 7.1 6 29 4.8 99 130 1.7
Fineberg Ind SChneider, 1982 5 0.20 0.40 2.0 10[~] 43[1] 4.3[d] 93 93 0.8
5 0.10 0.75 7.5 9[a] 74[1] 9."[d] 93 93 ·0.6
Aokt et 11, 1982 4 0.09 0.60 6.7 10 60 6.0 95 95 0.7
7 O.Og 0.65 7.2 10 110 11.0 95 95 0.6
[I] Venous P16s-1 Insultn CGncentration[b] Dtahettc Subjects
[e] Calculated fra. Equltton 42
[d] Calcullted fro- Equatfon 44
[e] Calculated fro- E~uatfon 49
[f] Quast-Stea~ Values obtained fro. -eln dill 45-75 .'n ~jter OGTT a~tntstrlt1on
centrations. For insulin, the mass balance equations for the peripheral
compartment (Equations 22 and ~3) at steady state give
(35)
Vp1o =- (I pV .. I pI ) - r pIC
r Ip
Addition of these equations yields
Io = Qp (I H - IpV ) - r pIC
which states that the rate of insulin removal from the vascular space
( 36)
(37)
equals its rate of tissue clearance at steady state. Solving Equation 36
for peripheral vascular insulin concentration
rI
I (--p--) IPV = r pIC + PIVp1
and substituti~g into Equation 37 gives
It will be shown lJter in the text that the rate of peripheral insulin
(38)
( 39)
clearance is rroportional to the rate of insulin presentation to peripheral
tissues, or
where F is a constant of propor'tional ity. Equation 39 may thus be rewritten
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(41)
It can be seen from this expression that
N I PI IH INIpI =-=--=B 18
H
I p1 H
and therefore normalized peripheral interstitial insulin concentration
equals normalized arterial insulin co~centration at steady state. In a
similar manner to the above, it can be shown that
I IF Tp Qo
= I pV [1 - (-) -~-]I-F Vp1
and thus
and the normalized peripheral interstitial insulin concentration also
equals the normalized peripheral venous insulin concentration at steady
st~te. Since the normalized interstitial, arterial, and venous insulin
(42)
(43)
(44)
concentrations are equal at steady state, the peripheral interstitial insu-
lin concentrations in Table 13 were computed directly from reported
arterial or venous data in the literature. For ~lucose, the peripheral
compartment mass balance equations (15 an1 16) at steady state give
(45)
Solving Equation 46 for peripheral vascular glucose concentration
rGpGpV = GpI + r pGU (---) (47)VpI
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and substituting into Equation 45 yields
(48)
The values for normalized peripheyoa·1 interstitial glucose concentration in
Table 13 were estimated from the steady state relationship
(49)
where uptake rates and arterial concentrations w~re taken as those reported
in the respective studies.
Presented in Figure 13 is a plot of normalized peripheral glucose
uptake rate as a function of norma"fized interstitial insulin concentration.
Data points in the figure represent results of forearm studies tabulated in
Table 13. Examination of the data indicates that peripheral glutose uptake
;s a strong function of the interstitial insulin level as the rate of
uptake varies over an order of magnitude within a physiologic range of
insulin concentration. In addition, there ;s indicated a secondary
mediation of peripheral uptake by interstitial glucose. In order to fit
the insulin and glucose multiplier functions of Equation 34 to the data,
each of the functions was assumed to have the hyperbolic tangent from of
Equation 27. Parameter adjustment using a Levenberg-Marquardt algorithm
(IMSL library computer subroutine ZXSSQ) was employed to obtain a least
squares fit of the multiplier functions; for n adjustable parameters, the
routine utilizes a finite-difference (derivative free) method to search for
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a minimum in the n-dimensional least squares error space. Results of ini-
tial fitting yielded an effect of interstitial glucose on glucose u~take
that was essentially a linear function passing through the origin; there-
fore, the glucose hyperbolic tangent fitting function was simply replaced
by
(50)
sUbsequent parameter adjustment of the insulin multiplier function then
yielded
I NMpGU = 7.03 + 6.52 tanh[O.338(I pI - 5.82)] (51)
This function, shown as the curve in Figure 13, represents the rate at which
glucose uptake would occur at a normalized interstitial glucose concentra-
tion of unity (M~GU= 1 in Equation 34). Using the ~nsulin multiplier
function of Equation 50, values of the glucose multiplier for each of the
forearm data points were calculated from Equation 34
(52.)
T
t~PGU
and these values are plotted as a function of interstitial glucose con-
centration in Figure 14. The data plotted in this manner shows the iso-
lated effect of interstitial glucose concentration on the rate of glucose
uptake, the line in the figure illustrating the glucose multiplier function
of Equation 50. As shown in Figure 15, the model multiplier functions for
the effects of interstitial glucose and insulin yield accurate p~"edictions
for the rate of peripheral glucose uptake over the range of available data.
Although the action of insulin in promoting peripheral glucose uptake
has long been recognized, the extent to which the mass action of glucos~
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alone affects peripheral uptake has remained controversial. In vitro stu-
dies on isolated perfused cat hind limb (Lundsguard et al., 1939) and rat
heart (Morgan et ale 1961) have demonstrated dependence of muscle glucose
uptake on glucose concentration over a phy~iologic range. The applicabi-
lity of these studies to human physiology has been questioned on the basis
of an early dye dil~tion forearm study in which Adres and Zierler (1958)
reported "stability" of glucose uptake during local arterial hyperglycemia.
To date, however, definitive experiments using glucose perfusions to change
forearm glucose concentrations in the presence of fixed insulin levels have
never been performed. Human. forearm data as correlated in Figure 14
suggests that increasing glucose concentration over a physiologic range can
roughly double the rate of reriphera~ glucose uptake. This is in good
agreement with results,of in vivo studies on eviscerated rabbits (Wick ~~d
Drury, 1953) in which elevating blood glucose concentration in 'the presence
of fixed insulin levels increased glucose disappearance by a factor of two.
Since insulin binds to specific cell membrane receptor~ to affect
increases in cell membrane glucose transport, it is the quantity of bound
insulin, that should reflect insulin enhancement of peripheral glucose
uptake. With this in mind, it might seem reasonable that the rate of
peripheral tissue glucose uptake would correlate with the rate of removal
of insulin from plasma by these tissues. In the early forearm studies of
Rasia et ale (1972) and Jackson et ale (1973), however, simultaneous
measurements of glucose uptake and insulin clearance showed no significant
correlation between these factors. The high degree of correlation that has
been demonstrated between glucose uptake rate and peripheral insulin con-
centration suggests that the sigmoidal curve of Figure 13 may represent a
rapid equilibrium binding curve re1ating interstitial insulin concentration
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to the relative quantity of bound insulin on the tissue cell membranes.
H) Hepatic Glucose Metabolism
1) Pathways of Glucose Metabolism in the Liver
The liver displays tremendous metabolic flexibility with respect to
glucose processing. The major pathways of hepatic glucose metabolism are
illustrated in Figure 16. Disposal routes for glucose entering the liver
cell are similar to those discussed for muscle and adipose tissue.
Following intracellular phosphorylation, glucose may be 1) stored as glyco-
gen, 2) oxidized to carb~n dioxide via the hexose monophosphate shunt
and/or the citric acid cycle, or 3) converted to triglyceride, either in
the glycerol moiety via glycerol 3-phosphate, or in the fatty acids
(acyl-CoA) via lipogenesis. An important feature of liver cells is the
presence of glucose-6-phosph~taseenzyme (Nordlie, 1981) which catalyzes
the conversion of glucose 6-phosphate to glucose (see Figure 16). This
enzyme gives liver cells the capacity to relea~e glucose into the blood.
Metabolic pathways contributing to hepatic glucose release include glycogen
breakdown and gluconeogenesis. The major precursors available as substra-
tes for gluconeogenesis include circulating lactate (from RBC and gut glu-
cose metabolism), glycerol (from adipose triglyceride breakdown), and
glycogenic amino acids (from muscle protein breakdown). The amino acids,
after deamination or transamination~ may enter the gluconeogenic pathway as
citric acid cyle intermediates or via conversion to pyruvate (see Figure
16).
2) Experinrental Measures of Splanchnic Glucose Metabolism
Before discussing liver glucose metabolism, it will be helpful to
define various terms with respect to measurement of hepatic processes and
71
GlUCOSE
1GLUCO_lr·.·~."ii ( ) ~..ui]~ I 4k,'WCOOiN 1[.-lao..INA.,1 ~ 11"5 ~Mr~A"
~. r'
C1.WCO,sE ,-, .......-. ~l"COS[ I·' GLVCOc;EN
1 ~
~......_--..... F«utTO~£ ,.,.
t "'.LY'U~ffHYDE J-, .... D,tt'iD,.OIlYAClTIINf P ....... .---------1
PHO~'HO£NOL,.Y.WVAT£ 1.",...11"" f-'''L - '.A Ga.VC£"OL 3-P! ( ~-_.nl.. J
I'4ALATI ..... OXALO,.,IT/.rE --.. CIT"ATE
I1
C.ITAIC ACIO CYCLE
r------....
I
I
I
I
I
rMAIIJ A"'lJltr,."
."" ,,,'"1_,,,,
Liver Tissue
PlasMA
A",NOAa,s KETONE10DIIS FFA T6
GL'(CElOL.
F1 g. 16 Major pathways of glucose metabolism in the liver.
72
how these quantitities are determined from experimental studies. A schema-
tic diagram of the splanchnic bed is shown in Figure 17. Anatomical posi-
tioning of the liver and gut tissues with respect to blood flow is the same
as that illustrated for the glucose model in Figure 5. Also indicated are
the metabolic processes which add or remove glucose from the spalanchn1c
organs; these processes are the same as those employed in the glucose model
except for the inclusion of a glucose input from gut absorption following
oral glucose. There are two experimental methods that are commonly
employed for study of splanchnic glucose metabolism, the hepatic venous
catheterization technique and the tritiated glucose infusion method. In
the hepatic venous catheterization technique (Wahren et al., 1976),
arterial and hepatic venous glucose concentrations are measured together
with hepatic blood flow rate. These values permit calculation of the rate
of net splanchnic glucose appearance rNSGA, given by
(53)
which represents the net rate at which the splanchnic metabolic processes
simultaneouly add and remove glucose (see Figure 16)
(54)
The hepatic venous cathetarization technique thus provides an experimental
measure of the net glucose release rate from the splanchnic bed as a result
of the four simultaneous metabolic processes indicated in Equation 54 and
Figure 17. The rate of hepatic glucose production rHGP can be determined
experimentally using isotope dilution methods (Hentenyl and Norwich, 1974).
In general, a glucose tracer such as [3H-3J-glucose is infusea at a
constant rate and both labeled and cold vascular glucose concentrations are
measured over the duration of the experiment. The rate of glucose turnover
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under steady (Wall et al., 1957) or nonsteady (Radziuk et al., 1974)
conditions is calculated from consideration of isotope dilution relative to
the rate of tracer infusion. Simulta~eous application of hepatic venous
catheterization and tritiated glucose infusion provides an experimental
measure of the rate of net splanchnic glucose uptake r NSGU ' defined by
(55)
which according to Equation 54 and Figure 17 represents
(56)
The contribution of oral glucose absorption has been included in parentheses
for completeness in Equation 56. For experiments in which glucose is
administ~red orally (and thus rOGA is nonzero), the oral glucose is lc!beled
with a tracer such as [D-1 14C]-glucose such that a double tracer analysis
can be employed to distinguish between liver glucose production and gut
absorption of oral glucose (Radziuk et al., 1978; Ferrannini et al., 1981).
Unfortunately , portal vei n measurements are not ava i 1abl e for humans.
From the above discussion, it is thus apparent that clinical studies do not
distinguish bt~tween liver and gut contributions to splanchnic metabol'ism.
As will be shown, quantification of hepatic glucose metabolism required
assumptions with respect to gut glucose metabolsm in order to estimate
liver contributions to observed splanchnic response reported ;n the litera-
ture.
3) Basal Liver Metabolism
Based on over 200 studies using [3H-3]-glucose infusions to quantitate
hepatic glucose production, DeFronzQ et. ale (1981a) have reported a mean
basal rate of 2.2 t 0.1 mg/kg (body weight).min. In 45 subject (DeFronzQ
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et al., 1979a; 1981a), hepatic venous catheterization techniques were
simultaneously employed. In these studies, a~teria1-hepatic venous gluco~e
concentration differences multiplied by hepatic blood flow rates indicated
a net basal rate of splanchnic glucose appearance (rNSGA in Equations 53
and 54) of 1.6 ± 0.1 mg/kg.min. Thus, of the total amount of ~tucose pro-
duced by the liver (2.2 mg/kg.min), 1.6 mg/kg-min is available for use by
the nonsplanchnic tissues of the bodYt and the remaining 0.6 mg/kg .min is
taken up by tissues ~n the splanchnic bed. Based on studies in dogs using
combined portal and hepatic catheterizations (Barrett et al. t 1980), it can
be estimated that the liver accounts for approximately half of the basal
splanchnic glucose utilization, while extrahepatic splanchnic tissues
(primarily the gut) account for the other half. Presented in Table 13A and
Figure 18 is a summary of glucose metabolism in a 70 kg man during t~e
basal postabsorptive state. As previously discussed, due to difficulties
in determining the basal rate of peripheral ti£sue giucose uptake directly
from extrapolations of experimental forearm studies, this value was deter-
mined from the differer~ce between the basal hapatic glucose production rate
and the sum of t~~e basal glucose uptake rates of the remaining tissues.
From studies examinin3 the splanchnic balance of gluconeogenic
substrates (Wahren et ~lc ': 1972; Nilsson et al. 9 1973; Dietze et al.,
1976), it can be estimated that in the basal state approximately 70 to 80
percent of hepatic glucose release results from glycogen breakdown and the
remaining 20 to 30 percent is due to gluconeogenesis. A summary of these
studies is presented in Table 14. Thpse results are in g00~ agreement with
studies of liver glycogen content. Nilsson and Hultman (1973) have
reported that measurements of glycogen in serial liver biopsy specimens
obtained over a 4 h period in postabsorptive humans indicate a glucose
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TABLE 13A. Summary of basal glucose balance in a 70kg man.
RATE(mg/min)
Hepatic Glucose Production 155 (2.2 mg/kg. min)
Total Glucose Uptake 155
Brain 70
tper1pheral (Muscle and Adipose) 35
Liver 20 (0.3 mg/kg. min)
Gut 20 (0.3 mg/kg. min)
Red Blood Cells 10
tThe rate of peripheral tissue glucose uptake determined from the difference
between the rate of hepatic glucose production and the sum of the remaining
tissue uptake rates.
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Fi g. 18 Basal glucose metabolism in a normal 70 kg man.
TABLE 14. Relative contributions of glycogenolysis and gluconeogens1s to hepatic glutose output in nonmal
po~tabsorptive man. (adapted from Gerich et al., 1981)
Wahren Nilsson Dietze
et al •• 1972 et al •• 1973 et al., 1976
Net Splanchnic Uptake (_g/min glucose equivalents)
lactate 23 22 21
Glycerol 2.8 1.2 6.5
Amino Acids 9.6 16 11
'.J I\.0 Pyruvate 1.4 1.6
-
sum of Uptake (mg/m1n glucose equ1valants) 36 45 41
Glucose Production (mg/min) 171 157 162
Gluconeogenic Contribution 21' 29' 25~
Glycogenolysis (mg/min) 135 112 121
Glycogenolysis Contribution 79' 711 751
release of 1.49 mg/kg~in. If total hepatic glucose output is assumed to
be 2.2 mg/kg.min, this corresponds to a 68 percent contribution from glyco-
genolysis.
Based on the splanchnic balance data presented in Table 14, the rela-
tive contributions of gluconeogenic substrates to hepatic glucose output
are compiled in Table 15. Data indicate that the lactate released from
extrahepatic tissues as a product of anaerobic glycolysis is quantitatively
the most important gluconeogenic precursor, the remaining glucose produc-
tion resulting from glycerol uptake and conversion of amino acids.
Since lactate and pyruvate resulting from anaerobic glycolysis are
reincorporclted into glucose (the Cor; cycle), amino acids represent the
most important de novo source of carbon for hepatic glucose production (see
Figure 18). Alanine is the primary amino acid precursor for hepatic gluco-
neogenesis, acc0unting for roughly 50 percent of the glucose production
from amino acid conversion. The primary source for circulating amino acids
is proteolysis in skeletal muscle, Muscle tissues release large propor-
tions of glutamine and, to a lesser extent, alanine relative to release of
other amino acid entities; however, glutamine removal and conversion to
alanine by the nonhepatic splanchnic bed (Wahren et. al., 1972) results in
the liver primarily seeing alanine as a gluconeogenic precursor. The net
quantitative importance of alanine to total hepatic glucose production ;s
similar to that of circulating glycerols.
4) Time Dependence of Hormonal Action in the Liver
Insulin binds to specific receptor molecules on the plasma mem~ranes
of target cells, forming a hormone-receptor complex which stimulates cellu-
lar activation (Goldfine, 1978; Roth et al~, 1979; Olefsky, 1981). The
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TABLE 15. Relative contributions of gluconeogenic precursors to
gluconeogenesis and total hepatic glucose production
~ of ~ of Total Hepatic
Gll'roneogenesfs Glucose Producti~n
Lactate 54 13
Pyruvate 4 1
Glycerol 13 4
Amino Acids 29 7
(Alanine) (15) (4)
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effects of insulin on cells are diverse and occur over different charec-
teristic time scales. In 0~neral, the effects of insulin may be charac-
terized as follows (Goldfine t 1978): 1) rapid alteration of plasma
membrane transport p,·operti es that occur wi thi n seconds to mi nutes; 2)
intermediate effects on cytoplasmic enzyme activation and protein synthesis
that occur within minutes to hours; and 3) delayed mediation of RNA and DNA
synthesis that occurs after hours to days. In peripheral tissues, the
dominant effect of insulin is to increase glucose transport across the cell
membrane (Levine et al., 1950). The liver cell membrane, however, ;s
highly permeable to glucose, resulting in free equilibrium of glucose bet-
ween plasma and liver intracellular water (Cahill et al., 1958). Thus,
insulin mediation of hepatic glucose metabolism must result from alteration
of intracellular enzyme functions. The liver is also the site of glucagon
action. Like insulin, glucagon binds t& s~ecific liver cell membrane
receptors (Rodbel1, 1972) and exerts its action through ~ffects on intra-
'c
cellular enzyme function (Harper et al., 1979). In view of the above
discussion, it would be expected that, whereas insulin action on peripheral
tissues is rapid, hormonal effect of insulin and glucagon on the liver are
more time dependent. As will be shown, such time dependence is supported
by experimental data, and this time dependence of hepatic hormonal action
has been included in the model formulation.
5) Hepatic Gl uC(J~e Production
Hepatic glucose production is mediated by changes in insulin, gluca-
gon, and glucose. These effects were modelEd in a multiplicative manner,
expressed
(57)
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a) Insulin r~ediation of Hepatic Glucose Product~ion
Presented in Table 16 are literature data establishing the steady
state effects of insulin on the rate of endogenous hepatic glucose produc-
tion. Data were correlated from literature studies in which tritiated glu-
cose infusions were used to measure endogenous glucose production during
euglycemic hyperinsulinemia in normal subjects (Gerich et al., 1981;
DeFronzo et al., 1983) and following inJulin withdrawal in Type I diabetics
(Miles et al., 1980). Normalized rates of glucose production were computed
directly from reported basal and steady state values. Liver insulin con-
centrations were estimated froln reported arterial val ues. For this pur-
pose, the insu1in model equations (17-23) were solved at steady state using
reported arteria1 insulin concentrations, correcting basal pancreatic insu-
lin release to account for insulin feedback inhibition ohserved during
euglycemic hyperinsulinemia (Liljenquist et al., 1978; Beischer et al.,
1979; DeFronzo et al., 1981c). Data from the euglycemic clamp studies
directly reflect the isolated effects of insulin on hepatic glucose produc-
tion, because plasma glucagon and liver glucose concentrations remained
essentially normal in these experiments. The data for insulin withdrawai
was more difficult to interpret since arterial glucose and glucagon levels
initially increased to roughly 1.5 times their basal levels; nevertheless,
the data indicated that hypoinsulinemia roughly doubled the rate of liver
glucose production since the effects of increasing glucose and glucagon
levels would t~nd to counteract each other.
Presented in Figure 19 is a plot of normalized rate of hepatic glucose
production as a function of normalized liver insulin concentration. Data
points in the figure represent results of the clinical studies listed in
Table 16. Since the data essentially re·nect the isolated effects of
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TABLE 16. literature studies establfshin~ the steady state effects of insulin on the rate of endogenous
hepatic glucose production.
Nonnalized tNonnalized
Rate of Hepatic Rate of Arterial PlaSl3a liver
Glucose Production Hepatic Insulin Cone. Plasma(mg/kg/m1n) Glucose (mUll) Insulin
Production Cone,
rN IN
Referenc~ Subjects Basal Steady HGP Basal Steady L
Miles. et al., 1980 71 2.38 4.3b 1.81 19 lOb 0.53
Gerich et al., 19B1 6 2.0c 0.80 0.40 llc 27 1.3
0.50 0.25 42 1.9
0.03 0.02 96 4.0
DeFronzo et al., 1983 4 2.27c 0.73 0.32 12c 37 1.6
3 0.31 0.14 53 2.2
6 0.05 0.02 101 3.8
aTy~e I Diabetics
bMean Response over 2 h Quasisteady Period Following Insulin W1thdriwal
cMean Basal Value for all SUbjects
tEst1mated on the basis of changes in arter'ial p'~sma insulin concentrat1on
IS predicted by solution of the insulin model equations at steay sta~e
(see text).
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Fl g. 19 Plot of normalized rate of hepatic glucose production as a
function of normalized liver insulin concentration. The solid
curve shows the model function fJ~ the steady state effect of
liver insulin concentration on glucose p~oduct1o~ rate(Equation 58).
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changes in liver insulin concentration on the rate of hepatic glucose pro-
duc~ion (M~GP = M~GP= 1 in Equation 57), the steady state insulin
multiplier function of hepatic glucose production rate was determined by
assuming a hyperbolic tangent form and adjusting the function parameters to
obtain a least squares fit to the data in Table 16 and Figure 19. The
resulting function
1m NMHGP ~ 1.21 - 1.14 tanh[1.66(I L - 0.89] (58)
is shown by the solid curve in Figure 19. The superscript 00 has been
included in Equation 58 to indicate that this the steady state effect of
insulin. The shape of the curve below a normalized liver insulin con-
centration of about 0.5 is somewhat arbitrary, but the data of Miles et ale
(1980) is the only hypoinsulinem;c data available for quantification in
this region. A rough approximation over hypoinsulinemic ranges is adequate
for modeling purposes, however, since hypoinsulinemia is never observed to
any appreciable extent in normal man.
The data presented in Figure 19 indicate the steady state effect of
insulin on hepatic glucose production. The time course of insulin action
will now be considered. Application of the euglycemic insulin clamp tech-
nique results in a very rapid step increase in arterial insulin con-
centration (DeFronzQ et al., 1979b). Presented in Figure 20 ;s data of
DeFronzo et ale (1983) for the time course of the rate of net splanchnic
glucose appearance rNSGA (hepatic venous catheterization technique)
following graded euglycemic hyperinsulinem;a. Since the net splanchnic
glucose uptake rate rNSGU remained approximately constant in these studies
(about 0.5 mg/kg-min), the dynamic changes in rNSGA as shown in Figure 20
are a direct indication of the time course of insulin suppression of the
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Fig. 20 Data of DeFronzo et al. (1983) for the time course of the rate
of net splanchnic glucose appearance, rNSGA (hepatic venous
catheterization technique) following graded euglycemic hyperin-
sulinemia. Numbers annotating curves indicate insulin infusion
rates in units of mU/kg/min.
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hepatic glucose ~roduction rate rHGP following step increases in insulin
concentration (see Equation 55). It may be noted that the "steady state"
data points presented in Figure 19 are the 60 to 120 min average va1ues
following initiation of the euglycemic insulin clamps.
From the time course data of Figure 20 it was inferred that following
a step change in insulin concentration, the rate of hepatic glucose produc-
tion changes from its basal to its steady state value in an expo~ential
manner with time. To test the validity of this hypothesis, it was assumed
that the data of Figure 20 could be represented by
rNSGA(t) - rNSGA(~) t
------- = exp[ - -]
rNSGA(O) - rNSGA(m) tI
(59)
where TI is the time constant for the first order proce~5, ~nd the data of
Figure 20 was replotted in semilog form as shown in Figure 21. The
resulting plot was linear within the scatter of the data, and the slope of
the best fit line yielded the time constant as given by
TI = - __1__ = 1 = 25 min
(slope) (-O.O~O min-I) ( 60)
For step changes in liver insulin concentration, Equation 59 is the
solution to
rNSGA(t) = rNSGA(O)
~ [rNSGA(c)] =~ [rNSGA(m) - rNSGA(t}]
I
or, normalizing with respect to basal rate
r~SGA(t) = 1
d N 1 N Ndf[rNSGA(t)] =TI [rNSGA(m) - rNSGA(t)]
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t < a
t ;> 0
t < 0
t ;> 0
(61)
(62)
(63)
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F1 g. 21 Replotting of the data of DeFronzo et al. (19B3) from Figure 20
in a semflog fon~ for determination of the first order time
constant associated with the time dependent effect of insulin
step changes on the rate of net splanchnic glucose appearance.
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Since the data in Figures 20 and 21 essentially reflect t;le isolated effects
of step changes in liver insulin concentration on the rate of hepatic glu-
(65)
(66)
t < 0
t ) 0
cose production (M~GP = M~GP = 1 in Equation 57), the above is equivalent to
I
MHGP(t) = 1
d I 1 I Idt [MHGP(t)] = TI [MHGP(oo) - MHGP(t)]
This expression was generalized from step changes to arbitrary changes in
liver insulin concentration as a function of time by
(67)
subject to the initial condition
(68)
1m N
where MHGpfrom Equation 58 can vary with time as liver insuiin levels (I L)
change. Equation 67 together with Equation 58 for M~GP(I~) give the
,"elationship between 1iver insul in concentration and its dynamic effect on
the rate of hepatic glucose production.
b) Gl ucagon t1ediation of Hepatic Gl ucose Production
Glucagon is the primary hormone of glucose counterregulation. When
blood sugar drops to hypoglycemic levels, circulating glucagon con-
centration increases, which in turn stimulates hepatic glucose production.
Glucagon directly stimulates both glycogen breakdown and gluconeogenesis in
the liver (Cherrington et al., 1981). The differential time course of
glucagon's effect on these pathways (a rapid transient increase in glycogen
breakdown followed by a slow steady increase in the rate of gluconeogenesis)
results in a rapid he~~t;c response which wanes with time. The time course
of hepatic glucose production in response to an isolated step change in
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liver glucagon concentration has been most definitively studied in the dog
where intraportal access ~s experimentally acceptable. Cherrington et ala
(1982) have given somatostatin (to block endogenous pancreatic insulin and
glucagon release) plus basal intraportal replacement amounts of insulin and
glucagon to conscious dogs. After 2 h, arterial glucose concentrations
were raised and maintained constant (hyperglycemic clamp technique). After
an hour of hyperglycenic stabilization, the glucagon infusion rate was
increased fourfold. Infusion of 3H-glucose was used to measure hepatic
glucose production. Mean results for six studies are presented in Figure
22. Of interest here is ~he data for the time course of hepatic glucose
production from 0-240 min, where an isolated step increase in glucagon con-
centration was introduced at 60 min. Following the glucagon step increase
there was a rapid increment in hepatic glucose production, and this incre-
mental effect decreased to roughly half its initial value within 180 min.
The reason for introduction of hyperglycemia prior to increasing the gluca-
gon level was to eliminate the changes in glucose concentrations which
would have otherwise resulted from the increase in liver glucose produc-
tion, as the glucose infusion rate could be adjusted so as to maintain
steady arterial glucose levels under the chosen experimental condi'cions
(see Figure 22). Together with the ability to independently adjust and
maintain liver insulin and glucagon ievels, the experiment was carefully
designed so as to isolate the singular effects of a glucagon step increase
on the in vivo rate of hepatic glucose production.
The time course of the hepatic glucose production rate following a
step increase in glucagon concentration in the above studies suggested use
of the general mathematical step response representation shown in Figure
23. The step response function was modeled in terms of two component func-
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Fig. 22 Data of Cherrington et al. (1982) showing time course of hepa-
tic glucose production in dogs following an isolated step
increase in plasma glucagon concentration.
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tions fl(t) and f2(t) where, as shown in the figure
r~GP(t) = 1
N
rHGp(t) = f 1(t) - f 2(t) + 1
t < 0
t ) a
(69)
( 70)
and
(71)
(72)
N +In these equations, rHGP(O ) equals the initial normalized rate of
hepatic glucose production resulting from the glucagon step change. Thus,
function f1(t) provides for the initial maximal effect of glucagon action,
and f 2(t) serves to degrade the maximal response to half its initial impact
at a rate proportional to the inverse of the first order time constant T •
r
Since the solution to Equation 72 ;5 given by
+N rHGP(O )-1
rHGp(t) -( )
2 t
--TT"'N--+---- = exp[--]
rHGP(O ) +1 Tr
( )
(73)
2
the data in Figure 22 was replotted in semilog form as presented in Figure
24 for determination of the time constant; linear regression fitting of the
data· in Figure 24 yielded
(74)1 1 = 65 min
(-0.015 min- )
1
(slope)
T =----=-1"
Since the data of Cherrington et al. (1982) reflect the isolated
effects of a step change in liver glucagon concentration on the rate of
hepatic glucose production (M~GP= M~GP= 1 in Equation 57), Equations 69-72
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Fig. 24 Semllog replotting af the data of Cherrington et al. {1982} for
the time course of the rate of hepatic glucose production
following an isolated step increase in plasma glucagon con-
centration. Upper scale indicates experimental time
corresponding to data as presented in Figure 22e
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are equivalent to
MAGP(t) = 1
M~GP(t) = MI~GP( 0+) - f 2(t)
tlhere
t < 0
t ) 0
(75)
(76)
(77)
In the general Clise, however, plasma glucagon concentration varies as an
arbitrary function of time; thus, generalizin~ the above step change for-
mulations yielded
(78)
(79)
subject to the i:1itial condition
(80)
where the initia'( effect of glucagon on the rate of hepatic glucose produc-
tion M~~p has bel:ome an arbitrary function of time as p1 asma gl ucacon 1eve1 s
rN vary. Equations 78-79 give the relationship betwe~n plasma glucagon con-
centration and its dynamic effect on the rate of hepatic glucose production.
The glucagon formulation was completed by quantifying the initial
I'Dnc:"~alized response of hepatic glucose product;un rate MHGP as a function of
plasma glucagon concentration. This relationship was formulated on the
basis of data from val"ious human studies as correlated from the 1iterature
in Table 17. Data points in the table were taken from studies of normal
subjects in which hepatic glucose production was measured during acute step
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TABLE 17. Literature studies relating initial response of hepatic glucose produ~tton rate to acute changes
in arterial plasma glucagon level.
Normalized Nonnalized
Rate of Hepatic Rate of Arterial Plasma L1'/er
Glucose Production Hepatic Glucagon Cone. Plasma
(mg/mfn) Glucose (pg/ml) Glucagon
Pro(tuction Concentration
In1tlal rN (0+) Post
Reference Subjects Basal Response HGP Basal Basal ~N
Felig et al., 1976 6 155 3ti5 2.5 102 403 3.9
Bombqy et al., 1977 4 95 219 2.3 100 450 4.5
Gerich, et al., 1981 8 130a 84a 0.65 110 70 0.65
B 126a 161a 1.3 120 165 1.4
IAssum1ng 70 kg body weight
~hangas in arterial glucago,~ rcncentration induced by glucagon infusion
alone (~elig et al.~ 1976; domboy et al~, 1977) or glucagon infusion com~
bined \~ith sonlatostatin and basal replacement of insul in (Gerich et al.»
1981). Normalized hepctic gliJc:osl~ production rates were cor!lpute~j iro~l i,;'
basal v~1ues and the init~al peak response following the glucagon step
changes. Normalized plasma glucagon concentrations were CO~1puted direc~ly
from the arterial data. In all of these studies, the initial increments in
hepatic glucose production preced~d significant changes in thE arterial
concentrations of either glucose or insu1in, thus, the data as presented
reflect isol~:ed responses to glucagon changes.
Results of the clinical studies listed in T~~le 17 are plotted in
Figl~re 25.. Since the data reflect the iso'fated initial effects of acute
glucagon changes on the rate of hepatic glucose production at constant
normal liv~r insulin and glucose levels (M~GP = M~GP = 1 in Equation 57),
the glucagon multiplier M~p was determined by assuming a hyperbolic
tangent functionality and adjusting the parameters to obtain a least
squares fit to the data in Table 17 and Figure 25.
ro [N]MHGP = 2c7 tanh 0.39 r
The resulting function
(81)
is shown by the curve in Figure 25. Equations 78-79 and 81 give the overall
analytical formulation relating plasma glucagon concentration to its dyna-
mie effect on hepatic glucose production rate.
c) Glucose Mediation of Hepatic Glucose Production
The degree to which glucose alone mediates hepatic glucose production
is difficult to interpret, especially during hypoglycemia. Presented in
Table 18 are data correlated from various human studies reporteJ in the
literature. Normalized rates were computed from values of glucose produc-
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Fig. 25 Plot of normalized initial rate of hepatic glucose production
as a function of normalized plasma glucagon concentration. The
curve shows the model f~nct1on for the initial effect of acute
plasma glucagon changes on the rate of hepatic glucose produc-
t~on (Equation 81).
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TABLE 18. Literature dlta used to quantify the effect of liver glucose con~entrltion on the rate of
hepatic glucose production. Dlta at ~poglyce.1c levels have been corr~llted to account for the
effects of siMultaneous insulin and glucagon changes which resulted at steady state in these
studies.
I
Nonul i zed tNonla11zed
Rite of Hepatic Rate of Arterial Pl1S111 Liver
Glucose Production Hepatic Insulin Cone. Glucose(lig/kg/_in) Glucose (IIIU/dl) Concentration
Production ~Reference Subjects Bllsal Steady N Basal Steadyr HGP
Slcca et al •• 1978 6a 1.9 0.40 0.21 77b 200b 2.6
Lfljenqufst et .1., 1979 4 1.ec 0.64 0.36 110 225c 2.1
Gerich et al., 1981 8 1.8 1.5 0.83 90 65 0.12
8 1.Sd 1.8 1.20 90 80 0.89
IType I diabetics rece1v~ng constate rate of insulin infusion
bYenous plls.a glucose values
fEstimated from change in arterial glucose concentration
cMean vlaue for euglyceltc control group (N-7)
ttEstimate from insulin model steady state miSS balances
dRefercnc~ value taken at stabilized insulin levels
--'
o
--'
TAB~E 18. Ltterlture dati used to quantffl the effect of liyer glucose concentration on the rate of
(CDntt~ued) hepatic glucose production. DltI at ~poglyce.tc levels hive been correlated to account for the
.ffects of st.ultaneous tnsultn Ind gluclgon chlnges whtch resulted at steady state fn these
ftudfes.
ttNoru'tzed
Insultn P1ISlll Glucagon
Artert.l P"IIII Multfpllar Gluc.gon *»rul1zed Multiplier of
Insultn Cone. Ltver of Hepattc Cone. P11$114 Hepatic Glucose
(lIlI/l) Insultn Glucose (pg/.') Glucagon Production
Cone., Productton Cone. Rate
I"
Rite
rN rReference 81sal Steady L ~6P B.sal Steady "HGP
Slee. et al., 1978
- - - - - - - -
Ltljenqutst et .,., 1979
- - - - - - - -
Gertch et .,., 1901 14 16 1.1 0.81 110 70 0.64 0.83 j
18 18 1.0 1.00 110 120 1.2 1.09
tion (measured by hepatic venous catheterization or tritiated glucose
infusion) before and after changes in glycemia. Hyperglycemic data was
taken from studies in which glycemic levels were acutely elevated in the
presence of fixed insulin aod glucagon levels by 1) infusion of glucose
into Type I diabetics stabilized by constant basal insulin infusion (Sacca
et al., 1978), or 2) by infusion of glucose into normals following blockage
of endogenous insulin and glucagon secretion with somatostatin infusion
(Liljenquist et al., 1979). "Isolated" hypoglycemia cannot be observed
directly, because low blood sugar levels must be induced by hypoglucagone-
mia or hyperinsulinemia. However, relative effects of glucose could be
estimated by using the previously determined multiplying factors to correct
for the glucagon or insulin contribution3 to the steady state hepatic glu-
cose production rates. The hypoglycemic data points in the table were
correlated from studies in which somatostatin infusion was combined with
either basal insulin replacement or basal glucagon replacement with mild
hyperinsulinemia (Gerich et al., 1981). It was assumed for all studies
that the normalized liver glucose concentration was roughly reflected by
the reported changes in systemic arterial glucose concentration; rigorous
preliminary analysis using steady state glucose mass balances for the liver
indicated that liver glucose concentration seldom varies by more than a few
percent from inflowing arterial glucose concentration independent of the
rate of endogenous hepatic glucose production.
A plot of the glucose multiplier of hepatic glucose production rate as
a function of normalized liver plasma glucose concentration is presented in
Figure 26. Data points in the figure were based on the tabulated values in
Table 18, where the isolated effects of liver glucose concentration have
been estimated ~r the hypoglycemic data by correcting the normalized hepa-
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Fig. 26 Plot of glucose multiplier of hepatic glucose production rate
as a function of normalized liver plasma glucose concentration.
The curve indicates the model function (Equation 82) resulting
from a least squares fitting of the data.
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tic glucose production rates by the proper insulin and glucagon multipliers
(M~GP and M~GP in Equation 57). A hyperbolic tangent functionality for
M~GP was fit to the data of Figure 26 by least squares optimization,
yielding
M~GP (G~) = 1.42 - 1.41 tanh[0.620(G~ - 0.497)] (82)
which is shown by the curve in the figure. Although there was insufficient
data available for characterizing the precise shape of the curve in the
hypoglycemic range, the function fitting procedure gave essentially a linear
relationship in this region; this would seem like the most reasonable guess
in view of the limited data and should yield accep:able extrapolated
predictions down to a hypoglycemic level of about one-half normal. The
general validity of the glucose model is questionable at hypoglycemic levels
lower than this level anyway because of exclusion of factors such as changes
in brain glucose uptake rates and regulation by stress-induced hormones such
as epiniphrine which would become imporant at extremely low glycemia.
Presented in Figure 27 is a plot of actual versus predicted values for
normalized rate of hepatic glucose production. Date points in the figure
represent experimental values emplo,yed for quantificution of the insulin,
glucagon, and glucose mediation effects, and predicted values were calcu-
lated from Equation 57 using the model multiplier functions. Good
agreement was obtained between model predictions and experimental delta over
the entire range of normalized hepatic glucose production rates.
6) Hepatic Gl ucose Uptake
Liver is the only site of mediated glucose uptake aside from muscle.
Thus, hepatic glucose uptake is important to overall glucose tolerance,
especially folloWing oral ingestion. Hepatic uptake of glucose is mediated
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by changes in liver insulin and glucose concentration, modeled
(83)
where, as previously discussed, the basal rate of uptake is 20 mg/min.
The int~ractions of glucose and insulin in regulating liver uptake of
glucose have been extensively studied. Considerable controversy has arisen
over the relative importance of portal vein ~nsulin in the control of hepa-
tic glucose uptake. Some investigators (Madison, 1969; Felig and Wahren,
1971) have promoted the view that insulin rather than glucose provides the
dominant stimulus for hepatic uptake of glucose. This opinion has been
formulated on the basis of studies demonstrating the inability of glucose
infusions to induce hepatic glucose uptake in portacaval shunted diabetic
dogs (Madison et al., 1963) and the observation that hyperglycemic diabe-
tics maintain normal or elevated hepatic glucose output which, during infu-
sion of glucose, is 10t suppressed as in normal subjects (Wahren et al.,
1972). It should be noted that dogs used in the former study were rendered
diabetic (by partial pancreatectomy and alloxan) at least three weeks prior
to investigation (Madison et al., 1960). Thus, the evidence cited above
reflects the response of livers subjected to the diabetic state for pro-
longed periods of time prior to study. This is an important consideration
in view of the mounting evidence that hepatic response to glucose is
impaired by chronic insulin deficiency. Bishop (1970) has reported that
glucose administration fails to activate glucose synthetase in pancreatec-
tomized dog~~. In studies of extracts from alloxan diabetic rats, Gold
(1970) has demonstrated that several hours of insulin exposure can reverse
impairment of glucose synthetase phosphatase activity and increase glycogen
formation. Diminished response to glucose has also been observed in the
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perfused liver (Whojtton and Hems, 1975) and isolated hepatocytes (Katz et
al$' 1979) of alloxan diabetic rats. Insulin is also required for the
maintenance of normal intracellular glucokinase levels (Sols et al., 1964).
In addition, recent studies have sho~n that intensive insulin therapy can
restore normal glucose tolerance in Type I diabetics (Foss et al., 1982)
through reactivation of the hepatic component of the glucose disposal
system (Aoki et al., 1983).
More than 40 years ago Soskin et ale (1938) observed a reciprocal
relationship between hepatic glucose output and blood glucose concentration
following dextrose administration in dogs, thus establishing the classical
view that glucose provides the major stimulus for liver glucose uptake
(Soskin, 1940). By the early 1970's, results of extensive studies with
animal livers had clearly demonstrated the capacity of insulin to inhibit
hepatic glucose release, but definitive evidence suggesting any significant
effect of insulin on hepatic glucose uptake remained elusive (for review,
see Mortimore, 1972). A series of systematic studies (Bergman and Bucala,
1973; Bucala et al., 1974; Bergman and Bucala, 1974) has since been under-
taken to determine the relative contributions of glucose and insulin in the
control of hepatic glucose balance. In these experiments, isolated puppy
livers were cross-perfused with blood from large adult dogs (pilot-liver
technique of Urquhart and Keller, 1971). In this system, source dogs pro-
vided blood with constant basal levels of glucose and insulin, to which
additional quantities were added to produce controlled increments in the
portal concentrations perfusing the isolated livers. A summary of results
from these studies is presented in Table 19. Reported values for the rate
of net hepatic glucose appearance rNHGA were determined by measurements of
flow rates and glucose concentration differences across the perfused
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TABLE 19. Effects of portal glucose and insulin levels on the steady state
glucose balance across the isolated, blood-perfused canine liver.
(Data taken from Bucalo et al., 1972 and Bergman and Bucala, 1972)
Number Portal Vein Increment Steady State
of NHGB
Glucose Insulin
Studies (mg/dl) (mUll) (mg/min/l00 9 Liver)
6 0 0 + 3.6 ± 2.0
5 70 0 - 5.0 ± 1.3
7 140 0 -10.3 ± 1.6
2 210 0 -14.1 ± 0.5
4 ot 500
- 1.0 ± 1.5
6 140 500
- 9.5 ± 2.6
7 140 200tt -20.8 ± 2:.~
tPortal glucose decreased due to hyperglycemia in source dog.
ttInsul1n preinfused for 90 min.
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1ivers; since measurements were made across the liver t
(84)
and the contributions of gut metabolsm as reflected by in vivo splanchnic
balances were excluded (compare Equation 54 for r NSGA ). In control studie$
(no glucose or insulin infusion), livers relea5ed glucose at a ffi~an output
rate of 3.6 mg/min-100g liver. Incrementing portal glu~ose ever a range of
70 to 210 mg/dl in the presence of basal insulin resulted in rapid
suppression of glucose output and stimulation of uptake, demonstrating
direct glucose autoregulation. In the reverse situation, however, raising
portal insulin by 500 ~U/l in the presence of basal glucose suppressed
hepatic product~on but failed to stimulate any significant uptake.
Finally, the effects of insulin on glucose-stimulated uptake were examined.
When portal glucose was incremented 140 mg/dl together with a simultaneous
insulin increment of 500 mUll, hepatic uptake was not significantly dif-
ferent than that observed for the glucose stimulation alone. However, when
insulin was incremented 200 mUll for 90 min prior to addition of a 140
mg/dl glucose increment, glucose uptake was almost exactly double that
observed for the isolated glucose stimulation.
Results of the canine liver perfusion studies suggest that glucose
provides the primary signal for glucose uptake, and that insulin serves to
modulate the glucose-stimulated response. Furthermore, the insulin
mediation appears to be time dependent and can be quantitatively signifi-
cant, capable of doubling the glucose-stimulated response within physiolo-
gic portal insulin levels.
Since portal measurements are not available in human studies, the
hepatic glucose uptake rate cannot be determined directly. Instead, com-
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bined application of hepatic vein catheterization and isotope dilution
techniques provides an experimental measure of the rate of net splanchnic
glucose uptake rNSGU as previously discussed (see Equation 55), and from
Equation 56
(85)
The rate of hepatic glucose uptake can thus be determined from Equation 85
given appropriate estimates for the contributions of gut to the net
splanchnic glucose uptake rate. As discussed earlier with respect to basal
liver metabolism, the rate of gut gluco~e uptake constitutes about 50% of
the net rate of splanchnic glucose uptake in the basal state,
B Bf GGU = 0.5 r NSGU (86)
and, as will be shown later, the rate at whi~h gut tissues remove glucose
for utilization as fuel remains essentially constant. Therefore, 5ubsti-
tuting the above expression into Equation 85,
(87)
For i~travenous studies, the rate of oral glucose absorption is zero, and
Equation 87 was normalized to yield
Br NSGU ~ 0.5 r NSGU
B B
r NSGU - 0.5 r NSGU
(88)
which was employed to calculate normalized hepatic glucose uptake rates from
net apl~nchnic glucose uptake rate data in the literature. For correlation
of data from oral glucose studies, Equation 87 was averaged over the total
time required for gut absorption of the oral glucose load (TA),
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1 TA
rHGiJ(t)dt 1
TA [r NSG~t) B OGA(t)] dt (89)-J -- f 0 0.5 r NSGU+ rT 0 TAA
0.5 B + rOGA (90)or r HGU = r NSGU - r NSGU
where overbars have been used to indicate time-averaged values. The reason
for time averaging was to allow estimation of the oral glucose absorption
rate term by
- TA Ora -. G1 ucose Dose
rOGA = fo rOGA(t) dt '" ------TA
(91)
Substituting into Equation 90 and normalizing with respect to basal uptake
yielded
-NrHGU =
B Ora1 Gl ucose Doser 0.5 r NSGU +NSGU - ------TA
B B
r NSGU - 0.5 r NSGU
( 92)
and this expression was used to calculate mean normalized rates of hepatic
glucose uptake following oral glucose administration.
Presented in Tables 20 and 21 are human data correlated from various
intravenous and oral studies, respectively. For intravenous studies,
Equation 88 was employed to calculate normalized rates of hepatic glucose
uptake from reported net splanchnic glucose uptake rate data. Liver glu-
cose concentrations were estimated using arterial concentrations and
splanchnic glucose appearance data; under quasi-steady conditions (see
Equation 53)
GL = GH _ (r
NSGA)
Q~
which upon nonnalization yields
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( 93)
.....
--'
N
7A8L~ 20. Correlatton of heplt1c glucose uptlke dltl taken ,..- intrlvenous glucose loading studtes tn the ltterature.
Kite or Net
Splanchnic Glucose NolWlltzed Nonulized
Uptake, r NSGU Rate of Artertal P1I.. Ltver Arterial P11S111 Noreal'zedHepltic Glucose Cone. Glucose Inriultn Cone. l1ver(mg/kg/_in) Glucose (lI9/dl ) Cone. tt (IIU/l ) Inful tn ttt
Uptl~et ~ Cone.,Reference !iubjects Blsil Steld1 r:GU 81511 Steady 81sa' StPoad,y I"L
DeFronzo It .1., 1978 21 0.5 1 1.1 3.4 96 223 2.1 11 191 16
DeFronzo et .,., 1983 3b 0.52 0.47 0.81 97 137 1.3 11 20 1.8
Sb 0.52 1.27 3.9 99 224 2.0 11 55 5
3b 0.52 0.63 1.4 99 224 2.1 15 10 0.6
,b 0.52 0.46 0.1" 94 92 0.86 15 101 6.3
3b 0.52 1.02 2.9 91 222 2.0 15 40 1.2
IBISed on dat. for 'NSGA .ss~tng rRGP • 2.2 ~/kg/.fn (DeFronzo et 11., 1981) Ind fHGp • 0 It steady Jtlte due to insultn suppression
tC.'culated fro. Equltton 88
ttCllcul.ted fro. Equation 94
tttEstt..ted on the bas3s of chlnges In afterial pll~ insultn concentratton IS predicted by solutton of the tnsultn IOdel equlttons It
steldy stlte.
bMean baSil ,~lue for enttre study group
--'
--a
W
TABLE 21. Corr.lltton of hepltic glucose uptake dltl taken fra. oral lo.ding studies in the ltter.ture.
MuM.r Orll Absorptton Averlge Vilufts Over Absorptton Tt.e TotllSpllnchnic
of Glucose Tt_, TA ett
uptake Reference
-* -** =" II Oral
Studte. LOld (_tn) rHSU r'NSGA rHGP rOGA rHGU rHGU Load)(JIg/.in) (ltg/_in) (1Ig/.in) (1Ig/_tn) (JIg/.tn)
(g)
10 100 180 22 - 220 0 555 312 14.2 60 Feltg et .,., 1915
3 95.5 211 l:;ttt
- 273 40 440 194 14.9 47 RI~ztuk at .1., 1978
10 100 180 18 - 287 0 555 251 13.9 48 Ferrlnnt"t et 11., 1980
4 70t 210 19ttt
- 198 67 333 183 9.6 61 Pfl0 et .1., 1981
22 100 240 18 - 285 0 416 113 6.3 31 Kltz et 11., 1983
t Orll LOld of 1 g/kg~ wetght
At B B~ rHGU • 15 percent of 'NSGA (DeFronzo et .,., 1981)
ttt r:SU • 11 percent of r~ (DeFronzo et .1., 1981)
~ r • or.l glucose lOld
6GA aDsorpt10n tl-e
.* Ca.puted froll Equation 90, Ind noting thlt r NSGU • T'NSGA - T'HGP
-'
.....I
~
TABLE 21. Correlltton of hepattc glucose uptake dltl tlken Ira. orll 10lding studtes tn the ltterlture.(Conttnued) .
I I I IIol1llltzed I I IIoIWA1tzl!d I
Artertal Pl.SIII Ltver Artertal Pl1511. Liver---- --
Gl ucose Cone. Glucose Insul in Cone. Insultn
(JIg/dl) Cone., t (IIU/l ) Cone.,tt
T1. ~ T1. ~Reference 815.' Averaged 81SI' Averlged
Feltg et .,., 1975 951 150· 1.7 6 35 6
Rldztuk et 11., 1978 100 140 1.6 b b
-
Ferrlnntnt et .,., 1980 100 147 1.5 b 29
-
Ptl0 It 11., 1981 100 150 1.6 b b
-
Kltz et 11., 1983 gole 1351 C I.Sc 14 70 5
IAss~'ng: (PlIS1i Gl~ose Cone) • (1.10)(Blood Glucose Cone.)
bInsultn DltI not Reported
CCa.puted dtrectly f~ reported heptlttc venous glucose concentrattons
tCa.puted fro. ti.. Iyerlgtng Equltton 94 oyer absorption tt.e TA
ttEstt.-ted on basis of chlnges tn Ir~ertll plls-l tnsultn concentratton IS predicted by solution
of insultn .odel equlttons at stel'~ state.
(94)
Normalized liver ins~lin concentrations were estimated from reported
arterial plasma values using the steady state insu1in model equations as
previously described for correlation of the hepatic glucose production rate
data of Table 16. For oral glucose studies, normalized hepatic glucose
uptake rates averaged over the time required for absorption of the oral
load were computed from Equation 92. Values of normalized liver glucose
concentration were approximated by averaging Equation 94 over the absorp-
tion time, except for the study of Katz et ale (1983) for which hepatic
venous glucose concentrations were reported and could be averaged directly.
Normalized liver insulin concentrations were estimated as for the case of
intravenous studies except that the arterial plasma insulin concentrations
were time averaged over the absorption period. No insulin data were
reported by Radziuk et al. (1978), Ferrannin; et ale (1980), and Pilo et
al~ (1981), but, based on similar studies, normalized values of about 5
were assumed.
Presented in Figure 28 is a plot of normalized rate of hepatic glucose
uptake as a function of normalized liver glucose concentration. Data
points in the figure correspond tv results of the intravenous (solid
symbols) and oral (open symbols) studies correlated in Tables 20 and 21,
respectively. Values in parentheses indicate normalized liver insulin con-
centrations.
The data of Figure 28 are difficult to inter~ret and demonstrate the
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Plot of normalized hepatic glucose uptake rate as a function of
normalized liver glucose concentration. The curve indicates
the model function for the effect of liver glucose on uptake
rate of glucose (Equation 97).
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reasons why much controversy has surrounded discussion of hepatic glucose
uptake. First, scatter in the human data has not provided a basis for
assessing the direct effect of insulin on hepatic glucose upt3ke. Second,
reported values of total splanchnic uptake following oral glucose have
ranged from about 30 to 60 percent of the ingested load (see Table 21).
Further complicating the situation is the observ~tion that measured rates
of hepatic glucose uptake in response to intravenous glucose have ~een
significantly lower than those reported during oral loading.
In order to model hepatic glucose uptake, it was first assumed on the
basis of the isolated canine liver perfusion studies that insulin exposure
doubles the rate of hepatic glucose uptake within a physiologic range of
insulin concentrations. Since this effect is time dependent, it was for-
mulated in a manner similar to that of insulin mediation of hepatic glucose
production. The asymptotic effect of liver insulin concentration on the
rate of hepatic glucose uptake was given by
M~GU = 2 tanh[O.55 I~] (95)
and the time dependent insulin multiplier was obtained by sUbstituting this
expression into (see Equation 67)
(96)
Equation 95 states that elevating the liver insulin concentration above
about three times normal will eventually double the rate of hepatic glucose
output according to the time dependence of Equation 96 •
. Having established a formulation for mediated glucose uptake in
peripheral tissues, pre1iminary model simulations were run to investigate
quantification of hepatic glucose uptake. The standard 0.5 g/kg body
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weight Intravenous Glucose Tolerance Test (IVGTT) was employed for these
simulation studies. The IVGTT was selected for two reasons: 1) following
the rapid (3 min) infusion which acutely increases plasma glucose levels,
mediated glucose uptake by muscle and liver quickly disposes of the exoge-
nous g'uco~e, and thus the time course for the decrease in plasma glucose
concentration is sensitive to these uptake rates; and 2) because of the
rapid insulin dynamics, the time dependent effect of insulin on hepatic
. glucose uptake (Equations 95 and 96) is minimal, and thus the hepatic
contribution disposal is dominated by the effects of glucose mediation.
For these simulations, pancreatic insulin release as a function of time was
adjusted and fixed such that plasma insulin concentrations predicted by the
model agreed closely with experimental data over the time course of the
IVGTT; in this manner it could be assumed that all insulin concentrations
were at their proper levels independent of changes in glycemia resulting
from adjustment of metabolic functions in the glucose model. Finally, a
hyperbolic tangent functionality was assumed for the effect of liver glu-
case concentration on hepatic glucose uptake rate, and parameters in the
function were adjusted by least squares fitting of model predictions to
experimental data for peripheral blood glucose concentrations following
IVGTT administration. The resulting function,
G NMHGU = 5.66 + 5.66 tanh[2.44(GL - 1.48)] (97)
is shown by the curve in Figure 28. This equation, together with the insu-
lin multiplier function of Equation 95 pr~dict the hepatic glucose uptake
data of Tables 20 and 21 and Figure 28 as shown in Figure 29.
To date, the discrepancy between data for orally and intravenously
stimulated hepatic glucose uptake has not been explained. Noting the dif-
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ference resulting from the route of glucose administration, DeFonzo et al.
(1978) first suggested that orally consumed glucose may cause release of a
gastrointestinal factor that enhances insulin-mediated glucose uptake by
the liver. This idea has been c~~a11enged on the basis of results obtained
in the dog (Bergman et al., 1982); when intraportl1 glucose and insulin
infusions were used to match the temporal patterns observed in the portal
vein during oral loading, there was no significant difference between the
uptake of intravenous and oral glucose. It is interesting to note from
Figure 29 that fitting of intravenous data (IVGTT) resulted in a model
function which y~e1ded predicted liver glucose uptake rates of various glu-
cose and insulin levels that corresponded to data from the oral loading
studies in the literature, supporting the notion that intravenous and oral
glucose are processed by the liver in the same way. However, it should be
emphasized that the model liver functions cannot predict the low l~vels of
glucose uptake that have been reported during intravenous stimulation. It
is worth mentioning that if such low uptake rates actually occur in
response to intravenous glucose, some form of oral gut factor augmentation
would be required on the basis of normal daily liver glycogen turnover con-
siderations. During postabsorptive periods, the liver releases glucose at
a rate of about 155 mg/min to provide for the fuel requirements of the
extrahepatic tissues (primarily brain). Since glycogen breakdown accounts
for roughly 80% of basal hepatic glucose output, or 124 mg/min, liver gly-
cogen stores are depleated at a rate of about 7.5 g/hr during fasting. The
highest total splanchnic uptake rate reported during intravenous stimula-
tion was about 1.3 mg/kg-min (DeFronzQ et al., 1983), or 90 mg/min, and
thus even total conversion of this glucose to liver glycogen (an
overestimate) would only provide about 5.5 g/hr. These estimates clearly
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indicate that hepatic glycogen deposition during postprandial periods
(about 10 h/day) must normally occur at a much higher rate than suggested
by intravenous data in the literature.
The disposal of glucose is dominated by liver and muscl~ uptake when
glycemia exceeds its normal level. Furthermore, it is the effect of
peripheral interstitial insulin concentration that predominantly regulates
the rate of peripheral tissue glucose uptake, and it is the changes in
liver g1ucose concentration that primarily regulate the hepatic glucose
uptake rate. Thus, there is a balance between the model fanttions for
these glucose disposal processes (M~GUfor periphery and M~GU for liver)
such that their underlying contributions sum to produce observed glucose
tolerance. Having established a functionror peripheral gluco~e uptake
sensitivity on the basis of forearm .studies, hepatic glucose uptake rate
sensitivity was quantified by parameter adjustment during simulation of an
IVGTT because human data for the liver contained to much scatter for direct
assessment. The model is quite sensitive to changes in either of the domi-
nant glucose uptake functions, but there is a compensating symmetry between
the peripheral and liver uptake functions which can always combine to give
the observed glucose tolerance during an IVGTT. This is shown in the sim-
mulation studies of Figures 30 and 31. In these studies, the parameter
adjustment methods emplo~ed for fitting of the liver glucose uptake rate
formulation on the basis of IVGTT simulations were repeated} but the
peripheral glucose uptake rate was arbitrarily increased and decreased from
normal sensitivity to insulin as shown in the upper panel of Figure 30.
These changes 1n peripheral glucose uptake sensitivity when combined with
the normal liver glucose uptake function caused deviations between model
predictions and clinical data for blood glucose levels during an IVGTT as
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rshown in the upper plot in Figure 31; however, readjustments of the liver
uptake function (least squares refitting of Equation 97) to compensate for
changes in the peripheral sensitivity restablished agreement between model
predictions and the IVGTT data. The liver glucose uptake functions that
reestablished the balance between peripheral and hepatic glucose uptake are
shown in the lower plot of Figure 30. Results of these simulation studies
clearly demonstrate the nonuniqueness problems that occur in attempting to
quantify nonlinear metabolic processes by fitting data that reflect
simultaneous balances in their respective contributions. In the glucose
model, the relative roles of liver and peripheral glucose uptake were uni-
quely established only because peripheral glucose uptake rate could be
quantified independently from forearm studies, although the resulting liver
formulation yielded good predictions of the available data for hepatic glu-
cose uptake following oral glucose administration. In the model, however,
there is a relatively delicate balance between the normal liver and
peripheral uptake functions, and model performance quickly degrades if
either of these functions is altered without appropriate compensation in
the conjugate function.
Since peripheral glucose uptake is dominated by changes in insulin
levels and liver glucose uptake is primarily regulated by liver glucose
levels, the in vivo interplay between these modes of glucose disposal are
interesting to examine. Because ingested glucose must pass through the
liver prior to entering the systemic circulation, the efficiency of the
liver in disposing of the incoming glucose is inversely related to eleva-
tion of circulating glucose levels. As arterial glucose concentration
rises, however, insulin is released by the pancreas and the subsequent rise
in circulating insulin levels signals the peripheral tissues in turn to
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dispose of the excess glucose which has escaped from the liver.
I) Gut Glucose Uptake
As previously discussed, under basal conditions the extrahepatic
splanchnic tissues (gastrointestinal tract, pancreas, and spleen), pri-
marily the gut, metabolize glucose at a rate of about 20 mg/min. In the
fasted state, the primary fuel requirements of gut tissues are derived from
glutamine and ketone body metabolism (Windmueller and Spaeth, 1980).
Portal ~atheterization studies in dogs (Barrett et al., 1980) have shown a
significant step increase in alanine and lactate from artery to portal
vein, suggesting that a large fraction of the glucose taken up by gut
tissues is converted to three carbon compounds. Results from in vivo stu-
.dies of rat small intestine metabolism (Windmuel1er and Spaeth, 1980) have
supported this conclusion, indicating that only about 10 percent of the
glucose extracted under basal conditions is oxidized.
Glucose utilization by gut tissues appears to be relatively insen-
sitive to postprandial stimulations. In the fed state, both gut lumenal
and arterial glucose becomes available to gut tisues, and circulating insu-
lin levels increase. Windmueller and Spaeth (1980) have shown that
arterial glutamine remains the most important energy source for gut tissues
in the fed rat, and that only about 3 percent of the gut lumenai gl'}cc~e ;s
metabolized during transport across the intestine. For modeling, gut glu-
cose utilization was assumed insensitive to changes in glucose and insulin
levels, and the rate of gut glucose uptake r GGU was assigned a constant
value of 20 mg/min.
J) Glucose Transcapillary Diffusion Time Constants
Since reliable values of glucose concl_,.tration in cerebrospinal fluid
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were available in the literature, the transcapillary diffusion time
constant for the brain compartment was estimated directly. The brain com-
partment glucose mass balance equations (9 and 10) at steady state give
(98)
VBIo =--- (GBV - GBI ) - r BGUTS
Solving Equation 99 for brain vascular glucose concentration
(99)
(100)
and sUbstituting into Equation 98 yields upon rearrangement and simplifica-
tion
TS
VBI (GH - Gal)
VB1 (101)--- --
r BGU Q~
Pryce et al. (1970) have correlated measurements of cerebrospinal fl uid
glucose concentrations for 89 normal males and reported a mean fasting
value of 55.9 mg/dl. Assuming a fasting arterial plasma glucose con-
centration of about 90 mg/dl ,lnd sUbstituting val ues into Equation 101
yielded an estimated brain transcapillary diffusion time constant of 2.1
min.
Direct, reliable measurements of peripheral interstitial glucose con-
centrations are not available, thus the transcapillary diffusion time con-
stant required estimation by indirect means. This was done by model
simulation. For a rapid intravenous infusion of glucose, the initial tlme
course of vascular glucose is determined by the balance between 1) the
rate at which glucose enters the circulation by infusion, and 2) the rate
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at which glucose leaves the circulation by dispersion into the peripheral
interstitial fluids. Presented in Figure 32 is a plot of peripheral blood
glucose concentration as a function of time for the initial period of a
standard IVGTT (0.5 9 glucose per kg body weight infused over 3 min). Data
points represent mean ± SEM values correlated from 111 studies of normal
males performed at the Joslin Research laboratory. Lines in the figure
illustrate the effect of varying the peripheral transcapillary diffusion
time constant on the simulated time course of blood glucose concentration.
The solid lines result from fixing all glucose metabolic rates at their
basal values in the glucose model. The dashed lines result from elevating
all of the mediated glucose metabolic uptake rates to their maximum values
upon initiation of.the glucose infusion~ It can be seen from the figure
that the initial simulated time course was sensitive to changes in the
value of the peripheral transcapillary diffusion time constant, and com-
parison between solid and dashed lines shows the relative insensitivity of
these results to changes in the rate of metabolic clearance of glucose.
Based on the simulation studies presented in Figure 32, a value of 5 min
was selected for the peripheral transcapillary diffusion time constant T~.
This value is in good general agreement with result~ of studies on the rate
of glucose diffusion from blood into dog hind limb lymph following IVGTT
administration (Rasia et al, 1968); these results were difficult to
interpret due to the transient nature of the experiment but suggested an
equilibration time constant on the order of 5 min.
K) Insulin Distribution in the Blood
The red blood cell membrane is impermeable to insulin; thus, unlike
glucose, insulin is only distributed thoughout the plasma volume of whole
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blood. The measured hematocrit of normal male blood, based on the volume
of packed red cells, is 0.45 liters per liter of whole blood (Harper et
al., 1979). The average body hemat~crit is approximately 87 percent of the
measured hematocrit (Guyton, 1976) because: 1) packed red blood cell
volume is a nonideal measure of hematocrit as a small quantity of plasma
becomes entrained in the interstices of the packed cell matrix, and 2)
axial streaming of red blood cells during flow through the smaller vessels
would reduce the total average in vivo hematocrit value. Therefore, the
average body hematocrit for a normal male is about O.~O liters per liter.
Although red blood cells are insulin insensitive with respect to glu-
cose metabolism, insulin binds to specific plasma membrane receptors of
erythrocytes (Kappy and Plotnick, 1979). It is thus important to consider
the extent to which RBC receptor binding may act as a reversible buffer for
insulin storage and release. The buffering capacity of red blood cells can
be estimated from the binding data reported by Kappy and Plotnick (1979);
presented in Figure 33 is a plot of insulin bound to RBe's as a function of
plasma insulin concentration. The ordinatp has been normalized with
respect to the number of RBC's normally contained in 1 ml whole blood
(about 3.6 x 109 RBC's/ml). For a fasting plasma insulin concentration of
15 ~U/ml, one ~illiliter of whole blood would contain roughly 9 ~U of free
insulin in plasma and 1.1 ~U of insulin bound to RBe's. During a standard
intravenous or oral glucose tolerance test, plasma insulin concentration
peaks at about 100 ~U/ml; at this maximum, one milliliter of whole blood
would contain roughly 60 uU plasma insulin and 4.4 uU bound insulin.
Therefore, to increase plasma insulin concentration from 15 ~U/ml to 100
~U/ml would require the addition of 54.3 ~U/ml whole blood, of which only
3.3 uU (6%) would bind to RBC's. Based on this estimation, neglect of RBC
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buffering capacity in the model introduces at most a 6% error into calcu-
laion of plasma insulin concentration. Since no data is available for
determining the time course of reversible RBC binding (data points in
Figure 33 represent steady state values), and since the maximum error is
quantitatively small» no correction for RBC binding was introduced into the
model.
For the insulin model, it was assumed that insulin is uniformly
distributed" in the plasma volume of whole blood. Since the average red
blood cell content of whole blood is about 40 volume percent, the blood
volumes and flow rates as estimated for a 70 kg n;an (Table 6) were reduced
by 40 percent for insulin modeling. The resulting vascular parameter
values as incorporated into the insulin model are included in Table 22.
L) Insulin Clearance
The primary sites of insulin clearance are the liver and kidney, with
a smaller contribution by peripheral tissues. Insulin clearance results
from a degradation process that occurs at the target tissue plasma membrane
and is associated with binding of ~nsulin to a degrat;ve enzyme complex
(Kahn, 1979). It is possible that degradation is linked in some manner to
insulin receptor binding, but this relationship is unclear at present
(Terris and Steiner, 1975; Duckworth, 1979).
1) Liver Insulin Clearance
Harding et al. (1975) have studied hepatic insulin clearance in
anesthetized dogs using intraportal insulin infusions. In 14 dogs, basal
clearance averaged 42 ± 20 percent of the insulin presented to the liver,
and the percentage of insulin cleared did not change when intraportal insu-
lin infusions were increased tenfold, elevating the portal -insulin con-
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TABLE 22. Vascular volumes and flow rates used in insulin model.(Based on whole blood plasma)
Vascul ar Fl ow Ratet Vascular Equilibration
Organ or "Ti ssue (1/m1n) Volume (1)
Brain 0.42 0.25
Heart and Lungs (3.12) 0.98
Liver 0.90 0.54
Gut (0.72) 0.43
Kidney 0.72 0.41
Periphery 1.08 0.75
(Hepatic Artery) (0.18)
-
TOTAL 3.12 3.36
tEntr1es in parentheses represent redundant flows and are thus excluded in
total sum value
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centration from 50 to 500 mUll. Madison and Kaplan (1958) have injected
insulin-I 131 into the portal veins of 15 patients undergoing abdominal
surgery. Based on arterial insulin concentrations measured 10 seconds
later, they have estimated that about 50 percent of the insulin presented
to the liver is cleared during a single transhepatic passage. Samols and
Ryder (1961) have studied the hepatic clearance of insulin in humans by
measuring the arteriohepatic insulin concentration differences in patients
with portal-systemic shunts. In four subjects, basal hepatic insulin
clearance averaged 41 percent, and in two subjects, elevation of arterial
insulin levels to 250 mUll by infusion of exogenous insulin did not result
in any significant change in the percentage of insulin clearance.
Both glucagon and glucose may affect hepatic insulin clearance (Field
et al., 1980). Rojomark et al. (1978) have reported that simultaneous
infusion of insulin and glucagon into dogs results in a significant
decrease in the fraction of insulin cleared by the liver. Studies of insu-
lin clearance in the perfused rat liver (Terris and Steiner, 1976; Honey
and Price, 1979), however, have shown no effect of glucagon variation.
Kaden et ale (1973) have reported that intraduodenal glucose administration
significantly increases the percentage of insulin cleared in the dog liver.
This conflicts with the rat liver perfusion results of Honey and Price
(1979) which indicate a significant drop in insulin clearance as a result
of increasing glucose concentration. To date, results of animal studies
are inconclusive, and further experimentation will be required to charac-
terize the effects, if any, of glucagon and glucose on hepatic insulin
clearance.
For the insulin model formulation it was assumed that, within phy-
siologic limits, the liver clears 40 percent of the insulin presented to it
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independent of plasma insulin levels. This was expressed
( 102)
where the fractional clearance of insulin by the liver FLIC equals 0.40.
2) Kidney Insulin Clearance
Chamberlain and Stimmler (1967) have studied the renal handling of
insulin by comparing insulin levels in arterial blood, renal venous blood,
and urine in normal subjects before and after an oral glucose load. Their
results indicate that the kidney clears about 30 percent of the insulin
presented to it independent of the arterial insulin concentration, and that
less than 2 percent of the insulin filtered at the glomerulus ;s excreted
into the urine.
In the insulin model, the kidney was assumed to clear 30 percent of
the insulin presented to it independent of the arterial insulin level.
This was given by
(103)
where the fractional clearance of insulin by the kidney FK1C equals 0.30.
3) Peripheral Insulin Clearance
The clearance of insulin by peripheral tissues has been studied by
measuring arteriovenous insulin concentration differences across human
forearm and leg. Presented in Table 23 is a summary of results compiled
from the literature. Included in the table for each study is a value for
the percentage of insulin cleared which is representative of the data
collected over the indicated arterial insulin concentration range. A
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TABLE 23. Peripheral tissue insulin clearance data compiled from the literature.
Arter1 a I Insu 11 n (;oncentrat10n
Reference Study Range (mUll) , Insulin Clearance
Butterf1~ld et al.,
1963 Forearm 100 - 1400 13
samols &~der, 1961 Leg . 15 - 230 10
Razio et al., 1972 Foreann 5 - 60 30
Jackson et at., 1973 Forearm 10 - 80 15
Kalant et al., 1979 Forearm 5 - 250 23
Fineberg &
SChneider, 1982 Forearm 80 - 330 43
review of the available literature indicates that peripheral tissues are
observed to clear a relatively constant percentage of the insulin presented
to them, but that the reported value for this percentage varies over a wide
range from study to study. Whether this is an artifact of experimental
technique or an indication of large individual variability is uncertain.
For the insulin model, it was assumed that 15 percent of the in5ulin
presented to peripheral tissues is cleared, which was expressed
(104)
where the fractional clearance of insulin by peripheral tissues FpIC equals
0.15. From a physiologic standpoint, however, it was desirable to formulate
peripheral insulin clearance as a function of the peripheral interstitial
fluid insulin concentration, since insulin is actually removed from the
interstitial fiuid space by binding and sUbsequent degradation on the
tissue cell membrane. Under psuedo-steady conditions, the peripheral insu-
lin mass balance formulations (Equations 22 and 23) give
(105)
(106)
(107)
It thus follows from these expressions and Equation 104,
I I VpI
r pIC = 0.15 Qp IH = Qp(I H - IpV > =--- (I pv - IpI )
r Ip
from which the arterial and peripheral vascular insulin concentrations were
eliminated to yield the desired relationship,
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I p1 (108)r pIC = rl1 - F 1
[( PIC) (_) P- (-)]
FpIC QI Vp1P
M) Peripheral Insulin Transcapillary Diffusion Time Constant
Diffusion is the most important process by which solutes are exchanged
between the blood and interstitial fluids. The rate of diffusion is pri-
marily dependent upon the size of the solute and the permeability of the
capillary wall. Insulin is less readily accessible to peripheral extra-
vascular fiuids than glucose, due in part to its large size (MW~800) rela-
tive to glucose (MW 180) (Rasiv, 1982). In addition, insulin diffusion is
restricted by the continuous capillaries of skeletal muscle and adipose
tissue which are less permeable than the sinusoids of liver or the
fenestrated capillaries of kidney and gut (Yoffey and Caurtice, 1970).
Studies in dogs (Rasia et al., 1968; Camu and Rasia, 1972) and hum~ns
(Rasia et al., 1967) have shown rapid equilibration of glucose and insulin
between blood plasma and thoracic duct lymph. Since thoracic duct lymph
drains the extravascular fluid spaces of the liver and gastrointestinal
tissues, these results provide direct confirmation that the capillaries of
these viscera are highly permeable. Similar measurements of insulin dif-
fusion into the hind leg lymph of dogs (Rasia et al., 1968), however, indi-
cate that the capillaries af peripheral tissues are much less permeable to
insulin; following an acute increase in arterial insulin concentration,
insulin measured in leg lymph rose to 60 percent of its equilibrium con-
centration in about 20 min. Based on these results, a transcapillary dif-
fusion time constant of 20 min was selected to characterize diffusional
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exchange of insulin in the peripheral compartment of the insulin model.
N) Pancreatic Insulin Release
Insulin is produced by beta cells located in the islets of Langerhans
of the pancreas. Here, insulin is synthesized and stored in a labile form
that can be rapidly released in response to stimulatory factors. In
humans, the islets are about 100 - 200 ~ in size and are distributed
throughout the exocrine pancreas, constituting only 1 to 2% of the total
pancreatic tissue (Steiner et al., 1972). The high vascularity and
fenestrated endothelial structure of the pancreatic islet microcirculation
(Lacy and Greider, 1972) provide for rapid transfer of newly secreted
insluin into the blood stream. Measurements of insulin in venous effluent
of the perfused rat pancreas (Curry et al., 1968) have demonstrated insulin
response within 30 s after a stimulating concentration of glucose reached
the pancreas. Because of anatomical positioning in the circulation, insu-
lin released by the pancreas in vivo enters the portal vein and thus tra-
verses the liver prior to entry into the systemic circulation.
1) Biosynthesis and Storage of Insulin in the Beta Cell
The insulin biosynthetic mechanism of the pancreatic beta cell
(Steiner et al., 1974) is summarized in Figure 34. The sequence of events
is initiated with the synthesis of proinsulin by ribosomes associated sith
the rough endoplasmic reticulum; proinsulin (see Figure 35), the b;osynthe-
tic precursor of insulin, is a single-chain polypeptide (MW 9600) con-
sisting of C-peptide and the disulfide linked A- and B-chains of insulin
(MW 5800). Proinsulin is next transferred by an energy-dependent proce5S,
possibly within microvesicles, to the Golg; complex. Within the Golgi
apparatus of the cell, early storage granules form as proinsulin is incor-
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Fig. 34 Schematic representation of beta cell insulin biosynthesis.(Steiner et a1., 1974)
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porated into membranous sacs derived from the Golgi tubules. As the
storage granules move away from the Golgi region and collect in the
cytoplasm, proinsulin is converted to insulin through cleavage of the C-
peptide segment by proteolytic enzymes. As insulin is lib~rated from
proinsulin, it forms a dense crystalline mair~x with zinc (beta granule).
With electron microscopy, the process of granule maturation is evidenced by
appearance of the beta granule surrounded by a fluid region (presumably
containing C-peptide) within the membranous sac. Finally, lnsulin release
occurs by the process of emiocytosis; the sacs fuse with the plasma
membrane of the beta cell, and the mature granules are extruded into the
extracellular space. Upon release, the crystalline granules undergo rapid
dissolution due to the high concentration of sodium in the extracellular
fluid (Lacy and Greider, 1972; Howell et al., 1969).
The times required for each of the major stages in the biosynthetic
sequence are indicated in the time scale on the right side of Figure 34.
These values refect experimental results obtained by introducing radioac-
tive amino acids into beta cells (primarily of rats) and monitoring the
movement of label through the synthesis sequence. Although label can be
detected in proinsulin within 1-2 min of incubation, 10-15 min are required
before small amounts of labeled insulin begin to accumulate in granules
(Steiner et al., 1972). The conversion of pro;nsulin to insulin behaves
like a first-order reaction with a half-life of about 1 hour (Steiner,
1967). Overall, there is an observed time delay of about 1 hour before
newly made insulin begins to appear as a secretary product (Steiner, 1967;
Sando und Grads ky, 1973; Howell and Taylor, 1967). In rabbi t pancreas sl i-
ces (Howell and Taylor, 1967), newly synthesized insulin was maximally
released 2.5-3.5 hour after start of a 20-min incubation with 3H-leucine
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label. The above evidence suggests that n~wly synthesized insulin does not
significantly contribute to short-term pancreatic response.
2) Factors Regulating Release of Insulin
a) Gl ucose
Glucose provides the primary stimulus for insulin release (Wilson,
1983; Gerich et al., 1976). A step change in glucose concentration elicits
a biphasic insulin response (see Figure 36) characterized by an initial
rapid release lasting about 5-10 min. (fir~t phase) followed bj' a more
sustained and gradual increase in the rate of release (s~cond phase)(Curry
et al., 1968; Grodsky et al., 1969; B~rgman and Urquhart, 1971). Dose-
response relationships in humans (Figure 37)(Cerasi et al., 1974) have
shown that the response of insulin to glucose is sigmoidal, with little
stimulation of release by glucose concentrations below normal fasting
levels, and the most sensitive secretory response induced by glucose con-
centrations just above fasting levels. The relatively high threshold for
glucose-stimulated insulin release (about 80..~100 mg/dl)(Malaisse, 1972;
Cerasi et al., 1974; Grodsky, 1972) suggest that glucose alone does not
regulate fasting insulin levels. An important action of fasting glucose is
most likely its modification of insulin release in response to other sti-
muli, such as gut hormones, glucagon, fatty acidS, arginine, and neuronal
factors that elicit little insulin secretion alone but are effectively
potentiated by the presence of low glucose concentrations (Gerich et al.,
1976) •
b) !Wino kids
A variety of amino acids stimulate insulin secretion in man (Fajans
and F1 oyd, 1972; Geri ch et al., 1976). The most potent st imul ator is argi-
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nine, followed by lysine and leucine (Fajans et al., 1967; Floyd et al.,
1966b). Amino acids cause a monophasic release of insulin in the absence
of glucose, whereas biphasic release is restored upon addition of small
quantities of glucose (Gerich et al., 1974). Results of studies comparing
the effects of various combinations of glucose and amino acid stimulations
of insulin release suggest that amino acids mimic but do not potentiate
glucose-induced secretion (Malaisse, 1972). Postprandial increases in
plasma levels of amino acids following protein feeding have been shown to
cause physiological stimulation of insulin release in man (Floyd et al.,
1966a; Berger and Vongaraya, 1966; Rabinowitz et al. 1966). It is unli-
kely, however, that the changes in plasma amino acid levels observed during
oral or intravenous glucose (Cahill et al., 1966; Wahren et al., 1972;
Felig et al., 1975) would cause quantitative effects on beta cell secre-
tion.
c) Free Fatty Acids
Although the possible role of lipid ingestion in augmenting insulin
release in man has been studied, resu1ts have been inconsistent and would
at best suggest a minor interaction (Fajans and Floyd, 1972). Plasma insu-
lin does not increase when the concentration of plasma free fatty acids
(FFA) is increased by intravenous administration of lipid emulsions (Felber
and Vannotti, 1964). Furthermore~ plasma insulin response to oral (Thorell
et al., 1956) and intravenous (Thorell et al., 1966; Pelkonen et al., 1968)
glucose is not enhanced by elevation in the concentraion of FFA.
d) Hormones
A number of hormones can directly affect pancreatic insulin release
(Gerich et al., 1976; Unger et al., 1978). Whether insulin exerts feedback
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regulation of its own secretion has generated much controversy. While stu-
dies using the prefused canine pancreas (Iverson and Miles, 1971) and
pancreatic islets of mice (Loreti et al., 1974) demonstrated inhibition of
insultn release with increased perfusate insulin levels, results of
investigations using the perfused rat pancreas (Grodsky et al., 1968) and
isolated rat islet preparations (Malaisse et al., 1967) indicated no such
inhibitory action. Recent studies have used C-peptide assay to determine
if exogenous insulin inhibits insulin secretion in man. DeFonzo et ale
(1981c) have shown that elevation of plasma insulin levels by about 24
~U/ml or more in the presence of basal glucose concentrations causes rouy1y
a 50% reduction in the rate of endogenou3 insulin release. L~rjenquist et
al. (1978) have reported that exogenous insulin does not result in inhibi-
tion of the pancreatic insulin response to hyperglycemic stimulus unless
prolonged (60 min) euglycemic hyperinsulinemia is maintained prior to
inducti~n of elevated glucose. Since euglycemic hyperinsulinemia does not
occur under natural conditions, it can be concluded from the above that
insulin feedback inhibtion does not play an important role in the normal
regulation of pancreatic insulin release.
In additon to insulin, two other hormones are produced in the islets
of Langerhans, glucagon (by the alpha, or A2 cells) and somatostatin (by
the delta, or Al cells)o In physiologic doses, each of these hormones
influences the secretion of at least one of the other pancreatic hormones.
Glucagon stimulates both insulin (Samols et al., 1965) and somatostatin
(Patton et al., 1977; Weir et al., 1977) release. Somatostatin inhibits
both insulin and glucagon secretion (Mortimore et al., 1974; Reichlin,
1983). Insulin inhibits glucagon release (Samols et al., 1972; Raskin et
al., 1975) and may inhibit somatostatin release (Reichlin, 1983b). Because
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of the complex interactions of these hormonal influences, Unger et al.
(1978) have hypothesized that a IIparacrinen system may exist within islets
in which regulatory action 1s exerted through hormonal communication bet-
ween neighboring islet cells via the interstitial spaces of the islets.
Although increasing evidence suggests that some form of an intraislet regu-
latory mechanism may exist (Kohen et al., 1983; Orci et al., 1975;
Reichlin, 1983b), its relative significance in the overall mediation of
insulin release has not been determined.
Gastrointestinal hormones cause a significant quantitative enhancement
of insulin release. Perley and Kipnis (1967) observed that the plasma insu-
lin response to oral glucose was about 3 times greater than that resulting
from intravenous glucose causing comparable glycemic levels. Similar
results have been reported by Elrick et al. (1964) and McIntyre et al.
(1965). In the presence of glucose, the gastointestinal hormones gastrin,
secretion, and pancreozymin, which are primarily involved with regulating
the motor and secretory functions of the splanchnic organs, can elicit
insulin release in vitro (Grodsky, 1970). Studies with humans, however,
have suggested that these hormones do not exert significant regulatory
action on insulin release in vivo (Dupr~ et al., 1969; Hayes et al., 1975;
Grayburn et al. t 1975). One of the more recently identified gastroin-
testinal hormones, gastric inhibitory polypeptide (GIP), is secreted by the
mucosal K-cells in the upper part of the small intestine (Solcia et al.,
1978). GIP has been shown to be a potent stimulator of insuli~ release in
the perfused rat pancreas (Pederson and Brown, 1978). Evidence suggests
that endogenous GIP secretion is an important stimulator of insulin release
in man (Morgan, 1979). Elahi et al. (1979) have demonstrated that GIP
infusions elevating plasma levels within physiologic ranges can inducce a
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significant plasma insulin response in the presence of hyperglycemia in
normal subjects.
e) Autonomic Nervous System
Both the sympathetic and parasympathetic nervous systems may play
important roles in the modulation of insulin release (Wilson, 1983). The
islets of Langerhans are enervated by sympathetic fibers from the greater
and lesser splanchnic nerves (Gerich et al., 1976). The sympathetic ner-
vous system may affect islet function in two ways: 1) by local release of
the adrenergic neurotransmitter norepinephrine, and 2) through adrenofile-
dul1ary release of epinephrine. Both norepinephrine (Porte, 1966a) and
epiniphrine (Porte, 1966b; Karem et al., 1966) inhibit insulin secretion in
man through simulation of the a-adrenergic receptor (Porte, 1967). 8-
adrenergic stimulation by isoproternol (a synthetic agent), however, eleva-
tes circulating insulin levels (Porte 1967; Gerich et al., 1974) and
enhances glucose-induced insulin release (Malaisse et al., 1967). Because
of the oppos)ng actions of a- and a-adrenergic stimulation, it has been
proposed that adrenergic tone may be important in the modulation of basal
pancreatic hormone secretion (Gerich et al., 1976), since both norepi-
nephrine and epinephrine stimulate a-adrenergic receptors to some degree.
In addition, events such as surgical stress (Allison et al., 1967) and
exercise (Hunter et al., 1968) are associated with decreased insulin
response to hyperglycemia, suggesting inhibition of insulin secretion
through sympathetic nervous system activation (Porte, 1969).
With respect to the parasympathetic nervous system, the pancreatic
islets are enervated by fibers originating from the vagus nerve (Wilson,
1983). The parasympathetic neurotransmitter, acetylcholine, augments insu-
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lin release in vitro (Iversen, 1973; Malaisse et al., 1967; Sharp et al.,
1974), and stimulation of the vagus nerve has been shown to cause an
increase in insulin secretion in the dog (Frohman et al., 1967). Vagal
denervation, however, has been reported to result in a marked decrease in
insulin response to oral and intravenous glucose in rats, although basal
insulin levels were not significantly affected (Hakanson et al., 1971).
Even though the role of parasympathetic regulation of insulin release has
not been clearly determined, these findings suggest the involvement of such
a mechanism in normal response to glucose.
3) Insulin Release Mechanism
The mechanism of insulin release from the beta cell has been exten-
sivelY studied (Malaisse, 1972; Randle and Hales, 1972). A model sum-
marizing the release process is shown in Figure 38. Glucose (acting
through a product of its cellular metabolism), leucine t and perhaps tolbu-
tamide (an insulin-inducing drug) stimulate cellular uptake and/or intra-
cellular redistribution of calcium ion. Amino acids which do not stimulate
insulin release by themselves, such as arginine, probably act by poten-
tiating ea 2+ flux through cotransport with Na+. Although Ca 2+ probably
plays a primary role in excitation of the release process, cyclic AMP most
likely plays a secondary or reinforcing role. It is through stimulation of
the adenyl cyclase receptor system that agents like glucagon could enhance
insulin release by elevating intracellular cyclic AMP levels. Likewise,
inhibition of insulin secretion by a-adrenergic eff~ctors could involve
inhibition of cyclic AMP formation (not shown in Figure 38). Excitation of
the release process is depicted as involving a coupling system which
mediates the effects of Ca 2+(and perhaps cyclic AMP}. Even though the
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release process involves ATP turnover, 'it is not known whether .l\TP is IJti-
lized directly for energy needs (as shown by its conversion to ADP) or if
ATP plays an indirect role through formation of cyclic AMP.
Irrespective of the stimulus, the mclecular basis of the release
system which constitutes the final common pathway of release ;s not known.
Lacyet ale (1968) have postulated that some of the insulin secretion gra-
nules are attached to a microtubule system, the microtubules of which
contract or change their physical conformation in response to stimulatory
factors, resulting in transport of granules to the cell surface where they
are liberated.
4) Models of Glucose-Stimulated Insulin Release
Release of insulin from the pancreas is complicated, involving synthe-
sis and release mechanisms in the beta cell which are not clearly
understood, and subject to a complex array of regulatory factors. Since
glucose is the primary stimulus of insulin secretion, mathematical models
to date have primarily focused on glucose-induced release. Within the con-
text of in vivo homeostasis modeling, such pancreatic insulin re1~use
models thus provide a quantitative relationship between glycemia and insu-
lin release. Although this a useful and meaningful approach, it is impor-
tant to recognize the range of physiologic situations for which such a
simplified relationship is invalid. Fir$t, glycemia related to oral glu-
cose must be distinguished, since insulin response is substantially
augmented by gastointestinal hormones. Additional situations which would
be anticipated to alter quantitatively the insulin response in normal man
include: 1) inhibited response caused by euglycemic hyperinsulinemia or
catichol intervention during stress, and 2) enhanced response resulting
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from protein ingestion. Finally, the degree of modulation exerted by
paracrine and/or other nervous system mechanisms remains to be determined,
but such influences could be important. In view of the above d;scussiu~,
glucose-induced insulin release models are strictly valid only for clinical
studies in which in vivo arterial glucose concentrations are varied as a
result of glucose infusions, such as intravenous glucose tolerance tests
and hyperglycemic clamps. In addition, there are a number of clinical
situations in which endogenous insulin release provides a small contribu-
tion to circulating insulin levels, such as intravenous insulin tolerance
tests, euglycemic insulin clamps, and continuous insulin infusions; for
such cases, the errors associated with omitting the effects of insulin
feedback inhibition on pancreatic insulin release would not be of any
quantitative significance.
In an early series of papers, Grodsky et ale (1969, 1970a, 1970b) pro-
posed a single two-compartment model of insulin release. A small labile
compartment (containing a few percent of the total stored insulin) was
assumed in slow exchange with a large storage compartment such that a rapid
stimulation of insulin release caused a partial depletion of the small com-
partment. This provided a mathematical description ot the biphas;c
response which had been observed experimentally in the perfused rat
pancreas (Curry et al., 1968). Subsequent perfusion studies using con-
tinuous staircase stimulations indicated that the initial spike of insulin
release was not due to depletion of a single labile compartment since more
insulin was elicited by each higher glucose step (Grodsky, 1970c). Grodsky
(1972) thus hypothesized that insulin in the labile compartment was nonho-
mogenous, stored in insulin packets that varied sigmoidally in their
glucose-threshold for release; this concept was incorporated into the
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mathematical model depicted in Figure 39. Here, m is a time constant
controlling the release rate of insulin from the labile compartment for
packets whose thresholds have been exceeded. The exchange of insulin bet-
ween the large and small compartments is controlled by rate paralTleters
K1(P) and K2- A postulated uprovisionary factor U P, which is a function of
glucose concentration, regulates the value of K1(P), thus controlling the
refill rate of the labile compartment. The model produces first phase
secretion by rapid depletion of the threshold-exceeded labile insulin
packets, and the slowly rising second phase secretion by refilling from the
large compartment as controlled by the value of P, which reaches steady
state in approximately 1 hr. Since insulin synthesized de novo would not
significantly contribute to insulin release for 1-2 hr following glucose
stimulation, no r~presentation of the syn~hesis pr~c~ss was included in the
mathematical formulation. Licko and Silvers (1975) subsequentlY used
regression analysis of the intravenous glucose tolerance test in normal
humans to readjust parameter of the threshold distribution model for pre-
dicting insulin response in man.
Bergman and Urquhart (1971) formulated a model based upon contemporary
views of the biosynthesis and release mechanisms of beta cell insulin
secretion (Figure 40) to simulate results of canine pancreas perfusion stu-
dies. Granular insulin (Ig) was postulated to form via a relatively slow
combination of "source" molecules into a precursor molecule (Ip)' which is
th~n transformed (via intermediate "b") into Ig• The granul ar insul in is
subsequently transformed to a labile form (1m) which is present at the cell
membrane. Glucose was assumed to ~timulate insulin synthesis through pro-
duction of an intermediate nail which increases the rate of combination of
source molecules into Ip• The conversion of granular insulin to labile
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Fig. 39 Schematic d;agram of the threshold distribution model of
pancreatic insulin release of Grodsky (1972). (O'Connor et
al., 1980)
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Initial conditions
Glucose ----------------------------------c
I : tt : da I
I I I
• I I
· 'tSource---l..-.. I p ~ b .. 19 --L.....1m .. Secretion
t t
I) ci = G-0.025 a
2) tp = 0.01 a -0.089 rp
31 D= 0.021 ID - 0.11 b
4) ~= 0.021 b - ~(O.065 +0.020 G) + 0.021
51 im= Iq(O.OI5 + 0.015 Gl- Im( 1.45 eo+- 0.75 d)
6) { c= 4.1 G OSGSO.25}c = 2.3 G + 0.59 G> Q25
7) d = 1.6 c - 8.0 d
8) Secretion == Im( 1.45 ;- 0.75 d1
1m(01 = 0.00331
la(O) = 0.319
Ffg. 40 Glucose-stimulated insulin secretory model of Bergman and
Urquhart (1971).
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insulin was also assumed to be glucose dependent. FinallYt glucose
triggered release of labile insulin through mediating intermediates flCIl and
IId ll , where production of IICIl by glucose was assumed to follow saturation
kinetics. The model was later modified (Bergman and Bucolo, 1973) to
include effects of amino acids.
Guyton et al. (1978) formulated a heterogeneous fast pool model of
human pancreatic insulin release (Figure 41) on the basis of plasma insulin
responses to various glucose infusion experiments. Insulin is synthesized
and stored in a large compartment (slow pool) which is in exchange with a
small capacity system of compartments (~eterogeneous fast pool) consisting
of sites for the holding and releasing of labile insulin. The process of
insulin synthesis was postulated to follow a sequence of steps similar to
those assumed in the model of Bergman and Urquhart (1971). Glucose in the
beta cell (GBC) acts through a metabolite (GMET) to .stimulate the for-
mulation of messenger RNA (MRNA) from "source ll molecules (i.e. amino
acids). Proinsulin (PROI) is produced from the MRNA and ;s transfered to
the 6019; conlp1ex (IGOL), where insulin is cleaved from the proinsulin.
Insulin formed in the 601g1 complex is converted to granular form and
transfered to the slow pool where it is stored (insulin in slow pool t ISP).
The heterogeneous fast pool consists of a set of four distinct compartments
(releasing sites with insulin, RSI; releasing sites that are emptYt RSE;
holding sites with insulin, HSI; and holding sites that are empty, HSE).
Insulin is rapidly released at a rate which is proportional to the quantity
of releasing site insulin (RSI). The heterogeneous fast pool ~s ba5ically
an alternative mathematical representation of the threshold distribution
model of Grodsky (1972). Whereas Grodsky employed a single inhomogenous
"compartment" of labile insulin packets with a sigmoidal glucose threshold
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d~Jtribution, Guyton et al. used a system of homogenous compartments with a
sigmoidal function relating glucose concentration to the quantity of sites
whose thresholds had been exceeded (releasing sites) relative to the quan-
tity of sites whose thresholds had not been exceeded (holding sites).
Thus, first phase insulin release from the heterogeneous fast pool results
from a rapid glucose-induced shift of holding site insulin (HSI) to
releasing site insulin (RSI). The second phase of release results from a
glucose-related increase in the rate of transfer of slow pool insulin (ISP)
to fill empty sites in the fast pool. In addition, glucose slowly augments
the number of fast pool sites (site synthesis) causing a potentiation of
insulin response following glucose exposure. The mathematical equations
for insul in synthesis and storage were g'iven by
%r (GBC) = [GA - (GBC)] (GDC) + (FMG)(GMET) - (FGMPM)(GBC) (109)(VBC)
ddt (GMET) = (FGMPM)(GBC) - [(FMMPM) + (FMG)](GMET) (110)
d (IGOL) = (PROI)dt TpR01
0
d (MD) Me - Medt =\ C Te
d (IGOL)(ff (ISP) =
T1GOL
h- (MRNA)
ddt (PROI)
= (EGMET) r~RNA - ~RNA)
TMRNA
B (PRO!)
= (MRNA) r p1R -~~TpROI
( I GOl)
TIGOL
+ (HSI) + (RSI)
- r ISTFTSO
(111)
(112)
(113)
(114)
(115)
where: GBC = Glucose in Beta Cell (mg)
GMET = Glucose Metabolite in Beta Cell (mg)
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MRNA = Messenger RNA Molecules (normalized)
PROI = Proinsulin (mU insulin equivalents)
IGOL = Insulin in 60lgi Complex (mU)
Mg = Delayed Effect of Glucose on Rate of Insulin Transfer from
Slow to Fast Pool (dimens ionl ess)
ISP = Insul in in Slow Pool (mU)
GA = Arterial Blood Glucose Concentration (mg/dl)
VBC = Beta Cell Volume = 0.01 dl
GDC = Beta Cell Glucose Diffusion Coefficient = 0.01 mg/(mg/dl) -min
FMG = Fraction of GMET Converted Back into Glucose per Minute
= 0.5 mi n- l
FGMPM = Fraction of GBC Metabolized per Minute = 2.0 mfn
FMMPM = Fraction of GMET Metabolized per minute = 1.0 mfn
EGMET = Nonlinear Effect of GMET on MRNA synthesis (dimensionless)
r~IR = Basal Rate of Pancreatic Insulin Release (mU/min)
TMRNA = MRNA" Time Constant = 20 min
r~NRA = Basal Rate of MNRA Synthesis (min-I)
TpR01 = Time Required for PROI Transfer to 6019; Complex = 20 min
TIGOL = Time Required for Insulin Transfer to Slow Pool = 20 min
Te = Time Constant for Delayed Effect of Glucose on rrSTF = 45 min
TSD = Time Constant For Site Degradation = 45 min
rISTF = Rate of Insulin Transfer From Slow to Fast Pool (mU/min)
and the nonlinear function EGMET is shown in Figure 42. The nonlinear
insulin transfer rate r ISTF was expressed
r = M [M MD r B ( {ISP) ) + ((HSI) + (RSI)) ] (116)
ISTF ABC PIR (ISP) T basal
basal SD
where the multiplier functions Mi are presented in Figure 43 (the delayed
effect M~ is determined from Figure 43 and Equation 114).
The fast pool insulin dynamics were given by
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ddt (HSI) = ( (HSE)) r + [( (RSI) ) )0+(HSE) + (RSE) ISTF (RSE) + (RSI) r a
+[( (HSI) ) r )0- _ (HSI) (117)
(HSE) + (HSI) a TSD
+
ddt (HSE) = - ( (HSE)) r + [( (RSE) ) r )0(HSE) + (RSE) ISTF (RSE) + (RSI) e
+[( (HSE) ) r ]0- _ (HSE) + (EGSS) rB (118)
(HSE) + (HSI) e TSD HSS
ddt (RSE)
+d (RSI) = ( (RSE)) r + [( (HSI)) r )0
dt (HSE) + (RSE) ISTF (HSE) + (HSI) e
+[( (RSI) ) r ]0- _iRS1 ) _ (RSI)
(RSE) + (RSI) e TSD T1R
: _ ( (RSE)) r + [( (HSE) ) r )0+
(HSE) + (RSE) ISTF (HSE) + (HSI) e
+[( (RSE) r ]0- _ (RSE) + (EGSS) r~SS
(RSE) + (RS!) e TSD
where: HSI = Holding Sites with Insulin (mU equivalents)
HSE = Holding Sites Empty (mU equavalents)
RSI = Releasing Sites with Insulin (mU equavalents)
RSE = Releasing Sites Empty (mU equivalents)
EGSS = Nonlinear Effect of Glucose on Sit~ Synthesis
(dimensionless)
r~SS = Basal Rate of Holding Site Synthesis (mU/min)
r~SS = Basal Rate of Releasing Site Synthesis (mU/min)
r e = Rate of Site Redistribution (mU/min)
TIR = Insulin Rel'ease Time Constar.t = 0.4 min
(119)
(120)
and the superscripts 0+ and 0- mean that the arguments in brackets assume a
value of zero unless they are greater or less than zero, respectively. The
nonlinear effect of glucose on site synthesis augmentation EGSS is shown in
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Figure 44. The rate of site redistribution fa was expressed
r =a
[(RSE)+(RSI)] - [(HSE)+(HSI)+(RSE)+(RSI)]e
Tors
(121)
where: TDIS = Site Redistribution Time = 0.2 min
and a represents the fraction of sites that are releasing sites,
e = ( R_S--..;E)~+.....,;",.(R_S_I,;""..,)__
(HSE)+(HSI)+(RSE)+(RSI)
(122)
The value of e was given as a nonlinear function of the beta cell glucose
metabolite concentration as presented in Figure 45. Since a was calculated
from the glucose metabolite concentration, the numeratOt· in Equation 121
yielded the error in the number of releasing sites at any given time, thus
providing the driving force for site redistribution. The rate of
pancreatic insulin release (the last term in Equation 119) was given by
r = (RS I)
PIR T
IR
(123)
By setting all of the time derivatives equal to zero at steady state, ini-
tial conditions were uniquely calculated from specification of the fasting
arterial blood glucose concentration (GA) and the assumption (arbitrary)
that the total quantity of sites was 2323 mU equivalents. For example, a
fasting arterial blood glucose concentration of 80 mg/dl yields the
following initial conditions:
GBC = 0.349 mg
GMET = 0.465 mg
MRNA = 1.00 (normalized molecules)
PROI = 437 mU insulin equivalents
IGOL = 437 mU
ISP = 200,000 mU
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HSI = 1990 mU equivalents
HSE = 217 mU equivalents
RSI = 8.75 mU equivalents
RSE = 107 mU equivalents
oMC = 1.0
and B 21.9 roU/minr p1R =
B 0.05 min- 1r MRNA =
B 49 mU/minr HSS =
B 2.6 mU/minr RSS =
In the mvdels of Grodsky (1972) and Guyton et ale (1978)t the rate of
insulin release was determined by the quantity of available insulin within
a small labile compartment; such formulations are referred to as storage-
limited models. Based on studies of glucose-insulin interactions during
intravenous glucose administration in man, Cerasi et alo (1974) assumed
that insulin is stored in a single large compartment and that insulin
release is directly associated with changes in glucose-induced signals
(Figure 46). This is an example of a signal-limited model. Glucose was
pGstulated to cause an instananeous multiplicative augmentation of insulin
release; this was expressed in terms of a sigmoidal function of glucose
concentration (f(g) in the figure) derived from dose-response studies. In
addition, glucose was assumed to enhance le~els of a potentiator (p)
through an intermediate (PI)' and insulin release to increase levels of an
inhibitor (b) through an intermediate (b I ). The exponential difference
between the potentiator (p) and inhibitor (b) levels was al~o assigned a
multiplicative effect on the rate of insulin release. In this model, first
phase release is caused by an instantaneous glucose-induced augmentation
signal followed by a rapid increase in the level of inhibitor b. Second
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phase release results form a gradual rise in the level of potentiator p
with prolonged glucose exposure. The effects of glucose on insulin synthe-
sis were not considered. The mathematical equations for this model were
given by
dPl 1~ = (- ---) PI + kp f(g)Tp1
(124)
{t = - 1.... (p
- PI) (125)Lp
db! 1
+ kb i (126)~ = (- tbl) bl r
db 1 (b - bl ) (127)(It - tb
i = e(p-b)f(g) (128)r
*r pIR = V. k. i (129)1P 1 r
where: p =
PI =
b =
bl =
Tpi =
Lp =
Lbi =
tb =
kp,k b =
Vip =
f(g) =
k. =1
; =r
*r pIR =
Potentiator Variable (dimensionless)
Intermediate Potentiator Variable (dimensionless)
Inhibitory Variable (dimensionless)
Intermediate Inhibitory Variabl~ (dimensionless)
Time Constant = 30 min
Time Constant = 30 min
Time Constant - 20 min
Time Constant 5 min
Parameters (min-I)
Distribution Volume for Secreted Insulin (ml)
Nonlinear Effect of Blood Glucose Concentration on
Initiating Insulin Secretion (dimensionless)
Pa rameter (lJU/m1 ·mi n)
Abstraction Representing Dynamics of Insulin Secretion
(dimensionless)
Insul in Release Rate Above Basal (lJU/min)
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and the nonlinear function f(g) is shown in Figure 47. Values for the
parameters kp ' kb , and ki were adjusted to obtain fits of individual plasma
insulin profiles following intravenous glucose administration in normal t
prediabetic t dnd diabetic subjects. Additional signal-limited mathematical
models (the excitor-inhibitor and delta-signal models) have been developed
by O'Connor pt ale (1980) to describe pancreati~ insulin release fro~ the
perfused rat pancreas.
Cabelli et al. (1980) conbined both storage- and signal-limited
features into a relatively simple model of insulin secretion (Figure 48).
The model consists of twa linearly connected compartments of stored (Xl)
and labile (X2) insulin. Insulin;s synthesized and transfered to the
insulin storage compartment at a rate which is determined by glucose con-
centration. The rate of insulin release from the labile compartment is
dependent on both the quantity of labile ~nsulin and the concentration of
gluc~se. The model is described by the following equations:
rSyN(G) = 0.5 a { 1 + tanh[b(G - GB + c) }
B
r pIR (G,X2) = 0.5 d { 1 + tanh[e(G - G + f)]}
where: Xl = Quantity of Stored Insulin (mU/kg body weight)
X2 = Quantity of Labile Insulin (mU/kg body weight)
rSYN = Rate of Insulin Synthesis (mU/m;n/kg body weight)
rpIR = Rate of Insulin Release (mU/min/kg body weight)
G = Glucose Concentration (mg/dl)
G!3 = Basal Gl ucose Concentration (mg/dl)
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Insulin
Release
with parameter values
k21 = 0.01 min-
1
-3 .-1k12 = 4.34 x 10 mln
a = 4.1 mU/min/kg body weight
b = 1.51 x 10-2 dl/mg
c = -92.3 mg/dl
d = 1.3 min- 1
e = 9.23 x 10-2 dl/mg
f = -19.68 mg/dl
and initial conditions
X1(O) = 75 mU/kg body weight
X2{O) = 7.5 mU/kg body weight
Numerical values for the parameters and initial conditions were obtained
from the experimental data of Bergman and Urquhart (1971) and Grodsky
(1972), although details of the qUdntification process were not reported.
Cabell; et ale normalized the ~odel with respect to body weight (values of
Xl' X2' and a were expressed per kg of body weight) and assumed the vali-
dity of interspecies extrapolation on the basis of simple linear body
weight proportionality.
Landahl and Grodsky (1982) modeled insulin secretion by combining
storage and signal models from previous papers (Grodsky et al., 1969;
a·Connor et al., 1980). The res'4lting "mixed model" of pancreatic insulin
release is shown in Figure 49. As with the threshold distribution model
(see Figure 39), a small labile insulin compartment was assumed in exchange
with a large storage compartment, with a glucose-stimulated provisionary
factor P regulating the rate of labile compartment filling. The labile
compartment, however, was assumed to be homogenous, while the insulin
secretion rate (5) was modified to incorporate signal-limited charac-
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teristics. The rate of insu1in release S ;s dependent on glucose con-
centration, the quantity of labile insulin (Q), and the difference in the
instantaneous levels of a glucose-enhanced excitation moiety (X) and its
inhibitor (I). The quantity of labile insulin (Q) available for release at
any given time was determined by the rate of exchange between the storage
compartments, an incremental rate of insulin transfer due to glucose-
stimulated provision, and the fate of loss resulting from insulin secre-
tion. This was expressed by the mass balance equation
dQ I
at = K Qs - KQ + yP - S (134)
I
where K and Kare rate constants and YP represents the incremental rate of
transfer due to provision (K1(P) in Figure 49 thus corresponds to the sum of
I
K Qs and YP). The mass balance formulation for the insulin storage compart-
ment was given by
dQs •
crt = KQ - K Qs - yP (135)
Because of the large capacity of stored insulin, the quantity of insulin in
the storage compartment (Qs) was assumed constant. For a glucose concentra-
tion of zero, yP was set to zero, and from Equation 135 at steady state,
(136)
where QQ represents the quantity of labile insulin (Q) when the glucose con-
centration is zero. Equ~tion 136 was used to eliminate Q
s
from the mass
balance Equation 134, and the complete system of equations for the
pancreatic insulin release model was given by
M= u (PJG) - P)
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(137)
dICrt = B (X(G) - I) (138)
~ = K (Q -Q) + yP - S(X-I,Q,G)
ut 0 (139)
+
S = [M1Y(G) + M2(X-I)O ] Q (140)
K,M1,M2 =
y =
S =
Qo =
X(G) =
G =
a, B =
p =
I =
Q =
Provisionary Factor (dimensionless)
Inhibitor (dimensionless)
Quantity of Labile Insul in (ug)
Inverse Time Constants (mi n-1)
Rate Constants (min-I)
Rate Constant (ug/mi n)
Rate of Pancreatic Insul in Release (lJg/m;n)
For G=O (llg/mi n)Quantity of Labile Insulin
Nonlinear Effect of Glucose on Early Insulin Release
(dimensionless)
= Secretory Effect of Glucose (dimensionless)
= Nonlinear Effect of Glucose on Late Insulin Release
(dimensionless)
Glucose Concentration (ug/d1)
Y(G)
P (G)c:o
where
The model parameters and nonlinear input functions were established from
dose-step response studies of the glucose perfused rat pancreas (Grodsky,
1972). For a step increase in glucose concentration from a to G at t=O:
1) at early times, the second term in Equation 140 dominates such that
first phase insulin release rate tends to be proportional to X(G); 2) at
late times or veady state, from Equations 139 and 140 (noting that X=I and
p= Pc:o)
a = K(Qo-Q) + yP 00- S(G,Q»)
S(G,c:o) = M1Y(G)Q
(141)
(142)
and solving Equation 141 for Qand substituting into Equation 142 yields
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(yP00(6) + KQo)M 1Y(G)S(G,oo) =------
K+ M1Y(G)
(143)
It can be seen from this expression that if the value of the parameter K is
small enough, the late phase insulin secretion rate is proportional to
P (G). Thus, the functions X(G) and P (G) could have been obtained purely
CX) CX)
by fitting empirical approximations of the early and late secretion data of
Grodsky (1972). Landahl and Grodsky, however, showed that the same results
could be achieved on the basis of theoretical assumptions. First, it was
postulated that two entities Xmust associate with some receptor system in
order that P can be produced or that the second component of insulin secre-
tion can occur, such that
X2(G) = P (G) = Y(G)
CX)
(144)
Secondly, it was assumed that if four molecu1es of G (or its fnetabolite in
proportion to G) combine in the presence of Ca 2; ana if X(G) is the fraction
with four associations with G, then X(G) would be expressed by G4 divided by
a fourth degree ~olynomial in G. For a high degree of cooperativity, a
function of the form
(145)
would be representative, where Go is the value of G for which X = 1/2.
For Go = 150 mg/dl, Equations 144 and 145 yielded good approximations of the
data of Grodsky (1972) as shown in Figure 50, The remaining parameters were
estimated by comparing model predictions with experimental data:
K = 0.035 min- 1
a = O. 05 mi n-1
O 6 .-1B = • ml n
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M1 = 0.27 min -1
· -1M2 = 0.9 mln
y = 0.45 ~g/min
Q = 1. 2 119o
Two mathematical representations of pancreatic insulin release have
directly incorporated the concept that insulin response is both sensitive
to glucose concentration and its rate of change with timeu Foster et al.
(1973) assumed that each of these factors had a nonlinear effect on insulin
secretion which when multiplied together times the basal insulin release
rate yielded the pancreatic rate of insulin release. An additional
multiplicative effect of free fatty acid concentration was also included in
the formulation. In a more recent model t Carson and Cramp (1976) have
employed an additive relationship of the following form:
where: rpIR = Pancreati c Insul in Release Rate (mU/mi n)
B Basal Insul in Rel ease Rate = 4 mU/minr p1R =
G = Glucose Concentration (mg/dl)
GB = Basal Gl ucose Concentration = 90 mg/dl
"" Constant 1.0 (ffiU/min) (mg/dl )-1l"l = =
C2 = Constant :. 2.0 (mU/min)(mg/dl .min)-l
(146)
With the above mode15, first phase release results from the terms that are
sensitive to the rate of change of glucose with time, and second phase
release is generated by the terms that are sensitive to the glucose con-
centration level.
A summary comparison of literature models of glucose-stimulated insu-
lin release ;s presented in Table 24. General mathematical features of
each model have been included in the table to provide a basic index for
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TABLE 24. su.-try ca.partson of insulin release .odels.
--'
.........a
'-D
COMPLEXITY
tI)OEL TYPE INSULIN BASIS
SYNTHESIS 01 fferentl11 NOnlinear
Equations Parilleters Input Functions
Grodsky, 1972 Storlge No 3 15 2 Perfused rat pancreas
BergIN" and Urquhlrt, 1971 Storage I S1gnll Yes 6 23 1 Perfused dog ~ncreas
Foster et 11., 1973 G, ~ sensittve No 0 2 3 Plasma appearance 1n .an
Cerlst et 11., 1974 Signal No 4 9 1 P11~a appearance in .an
Guyton et 11., 1978 Storage Yes 11 14 6 Pla~a Ippearance in man
Cobel11 et .1., 1980 Storage I S1gnal Yes 2 10 2 Perfused dog/rlt pancreas
O'Connor et 11., 1980 Signal No 3 9 2 Perfused rat pancreas
I
Cr~p Ind Clrson 1981 G, ~ sensitive No 0 3 0 Plasaa appearante tn .an
I Lindahl and Grodsky 1982 Storage I 51 gna1 No 3 8 2 Perfused rat pancreas
comparing relative model compl~xities. Although attractive because of
their simple forms, the models of Foster et al. (1973) and Cramp and Carson
(l981), which are sensitive to glucose concentration and its rate of
change, bear the least physiologic correspo,~dAnce to beta cell function.
In addition, the formulation of Cramp and Carson (see Equation 146) yi~lds
basal insulin release for all degrees of hypoglycemia and generates a
linear dose-response to hyperglycemia. Since human glucose dose-response
is highly nonlinear (sigmoidal) (Cerasi et al., 1974), the general predic-
tive power of this model is questionable. Bergman and Urquhart (1971) and
Guyton et al. (1978) included physiologic representations of the insulin
biosynthesis pathway in their models; this increased the relative mathema-
tical complexities of these models, and since the mechanisms of insulin
synthesis are not fully characterized, increased the number of parameters
requiring estimation. Furthermore, the contribution of newly formed insu-
lin to short term (~1-2 h) response is probably not important. Due to the
use of four compartments to represent storage-limited release of labile
insulin, the model of Guyton et ale encompasses an extra degree of
complexity with respect to the complicated filling and redistribution dyna-
mics of these compartments, and also employs a large number of nonlinear
irput table functions in the formulation. Cerasi et al. (1974)
demonstrated that a relatively simple signal model could predict the impor-
tant features of biphasic insulin response to intravenous square-wave glu-
cose stimuli in man. Cobelli et al. (1980) combined storage and signal
aspects to develop a relatively simple mathematical formulation which
included input from glucose-stimulated synthesis of insulin, although
details of the synthesis pathway were omitted. The model, based on dog and
rat data, was normalized with respect to body weight and used to predict
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insulin release in the perfused canine pancreas and in man without para-
meter readjustment (Cabelli et al., 1980). Since the relative glucose
dose-response curves of the rat (Grodsky, 1972) and man (Cerasi et al.,
1974) appear to be significantly different (the sigmoidal glucose dose-
response curve in man saturates at a much higher glucose concentration),
direct interspecies extrapolation on the basis of body weight may be an
oversimplification. Over the years, Grodsky and his coworkers have studied
response of the perfused rat pancreas to a wide variety of -glucose pat-
terns, including step, staircase, multiple square wave, and slow and fast
ramp stimuli. Cumulative results form these studies have provided a broad
basis upon which to elucidate the impartant characteristics of pancreatic
insulin response to glucose. Although the storage (Grodsky, 1972) and
signal (O'Connor et al., 1980) models were partially successful in pre-
dicting the experimental data, the recent combined model (Landahl and
Grodsky, 1962) is the only model that can predict in a semiquantitative
manner all of the regularly appearing dynamic features of insulin response
over this wide range of glucose simuli. In addition, the model of Landahl
and Grodsky is of simple mathematical complexity, while incorporationg a
reasonably high degree of physiologic correspondence with respect to rele-
vant aspects of insulin storage and release.
5) Modeling of Glucose--Stimulated Insulin Release in Man
The pancreatic insulin release model of Landahl and Grodsky (1982) w~s
selected as the basis for modeling in vivo pancreatic insulin secretion in
man. Although simple in form, the model's mathematical structure has pro-
ven to generate accurate predictions of dynamic insulin response over a
very wide range of glucose stimuli in the perfused rat pancreas. In addi-
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tion to its demonstrated performance, the model encompasses a reasonable
degree of physiologic correspondence. For example, in man the normal adult
pancreas contains about 250 U of extractable insulin (Wrenshall et al.,
1951). Since this quantity of stored insulin represents about 5 to 10
times the total normal daily insulin requirement, exclusion of the insulin
synthesis process and the assumption that the quantity of stored insulin in
the pancreas remains quasisteady is well justified. It should be men-
tioned, however, that even though newly synthesized insulin does not begin
to appear in secreted insulin for about 1-2 h following glucose stimulation
of the beta cell, experimental evidence has suggested that, once formed,
new insulin granules may be secreted preferentially (Gold et al., 1982);
thus, during prolonged hyperglycemia, release of newly formed insulin could
conceivably be important even though its relative contribution to the total
quantity of pancreatic insulin remains small. The labile compartment of
the model, which constitutes only a few percent of the tJtal pancreatic
insulin, could represent those insulin storage granules in the cytoplasm of
the beta cell that are associated with the microtubule system. Besides its
apparent physiologic correspondence, antoher advantage of the model is its
direct use of a glucose dose-response relationship as a primary input func-
tion, since such a relationship may be determined experimentally.
The model of Landahl and Grodsky (Figure 49, Equations 137-140) was
modified for human applications by first considering the importance of
basal insulin release in vivo. In normal subjects, basal plasma insulin
concentrations range between about 10-20 mUll. Bagdade et ale (1967)
studied the relationship between fasting insulin levels and insulin
response to glucose in nondiabet~c males. Results indicated that in£ulin
responses could not be evaluated without consideration of fasting insulin
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I~evels because there was a highly significant linear correlation between
basal insulin and insulin response to glucose. In addition, basal insul in
.evels d~d not significantly correlate with fasting glucose concentrations.
The above evidence suggests that pancreatic insulin release should be
modeled in terms of a multipliative scaling of the basal secretion rate,
with the basal release rate being decoupled from the precise fasting level
of arterial glucose concentration. This was achieved by letting
(147)
where
and
B
r p1R = f (basal plasma insulin levels)
(148)
(149)
Here, the insulin secretion rate S(GH) from Equation 140 is normalized with
Brespect to its basal value S(GH = GH). The rate of pancreatic insulin
release rpIR(GH) is then co~puted from multiplying the resulting normalizing
secretion rate SN(GH) by the basal pancreatic release rate r~IR. As denoted
by Equation 149, the basal release rate is determined by factors external to
the pancreas. Specification of fasting insulin levels gives the basal rates
of insulin degradation in t~e liver, kidney, and periphery by ~V~ving the
steady state insulin model mass balance equations (17-23). For steady basal
conditions, the rate of pancreatic insulin release must equal the total rate
B
of body insulin degradation, and thus r p1R can be determined from specifica-
tion of tn~ basal insulin levels.
The second major consideration in adapting the pancreatic release model
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was specification of the nonlinear glucose dose-response relationship X(GH).
The functional relationship used by Landahl and Grodsky for the rat (Figure
50, Equation 145) was obtained from graded glucose step-response data with
the isolated perfused pancreas. The ideal in vivo analog for humans would
require measurement of peak portal plasma insulin responses to step
increases in arterial plasma glucose c~ncentration. Since such data is not
available, the sigmodial shape of the insulin response curve was instead
determined from relative peak plasma insulin concentrations following rapid
intravenous glucose infusio~s of varying doses. Presented in Table 25 is
data for IVGTT experiments in which 3-min glucose infusions were admi-
nistered at doses ranging from 0.05-0.75 g/kg body weight. As indicated by
the data, the graded glucose infusions caused acute increases in venous
glucose levels and elicited rapid plasma insulin responses. Since arterial
rather than venous plasma glucose concentration stimulates pancreatic insu-
lin release in vivo, it was desired to correlate peak insulin responses
against arterial glucose concentration instead of the reported venous qUdn-
tities. Because of its physiolcgic design, the glucose model was used for
the purpose of predicting the peak arterial glucose concentrations induced
by each of the respective glucose dose levels. As shown previously (see
Figure 32), such simulations of plasma glucose levels immeidately following
rapid intravenous glucose administration are insulin insensitive. r10del
~redictions for peak arterial plasma glucose concentrations are listed in
Table 25. Also included in the table are simu~ated values for peripheral
venous blood glucose conce~trations 1 min post-infusion; comparison of
these values with the actual experimental data demonstrates the extreme
accuracy with which the model predicted the observed venous glucose levels
during these simulations. A plot of peak insulin response as a function
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TABLE 25. Tabulation of experiMental data and ~,el st.ulat1ons for variable-dose IYGTT studies. (Experimental data Measured in 15 no~l
subjects at the Joslin Research Laboratory. Boston)
DOSE EXPERIMENTAL DATA MOD£l SI~ULATION(g/kg body weight) ~N·15 no~al subjects}
Venous ·Olood Glucose Venous PlaSlllft InSUlln venous BlOOd GluCOse Arterlal PI&SIII Glucose
Concentration (mg/dl) Concentration (pU/.') Concentration (mg/dl) Concentration (~/dl)
Basal 1 mtn 61sal I .,n. I (;nange 1 .1n. o .'n.
0.05 76 109 18 57 217 113 159
0.1 76 130 17 78 359 128 220
0.2 77 180 19 106 458 177 340
0.33 75 242 19 116 511 246 495
0.5 76 318 19 134 605 315 695
0.75 72 380 21 162 671 371 991
of peak arterial plasma glucose concentration is presented in the upper
panel of Figure 51. The relative insul in response curve was obtained by
linearly rescaling the peak insulin response data such that basal and maxi-
mal responses corresponded to relative responses of 0.2 and 0.9,
respectively; althouQh this was an arbitrary scaling from a mathematical
standpoint, it resulted in a realistic representation in a physiologic
sense. The model function for X(G ) was then determined by fitting the
relative insulin response data in the lower plot of Figure 51 to a function
of the form
(GH)A
X(GH) -. -----
(Ga)A + B(GH)C
where parameters A,B,C, and Go(mg/dl) were adjusted to obtain a least
squares fit (IMSL library computer subroutive ZXSSQ). The resulting
empirical functional fit, given by
(150)
;s shown by the curve in the lower plot of Figure 51. Comparison of the
sigmoidal functions X(GH) for the rat (Equation 145 and Figure 50) and the
human (Equation 151 and Figure 51) indicates that the human insulin response
curve does not saturate at the low glucose levels (about 300 mgidl) observed
to cause saturation of the rat pancreas response. Such behavior is also
suggested by the human insulin secretion function f(g) derived by Cerasi et
al. (Figure 47).
The final step in adapting the insulin rel~ase model involved
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readjustment of the mOu~l parameters Kt at at MIt M2t yt and Qo. In
addition, since good human data for late phase insulin response to prolonged
graded hyperglycemia was not available for quantification of the late
insulin response function P~(GH)' it was assumed (on the basis of Equation
144)
(152)
where parameter 0 was also allowed to vary during parameter adjustment.
Having established the nonlinear glucose dose-response input function X(GH),
model simulations of a standard 0.5 g/kg body weight IVGTT were run and the
above parameter values were varied so as to minimize the difference between
model precdictions and experimental data (N = 110 normal adult males) for
the time course of plasma insulin concentrations over a period of 180 min
following glucose infusion. The IMSL library computer subroutine ZXSSQ was
employed to generate a least squares fit of the nonlinear insulin model
output to the experimental data. Until a pancreatic insulin release model
was developed, IVGTT simulations used for adjust'ing liver metabolism in the
glucose model were performed by arbitrarily fixing the rate of pancreatic
insulin release as a function of time, rpIR(t), such that the plasma insulin
time course in the insulin model matched experimental data (see Figure 30).
In this manner, all insulin model concentrations were maintained at their
proper levels while the glucose physiology was established. Once the glu-
cose model was properly adjusted resulting in matching of the glycemic da~a
during IVGTT simulation, the proper arterial glucose concentration as a
function of time, GH(t), was in turn used as a fixed input during adjust-
ment of the model pancreas parameters.
The resulting parameter set is listed in Table 26. As will be shown
later in the results section, these parameter values yielded an excellent
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TABLE 26. Parameter values for the insulin release model of Landahl and
Grodsky (1982); comparison between rat values and those obtained
for humans by parameter adjustment.
Model Parameters Rat Model Human Model
K(min- 1 ) 0.035 0.00794
a(min- 1) O~O5 0.0482
a(min- 1) 0.6 0.931
M
1
(m;n- 1 ) 0.27 0.00747
M
2
{m;n- 1) 0.9 0.0958
y 0.45 ~g/min 0.575 U/min
Qo 1.2 ].19 6.33 U
0 (2)a 1.11
aNot varied during rat model parameter adjustment (fixed on basis of
experimental data)
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fit of the 0.5 g/kg body weight IVGTT plasma insulin data; a standard F
test analysis of variance gave P<O.Ol for a nonsignificant correlation.
Furthermore, even though it was established on the basis of a single IVGTT
study, the pancreatic insulin release model gave good predictions of plasma
insulin responses to a wide variety of glycemic patterns without any
further readjustment~
The parameter values for the human model were interesting in several
respects. The reference quantity of insulin in the labile compartment Q
o
assumed a value of 6.3 U or roughly 2.5% of the total insulin content of
the human pancreas. This was a reasonable result on a theoretical basis,
since the fraction of labile insulin in the rat model was about 2% of total
pancreatic insulin. In the rat model, the relationship between earl" and
late insulin response was given by 0=2 in Equation 152. Initial attempts
to fix 0 at this value for the human model resulted in failure to attain a
reasonable fit of the IVGTT data. In retrospect, the value of <5 was an
artifact of the scaling of the "relative ll insulin responsE" r:urve of Figure
51; the resulting value of o~l for the human model is significant only with
respect to the scaling of the function X(GH) which was necessarily
arbitrary since data below basal glucose concentrations was not available
for its absolute determination. Although the parameter set listed in Table
26 appeared to be unique with respect to fitting of the IVGTT data, there
was a reasonably high degree of parameter interaction and no formal attempt
was pursued to determine if a global minimum in the least squares parameter
space was truly realized.
The approach employed in the present study was conceptually similar to
that used by Licko and Silvers (1975). Licko and Silvers used a threshold
distribution model of pancreatic insulin release similar to that postulated
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by Grodsky (1972) to analyze human IVGTT data. The insulin release model
was coupled to a single-compartment plasma insulin distribution and metabo-
lism model, and parameters of the insulin release model were adjusted by
regression analysis to fit the observed time course of plasma insulin
response following IVGTT administration in normal subjects. Licko and
Silvers reported that parameter adjustment of the threshold distribution
insulin release model could account not only for mean response of the 26
subjects studied, but also for the variety of observed individual response
patterns (through adjustment of a particular parameter sUbset). Since
earlier threshold distribution insulin release models cannot accurately
account for insulin response over the wide range of glucose stimuli that
can be predicted by the recent mixed model of pancreatic insulin release of
~~ndahl and Grodsky (O·Connor et al., 19~O), the general predictive capa-
city of Licko and Silvers· human insulin release model would be less cer-
tain than that ~f the insulin l~elease model derived in the present study.
A final factor which may be of importance in the modeling of insulin
release involves the recent discovery that basal plasma insulin con-
centrations oscillate in monkeys (Goodner et al., 1977) and in man (Lang et
al., 1982) with a periodicity of 14 min. Such oscillations have been found
to exert a greater hypoglycemia effect than maintenance of similar constant
mean plasma insulin levels (Matthews et al., 1983). Since receptors become
less sensitive to hormonal stimuli when exposed to high steady con-
centratons, it has been suggested (Matthews et al., 1983) that oscillatory
hormonal stimuli could help to maintain receptor integrity. The regulatory
factors producing the oscillations in pancreatic insulin release have not
been identified. One possibility ;s local islet regulation by autonomic
nervous control. Alternately, a paracrine control system involving complex
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relationships between alpha, beta, and delta celi hormonal interactions
could be involved J since basal plasma glu~agon concentrations also
oscillate with the same periodicity as insulin levels but with a phase lag
of 2 min (Lang et al., 1982). The possible role of basal somatostatin has
not been investigated. Since neither the exact oscillatory nature of insu-
lin release in man nor its physiologic significance have yet been deter-
mined, no attempt was made to introduce oscillatory behavior into the
present model of pancreatic insulin release.
6) Comparison of Pancreatic Insulin Release Models
Because insulin release data is not available for the perfused human
pancreas, there is no basis for direct comparison of model predictions with
experimental data for known or controllable glucose stimuli. In vivo data
relating arterial glucose concentration to plasma insulin response requires
some interpretation. Since portal vein measurements are not attainable,
insulin released from the pancreas must pass through the liver, a major
site of insulin clearance, prior to systemic detection. Furthermore, hepa-
tic venous effluent mixes with venous blood from other organ and tissue
regions in passing through the cardiopulmonary system. The relationship
between pancreatic insulin release and observable quantities such as
arterial or peripheral venous plasma insulin is thus rather complicated,
involving both dynamics of circulatory distribution and tissue clparances.
As a result of the complexities involved in interpreting the plasma
insulin appearance data, models of insulin distribution and metabolism are
generally employed to determine the pancreatic insulin release dynamics
upon which the parameters of the insulin release model are then based.
From a quanitative standpoint, insulin release models are thus no stronger
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than the insulin distribution and metabolism models with which they were
coupled during parameter adjustment. In the present study, effort was
taken to formulate and independently quantify all aspects of the insulin
model external to the pancreas prior to parameter adjustment of the insulin
release equations. The importance of sv:h independent quantification of
internal model processes cannot be overstated. For example, of the recent
physiologic models only in that of Cramp and Carson (1981) was insulin
removal from plasma assumed to be a non1 inear process; it is interesting,
bu~ not surpr;~;ng, that this was also the only model in which pancreatic
insulin release was assumed linear. The mathematical ease with which nonu-
nique internal components of a model can be couplect to produce an obser-
vable nonlinear output relationship is the major concern in development of
complex physiologic sj·stem representations.
Attempting to compare the different insulin release models on a commop
basis was difficult because of differences in the operational and struc-
tural characteristics of the respective models. The best data base upon
which to elucidate some of the basic characteristics of pancreatic insulin
response to glucose is provided by the rat pancreas perfusion stUdies of
Grodsky et al. One approach to comparing insulin release model would be to
fit the parameters of all of the models to the rat data and to determine
how the model fits compared with experimental data. However, there are a
number of problems which arise in attempting to cOlnpare recent human insu-
lin release models on this basis: 1) the model of Cobe:li et ale (1980)
has no definable steady state for an initial glucose concentration of zero,
and the relationship between the nonlinear dose-response function for this
model and its derivation from experimental data is unclear; 2) the model of
Guyton et al. (1978) has 6 nonlinear input functions in addition to a
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number of parameter values that could not be determined a priori from the
available rat data; and 3) the model of Cramp and Carson (1981) has no
dose-response saturation due to its linearized formulation, and thus selec-
tion of a single glucose level at which to quantify the absolute magnitude
of insulin response would be rather arbitrary. In this section, recent
models ~f human pancreatic insulin release are instead compared byexa-
mining their dynamic response characteristics to patterns of glucose stimu-
lation analagous to those employed in the rat panGrpas perfusion studies in
the literature. This approach allows a direct qualitative comparison bet-
\'1een the general response characteristics of the human insul in release
models together with an indication of the desired response behavior as
exhibited by the experimental response data of the rat pancreas.
Comparison on this basis provides a meaningful assessment of the human
models' relative capacities to predict successfully observed charac-
teristics of insulin response over a wide range of glucose stimuli.
The human insulin release models were treated as the isolated pel~fused
pancreas for these simul at ion~. 5i nce di ffet-ent models used di fferent
basal glucose steady state set points and respective insulin release rate
outputs, the first step was to define a common basis for comparing model
responses. Although the baseline or initial glucose stimulation level in
the rat studies was a mg/dl, the model Jf Cabelli et al. (1980) had no
definable steady state at this glucose concentrationo For the human per-
fusion simulations, a baseline glucose input of 100 mg/dl ~as selected, as
this represents a typical basal arterial plasma glucose level. All of the
insulin release models had a steady state secretion rate for a glucose
input of 100 mg/dl, but these values varied from model to model (see Table
27). Insulin release rates were thus normalized with respect to values at
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TABLE 27. Comparison of steady state 1nsuli~ model release rates for a
glucose 1np~t of 100 mg/d1.
Modal
Guyton et al., 1978
Cabell; et a1., 1980
Cramp and Carson, 1981
Landahl and Grodsky, Adapted
Insulin release rate (mU/min)
14.0
24.5
a70 kg body weight, GO =91.5 mg/dl in Equations 3 and 4
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a glucose input of 100 mg/dl, i.e. insulin reledse rates were expressed by
Normalized Insulin Release Rate
for model comparisons.
(153)
Experimental results and model predictions for insulin response to
multiple glucose step changes are presented in Figure 52. General response
characteristics are demonstrated by the rat pancreas perfusion data in the
upper left plot. Simulated response of the rat pancreas using the model of
Landahl a~d Grodsky (1982) is included for comparison in the lower left
plot. Model predictions for human pancreatic respcsne to a similar pattern
of glucose stimulation are shown in the figures to the right. For the ini-
tial step increase in glucose, all of the models yielded a biphasic
response in insulin release, although the characteristic gradual increase
1n the rate of second phase release was not predicted by the model of Cramp
and Carson. As shown by the rat data, repetition of the step increase in
glucose following a short interim period elicited a greater insulin
response. Similar potentiation of insulin release on repeated stimulation
by glucose has been observed in mdn (Ceras; et al., 1974). The models of
Landahl and Grodsky and Cobelli et al. predicted this potentiation effect
of glucose exposure, whereas the model of Guyton et al. gave diminished
response and that of Cranlp and Carson yielded identical response. In com-
paring the human models there is roughly an order of magnitude difference
in the predicted range of relative insulin responses. This cannot be
ex;>lained by the differences in respective release rates for a glucose
input of 100 mg/dl. The low response predicted by Cabell; et ale can be
primarily attributed to rapid saturation of the glucose dose-response curve
used in this model; a step increase in glucose concentration as small as
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Fig. 52 Experimental data (rat) and model predictions (rat and human)
for insulin response of the perfused pancreas to multiple
glucose step changes.
from 100 mg/dl to 120 mg/dl essentially elicits maximal initial insulin
response. The linear release model of Cramp and Carson, on the other hand,
does not incorporate any dose-response saturation, and thus predicts much
greater relative insulin response at high glucose concentrations.
Insulin response to a 50 mg/dl staircase glucose stimualtion pattern
is shown in Figure 53. For the rat, each successive step increase in glu~
case concentration elicited a rapid spike response (above the threshold
glucose level of 50 mg/dl). Staircase glucose stimulations of insulin
release inman have induced similar early phase insulin release charac-
teristics (Karam et al., 1974)5 Depletion of the labile insulin compart-
ment by the initial glucose step in the model of Cobell; et ale resulted in
the appearance of only one spike response. Both the models of Guyton et
al. and Landahl and Grodsky predicted successive response spikes 0f
decreasing magnitude. This is quite reasonable considering the glucose
range being tested. For both the rat and man, the most sensitive region of
the glucose dose-response curve lies between 100 and 150 mg/dl, and thus
the step increase in glucose from 100 to 150 mg/dl should be expected to
ca~se the maximal response in both cases, with decreasing release for glu-
cose steps to either side of this range. Noting that the first step
increase in the human simulations corrsponds to the maximal step response
in the rat studies, the step responses for human release should decrease
with each successive glucose step. This is contrary to the linear response
predictions of Cramp and Carson's model which will always increase with
glucose concentration.
Insulin response to a slow glucose ramp of about 5 mg/dl ~in is pre-
sented 1n Figure 54. Again, due to differences in the glucos~ ranges
covered and the relative shapes of dose-response curves, comparison between
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Fig. 54 Experimental data (rat) and model pr~d1ct1ons (r~t and human)
for insulin response of the perfused 9ancreas to a slow ramp
glucose stimulation of about (5 mg/dl)/min.
the rat data and human response predictions is difficult. Of interest is
the comparative sensitivities of the human models for triggeril~g of first
phase insulin release. Whereas the small 5 mg/dl ~in increa~e in glucose
concentration elicited a distinct spike response similar to those caused by
a step change in glucose concentration from the model of Cabelli et al.,
the contributon of first phase release was practically negligible in the
response predicted by the model of Cramp and Carson. The model of Landahl
and Grodsky yielded a subtle but noticeable initial first phase contribu-
tion, while that of the model of Guyton et al. was less subtle and
displayed rather unstdble characteristics. Since the glucose ramp was ini-
tiated at a glucose level of 100 mg/dl in the human simulation and this is
a region of maximum dose-response sensitivity, it would seem reasonable
that some degree of first phase releas,~ could be triggered. The shape of
the rat response data over this glucose region, however, would s~ggest that
such a contribution would most likely not be dominant. The response pre-
dicted by the model of Landahl and Grodsky would thus appear to be the most
realistic.
Insulin response to a faster glu:ose ramp of about 50 mg/dl ~in is
shown in Figure 55. Here the rate of in~rease in glucose concentration was
clearly sufficient to induce first phase response characteristics with peak
release occurring prior to attainment of the maximum glucose level. This
behavior was predicted with varying degrees of success by all of the human
model except that of Cramp and Carson for which the maximum release rate
coincided with termination of the glucose ramp at the maximum plateau
level. The peak rsponse predicted by the model of Cabell; et ale occurred
within 1 min of initiating the glucose ramp and was identical to the maxi-
mal response elicited by an instantaneaous glucose step increase to 500
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Experimental data (rat) and model predictions (rat and human)
fQr insulin response of the perfused pancreas to a fast ral~~
glucose stimulation of about (50 mg/d'I)/mfn.
mg/dl (refer to Figure 52). The peak response rates predicted by the
models of Landahl and Grodsky and Guyton et ale were delayed relative to
those elicited by an instantaneous glucose step increase, a characteristic
supported by the rat data.
In general, the pancreatic insulin release model of Landahl and
Grodsky was the most successful ir. predicting the characteristics of insu-
lin response, its positive attributes not having been affected by human
parameter readjustment. The model of Cobelli et al. appeared overly reac-
tive, giving essentially a similar maximal biphasic insulin response to all
glucose stimuli. In addition, this model lacked the capacity to produce
rapid successive first phase spike responses to a staircase glucose stimu-
lation. The model of Guyton et ai. did not demonstrate expected poten-
tiation characteristics and was somewhat unstable with respect to first
phase insulin release during a gradual rise 1n glucose concentration.
Finally, the simplistic linear model of Cramp and Carson did not predict
any of the more subtle features of pancreatic insulin release and displayed
unrealistic trends in relative response magnitudes due to omission of a
sigmoidal dose-response characteristic.
0) Distribution of Glucagon in the Body
The total distribution volume for glucagon in the human body may be
assumed to equal that for insul in. Thus, summing the vascul ai' and
interstitial fluid volumes of the insulin model gives a glucagon distribu-
tion volume of 11.31 1.
P} Heterogeneity of Plasma Glucagon
Glucagon is a single polypeptide of 29 amino acids with a molecular
weight of 3,485. Measurements of plasma glucagon by radioimmunoassay was
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pioneered in the late 1950·5 (Unger et al., 1961). It was later disco-
vered, however, that most of these antisera were not specific to pancreatic
glucagon and cross-reacted with a protein called gut glucagon-like immu-
noreactivity (GLI) (Moody, 1972). It was not until the late 1960·5 that a
specific antiserum for pancreatic glucagon was discovered (Eisentraut et
ale 1968). Since plasma GLI may comprise more than 90% of the total plasma
"glucagon" measured with the nonspecific antiseria (Unger et al., 1970),
the quantitative validity of early studies with respect to measured values
of plasma glucagon in man is questionableo
Subsequent to development of specific radioimmunoassay techniques, it
has become evident that plasma immunoreactive glucagon (IRG) exists in a
number of different forms in both normal sUbjects and patients with a
variety of disorders (Jaspan and Rubenstein, 1977). Circulating IRG con-
sists of as least four fractions: 1) < 2,000 daltons, 2) 3,500 daltons, 3)
9,000 daltons, and 4) > 40,000 daltons. The biologic significance of frac-
tions other than the 3,500-dalton moiety (true glucagon) has not been
established. After an overnight fast, the basal IRG level of a normal
individual is about 75 pg/ml ~ of which only about 25 pg/ml is true glucagon
(Unger and Ore;, 1976).
Unfortunately, the glucagon model must be formulated from reported
observations of IRG levels since distiction between the component fractions
seldom appears 1n the literature. Thus the "glucagon fl model predicts IRG
levels, which in turn are used for correlating physiologic response in the
glucose model. Thus, the distinction between biologically active glucagon
and total measured IRG response is also lost in the model formulation. For
example, elevation of glucose and insulin levels following a 100 9 oral
glucose load results 1n almost complete supression of true glucagon levels
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in the circulation (Kuku et al., 1976); measured IRG concentrations seldom
decline below about 50 percent of the fasting level, however, because the>
40,OOO-dalton moiety remains essentially constant under these conditions.
The glucagon model predicts this change in IRG concentration by assuming a
50 percent reduction in pancreatic IIglucagonll release. In the future, it
may be possible to develop a model which directly predicts circulating
levels of active glucagon, but such a formulation will require additional
research to distinguish the relative fractions of IRG and their signifi-
cance under various physiologic conditions.
Q) Metabol ic C1 earance of G1 ucagon
Plasma IRG is primarily cleared by the liver, which extracts only the
3,500-jalton component, and ttle kidney, which metabo'lizes both the
3,500-dalton fraction (by g~omerular filtration and peritubular uptake) and
the 9,ODO-dalton component (by. peritubular uptake) (Jaspan and Rubenstein,
1977). Fisher et al. (1976) have studied the whole-body metabolic
clearance rate (rMrC) of glucagon by continuous infusion of crystalline
glucagon in postabsorptiv2 subjects; over the plasma IRG concentration
range studied (200-600 pg/ml), glucagon removal was a linear function of
plasma concentration with a mean calculated metabolic clearance rate of
13.5 ± 0.6 rnl/kg-min based on results of 32 studies. Similar results have
been reported by Al ford et al. (1976) 'For studies in 9 normal subjects.
Therefore, the metabolic clearance r~te rMrC for an average 70 kg man is
about 0.91 l/min, and the total rate of plasma glucagon clearance from the
body rprC was expressed
(154)
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R) Pancreati c Gl ucagon Rel ease
Glucagon is secreted by the a? cells of the islets of Langerhans of
'-
the pancreas. Secretion of glucagon is regulated by a number of factors,
including substrate and hormonal levels, and neural stimuli (Foa, 1972;
Unger, 1976; Gerich, 197Ga). For situations of interest here, the major
factors infl uenc i ng gl ucagon secreti on woul d be g1 ucose and insu'J in con-
centrations in arterial blood (Gerich, 1976). Amino acids (Rocha et al.,
1972; Ohneda et al., 1968), particularly arginine and alanine) stimulate
glucagon release. Following ingestion of a mixed meal, amino acids derived
from the protein probably constitute an important stimulus for glucagon
secretion (G~rich, 1976); in this situation~ glucagon release is believed
to prevent hypoglycemia secondary to aminogenic insulin secretion (Unger et
al., 1969). Conditions of stress, such as trauma or infection, are asso-
eiated with hyperglucagonemia (Unger, 1971; Bloom, 1973); in such cases,
central nervous system· response and increased secretion of adrenomedullary
catecholamines playa key role.
Glucose and insulin are inhibitors of pancreatic glucagon release. Of
primary physiologic significance is the glucagon-stimulating effect of
hypoglycemia which signals the liver to increase glucose output. The
effects of gl ucose and insul in on pancreatic IRG secretion were model etj in
terms of basal multiplying factors,
(155)
Under quasi-steady conditions, the plasma IRG level is constant, and the
rate of glucagon release equals its rate of clearance (Equation 24),
(156)
206
Thus, for the basal state,
(157)
and the basal ro~e of release can be determined directly from the basal IRG
concentrJtion. In addition, since the rate of glucagon clearance is
proportional to the plasma IRG concentration,
(158)
Therefore, for any change from the basal to a quasi-steady state, the nor-
malized change in plasma IRG concentration dir~ctly reflects the normalized
change in pancreatic IRG release.
Presented in Table 28 is pancreatic IRG release rate data correlated
form results of studi~s reported in the literature. The data were compiled
from various studies of normal subjects in which plasma IRG levels were
reported in response to 1) insulin-induced hypoglycemia (Gerich et al.,
1974c; Sacca et al., 1979), 2) euglycemic hyperinsulinemia (Raskin et al.,
1975), and 3) hyperglycemia caused by glucose infusions alone (Unger et
al., 1970) or combined glucose-ins~lin infusions (Raskin et al., 1975).
Also included are data of Palmer and Ensinck (1975) for glucagon response
to ethanol-induced hypoglycemia in normal subjects; since ethanol inhibits
hepatic gluconeogenesis, ethanol consumption results in combined hypoglyce-
mia and hypo;nsulinemia. In the table, normalized rates of pancreatic glu-
cagan release were computed directly from reported plasma IRG
concentrations (see Equation 158). It wa3 desirable for modeling to corre-
late dat~ in terms of arterial glucose and insulin levels since alpha-cell
response results from sensed changes in the arterial plasma concentrations
of blood perfusing the pancreatic islets. From the steady £tate peripheral
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TABLE 28. Correlation of literlture dltI reli;ttng pancreatic gluclgon relelse to arterial glucose ..nd tnsultn levels.
No....,tzed Nonultzed Norultzed
PllS111 IRG Plncrelttc Venous P11S111 Arterial Venous Plaul Arterial
Cone." r Glucagon Insultn Cone. PlaSilI Gl ucose Cone •• Plawl(P9/·
'
) Relelse (IIU/l ) Ins."tn (lig/dl ) Glucose
Jllte.t Cone •• tt Cone •• ttt
Reference Subjects 81511 Steldy N BISI' Steady IN Blsal Steady GNr prR l L
Unger .t ., •• 1970 8 100 57 0.57 8 46 5.8 90 250 2.9
Sdrtch et 11 •• 1974 15 150 420· 2.8
- -
(>5)b 85 35 i I 0.453 160 75 0.47
- -
(~)b 88 175 2.1
Riskin at ., •• 1975 10 75 52 0.67 8 40 5.0 75 75 1.1
5 73 44 0.60 8 45 5.6 80 150 !.9
Palmer I Ensinck. 1975 6 57 58c 1.2 10 SC 0.5 90 SOC 0.91
l00d 1.8 Sd 0.5 71 d 0.79
2608 4.6 2e 0.2 Sse 0.61
Slcel et 11 •• 1979 6 140 155 1.1 11 26 2.4 90 68 0.12
5 100 220 2.2 8 43 5.4 87 5S 0.63
Esti.ated f~: tEquation 168; ttEqultlon 171; tttEqultion 176
~an Quist-steady vllue: t • 30-60 .fn
bAss.ed (dati not reported)
QUist-steady Yllues: ct· 44hi dt • 56h; It • 60h
compartment insulin mass balance (see Equation 107),
(159)
Solving for arterial insulin concentration gives
(160)
It t!IUS fo11 ows
(161)
and normalized arterial insulin concentrations were therefore calculated
directly from reported peripheral venous insulin concentrations in Table
28. The peripheral compartment glucose mass balance equations (15-16) at
steady state give
(162)
(163)
from which it follows
(164)
Solving for arterial glucose concentration yields
(165)
and thus normalized arterial glucose concentration is given by
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(166)
Normalized arterial glucose concentrations in Table 28 were calculated from
reported peripheral venous values using this expression to correct for the
effects of peripheral glucose uptake. In these computations, rates of
peripheral glucose uptake at the prevailing glucose and insulin levels of
each study were estimated using the model functions for this metabolic pro-
cess (Equations 50 and 51).
Presented in Figure 56 is a plot of normalized pancreatic glucagon
release rate as a function of normalized arterial glucose concentration.
Data points in the figure represent values correlated in Table 28 from stu-
dies in the literature. The glucose and insulin mUltiplier functions of
Equation 155 were assumed to have the hyperbolic tangent form of Equation
27, and parameters were adjusted to obtain a least squares fit of the
multiplier functions to the experimental data (IMSL library computer
subroutine ZXSSQ). Results of the parameter adjustment yielded
M~rR = 2.93 - 2.10 tanh[4.18 (G~ - 0.61)]
~~rR = 1.31 - 0.61 tanh[I.06 (I~ - 0.47)]
(167)
(168)
for the effects of arterial glucose and insulin levels on pancreatic gluca-
gon release rate, respectively. The glucose multiplier function M~rR is
shown by the curve in Figure 56. The isolated effects of arterial insulin
on pancreatic glucagon release rates are shown in Figure 57. Here, using
the glucose multiplier function of Equation 167, values of the insulin
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Fig. 56 Plot of normalized rate of pancreatic glucagon release as a
function of normalized arterial glucose concentration. The
curve fnrl1cates the model function for the effect of arterial
glucose concentration on pancreatic glucagon release (Equation
167). .
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multiplier for each of the
puted from Equation 155
N
I r prR~1prR ---
G
'.1 p rR
data points (Table 28 and Figure 56) were com-
(169)
and these values were plotted versus normalized arterial insulin concentra-
tion. The curve in Figure 57 indicates the insulin multiplier function of
Equation 168. As shown in Figure 58, the moiel multiplier functiQns for
the effects of arterial glucose and insulin concentration yielded good pre-
dictions for the rate of pancreatic glucagon release over the range of
available data.
S) Summary of Model Equations, Parameter Values, and Mathematical
Nomencl ature
In this section, a complete summary of the mathematical model is pro-
vided, including the differential mass balance equations, the metabolic
source and sink function equations, all parameter values in their proper
units, and a reference summary of the mathematical nomenclature employed
for defining the variables i,1 the no r1T':a 1 model.
Gl ucose Model
Mass Balances:
BRAIN:
HEART AND LUNGS:
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GUT:
LIVER:
KIDNEY:
PERIPHERY:
v~ (G - G )G PV PI
Tp
Metabolic Sources and Sinks:
rBGU ~ 70 mg/min (constant)
rRBCU~ 10 mg/min (constant)
rGGU = 20 mg/min (constant)
1GB
r pGU = MpGUMpGUrpGU
r~GU = 35 mg/min
I NMpGU = 7.03 + 6.52 tanh[O.338{I p1 - 5.82)]
r~GP = 155 mg/min
\1 = 25 mi n
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I~ NMHGP = 1.21 - 1.14 tanh[1.66(I L - 0.89)1
~'~P = 2. 7 tanh[ o. 39 ~]
r~ ro _ 1
!!..-[f..] =.!..- [( HGP ...
dt l. 1:r 2
T r = 65 mi n
G NMHGP = 1.42 - 1.41 tanh[0.62(Gl - 0.497)]
I~ . NMHGU = 2.0 tanh[O.55 IL]
M~GU = 5.66 + 5.66 tanh[2.44(G~ - 1.48)]
( ., {71 + 71 tanh[O.11(GK- 460)] 0, GK< 460 mg/minrKGE mg/min J =
-330 + 0.872 GK GK) 460 mg/min
Pa rameter va 1ues :
G 3.5 dl Q~ 5.9 dl/min TB = 2.1 minVBV :::: =
VBI = 4.5 dl QG = 43.7 dl/min TG = 5.0 minH p
VG = 13.8 dl QG = 2.5 dl/minH A
VG = 25.1 dl QG = 12.6 dl/minL L
G 11.2 dl QG = 10.1 dl/minVG = G
216
f"
V - 6.6 dlK -
GVpV= 10.4 dl
Variables:
QG = 10.1 dl/minK
Q~ = 15.1 dl/min
NO'~ENCLATURE
G = glucose concentratiolt (mg/dl)
Q = vascular blood water flow rate (dl/min)
r = metabolic source or sink rate (mg/min)
M = multiplier of basal metabolic rate (dimensionless)
T - transcapillary diffusion time constant (min)
v = volume (dl)
T = time constant (min)
t = time (min)
First Subscript: Physiologic Compartment
B = brain
G = gut
H = heart ar.d 1ungs
L = liver
p = periphery
(A = hepatic artery)
Second Subscript: Physiologic SUbcompartment (if required)
I = interstitial fluid space
v = vascular blood water space
Metabolic Rate Subscripts:
BGU = brain glucose uptake
GGU = gut glucose utilization
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HGP = hepatic 91 ucose production
HGU = hepatic glucose uptake
KGE = kidney glucose excretion
PGU = peripheral glucose uptake
RBCU = red blood cell glucose uptake
First Superscript
G = glucose model
I = insulin
r = glucagon
B = basal value
N = normalized value (divided uy basal value)
Second Superscript
o = initial value (normalize~ value as t + 0+)
~ = asymptotic or final steady state value (normalized)
Insu" in Model
Mass Ba1ances :
BRAIN:
I dIS IVa - = QB(I H - Ia)dt
HEART AND LUNGS:
I d I H I I I QI T IVH- = QBIS + QLIL + n;<I K+ p"'PV- QHI Hdt
GUT: I dIG IVG- = QG(I H - IG)dt
LIVER:
I d I L I I IVl - = QAI H + QGI G - QLI L + r pIR- r LICdt
KIDNEY: I d I K IVK- = QK (I H - l K) - r K1Cdt
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I dI PV I VPERIPHERY: VpV -- = Qp (I H - IpV ) - ~ (I - Ipl )dt I PVTp
dI pI VpI Ipl )Vp1 -- = - (I pV - - r pICdt T1p
Metabolic Sources & Sinks:
I I
r L1C = FL1C[QA1H + QGI G + r pIR]
FL1C = 0.40
I
r K1C = FK1C[QK1K]
FK1C = 0.30
I-F pIC 1 r
l
[( -- )( -,. ) - (-p )]
FpIC Q~ Vp1
FpIC = 0.15'
[pancreatic insulin release model]
dIat = a[X-I]
~ = K( Q- Qo) + yP - S
0+ .
S = [M1Y + M2(X-I) ]Q
(G )3.27
X = H
(132)3.27 + S.93(GH)3.02
p = Y= (X)I.11
00
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P = potentiator (dimensionless)
I = inhibitor (dimensionless)
Q = labile insulin (U)
S = secretion rate (U/min)
X,y,p~ = intermediate variables (dimensionless)
Constants: 0.0482 min- 1 M2 =
· -1
= 0.0958 mln
= 0.931 min- 1 = 0.575 U/mi n
K = 0.00794 min- 1 Qo = 6.33 U
M1 = 0.00747 min-
1
Parameter values:
VI
= 0.26 1 QI = 0.45 l/m;nB B
VI
= 0.99 1 QI = 3.12 1/minH H
VI
= 0.94 1 Q~ = 0.18 l/minG
VI
= 1.14 1 QI - Oc72 l/m;nL K
VI
= 0.51 1 Q~ = 1.05 llminK
I 0.74 1 QI 0.72 1/minVpV = =G
Vp1 = 6.74 1 QI = 0.90 1/m;nL
NOMENCLATURE
Variables:
I = insulin concentration (mU/dl)
Q = vascular plasma flow rate (l/min)
r = metabolic source or sink rate (mU/min)
F = fractional cleardnce (dimensionless)
T = transcapillary diffusion time constant (mi n)
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r I = 20 mi np
v = va1ume (1)
t = time (min)
First Subscript: Physiologic Compartment
B = brain
G = gut
H = heart and lungs
L = liver
p ::: periphery
(A = hepatic artery)
Second Subscript: Physiologic Subcompartment (if required-l
I = interstitial fluid space
v = vascular plasma space
Metabol ic Rate Subscri pts :
KIC = kidney insulin clearance
LIe = liver insulin clearance
PIC = peripheral insulin clearance
PIR = pancreatic insulin release
First Superscript
I = insulin model
B = basal value
61 ucagon ~1odel
Mass Sa1ance:
Metabolic Sources &Sinks:
rMrC = 9.10 ml/min
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M~rR= 2.93-2.10 tanh[4.18(G~ - 0.61)J
M~rR= 1.31-0.61 tanh[1.06(I~ - 0.47)J
Parameter val ues: vr = 11310 ml
NOMENCLATURE
Variables:
r = glucagon concentration (pg/ml)
V = glucagon distribution volume (ml)
r = metabolic source or sink rate (pg/min)
M = multiplier of basal metabolic rate (dimensionless)
t = time (min)
Metabolic Rate Subscripts:
Pre = plasma glucagon clearance
MrC = metabolic glucagon clearance
PrR = pancreatic glucagon release
First Superscript
G = glucose
I = insul in
r = g1 ucagon
B = basal value
N = normalized value (divided by basal value)
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III. LITERATURE MODELS OF GLUCOSE METABOLISM
A} Review of Literature Models of Glucose Metabolism
Early mathematical models of glucose metabolism used a linearized two-
compartment formulation as originally postulated by Bolie (1960). The
model of Atkerman et al. (1965)(Gatewood et al., 1968), shown in Figure 59,
provides an example of this u~proach. Here, glucose in the blood was
represented by one compartment (labeled G) and insulin in the blood by a
second compartment (labeled H). Glucose was assumed to enter the blood
from the intestines at a rate J(t) following an oral dose (model input)e
In response to this stimulation, glucose and insulin were known to appear
and disappear from the bluod as a result of various metabolic processes in
the body (identified by solid arrows in the figure). In order to minimize
mathematical complexity, these metabolic sources and sinks were assumed to
cdd or remove glucose and insulin at rates proportional to the levels of
glucose and insulin in the blood compartments. Concentrations of glucose
(G) and insulin (1) in the blood were determined qy writing mass balances
for the blood compartments, given by
(170)
(171)
where VB is the volume of the blood compartments, and coefficients mi are
the rate constants for the respective metabolic sources and sinks defined
1n Figure 59. In order to estimate values for the rate constants, Ackerman
et al. assumed a functional representation for the gut glucose input rate
J(t) anj matched predictions from Equations 170 and 171 with experimental
data for the time courses of glucose and insulin during oral glucose
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Linearized two-compartment glucose metabolism model of Ackenman
et al. (1965). .
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tolerance tests. Similar methods wer~ later employed by Segre et al.
(1973) to estimate a set of linearized rate constants for predicting blood
glucose and insulin concentrations during intravenous glucose tolerance
tests. As acknowledged by the authors, these second-order mathematical
mo~els were extremely simplified representations of the glucose regulatory
system, particularly with respect to linearization of the metabolic rate
functions; for example, use of linearization required omission of urinary
removal of glucose, because this metabolic process was known to occur only
above a threshold level of blood glucose concentration. In addition, the
method of using a single input to establish the response characteristics of
a model mayor may not yield a representation which is adequate in pro-
viding a general description of response rver a wider spectrum of inputs.
The model of Charette et al. (1967) was one of the first to incor-
porate nonlinear representatio~s and multihormonal control in describing
the glucose mptabolic system (for a comprehensive review of earlier models,
see Char~tte et al., 1969). A schematic representation of this model in
control system block diagram form (Laplace space) is shown in Figure 60.
The mathematical equations for this system were given by
~ [C]= -KI9C + K18[F+fLO{C,X2}-fLU(C,XI'Y3}-fR(C}-fU(C,X2}-GU] (172)
~ [XI]= -KaXI+ K7 [I+fl(C}] (173)
~ [X2]= -K11 X2 + K10[G+f2(C)] {175}
where: C = Pl asma G1 ucose Concentration
Xl = Pl asma Insulin Concentration
X2 = Plasma Glucagon Concentration
Y3 = Liver Glycogen Content
F
-
Intravenous Glucose Input Rate
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Fig. 60 G'ucose metabolism model ~~ Charette et al. (1967) shown in
control system block dfag)·~ fonn (lapl ace space). (From
Charette et al •• 1969)
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GU = eNS Glucose Utilization Rate
I = Intravenous Insulin Input Rate
G = Intravenous Glucagon Input Rate
f LC (C,X 2) = Liver Glucose Output Rate
f LU (C,X1 'Y3) = Liver Glucose Uptake Rate
fR(C) = Renal Excretion Rate
fU(C,X1) = Insulin-Dependent Peripheral Tissue Glucose Uptake Rate
f 1(C) = Insulin Secretion Rate
f 2(C) = Glucagon Secretion Rate
K18,K7,KIO = Circulation Volumes
K19,KS,K11 = Inverse Degradation time Constants
In this model, single compartment representations were included for plasma
glucose, insulin, and glucagon, respectively, with an additional equation
used to monitor liver glycogen content. Hormonal secretion rates f i were
expressed in terms hyperbolic tangent functions of the plasma glucose
concentration, and glucose metabolic rates f were given by nonlinear
functions of the plasma glucose and hormone levels. The system was defined
to represent a normal, 70 kg unstressed adult. Model parameters were
obtained from intrepretation of the literature, and refined by simulating
glucose and insulin infusion experiments.
The glucose homeostatis model of Foster et ale (1973) (Foster, 1970)
is shown in Figure 61. In this model t glucose metabolism was formulated in
terms of three compartments, representing blood glucose, liver glycogen,
and muscle glycogen. In addition, single compartment representations were
included for plasma insulin, glucagon, and free fatty acids. The nonlinear
metabolic process~s causing addition or removal of substances from their
respective compartments are identified in the figure. The mass balance
equations for this model were given by
%t[GG] = INJ-U-NSU-RBCU+GLUNEO+GLYO-GLYS-ATU-MU+LULAC
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(175)
F'1g. 61
F~•• l S,mbola: Th. ='8CUnll•• repre..nt level. (I•••, amounts-units
.,. In m•••, viz., ml, mEq., etc). Tho decaCltf)r-.haped filur.s rep-
r••ent rate. (I.e., ml/mln, etc.). The Imall ",,,"I., shapee ,epr.·
Hnt compartments. (The number••'11 computer protrammlnl
d••ilnallons and c.n be diare••rded.)
The ba.lc f.atur•• alld components of the mod., for glUCose home-
••t.ai. are .hown with a provl.ion for 'ntravenoul perturb.tlon. with
,'ucom. (lNJ). The ,Iuco.eln the ,Iuco•••pace (GG) can e:dt or enter
••• mUltipl. p.ttlwa,. Ineludin, urine los. (U), nervoua .,.tam up-
tak. (NIU), red blood cell uptake (R.CU), ,luconeogen••ls (GLU-
NEO), adlpo.e U••u. L!~lIlzatJon (ATU), or muscl. uptllt. (MU).
P.rlph.r.' .'ueo•• Itora,. (p4!]S) II prlmarll, mUlcle. Muscle re-
I•••• 0' lacut. (MRLAe) and IIv., uptake of lacute (LULAC) ar.
Ihown. In addition, provl.'on I. m.de for mUlel. utilization of Ilu-
eose '0' .n.rIY (PEG).
The hepatic ,'ueol. uptake rat. COLYS), fI.p.tlc glucose r.I••••
rate (Ga. YO) and ,I,c..en br.akdown ,at. (GLY8) regulate the h.patlc
IlrcOI.n stor•• (GLYLIV).
Th. amount 0' inlulln In the glucos. space (I) I. re,ul.ted by tho
In.ulln ••cretlon r." (IS!C) and In.ulln d.I,.d.tlon r.t. (IDEC).
Similarly. the amount of glucagon In the Ilucos••pace (0) II r..gu-
lated by bo.h ttl. glucagon ••cr.tlon rate (GSEC) and the ,Iucagon
d••radatlon r." (GDEG}.
Th. fr•• fatty acld.'n the fr•• fatty .cld Ipace ('FA) ar. regUlated
by both the fre. 'alty acid production rate (FFAP) and the 'ree fatty
acid utlllzatioft r." (FFItU) (frOlil ref.nnce (11]).
Physiologic model of glucose metabolism as formulated by Foster
et a1. (1973).
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~[GLYLIV] = GLYS-GLYB (176)
~[PGS] = MU-PEG-MRLAC (177)
-h:[FFA] = FFAP-FFAU (178)
keG] = GSEC-GDEG (179)
-h:[ I] = ISEC-IDEG (180)
where: GG = 61 ucose in G1 ucose Space
GLYLIV = Liver Glycogen
PGS = Peri pheral Ti ssue G1 ucose Stores
FFA = Free Fatty Acids in FFA Space
G = 61 ucagon in G1 ucagon Space
I = Insulin in Insulin Space
INJ = Intravenous G1 ucose lnfus; on Rate
U = Uri nary G1 ucose Loss Rate
NSU = Nervous System Glucose Uptake Rat~
RBCU = RBC 61 ucose Uptake Rate
GLUNEO = Rate of Glucose Production by Liver Gluconeogenesis
GLYS = Rate of Glucose Conversion to Liver Gl.ycogen
GLYO = Rate of Glucose Production from Liver Glycogen Breakdown
ATU = Adipose Tissue Glucose Uptake Rate
MU = Musel e Gl ucose Uptake Rate
LULAC = Rate of Liver Lactaie Uptake
PEG = Rate of Muscle Glucose Utilization for Energy
MRLAC = Muscle Lactate Release Rate
FFAP = FFA Production Rate
FFAU = FFA Utilization Rate
GSEC = Glucagon Secretion Rate
GDEG = Gl ucagon Degradation Rate
ISEC = Insulin Secretion Rate
IDEG = Insulin Degradation Rate
Particular attention was focused on developing a representation of
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pancreatic insulin secretion rate (ISEC) as related to the dynamics of
blood glucose following rapid glucose infusion. By assuming that the rate
of pancreatic insulin release was a function not only of the glucose con-
centration but also of the rate of change of the glucose concentration with
time, the model was quite successful in predicting the qualitative features
of the plasma insulin dynamics following rapid glucose infusion.
Cerasi et ale (1974) developed a mathematical model for the purpose of
analyzing the interplay of glucose and insulin during glucose infusions.
The model used a single compartment to represent glucose dynamics during
hyperglycemia and included nonlinear glucose removal by tissues, endogenous
glucose appearance during hypoglycemia, and glucose excretion through
urine. Insulin dynamics were modeled in terms of a three-compartment
representation. This formulation was originally derived by Silvers et al.
(1969) to describe the rate of plasma insulin_I 131 disappearance in man,
and assumed that insulin was distributed in plasma, interstitial fluids,
and a third, hypothetical compartment. The glucose metabolism model, shown
in schematic block diagram form in Figure 62, was described by
di~ = -(T~p)ip-ri(ip-iL)+ClrpIR(g)
di Ldt = r i €i (i P- \ )- r i L (i L- i 3)
(181)
(182)
(183)
(184)
where: 9 = Glucose Concentration Above Fasting Level
i p = Plasma Insulin Concentration Above Fasting Level
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r KGE
r GIH =
r pGU ~
r pIR =
T; p' Li 3' =
r; ,r;L =
£i ' £i L =
C1 =
i L = Interstitial Fluid Insulin Concentration Above Fasting
"Level
i 3 = Insul in Concentration Above Fasting Level in Hypothetical
Compartment
V = Glucose Distribution Volume9
G. = Intravenous Glucose Infusion Rate1n
Kidney Glucose Excretion Rate
Rate of Glucose Input during Hypoglycemia
Peripheral Tissue mucase Uptake Rate
Pancreatic Insul in Release Rate above Basal
Insulin Degradation Time Constants
Insulin Transfer Rate Constants
Dimensionless Distribution Parameters
Fraction of Insulin Passing Through Liver Without Being
Degraded
Cerasi et ala combined modeling studies and experimental studies primarily
to elucidate the factors governing glucose stimulation of insu1an release
rate from the pancreas (r pIR ).· Based on the experimental observation that
repeated glucose stimuli induced different insulin responses depending on
the time-intervals of the infusion and recovery periods, time variance was
introduced into the model functions for insulin secretion. The resulting
formulation employed a series of 5 equations (4 differential equations) to
relate the rate of insulin release to the blood glucose concentration.
This submodel of pancreatic insulin release (see review in pancreatic insu-
lin release section) incorporated hypothetical potentiators and inhibitors
of insulin release that varied with time as a result of hyperglycemia, this
providing an empirical formulation to account for the observed variances in
insulin response to repeated glucose stimulation.
lnsel et ale (1975) used insulin and glucose models to analyze insulin
mediated glucose disposal during euglycemic hyperinsulinemia (glucose clamp
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technique) in normal subjects. Three-compartment glucose and insulin
models were employed as illustrated in Figure 63. The glucose model
included a central blood water compartment (6) in rapid equilibrium with a
smaller compartment (9) and in slow equilibrium with a larger compartment
(7). Metabolic glucose sinks included constant central nervous system glu-
cose removal from the blood and insulin-dependent glucose removal from the
rapidly equilibrating compartment. Glucose inputs included endogenous
(liver) glucose production and the intravenous glucose required to maintain
euglycemia following elevation of plasmn insulin levels. The insulin model
was that originally developed by Sherwin et al. (1974) based on studies of
insulin kinetics in man: plasma insulin (compartment 1) was assumed in
rapid equilibrium with a small compartment (2) and in slow equilibration
with a larger compartment (3). Insulin was removed from the plasma by a
linear first-order process, and endogenous (pancreatic) insulin release was
assumed to remain constant at its basal value during euglycemic clamping.
Intravenous insulin was also included as a plasma insulin input. During
the euglycemic clamp experiments, [14C]-glucose turnover was used to
measure the rate of endogenous glucose production. Thus, the total rate of
glucose disposal could be calculated from the difference between the glu-
cose infusion input required to maintain normal glycemia and the endogenous
gluco$e production rate. By comparing model simulations with experimental
data, Insel et al. observed that following elevation of plasma insulin
levels, the increase in glucose disposal correlated well with insulin con-
centration in the slowly aquilibrating insulin model compartment. It was
thus proposed that the change in glucose disposal per unit change in the
slowly equilibrating insulin compartment could provide a clinical index of
patient insulin sensitivity.
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case utilization correlated well with concentration of insulin
in the slowly equilibrating insulin model compartment.
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Over the last decade, accumulation of experimental data has provided
greater insight into the mechanisms of glucose regulation. This has
spawned a new generation 0f mathematical models. Recent models include
that of Cramp and Carson (1981) which is shown in Figure 64. The role of
the liver in ylucose metabolism was emphasized by inclusion cf compartments
for hepatic glucose 6-phosphate and hepatic glycogen in addition to plasma
and portal glucose compartments. Portal and plasma compartments were pro-
vided for insulin and glucagon, and a single compartment for plasma adrena-
lin. Metabolic processes causing addition or removal of substances from
their respective compartments are identified in the figure. In this model,
the pancreatic insulin release rate was assumed to be proportional to both
the portal glucose level and its rate of change with respect to time.
Nonlinear representations were employed to model the rate of peripheral
tissue uptake of plasma glucose and the enzymatic reactions involved in
liver metabolism. Mass balance formulations for each compartment resulted
in a set of 9 nonlinear ordinary differential equations. Plasma and hor-
monal distribution volumes were selected to represent a 70 kg subject with
a liver mass of 1.5 kg. The mass balance equations for this model ~ as
published, were difficult to interpret because numerical values were
inserted directly into the formulations without any ~erm-by-term iden-
tification of the contributing processes. Furthermore, the compartment
volumes were apparently abstractions, since both "plasma u and "portal"
distribution volumes were assigned equal values of 3.2 1. Finally, the
model·s initial conditions were cited in units that were not in agreement
with the units specified in the equations. Unfortunately, communication
with the authors failed to clarify these issues.
The modei of Cabelli et al. (1982) is presented in Figure 65. Glucose
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Fig. 64 SChematic representation of glucose model developed by Cramp
and Carson (1981).
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was described by a single compartment representing extracellular flulds.
The metabolic processes associated with glucose metabolism included renal
excretion, liver glucose uptake and production, glucose utilization by
muscle and adipose tissues, and insulin independent glucose utilization by
the central nervous system and red blood cells. Insulin distribution was
formulated on the basis of the three-compartment model originally developed
by Sherwin et al. (1974); based on the analysis of studies of insulin kine-
tics in man, pla~ma insulin was assumed to equilibrate with two extravascu-
lar compartments: a large compartment associated with interstitial fiuids
(slow equilibration), and a small compartment assumed to be liver (rapid
equilibration). Insulin secretion was formulated in terms of a two-
compartment model (Cabell; et a1., 1980) in which insulin synthesis and
secretion rates were non1 ; nearl y contro,.l ed by gl ucose. Gl ucagon was
described using a single compartment. The model formulation resulted in a
set of nonlinear ordinary differential equations, given by
(186)
(187)
(188)
(189)
where: Xl = ~antity of Gl ucose in Pl asma and Extracellular Fl ui ds
uII = ~antity of Insul in in Pl asma
u12 = ~antity of Insulin in Liver
u13 = ~antity of Insul in in Extracell ul ar Fl uids
u2 = ~antity of Gl ucagon in Pl asma and Extracell ul ar Fl uids
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F1(Xl1'u 12 ,u Z) = Liver G1 ucose Product ion Ra te
F2(xl'u 12 ) = Liver Gl ucose Uptake Rate
F3(x1) = Renal Glucose Excretion Rate
F4(xl'u 13 ) = Peri phera1 Insul in-Dependent Gl ucose Upta ke Rate
FS = Peripheral Insulin-Independent Glucose Utilization Rate
I = Intravenous Glucose Infusion Ratex
m•• = Insul in Transfer Rate ConstantslJ
h02 = Inverse Time Constant for Gl ucagoil Degradation
F7(x l ,u 13 ) = 61 ucagon Secretion Rate
F6(x l ) = Insul in Secretion Rate
and where the rate of pancreatic insulin secretion F6(xl) was calculated
from the two-compartment insulin release model previously reviewed in the
pancreatic insulin release section of the text. Distribution volumes of
the various compartments were assumed to constitute a fixed percentage of
body weight and metabolic rates were formulated on a per kg basis. The
nonlinear metabolic functions F; were formulated in terms of multiplicative
hyperbolic tangent functions.
Tiran et ale (1975) have employed compartmentalization techniques
similar to those origlnal1y developed for simulating drug distribution. As
shown in Figure 66, the body was divided according to the main organs and
tissues involved in glucose dynamics, and the resulting compartments were
interconnected according to their relative locations ift the circulatory
system. Mass balance formulations with respect to this approach were
explained in detail earlier in the text. Physiologic parameters
(distribution volumes and blood flow rates) were selected to represent a 70
kg man. This model was employed to simulate the initial dynamics of glu-
case distribution following rapid intravenous glucose infusions. For these
preliminary studies, the glucose model was not coupled with an insulin
representation and mediation of glucose metabolism was not included in the
239
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Fig. 66
PORTAL VEIN
HEPATIC ARTERY
...HEPATIC
CAPILLARIES
SChematic diagram of physiologic compartmentalization employed
by T1ran et ale (1975).
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formulation. Since publication of these initial studies with the human
model, liran et al. have directed their efforts toward mathematical
modeling of glucose and insulin dynamics in the dog. Here, the basic com-
partmentalization illustrated in Figure 66 was retained, and physiologic
parameters typical of a 12 kg dog were selected. A model of insulin dyna-
mi cs (Ti ran et al., 1979) was developed fi rst. In' thi s model, the ki dney
and liver removed insulin in direct proportion to its rate of delivery (in
the blood), while peripheral tissue insulin removal was represented in a
nonlinear fashion. No formulation for pancreatic insulin release was
included. The insulin model was later coupled with a glucose model (Tiran
et al., 1980). The glucose model included constant glucose utilization by
brain, gut, and red blood cells, kidney glucose excretion, and nonlinear
glucose and insulin m~diated glucose utilization by liver and periperhal
tissues. The combined model was used to simulate experimental results
obtained during glucose and insulin infusions in pancreatectomized dogs.
and has subsequently been modified (Tiran et al., 1981) to include separate
compartmentalization of red blood cells within each vascular space. This
improved model performance by taking into account the limited permeability
of dog erythrocytes to glucose. The complete glucose-insulin model for-
mulation of Tiran et ale (1981) resulted in a total of about 40 compart-
ments and is shown in block diagram form in Figure 67.
Guyton et al. (1978) (Guyton, 1973) have used the tissue and organ
compartmentalization approach to model glucose metabolism in man. A sche-
matic representation of the model is shown in Figure 68. Physiologic para-
meters were selected to represent a 70 kg adult man. In the glucose model,
glucose utilization by red blood cells, brain, and central organ compart-
ment tissues (gut and heart muscle) were constant. Loss of glucose through
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Fig. 67 System block representation of models develped by Tiran et ale
for simulation of glucose and insulin dynamics in the dog.(from T1ran et al., 1981)
Fig. 68
Design of glucose circulation. lAM/s are represented by
boxes and rllllJ by solid arrows. Cloud-like figures repre-
..nt entrance and exit iunctu,.. for glucose. The func-
tional Nlationships that govem rate. of glucose flux are
represented by numbered circles and broken line•. The
box.~ repre.ent leve'. that aHect glucose dynamics.
SChematic representation of the glucose metabolism model of
Guyton et al. (1978).
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urinary excretion resulted if a threshold glucose concentration was
exceeded in the kidneys. A nonlinear representation of peripheral tissue
glucose uptake included glucose and insulin mediation. Hepatic glucose
exchange was modeled in terms of the separate metabolic pathways contri-
buting to liver glucose production (glycogen breakdown and gluconeogenesis)
and liver glucose removal (glycogen synthesis). Glucose removal by hepatic
glycolysis was not considered. A liver glycogen compartment was included
in the formulation, and metabolic rates were given as nonlinear functions
of glucose, insulin, and liver glycogen levels. Insulin mediation of glu-
cose metabolism was assumed to occur via a 3-min time delay in all phy-
siologic rate representations. In the insulin model, insulin was removed
as a linear function of its rate of presentation to liver, kidney, and
peripheral tissues. The model incorporated a heterogeneous fast pool
theory of pancreatic insulin release (reviewed in pancreatic insulin
release section of text). This formulation for insulin release was struc-
tured to account for observed patterns of plasma insulin appearance
following various glucose infusions and related the rate of pancreatic
insulin secretion to arterial glucose concentration through a rather
complex set of 11 nonlinear ordinary differential equations. The complete
model of glucose and insulin dynamics yielded a system of 32 simultaneous
nonlinear ordinary differential equations. The model was sUbsequently
modified by Hillman (1977) to incorporate physiology unique to the simula-
tion of oral glucose challenges, including gut hormone augmentation of
pancreatic insulin release and modeling of a 100g OGTT gut glucose absorp-
tion function. Although the original formulation of Guyton's model ~~S
programmed in a computer language called DYNAMO (a forward-difference
numerical integrating package), the mathematical equivalent of the model
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was later implemented in FORTRAN by Sorensen et al. (1982) for integration
using a fourth-order Runge ~tta method. The restructured model of Guyton
et ale (including the modifications of Hillman) was presented by Sorensen
et al. in a more traditional organ and tissue compartmentalization format
as shown in the schematic diagram in Figure 69. The mathematical equations
of the model are documented in Appendix B of the text.
Bergman et al. (1981) have used mathematical modeling of glucose and
insulin dynamics to develop clinical indices of value in characterizing
individual response. The objective here was not to develop generalized
physiologic models yielding predictions of mean normal response over a wide
variety of inputs, but rather to generate minimal mathematical models
capable of explaining variations in individual response to a single input,
the IVGTT. The general minimal modeling approach employed by Bergman et
al. is shown in Figure 70. Following intravenous glucose infusion, the
time courses of plasma glucose"G(t) and insulin I(t) were determined
experimentally. The parts of the system above and below the dashed line in
the figure were then considered separately: 1) beta cell sensitivity to
glucose (Toffolo et al., 1980) was modeled using G(t) as the input and
testing various black box mathematical formulations that, by parameter
variation, could predict I(t); and 2) insulin sensitivity of glucose utili-
zation (Bergman et al., 1979) was modeled using I(t) as the input and
testing black box mathemat'ical formulations that could predict G(t) by
parameter adjustment. The black box mathematical formulations were tested
in order of increasing complexity until all observed individual variations
could be accounted for by simple adjustment of parameters within a si~gle
minimal model. Thus, by comparing parameter values of the individual
against those of a population, quantitative indices of beta cell sen-
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sitivity to glucose and of glucose utilization insulin sensitivity were
defined.
B) Comparison of Models of Glucose Metabolism
Because of the wide range of variation in form and detail, direct com-
parison of the various models of glucose metabolism is virtually
impossible. (This may account for the fact that there have been no
attempts to do so in the recent literature.) It is important, however, to
discuss distinguishing features of these models and to attempt to assess
the probability that respective model structures would lead to sound mathe-
matical representations of the glucose regulatory system.
The linearized two-compartment formulations utilized in the early
models of Bolie (1961), Ackerman et ale (1965), Gatewood et ale (1968), and
Segre et ale (1973) were clearly oversimplifications of the glucose regu-
latory system, both with respe~t to the degree of body compartmentalization
and linearization of the metabolic sources and sinks. In particular, use
of a single plasma insulin compartment to model the regulatory effects of
insulin on glucose metabolism cannot be appropriate, since the insulin-
dependence of glucose disposal correlates with insulin levels in a compart-
ment in slow equilibrium with plasma (Sherwin et ale 1974; Insel et al.,
1975), or alternatively via a time lag in the hormonal action. Because
parameters in the above models were established by fitting experimental
data of a single glucose input (either an IVGTT or an OGTT), however, it
was necessary to use extremely simplified models to avoid complete
arbitrariness in the resulting parameter sets.
Charette et al. (1967) and Foster (1970) retained simple compartmen-
talization formats but included nonlinear metabolism in their models. With
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the introduction of nonlinear functions, concern arose (and justifiably so)
as to the uniqueness and correctness of metabolic formulations derived
through parameter adjustment techniques. Both Charette et ale and Foster
consulted the literature to formulate, at least in a qualitative sense, the
metabolic source and sink characteristics. Model simulations were then
employed to test and refine the models. The model of Foster et al. (1973)
included metabolic scrutiny on a rather detailed level, far in excess of
available information for direct quantification; the model, however, wa~
reasonably succcessful in predicting the qualitative features of insulin
and glucose response to intravenous glucose. Inclusion of amino acid and
FFA acid compartments also suggested that variation in the plasma levels of
these entities exerts little regulatory influence on glucose and insulin
dynamics following intravenous glucose. In addition, the success of Foster
et al. in qualitatively predicting insulin repsonse using a simple insulin
release model based on glucose level and its rate of change with respect to
time w~s notable.
Cerasi et al. (1974) and Insel et ale (1975) adopted similar three-
compartment insulin formulations from the literature for their modeling
efforts. This provided an improvement over earlier one-compartment insulin
models as previously discussed. Cerasi et al. (1974) primarily employed
modeling to study glucose-insulin interactions following intravenous glu-
cose and to formulate an insulin release model, while Insel et al. (1975)
were primarily concerned with a~alyzing euglycemic insulin clamp data. To
this end, the metabolic processes causing addition and removal of glucose
were cast into somewhat abstract terms in these models; for example,
insulin-dependent glucose disposal was not partitioned between muscle and
liver in these formulations. These models served their respective pur~
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poses, but were not intended to be good physiologic representations of
widespread applicability.
Improved understanding of glucose metabolism and its regulation has
led to the recent development of several explanatory physiologic model ~r­
mulations, including the model presented herein. A general comparison of
the relative mathematical complexities of these models is provided in Table
29. Differences in the number of differential equations primarily reflect
the degree of body compartmentalization employed, with the tissue ana organ
compartmentalization models of Guyton et al. (1978), Tiran et ale (1981),
and the present model utilizing significantly larger differential equation
sets than the lumped compartmental models of Cramp and Carson (1976) and
Cobelli et ale (1982). Interestingly enough, a similar number of parame-
ters entered into each of the model formulations with the exception of the
model of Guyton et al. (1978) hhich employed a higher parameter count as a
result of the relatively complex pancreatic insulin release formulation
used therein. The number of nonlinear functional relationships utilized
for modeling metabolic sources and sinks ranged from a high value of 16 for
the model of Guyton et al. (1978), because of its complicated insulin
release formulation, to a low value of 6 for the canine model of liran et
al. (1981), due to exclusion of glucose counterregulation and insulin
release considerations in this model.
In assessing the model of Cramp and Carson (1981), a number of issues
were of concern from a physiologic standpoint. For a 70 kg subject, the
total distribution volume for glucose, as well as for the hormones insulin,
glucagon, and adrenal;n, was 3.2 1; since this value roughly corresponds to
total blood plasma volume, consideration of interstitial fluid distribution
was clearly omitted from the model formulation. Furthermore, the vascular
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TABLE 29. SUmmary comparison of the relative mathematical complexities of r~cent
physiologic models of glucose metabolism.
MATHEMATICAL COMPLEXITY
MODELS
Differential
Equations
Nonlinear Input
Parameters Functions
Guyton et al. 1978 32 70 16
Cramp and carson 1976, I1J81 9 48 11
tT1ran et al. 1979, 1980, 1981 40 50 6
Cnbel11 et '1. 1982 7 54 13
New Model 22 42 11
tCan1 ne Model
21:;1...., .
distribution volume for glucose should be significantly larger than for
hormones because of glucose penetration into red blood cells. In addition,
use of a lumped compartmentalization approach for insulin required ;nsuiin-
dependent peripheral tissue glucose uptake to be modeled as an instan-
taneous function of plasma insulin concentration; this conflicts with the
observation (Sherwin et al., 1974; fnsel et al., 1975) that glucose uptake
is mediated by an insulin compartment in slow equilibrium with plasma
during euglycemic insulin clamps. Cramp and Carson emphasized underlying
biochemistry by modeling metabolic sources and sinks for glucose in terms
of enzyme kinetic expressions. Mathematically, such expressions yield
nonlinear sigmoidal response curves similar to those resulting from hyper-
bolic tangent functions. An interesting aspect of the model was the repre-
sentation of liver glucose metabolism in terms of the major contributing
biochemical pathways (glycolysis, gluconeogenesis, hepatic glycogen synthe-
sis and br~akdown) and the inclusion of hepatic glucose 6-phosphate and
hepatic glycogen compartments (see Figure 64). Whether scrutiny of liver
metabolism to such a high degree can be justified from a quantitative
standpoint, however, is questionable; no evidence was presented to verify
the accuracy with which the model liver formulation could predict
measurable in vivo response, such as net hepatic glucose production and
uptake. Although the model was used to simulate intravenous glucose
tolerance tests, no provision for kidney glucose excretion was included in
the formulation. Pancreatic insulin release was modeled in terms of an
extremely simplified linearized formulation (as previously discussed in the
section on pancreatic insulin release models), and although gut hormone
intervention significantly augments pancratic i~sulin response to oral glu-
cose, Cramp and Carson employed the same insulin release model for simu-
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lating both intravenous and oral glucose challenges. Finally, inclusion of
adrenal;n (epinephrine) may not have been necessary, as changes in plasma
epinephrine levels under normal unstressed conditions probably do not cause
quantitative alterations in glucose regulation. (Gerich et al., 1981). The
model of Cramp and Carson was successful, at least in a qualitative sense,
in predicting normal response to intravenous glucose, insulin and glucagon.
The model was further employed to study the effects of altering enzyme
activity on overall plasma glucose response.
Although the canine model of liran et alo (1981) cannot be used ror
prediction of human response, it certainly deserves mention. This tissue
and organ compartmentalization model was well conceived and maintained a
high degree of physiologic correspondence. The same basic compartmental
design was employed in this model as was used in the formulat'ion of the
present human model, except for inclusion of limited glucose permeability
of red blood cells (the canine RBC is less permeable than the human nBC)
and introduction of separate vessel volumes to represent blood in the large
arteries and veins. Sin~e the longest time constant for any of the vessel
volume compartments was only 0.37 min, their inclusion offered refinement
in the rapid dynamics of blood pool mixing over small time scales; thus,
lumping of these volumes into the organ and tissue vascular volumes would
have most likely introduced minimal error for situati0ns of interest. To
date, the canine model has been used to analyze glucose and insulin infu-
sion experiments in pancreatectomized dogs, and thus pancreatic insulin
release and glucagon counterregulation have not been considered in the
model formulation. liran, et ale did not distinguish between liver glucose
uptake and production, but rather modeled liver glucose metabolism in terms
of net hepatic glucose release rate (or net hepatic glucose balance) which
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could assume positive or negative values. Because sufficient data was not
available to define the net hepatic glucose release and peripheral glucose
uptake functions, the authors stated that lithe details (but not the
character)1I of these relationships constituted the major assumptions in the
model. Because of the care employed in its formulation, however, the model
yielded reasonably good agreement between simulated model predictions and
experimentally observed data following glucose and insulin infusions in the
dog.
Cabell; et ale (1982) used a lumped compartmental representation and
relied heavily on adaptive fitting techniques to match model predictions to
experimental data in a variety of sim~lation studies. Although utilization
of a single glucose distribution space was an obvious simplification, this
approach may have been reasonable since glucose equilibrates fairly rapidly
between vascular and extravascular interstitial fluids in the body; infor-
mation is lost, however, with respect to local variations in glucos2 con-
centrations, such as differences in arterial, venous and portal
concentrations during an OGTT. The three-compartment in~ulin distribution
model was originally derived by Sherwin et al. (1974); this was the minimal
linearized model that, through adjustment of its 10 parameters, yielded
good predictions of plasma insulin concentrations following insulin injec-
tion and euglycemic insulin clamping (high and low doses) in normal sub-
jects. The compartments of this black box mathematical model were later
. assigned a somewhat abstract physiologic interpretation based on their
respective volumes and relative equilibration times with plasma insulin,
i.e. the small rapidly equilibrating compartment was assumed to represent
liver and the large slowly equilibrating compartment was assumed to repre-
sent peripheral interstitial fluids. The general applicability of this
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insulin distribution and metabolism model should be questioned because of
1) the limited variety of data upon which it was derived, and 2) the nonu-
niqueness of the three-compartment model in fitting the data. Indeed,
Sherwin et al. demonstrated that an alternative three-compartment model
explained the data equally well, a model for which no degradation was
assoicated with the "liver ll compartment! The pancreatic insulin release
model employed by Cobell; et ale was extrapolated from perfused canine
pancreas studies and was reviewed earlier in the pancreatic insulin release
section of the text. A simple one-compartment model for glucagon was
included to account for counterregulation during hypoglycemia. It was
curious that the effect of insulin on pancreatic glucagon release was
expressed as a function of "interstitial" insulin concentration (slow
equilibration with plasma) since arterial insulin would be expected to
exchange rapidly with pancreatic islet cells. Cobelli et al. (1982) were
extremely conscious of the fact that use of parameter fitting to establish
the nonlinear metabolic source and sink functions in the model could lead
to nonunique, incorrect partitioning of glucose disposal among the organs
and tissues. A wide variety of simulation studies (glucose and insulin
infusions) were thus employed to establish a single set of model parameters
that yielded reasonably good agreement between model predictions and
experimental observations. In recently attempting to validate the model's
performance with respect to predicting OGTT data, however, Cabelli and Mar;
(1983) had to alter significantly virtually all of the internal model para-
meters, incl uding changing the functional forms of the 1iver 91 ucose pro-
duction and uptake functions to increase the number of adjustable
parameters. Considering that the newest revised model uses 20 parameters
to adjust the nonlinear metabolism associated with liver and peripheral
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tissue handling of glucose, the uniqueness and physiologic correctness of
this model remain an issue of concern.
Guyton et al. (1978) used a tissue and organ compartmentalization
similar to the model presented in the text except for t~e following
differences~ 1) the gut tissues were lumped into the central organs com-
partment in the glucose model; 2) both brain and gut tissues were lumped
into the central organs compartment in the insulin model; and 3) a small
but non zero transcapillary diffusion time was included for plasma insulin
exchange with liver and kidney interstitial fiuid spaces. In addition,
glucagon counterregulation was not explicitly included in the model;
however, a nonlinear effect of low arterial glucose concentration was used
to potentiate liver glucose production during hypoglycemia. Guyton et al~
used the heterongeneous fast pool model of pancreatic insulin re·lease (see
section on pancreatic insulin release); this hypercomp1ex insulin secretion
model added greatly to the overall mathematical complexity of the glucose
metabolism model. L~ver glucose metabolism was modeled in terms of bioche-
mical pathways, except the pathway of glycolysis, a major route of hepatic
glucose processing, was neglected. The metabolic processes for the liver
were quantified from reviewing data in the literature; the available data,
however, was insufficient to provide a firm basis for determining such fine
detail. The resulting liver formulation does not accurately predict hepa-
tic response on the whole organ level. For example, liver glucose output
from gluconeogenesis in the mo~el was assumed never to fall below about 50%
of the basal glucose production rate because this process is limited by
substrate availability (flux of gluconeogenic presursors to the liver).
This is inconsistent with in vivo measurements indicating complete
suppression of hepatic glucose production in response to modest increases
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in plasma insulin levels, even if gluconeogenic presursors are available to
the liver. Furthermore, recent studies (Shakima and Ui, 1978) have
suggested that glucose loading can divert hepatic glucose 6-phosphate pro-
duced from gluconeogenesis to glycogen storage. Once the model functions
for liver glucose metabolism had been established, insulin-dependent
peripheral glucose uptake was quantified by simulating variable-dose IVGTT
experiments and fitting model predictions to experimental data for blood
glucose responses. Thus, peripheral glucose metabolism was simply adjusted
to compensate for errors in the liver glucose metabolic formulations such
that the model acurately predicted glucose response to intravenous
challenges. The ease with which such arbitrary balances in liver a,d
muscle metabolism can be used to predict glucose profiles during IVGTT's
was clearly demonstrated in the texto
Of the tissue and organ compartmentalization models of glucose metabo-
lism, the new model presented herein used the least number of differential
equations, primarily because of its simplified pancreatic insulin release
formulation. At first it might seem that tissue and organ compartmen-
talization, although yielding a high degree of physiologic correspondence,
introduced a large number of parameters into the formulation, and thus was
disadventageous relative to simpler lumped compartmental ~rmulations. Due
to the high level of physiologic correspondence, however, the parameters so
introduced, such as tissue volumes and blood flow rates, could be directly
established from available data in the literature. For example, external
to the model pancreas formulation, not a single parameter in the model of
insulin distrfbution and metabolism needed to be established by parameter
fitting. Likewise, the entire glucose distribution model (neglecting the
metabolic sources and sinks) required fitting of only a single parameter,
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the peripheral transcap~11ary diffusion time constant. The simpler three-
compartment insulin distribution model employed by Cabell; et ale (198:),
however, was basically established by a lO-parameter fitting of experimen-
tal data. Over lthe course of developing and using the present model, a
great advantage of organ and tissue compartmentalization resulted from the
ability to distir.Juish between arterial and venous concentrations in the
model; this meant that any measured quantity in the literature directly
corresponded to a quantity in the model, thus facilitating model develop-
ment and testing. With respect to modeling of the nonlinear metabolic
source and sink relationships, it ~as immediately ackuQwledge that con-
fidence in the physiologic correctness of the model would reside in direct
quantification of the component metabolic processes. To this end, a great
deal of painstaking work was directed toward collecting, interpreting, and
correlating experimental data from the literature. Sufficient local organ
response data was available to quantify kidney glucose excretion,
peripheral glucose uptakes hepatic glucose production, tissue and organ
insulin clearances, and pancreatic glucagon secretion. The only model
functions that required- fitting of IVGTT plasma response data for quan-
tification were hepatic glucose uptake, because the human liver data was
too inconsistent and scattered, and pancreatic insulin release, because
plasma insulin appearance was the only access'ible indicator of pancreatic
activity in humans. Since single sink and source functions required
fitting in the glucose and insulin models, respectively, these functions
were adequately determined by parameter adjustment during a standard IVGTT
simulation. The major pitfalls of parameter fitting were thus avoided: 1)
the problem of nonunique interpretations when multiple nonlinear functions
are fit simultaneouslys and 2) the need to use adaptive fitting to iterati-
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ve'y tune the model over a wide spectrum of simulation studies. It should
be mentioned that the resulting hepatic glucose upta'(e function agreed well
with oral uptake data in humans, while the pancreatic insulin release
model, having been adapted from a well tested animal model, displayed good
physiologic behavior. Finally, liver glucose metabolism in the present
model was scrutinized only on the level of whole organ production and
uptake, since thesz quantities are independently measureable in humans. It
would appear that some modelers have attempted to incorporate biochemical
detail at the expense of accurately quantifying whole organ response; an
interesting exercise would be to ~se the more accurate production and
uptake liver model as an overall constraint in further studying the rela-
tive partitioning of glucose movement through the underlying biochemical
pathways. A unique feature of the present model was incorporation of time
dependence into the hormonal regulation. of liver glucose metabolism on the
basis of direct interpretation of experimental data in the literature. The
time dependence of liver hormonal action further supports the notion that
plasma insulin levels have an indirect, or delayed effect on glucose meta-
bolism.
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IV. SIMULATION STUDIES FOR ASSESSING PERFORMANCE OF NORMAL MODEL
A) Computer Formulation and ~bdel Initialization
Final formulation of the glucose metabolism model resulted in a system
of 22 simultaneous nonlinear ordinary differential equations: 11 associated
with the gl~cose model (of which 3 were for time dependent li~er
metabolism), 10 with the insulin model (of which 3 were for the model
pancreas), and 1 with the glucagon model. The model of glucose metabolism
was programmed on a Digital Equipment Corporation VAXll/780 computer system
at the MIT Joint Computer Facility. A printout of the computer source code
(Fortan 77) is include~ in Appendix A. Numerical solutions were generated
using a fourth-order Runge-Kutta integration provided by a library routine
DYSYS (DYnamic SYstem Simulator) on the Joint Computer Facility system. A
time step of 0.1 min was used for all model simulations.
The initial condition for. the model was defined as the basal postab-
sorptive state. For model initialization, the metaboli~ sources and sinks
in the glucose model must assume their basal values by definition, and all
multipliers of the basal metabolic rates are identically unity. This
decQuples the glucose model from the insulin and glucagon models. Setting
the time derivatives of the glucose model mass balance equations (9-16)
equal to zero (steady state) results in a set of 8 simultaneous linear
algebraic equations in 8 unknowns. The eight glucose concentrations cannot
be uniquely determined from this set of algebraic equations, however~
because the coefficient matrix for this system is rank 1 (i.e. one of the
equations is not linearly independent, as summing the equations yields can-
cellation to zero). Thus, the single degree of freedom was eliminated by
specifying anyone of the initial basal glucose concentrations in the glu-
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cose model, and this uniquely determined the remaining 7 glucose con-
centrations. Equating the time derivative of the pancreatic insulin
release model equations (137-139) to zero yields a set of three simulta-
neous algebraic equations that can be solved uniquely for th~ initial
values of P,l, and Qonce the initial arterial glucose concentration has
been determined. Setting the time der;vati1es in the insulin model mass
balance equations (17-23) to zero yields a set of 7 algebraic equations.
This set of simultaneous algebraic equations is linear because: 1) the
rates of liver, kidney, and peripheral insulin clearance are linear func-
tions of insulin concentrations, and 2) as discussed in the text, initiali-
zation of the pancreatic insulin release model does not determine the basal
rate of pancreatic insulin release (it is essentially an unknown, thus
decoupling the insulin model from the glucose ~odel). The insulin model
algebraic equation set has a coefficient matrix of rank a and forms a
system of 7 equations in 8 unknowns (the seven initial insulin con-
centrations and the basal pancreatic insulin release rate). Thus, specifi-
cation of anyone of the initial insulin model concentrations or the basal
pancreatic insulin release rate allows unique initialization of the insulin
~,;ode1•
Since equating the time derivative in the glucagon model mass bdlance
equation (24) yields a single algebraic equation in one unknown, one method
of initializing the glucagon model would have been to specify directly the
initial basal glucagon concen~ration. An alternative approach was employed
for glucagon model initialization, however, for two reasons: 1) plasma
glucagon levels are seldom reported for studies in the literature, and 2)
,when reported, basal plasma glucagon concentrations vary over a wide range
(typically 50-150 pg/ml) due primarily to variations in the specificity of
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the assays employed by different investigators. Because of these reasons,
and for convenience, the need for specifying an initial condition for the
glucagon model mass balance equation was circumvented. Since the glucagon
model uses a one-compartment formulation, initialization requirements co~ld
be eliminated by simply normalizing the glucagon mass balance equation such
that the dynamic variable was transformed from r(t) to rN(t). This was
accomplished as follows. The glucagon model mass balance equation (24) was
divided through by the basal plasma glucagon concentration rB, yielding
Using Equations 154 and 155 to expand the metabolic rate terms gives
Vr d~ _ MI MG (rPrR ) Ncrt - PrR PrR -- - r MrC r
rB
But, under steady basal conditions (from Equation 157),
Substituting Equation 192 into Equation 191 and simplifying yields
V rd~_ N(l11 MG )crt - r .1 PrR PrR" rNrC
for which the basal state initial condition is always given by
(190)
(191)
(192)
(193)
(194)
by definition. Use of Equation 193 as an alternative (but equivalent)
representation of the glucagon model mass balance equation in the computer
formulation thus eliminated the requirement for specifying a basal plasma
glucagon value for each simulation. For those simulations in which the
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time course of plasma glucagon concentration was desired for comparison
with reported data, the plasma glucagon concentration was simply determined
from Equation 193 and specification of the basal glucagon concentration
value rB according to the relationship
(195)
To summarize, model initialization required specification of a single
glucose concentration and a single insulin concentration (or the basal
pancreatic insulin release rate), with specification of the basal plasma
glucagon concentration being optional. The computer program was designed
to calculate the model initial condition valuc5 from the two required input
specifications on the first integration call. For most simulations, basal
state arterial or peripheral venous glucose and insulin concentration
values were used to initialize the model, as these were most commonly
reported for experimental studies in the literature. A summary of the
model initialization calculations starting from specification of peripheral
venous or arterial glucose and insulin concentrations is presented in Table
31. Also included in the table is a listing of the variables for which the
basal state values must be stored for reference during subsequent com-
putations. For simulation of studies for which no basal values were
reported for one or both of the required initialization specifications, the
following values were assumed for default purposes: 1) peripheral blood
glucose concentration equaled 75 mg/dl corresponding to GPV = 89 mg/dl; and
2) peripheral venous plasma insulin concentration equaled 13 mUll
corresponding to IpV = 13 mUll. The above represent mean rrasal state
values measured in 256 normal adult males as compiled from the Joslin
Research Laboratory data base.
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Table 31. Summary of model initialization calculations corresponding to
specification of peripheral venous (or arterial) glucose and insulin
concentrations.
Glucose Model
Mass Ba 1ances :
Gpv = [input peripheral venousglucose cone.]
Bf pGUGH = GpV + Q~
or
GH= [input arterial glucose cone.]
G = G -
r GGU
G H QGG
GL =
1 G G B B
Q~ (QAGH + QGGG + r HGP r HGU )
GBI GBV
r BGUTB
=
VBI
Metabol ism:
IMHGP = 1
IMHGU = 1
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Table 31. Summary of model initialization calculations corresponding tc
(cant.) specification of peripheral venous (or arterial) glucose and insulin
concentrations.
Insul in ."10 del
---~,....---
Mass Ba 1ances :
I pV = [input peripheral venousinsulin cone.]
IpV
IK = IH (l-F K1C )
IS = IH
IG = IH
QIrI
I pI = IpV - [ P P (I Ipy )]H -VpI
or
IH = [input arterial insulin cone.]
IL = -{-(Q~IH - Q~IB - Q~IK - Q~Ipy)
QL
B Q~ I I
r pIR = ( }IL - QGIG - QAIH)I-FLIC
r~odel Pancreas:
x =
(132)3.27 + 5.93(GH)3.02
p = Xl •ll
CD
y
=
XI•II
P = PCD
I = X
HQ + yP 00
Q 0=
H + M1Y
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Table 31. Summary of model initialization calculations corresponding to
(cont.) specification of peripheral venous (or arterial) glucose and insulin
concentrations.
Gl ucagon Model
Mass Ba 1ance:
rN = 1
r = [input plasma glucagon cone.] (optional t see text)
Stored Va 1ues
The following basal values are stored for reference and are required for sub-
sequent computations:
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B) Simulation Studies
A number of clinical experiments were simulated and model predictions
compared with experimental results to assess model performance. A listing
of these clinical simulations is provided in ~ble 30. As indicated in the
table, these experimental situations encompassed a wide variety of response
behavior, not only with ~~~pect to relative glycemia and hormonal levels,
but also with respect to relative temporal dynamics. With the exception of
the standard 0.5 g/kg IVGTT study, which was employed for parameter deter-
m;nations, the model simulations were run without any interactive modifica-
tion of the mathematical model and tnus demonstrated the general predictive
capacity of the physiologic model formulation.
Before reviewing the simulation studies, a few aspects of general
methodology should be clarified. For all simulations, the initial con-
dition was defined as the basal postabsorptive steady state, and the mathe-
matical model was initialized as previously discussed using actual reported
basal arterial or venous concentrations (whenever available). Since
experimental infusions are introduced intravenously, the infusate is
rapidly transported via the venous circulation to the cardiopulmonary pool
where it is rapidly mixed and distributed to the body via the arterial cir-
culatione Thus, for simulations, glucose and insulin infusions were input
as source terms in the heart and lung compartments mass balan~e equatio~s
of the glucose (Equation 11) and insulin (Equation 18) models,
respectively:
Intravenous Glucose Infusion: (modification of Equation 11)
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TABLE 30. Listing of simulation studies employed for testing model perfonmance.
LEVELS RELATIVE TO BASAL Used for
Dynamics Parameter
Clinical Experiment Detenn1nat1on
Glucose Insulin Glucagon
Standard 0.5 g/kg IVGTT + + 0 rapid yes
Variable Dose IVGTT + + 0 r~ap1 d no
0.04 U/kg IVITT
-
+ + rapid no
N
m
00 I 0.25 mU/min/kg Insulin Infusion + + slow no-
0.40 mU/min/kg Insulin Infusion
- + + slow no
Euglycemic Insulin Cia1m 0 + - combined no
Deactivation of Insulin Action 0 +
-
combined no
Hyperglycemic Clamp + + - combined no
Standard 100 9 OGTT + + 0 slow no
where: rrVG = intravenous glucose infusion rate (mg/min)
Intravenous Insulin Infusion: (modification of Equation 18)
(18a)
where: rIVI = intravenous insulin infusion rate (mU/min)
Because peripheral venous infusions enter blood which has already perfused
tissue capillary beds, such infusions should not be input as source terms
in the peripheral compartment blood space; this has been a point of con-
fusion in a number of past modeling studies. For simulating the 100g oral
glucose test, the rate of gut glucose absorption was introduced as a source
term in the gut compartment mass balance equation of the glucose model
(Equation 12):
Oral Glucose Challenge: (modification of Equation 12)
(12a)
where: rOGA = gut oral glucose absorption rate (mg/min)
1) Standard 0.5 g/kg IVGTT
Plotted in Figure 71 are simulated normal response curves for a stan-
dard 0.5 g/kg 3-min IVGTT. Also plotted for comparison are the mean
experimental results for 110 normal adult males whose body weights averaged
near ideal for their ages and heights. This clinical data base was
collected at the Joslin Research Laboratory in Boston. The basal state
initial conditions were as follows: 1) peripheral venous blood glucose con-
centration equaled 75 mg/dl (corresponding to G~v= 89 mg/dl); peripheral
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B
venous insulin concentration equaled 12.8 mUll (I pV= 12.8 mUll).
As indicated in Figure 71, the final model formulation was extremely
accurate in predicting glucose and insulin response to the standard IVGTT.
This was not particularly surprising, however, since, as discussed in the
text, liver glucose metabolism was adjusted to minimize differences between
model predictions and experimental data for glucose response, and insulin
release parameters were adjusted to minimize the difference between model
predictions and experimental data for insulin response. Furthermore, the
glucose peripheral transcapillary diffusion time constant was established
from the initial postinfusion glucose data. Nonetheless, the model IS capa-
city to predict some of the more subtle response dynamics was noteworthy.
Use of the model of Guyton et ale (1978) to predict glucose and insu-
lin responses to the standard 0.5 g/kg 3-min IVGTT is illustrated in Figure
72; here, the Joslin Research Laboratory clinical data has again been
included for comparison. Although Guyton (1973) used IVGTT data to adjust
peripheral glucose metabolism and insulin release functions in the model,
he employed trial and error instead of more sophisticated mathematical
methods for fitting model predictions to experimental data. This, coupled
with other less accurate physiologic representations in the model, resulted
in reasonable but not extremely accurate model predictions of IVGTT
response. In particular, the model tended to return to steady state too
rapidly, indicating problems associated with the counterregulatory modeling
and its time dependence.
2) Variabl e-Dose IVGTT
A comparison between model predictions and clinical data is presented
in Figure 73 for normal responses to 3-min IVGTTl s in which the glucose
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dose was varied between 0.05 and 0.75 g/kg body weight. Clinical data in
the f'jgure represent mean responses of 15 normal subjects measured at the
Joslin Research Laboratory. The initial basal state conditions for these
studies are tabulated in Table 32.
Variation of the glucose dose over an order of magnitude resulted in
glucose and insulin responses covering a broad concentration range. As
demonstrated in Figure 73, the model predictions were in good agreement
with the clinical data over the entire range of investigation.
In working with the model it became apparent that insulin responses
predicted by the insulin model were quite sensitive to the basal plasma
insulin concentration level. This was because referencing pancreatic insu-
lin release as a multiplicative function of the basal release rate resulted
in a highly leveraged insulin release model, as circuiating insulin levels
can normally increase by a factor of 10-20 times basal. The impact of such
a leveraging effect can be seen by comparing the 0.5 g/kg dose levels of
Figures 71 and 73. Although the glucose infusions caused similar glycemic
responses in both of the experimental groups, the insulin response of the
group in Figure 71 was significantly lower rela~ive to the insulin response
of the group in Figure 73; for example, the peak plasma insulin con-
centration in Figure 71 was about 100 mUll, whereas the peak value in
Figure 73 was roughly 135 mUll. The model accurately pr'edicted the dif-
ferent insulin responses of both groups, however, because the mean basal
venous plasma insulin (Qncentration of the former group (13 mUll) was also
significantly less than that of the latter group (17 mUll). In studying
the relationship between fasting insulin levels and insulin response to
glucose, Bagdade et al~ (1967) first postulated a significant correlation
between basal insulin and insulin response. The fact that insulin response
274
TABLE 32. Basal state initial conditions for variable-dose IVGTT studies.
Glucose Conc.{mg/dl) Peri phet·a1
Dose Peripheral Correspondlng Venous Plasma
(g/kg) Venous Model. Input Insulin Cone., IpVBlood GpV (mUll)
0.05 76 90 18
0.2 77 92 19
0.5 76 90 17
0.75 72 86 21
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was well represented by multiplicative rather than additive (or
incremental) response behavior may explain to some extent the high degree
of variability and scatter characteristic of insulin response data.
3) 0.04 U/kg Intravenous Insulin Toleronce Test (IVITT)
Plotted in Figure 74 are simulated results for normal response to a
0.04 U/kg 3-min IVITT. Included for comparison are experimental data
reported by Gerich et ale (1980) for mean responses measured in 15 normal
subjects. Initial basal conditions for this study were as follows: 1)
venous plasma glucose concentration equaled 91 mg/dl (corresponding to GpV
= 98 mg/dl); 2) venous plasma insulin concentration was not reported, so a
default value of 13 mUll was assumed, (IpV = 13 mUll); 3) plasma glucagon
concentrat ion equa1ed 120 pg/ml (r = 120 pg/ml).
The IVITT insulin infusion causes an acute transient elevation of
plasma insulin concentration, as shown in the center panel of Figure 74.
Elevated insulin levels in turn cause suppression of hepatic glucose pro-
duction ~nd increase peripheral tissue glucose uptake, leading to a rapid
decrease in glucose concentration. As insulin levels return to normal,
glucose counter-regulation in response to hypoglycemia rapidly enhances
liver glucose pronuction rate causing glucose levels quickly to rebound
back to normal. As demonstrated in Figure 74, the model was quite success-
ful in predicting the transient hypoglycemia of the IVITT, and, as shown in
the lower panel of the figure, the simple one-compartment glucagon model
yielded reasonably good predictions of the plasma glucagon CQunter-
regulatory response. The IVITT provided a good test of the model's
counterregulatory functions, particularly with respect to hepatic glucose
production, since the rapid interplay between the dynamic effects of insu-
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lin, glucose, and glucagon on the hepatic glucose production rate would be
primarily responsibile for determining the transient hypoglycemic response
characteristics.
4) Continuous Intravenous Insulin Infusions
Shown in Figure 75 is a comparison between model predictions and
experimental data for response to a 0.25 mU/kg/min continuous intravenous
insul in infusion. Experimental data in the figure represent mean values
reported by Sacca et ale (1979) for 5 normal subjects. The initial basal
state conditions for this study Here: 1) venous plasma glucose con-
centration equaled 90 mg/dl (corresponding to GpV = 97 mg/dl); 2) venous
plas~a insulin concentration equaled 11 mUll (IpV = 11 mUll).
The continuous insulin infusion experiment differs from the IVITT
because of the sustained rather than transient elevation of plasma insulin
1evel s. The cont i nous i nsul in. i nfus i on thus resul ts in atta i '.iaent of a
hypoglycemic steady state, the plasma glucose level of which is determined
by the balance between insulin's action in lowering glucose levels and
hypoglycemic counterregulation of this action. As shown in Figure 74,
model predictions agreed well with experimental data for the time course of
plasma glucose concentration during the prolonged continuous insulin infu-
sion experiment, both with respect to the final hypoglycemic steady state
level and the dynamics of the transition to this state.
Presented in Figure 76 is a comparison between model predictions and
clinical data for response to a continous insulin infusion at a higher dose
level of 0.4 mU/kg/min. Experimental data in the figure are mean values
reported by Sacca et al. (1979) for 6 normal subjects. The initial basal
state for this study was defined by the following: 1) venous plasma glucose
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concentration equaled 88 mg/dl (corresponding to GpV = 95 mg/dl); 2) venous
plasma insulin concentration equaled 8 mUll (IpV = 8 mUll); and 3) plasma
glucagon concentration equaled 110 pg/ml (r=110 pg/ml). The higher insulin
dosage resulted in a more pronounced drop in glycemic levels, and again
good agreement was obtained between model predictions and experimental
data.
A comparison of model predictions for the 0.4 mU/kg/min continuous
insulin infusion experiment is presented in Figure 77. Here, predictions
of the present model and the experimental data of Figure 76 have been com-
pared with 1) predicti0ns reported for the model of Cabell; et al. (1982),
and 2) predictions obtained from simulations using the model of Guyton et
ale (1978). As shown in the upper p~1el of the figure, the present model
was the only one to predict correctly the time course of plasma glucose
concentration; whereas Guyton1s model underestimated the hypoglycemic
impact and attained a premature steady state behavior, COLcllils model
failed to predict a hypoglycemic steady state with glucose concentration
continuing to decline at termination of the study. Elevation in plasma
insulin concentration resulting from the insulin infusion was predicted
reasonably well by Guyton's model as shown in the center panel of Figure
77. Cobelli et al. (1982) did not report insulin response predictions for
this study. Although there was considerable scatter in the plasma glu(agon
response data (lower panel of Figure 77), the simple one-compartment gluca-
gon model formulation of the present model yielded a somewhat more accurate
prediction of plasma glucagon response than did that of Cobelli's model.
Guyton's model did not include glucagon in the formulation.
5) Euglycemic Insulin Clamp
In the euglycemic clamp technique, arterial plasma insulin is acutely
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raised by intravenous infusion of a preset empirical insulin dose while
arterial plasma glucose conc~ntration is maintained at basal level by
periodic adjustme~t of an intravenous glucose infusion rate. The insulin
dose schedule and glucose infusion algorithm have been described in detail
in DeFronzo et ale (1979). The insul in dose schedule for a 70 kg subject
is given in Table 33. As indicated in the table, the insulin infusion con-
sists of an initial IO-min priming dose followed by a continuous steady
infusion rate. Arterial plasma glucose concentrations are measured at
5-min intervals (starting at t=IO min), and these measured values are used
to adjust a glucose infusion according to the following algorithm (70 kg
s ubj ect) :
r = a 0 , t <4 min (196)
r = 140 4 ( t <10 mi n (197)
r 1= y (Gb - G.) + SM. i Lit ~< (i + 1) Lit ; i=2,3, ••• (198)1 1 Lit = 5 mi n
SM. = St;1. 2 x F~1; _1x F~1 i (199)1 1-
FM.
Gb (200)
--1 G.
1
'f/her'e: r = glucose infusion rate (mg/min)
G; = arterial p1 asma gl ucose concentration at t = i Lit (mg/dl)
Gb = basal arterial plasma glucose concentration (mg/dl)
SM = metabolic infusion component (mg/min)
FM = correction factor (dimensionless)
y = empirical constant = 8.87 dl/min
with initial conditions:
SM = 280 mg/min0
SM1 = 280 mg/min
Ft~l = 1.0
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TABLE 33. Preset empirical insulin dose schecule calculated to raise plasma
insulin concentration 100 uU/ml during the euglycemic clamp in
a 70 kg subject.
~fme Insulin Infusion
(min) Rate (mU/min)
0-1 221
1-2 197
2-3 175
3-4 156
4-5 139
5-6 124
6-7 110
7-8 98
8-9 87
9..10 78
10-120 69
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Model simulation of a euglycemic insulin clamp experiment is presented
in Figure 78. Included for comparison in the figure are mean experimental
values measured in 11 normal subjects during the euglycemic insulin clamp
studies of DeFronzo et al. (1979). The basal state initial conditions for
this study were: 1) arterial plasma glucose concentration equaled 92 mg/dl
(corresponding to GH = 99 mg/dl); 2) arterial plasma insulin concentration
equaled 14 mUll (IH = 14 mUll).
As shown in the lower panel of Figure 78, model predictions agreed
well with experimental data for"the arterial plasma insulin response to the
empirical primed-continuous insulin infusion, both with respect to the
rapid initial distribution dynamics in response to the priming dose and the
steady state plasma insul;~ level achieved by the continuous infusion. As
indicated in the upper panel of the figure, the glucose infusion algorithm
varied the glucose infusion rate such that the simulated arterial plasma
glucose concentration remained essentially constant at its initial basal
value (92 mg/dl). From a physiologic standpoint, the euglycemic insulin
clamp experiment is particularly interesting because it provides an
assessment of the insulin sensitivity of the body·s glucose disposal pro-
cesses independent of changes in glycemia. Assuming hepatic glucose pro-
duction is essentially suppressed completely by the elevated insulin
levels, the rate of glucose infusion required to maintain euglycemia must
just balance the total rate of tissue glucose disposal in the body. The
glucose infusion rate thus provides an index of insulin sensitivity. As
shown in the upper panel of Figure 78, the glucose infusion rate required
to maintain euglycemia for the model gradually increased to a steady value
of approximately 5.5 mg/kg-min. For the group of subjects studiej by
Defronzo et ale (1979), the glucose infusion rate followed essentially the
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same time course but rose to a somewhat higher final value of about 8 ±
0.75 mg/kg.min by 12G min. This could suggest that the insulin-sensitivity
of glucose disposal is greater than its quantification in the glucose
model; however, as will be shown in the next simulation study, the model
accurately predicted the 120 min glucose infusion rate reported during
euglycemic clamps for the group of 8 subjects studied by Gray et ale
(1982).
6) Deactivation of Insulin Action
Model simulation of a study designed by Gray et al. (1982) to examine
the deactivation of insul in action in man ;s presented in Figure 79.
Following a 120-min euglycemic insulin clamp, insulin infus'ion was abruptly
discontinued (t = 0) whiie arterial glucose concentration remained clamped
at euglycemic through use of a variable-rate glucose infusion. The eugly-
cemic insulin clamp (initiated.dt t ~ -120 min) employee the same insulin
infusion pattern and glucose infusion algorithm as described in the pre-
vious section (Table 33 and Equations 196-200)8 Experimental data included
in Figure 79 are mean responses of 8 normal subjects reported by Gray et
ale (1982). The initial basal state conditions (t = -120 min) for the
study were as follows: 1) arteridl plasma glucose concentration equaled 91
mg/dl (cor~·esponding to GH = 98 mg/dl); 2) arterial plasrna insul in con-
centrat~ion equaled 1~ mUll (IH = 12 mUll).
As shown in the upper panel of Figure 79, termination of the insulin
infusion caused tin acute decrease in artei~ial plasma insulin concentration.
Of interest here was the observation that the simulated plasma insulin
response did not drop significantly below experimental values during the
i nit i e.l rap i d dec 1i ne~. aresu1t t hat wo u1rl have bee n ex pee ted 11 ad the re
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been a significant release of reversibly bound insulin in the body. In the
center panel cf the figure, the total rate of body glucose disposal was
expressed in terms of incremental glucose disposal, defined as
Incremental glucose disposal rate = (gluco~e infusion rate) (201)
+ (hepatic glucose production rate)
- (basal hepatic glucose production rate)
where the glucose infusion rate was that required to maintain euglycemic
levels. A body surface crea of 1.73 m2 \'/as assumed for an ideal weight 70
kg man in order to convert model results to units used by Gray et al. Data
in the ceuter panel of Figure 79 indicate the decline in the total body
glucose disposal rate as insulin levels returned to normal following ter-
mination of the 120-min euglycem;c insulin clamp. As mentioned previously,
in this study the glucose infusion rate required to maintain euglycemia at
termination of the euglycemic insulin clamp was accurately predicted by the
model (~5 mg/kg-min), but this was significantly lower than the infusion
rate reported by DeFronzo et ale (1979) (~8 mg/kg .min)_ In the lower
panel of Figure 79 is a comparison between simulated and experimentally
measured rates of hepatic glucose production. By comparing the top and
bottom panels in the figure it can be seen that there was a significant
delay associated with hepatic recovery from insulin exposure. The model
was quite successful in predicting this interesting result, a consequence
of incorporating time dependence into the formulation of hormonal regula-
tion of hepatic processes in the mod~l.
7) Hyperglycemic Clamp
In the hyperglycemi c c'l amp method, arteri a1 p1 asma gl ucose con-
centration is acutely raised by intravenous infusion of a preset empirical
glucose priming dose, and is maintained at the hyperglycemic level through
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the duration of the study by use of a periodically adjusted glucose infu-
sian. The glucose priming dose and infusion algorithw were described in
detail in DeFrohzo et al. (1979). Arterial plasma glucose concentrations
are measured at 5-min intervals (starting at t = 10 min), and these
measured values are employed to maintain the desired hyperglycemic arterial
plasma glucose concentration. The following equations describe the glucose
infusic~ for a +125 mgjdl hyperglycemic clamp (70 kg sUbject):
Primi ng Dose: r = 3059
r = 2470
r = 2000
r = 1588
r = 1353
r = 1118
r = 941
r = 765
r = 706
r = 647
a , t < 1 mi n
1 ( t < 2 mi n
2 , t < 3 mi n
3 , t < 4 mi n
4 , t < 5 mi n
5 ( t < 6 mi n
6 ( t < 7 mi n
7 ( t < 8 mi n
8 ( t < 9 mi n
9 ( t <10 min
(202)
Al gor; thm: r· = ~(Gd - G.) + SM.111 i Lit d <(; + 1) Lit; ; =2, 3, •••Lit = 5 mi n (203)
SM. =
1
FM. =
1
S~1. 2 x FM. 1x FM.1- 1- 1 (204)
(205)
where: r
G. =1
Gb =
Gd =
glucose infusion rate (mg/min)
arterial plasma glucose concentration at t = i Lit (mg/dl)
basal arterial plasma glucose concentration (mg/dl)
desired arterial plasma glucose concentration (mg/dl)
= Gb + 125 mg/dl
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SM - met;;boli,: infusion component (mg/min)
FM = cJrrection factor (dimensionless)
« ~ empirical constant = 8.87 dl/min
with intial condition5:
SMa = 412 mg/m;n
st~tl = 412 mg/m; n
FM1 = 1.0
tr10del simulation of a +125 mg/dl hyperglycelnic clamp experiment is
presented in Fi gure 80. Incl uded in the fi gure for cornpari son are mean
experimental values measured in 11 normal subjects during the hyperglycemic
clamp studies of DeFronzo et al 0 (1979). ThG basal state initial con-
ditions for this study were as follows: 1) arterial pla~ma glucose con-
centration equaled 92 mg/dl (corresponding to GH = 99 mg/dl); 2) arterial
plasma insulin concentration equaled 14 mUll (IH = 14 mUll).
As shown in the upper panel of Figure 80, the initial glucose priming
dose caused an acute elevation in the simulated arterial plasma glucose
concentration of about 125 mg/dl, and the infusion algorithm varied the
sUbsequent glucose infusion rate such that this level of hyperglycemia was
maintained. The hyperglycemic clamp method is particularly interesting
because plasma insulin response reflects in vivo pancreatic insulin
response to essentially a step change in arterial glucose concentration.
As incicated in the lower panel of Figure 80, model predictions agreed
reasonably well with lrterial pla~ma insulin concentration data over
roughly the first hour of hyperglycemia, reflecting the biphasic nature of
pancreatic insulin response to a step increase in glucose concentration.
Between 60-120 min, however, the predicted insulin response began to noti-
ceably lag below the experimental response data. Recalling that no provi-
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sian for insulin synthesis was included in the pancreatic insulin release
model, t~is behavior could have been anticipated. Experimental studies
have shown that newly synthesized insulin begins to appear in secreted
insulin about 1-2 hours following glucose stimulation of the beta cell
(Gold et al., 1982), with maximal contribution of newly synthesized insulin
oecuring within about 2.5 - 3.5 hours of stimulation (Hriwell and Taylor,
1967). A pancreatic insulin release model intended to yield accurate pre-
dictions over long time scales of prolonged hyperglycemia would thus
require consideration of the insulin synthesis process and its delayed
augmentation of insulin secretion.
8) Standard 100g Oral Glucose Tolerance Test (OGTT)
In attempting to simulate an oral glucose challenge there were two
important issues to consider that had not been encountered in the studies
presented thus far. First, since gut hormone "intervention quantitatively
enhance$ pancreatic insulin response to oral glucose (Perley and Kipnis,
1967; ~rick et al., 1964; McIntyre et al., 1965), the model pancreas could
not be expected to yield good predictions of insulin response to glycemia
resulting from an Jral challenge. Second, since portal glucose con-
centration measurements are not attainable in human studies, the ~ate of
gut absorption of a 100 g oral glucose load has never been directly quan-
tified, and thus the model input for simulating a 100 9 OGTT could not be
defined a prior;. With these considerations in mind, the objectives of the
OGTT simulation studies were as follows: 1) to use the physiologic model
together with experimental plasma glucose and insulin response data to pre-
dict the time course of gut glucose absorption, and 2) to use the model to
examine the underlying metabolic processes which contribute to th~ observed
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glucose tolerance, in particular the partitioning of glucose disposal among
the tissu~s.
The data base emplojed for the OGTT simulation studies was obtained
from the Joslin Research Laboratory and consisted of venous blood glucose
and plasma insulin measurements correlated from 100 9 OGTT's administered
to a population of 145 normal adult males whose body weights averaged near
ideal for their ages and heights. Mean basal state data for this group
were as follows: 1) peri-pheral venous blood glucose concentration equaled
75 mg/dl (corresponding to GPV = 89 mg/dl); 2) peripheral venous plasma
'insul in concentration equaled 13 mUll (IpV = 13 mUll).
Since the model pancreas could not be used for predicting insulin
response, the first task was to determine the time course of pancreatic
in~ulin release. This was accomplished by bypassing the pancreatic insulin
release model (which' decoupled the insulin model from the glucose model)
and iteratively adjusting the rate of pancreatic insulin input into the
insulin model until the predicted plasma insulin time course matched the
experimental data. The final pancreatic insulin release rate input func-
tion, derived by trial and error, is shown in the lower right plGt in
Figure 81. Use of this insulin input function yielded excellent correspon-
dence between model predictions and experimental data for the time course
of plasma insulin concentration, as demonstrated in the lower left plot of
the fi gure.
Having established a pancreatic insulin input capable of generating
proper dynamic response in the insuiin model, the glucose model (through
its metabolic processes) was again recoupled with the insulin ~nd glucagon
models. Next, a test input function for the rate of gut oral glucose
absorption was inserted and adjusted so as to match model predicitons with
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experimental data for the time course of peripheral blood glucose response.
The method employed for iterating trial gut glucose absorption ~nput func-
tions was as follows: 1) values for the rate of absorption were specified
at 25-min intervals over the 30G-min duration of the study; 2) a smooth gut
absorption rate curve was generated from the discrete time values by cubic
spline interpolation; 3) the smoothed continuous gut absorption curve was
input to the glucose model for OGTT simulation. This technique proved
quite successful for providing a means of rapidly and easily adjusting and
testing the trial inout functions.
Seven trial and error iterations wert required to obtain the input gut
g1ucose absorption rate function shown in the upper fight plot in Figure
81. Use of this input function resulted in matching model predictions and
experimental data for the time course of blood glucose concentration
response, as demonstrated in the upper left plot of the figure.
In order to assess the physiologic significance of t~e resulting glu-
cose absorption curve, the area under the curve was first calculated to
determine the total dose. The value obtained was 100.3 9! This was an
amazing result; based on the time courses of glucose and insulin over the
30G-min postprandial period, the model predicted tolerance of exactly the
correct quantity of exogenous glucose. Although the extremely smal I magni-
tude of the error (0.3%) must be attributed in part to some good fortune,
the implications of the result in a more general sense clearly suggest
extreme accuracy of the model in predicting glucose disposal within these
plysiologic ranges of glucose and insulin concentration.
With respect to the temporal patterning of the resulting gut glucose
absorption curve, the glucose absorption rate initially rose rapidly to a
maximum of about 800 mg/min which was sustained for roughly 40 min. Such
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an initial rapid plateauing re5ponse is characteristic of intestinal
absorption behavior and has been demonstrated in animal studies from portal
glucose measurements following oral loading (Waddel and Sussman, 1967).
Intestinal absorption of glucose occurs via active transport of glucose
across the intestinal mucosa, a process that may be rate-limited by intra-
lumenal diffusion and/or carrier availability (Wilson, 1962; Csaky, 1975).
The inital plateauing in the glucose absorption rate most likely
corresponds to effective saturation of the intestinal absorption mechanism
upon initiation of gastric emptying of a large glucose load (Langerlof et
al., 1976). The maximal absorption rate of 800 mg/min agrees well with the
value estimated by Hillman (1977) based on his review of available data
from intestinal perfu~ion studies. Following the maximum absorption
response, the gut absorotion curve of Figure 81 indicated a slow decline in
the absorption rate back to the baseline. The temporal behavior of the
decline in the glucose absorpt1on rate appeared to follow a general first
order exponential decay, but with superimposed secondary increases in the
rate of absorption centered at about 120 and 200 min (see Figure 81). Such
secondary absorptive increases have been commonly observed in experimental
studies and presumably reflect multiple gastric injections of glucose into
the duodenum (Bergman et al., 1982). Multiple gastric emptying, as evi-
denced by secondary increases in the .'ate of splanchnic glucose release,
has been demonstrated by direct hepatic venous catheter;zatlon measurements
(Fel1g et al., 1975) and double tracer turnover analysis (Pilo et al.,
1981; Radzuik, 1981) in humans following 100g oral g1ucose ingestion.
Finally, with respect to the total duration required for complete absorp-
tion of the glucose load, it was originally believed that gut glucose
absorption was completed within about 180 min following 100g oral glucose
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administration. This was because measured blood glucose levels return to
(cross) basal by 180 min, as shown by the blood glucose response curve in
Figure 81. However, recent tracer experiments (Radziuk et al., 1978; Pilo
et al, 1981) as well as studies using indirect calorimetry (Jacot et al.,
1982) have indicated that complete absorption of such larJe glucose loads
takes considerably longer than 2-3 hours. The 30G-min absorption time pre-
dicted in the present study is "in good agreement with such recent findings.
Noting that plasma insulin concentration remains elevated at about 3 times
basal level at 180 min (see Figure 81), and that such insulin levels are
sufficient to suppress endogeneous hepatic glucose production, the return
of blood glucose levels to basal at 180 min would correspond to the
situation in which the rate of intestinal glucose absorsption just balances
the suppression in hepatic glucose production rate from normal. W~le(~~s
recent tracer experiments can distinguish between endogenous and oral glu-
cose output from the splanchnic organs, traditional hepatic venous cathe-
terization measurements would simply suggest the splanchnic glucose output
had returned to normal by 180 min, thus providing a false indication that
gut glucose absorption was completed.
Predicted rates of glucose metabolism during the 100g OGTT are pre-
sented in Figure 82. As shown in the figure, hepatic glucose production
was rapidly suppressed and remained so for about 200 min following glucose
administration, gradually returning to its basal rate by 300 min.
Peripheral and hepatic glucose uptake rates, on the other haod, rapidly
increased to dispose of the incoming oral glucose load. In order to exa-
mine partitioning of the glucose load among the various metabolic disposal
routes, the curves in Figure 82 were integrated and the results were used
to compile the 180 min 100g OGTT glucose balance sheet presented in Table
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34. Only 7% of the glucose load remained unabsorbed after 180 min. Since
endogenous liver glucose production was almost completely suppressed,
tissue uptake accounted for nearly balancing the quantity of exogenous glu-
cose load introduced over this period. Although obligatory utilization of
glucose by the insulin insensitive tissues (primarily brain) accounted for
disposal of 19 9 of glucose, muscle and liver played relatively equal roles
in disposing of the remaining 77 9 of glucose. The results presented in
Table 34 are in excellent agreement with direct experimental measurements
reported in the literature. First, Jackson et ale (1973) measured the time
course of forearm glucose uptake during the lBO-min period following 100 9
oral glucose administration in 25 normal sUbjects; by integrating the
forearm glucose uptake curves over the duration of the experiment and
extrapolating the results to total muscie mass, the quantity of peripheral
glucose uptake may be estimated to total 41 g, a value in excellent
agreement with model predictions. Second, including consideration of the
quantity of unabsorbed glucose remaining in the gut, hepatic glucose
uptake, and the insulin-insensitive gut tissue utilizatio~ of glucose, the
total predicted quantity of glucose remaining in the splanchilic bed at 180
min was 48 g. Correcting this value to account for endogenous liver glu-
cose production, the model predicted an apparent total lBO-min splanchnic
glucose retention of 45 g, or 45% of the total glucose load. Although
experimental estimates of splanchnic glucose retention vary over a large
range (30-60%) (see Table 21), the model prediction of 45% represents a
good average of the available human data.
Although several other investigators have used models of glucose meta-
bolism to simulate the OGTT, these studies have differed from the methods
of input-output inversion employed in the present modeling study. Hillman
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TABLE 34. 1009 OGTT balance sheet (180 min).
Unabsorbed after 180 min 7
Insulin-Independent Tissue Uptake
Brain 13
RBC 2
Gut 4
Insulin-Dependent Tissue Uptake
Muscle 40
Liver 37
Uri nary Loss 0
Remaining in Glucose Space at 180 min ~
TOTAL 103
-Endogenous Glucose Production
Liver -3
TOTAl 100g
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(1977) modiTied the physiologic model developed by Guyton (1973) for simu-
lation n: the 100 9 OGTT. Hillman modified the heterogeneous fast pool
pancreat~c insulin release model of Guyton so as to potentiate insulin
response to oral glucose, and assumed a gut glucose absorption rate input
function derived primarily on the basis of theoretical considerations and a
review of available gut absorption data in the literature (~ee Appendix B).
The resulting model predictions for glucose and insulin response during a
100 9 OGTT are compared with experimental data in Figure 83. As indicated
in the figure, Hillman's approach was only modestly successful in yielding
response predictions. Cramp and Carson (1981) presented model simulations
of a 50 9 OGTT. In these studies, gut glucose absorption was assumed to
rise instantaneously to a maximum rate that remained constant for 30 min,
followed by an exponential decay back to zero over a period of about 20
min. No modification in the pancreatic insulin release formulation was
provided to account for agumented insulin response to oral glucose. The
resulting model predictions for the time courses of glucose and insulin
response to the 50 9 OGTT agreed, at least in a qualitative sense, with the
general temporal response patterns observed experimentally in humans.
Finally, Cobelli and Mari (1983) used the basic model presented by Cabelli
et ale (1982) to simulate the 100 9 OGTT. Since a single compartment glu-
cose model was used, a prespecified fraction of the oral glucose load (8%)
was assumed to be removed by the li'ler on initial passage, and the oral
glucose input became the rate of splanchnic glucose release to the systemic
pool. Parameters in the model were then adjusted such that the desired
level of partitioning of the glucose load ~mong the various tissues was
realized while matching the time course of plasma glucose concentration
with e,(perimental data. Since tile single "plasma glucose concentration" in
302
l&J(II
8=120
::)~
GeliD
0-
8~(oo
...J-
mit(
...JCI: 90
efl-
ffi ffi 80
f~
~8 70
LU
Q.
- Prediction
f Experimental Dato
(Mean:t SEM.n=145)
- Prediction
~ Experimental Data
(Menn:t SEM.n=145)
50 100 150 200 250 300
TIME (r."nutes)
Fig. 83 Comparison between experimental data and model predictions for
glucose and insulin response during a standard 100g OGTT.
Model predictions were generated using Hillman's modified ver-
sion of the glucose metabolism model of Guyton. (Data from
Joslin Research Laboratory; f1gur~ from Sorensen et al., 1982)
303
the one-compartment glucose model could not directly aCCQunt for differen-
ces between splanchnic glucose levels (that affect liver glucose uptake)
and systemic glucose levels (that influence peripheral tissue glucose
uptake) during oral glucose loading, the physiologic correctness of the
resulting metabolic functions adjusted on t~e basis of this OGTT study
should be viewed with some skepticism.
C) Conclusion
Using a single set of model parameters, model predictions agreed well
with clinical data over the wide range of physiologic conditions encom-
passed by the simulation studies. The model·s unique design offered a
higher degree of physiologic correspondence and demonstrated predictive
capacity and accuracy superior to prior models. The physiologic model Gf
glucose metabolism in normal man thus provided a firm foundation for sub-
sequent development of diabetic models for assessing efficacies of new
diabetic therapies.
304
v. MODELING OF GLUCOSE METABOLISM IN TYPE I (INSULIN-DEPENDENT)
DIABETES MELLITUS
A) Diabetes Mellitus: A General Overview
1) Aberrent Homeostasis and the Overt Symptoms of Diabetes
In general, diabete~ mellitus is caused by an insufficiency of insulin
relative to the requirements of the tissues for this hormone. As implied
by this definition, the diabetic state can result from abnormal ties asso-
ciated with both availability of insulin to the tissues and tissue sen-
sitivity to the available insulin. In either case, one of the major
manifestations of diabetes mellitus is an excessively high level of glucose
in the circulation.
Diabetic homeos-t:asis has been described as a "super-fasted" state
(Cahill and Soeldner, 1969) because the normal modes of fuel mobilization
characteristic of the fasting ~tate are accelerated ;~ the diabetic state,
in spite of the excessive circulating fuel levels which result. Illustrated
in Figure 84 is typical basal glucose metabolism in the fasting diabetic.
Breakdown a~d release of muscle protein supplies excessive quantities of
circulating amino acids for liver gluconeogenesis, but much of the glucose
thus produced is in excess of the fuel requirements of the glucose-
consuming tissues. This additional glucose, generated at the expense of
muscle protein, begins to spill into the urine when the blood glucose con-
centration exceeds the renal threshold. Because of the osmotic effect of
glucose in the kidney tubules to prevent tubular reabsorption of fluid,
loss of glucose in the urine causes diuresis. Consequently two classic
symptoms of diabetes are polyuria (excessive urination) and polydipsia
(excessive thirst).
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Fig. 84 Typical basal glucose metabolism in the fasting diabetic.
In a similar manner, breakdown of triglycerides in adipose tissue
supplies circulating fatty acids. Fatty acids are converted to ketone
bodies (B-hydroxybutyrate and acetoacetate) by the liver. Hepatic
ketogenesis is normally the primary source of energy production for liver
tissues during fasting, as the a-oxidation of fatty acids produces high
energy phosphate bonds. In the diabetic states however, ketogenesis
increases, and the rate of hepatic ketone body production exceeds the rate
of their uptake and utilization for energy by peripheral tissues. As a
result, the circulating concentration of keto acids in the blood may rise
from a normal value of about 1 mEq/l to as high as 30 mEq/l. Keto acids
have a low threshold for excretion by the kidneys, and thus begin to spill
into the urine. Both hyperketonemia and ketonuria contribute to acidosis
in diabetics. Both B-hydroxybutyrate and acetoacetate are moderately
strong acids, and thus increases in their circulating concentrations
contri bute di reetl y to ac idosos is. Even rnore important in the case of ac;-
dosis is the indirect effect of sodium loss which accompanies ketonuria.
Since ket0 acids are fairly strong, only a small portion are excreted in
acidic form, but most combine with sodium derived from extracellular fluid.
Thus, sodium ion concentration in extracellular fluid decreases, and this
depletion of alkali buffering reserve further exac~rbates the acidosis
already present from excessive keto acid levels. The combined effects of
hyperketonemia and ketonuria, called ketosis, thus lead to acidosis, or
ketoacidosis. Ketoacidosis is a very serious complication of acute and
marked insulin deficiency may be fatal if left untreated.
2) Classification, Diagnosis, and Etiologies of Glucose Intolerance
In 1979, the National Diabetes Data Group of the NIH publ ished the
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results of an international workgroup which was convened for the purpose of
developing standardized criteria for classification and diagnosis of
various modes of glucose intolerance, includi~g diabetes mellitus
(National Diabetes Data Grou~, 1979). Because of the sUbsequent wide
acceptance of their recommendations, a brief review of the terminology and
classification system is presented in the section, along with supplementary
discussion regarding etiologic factors.
In order to provide for standardized clinical classifications, the
heterogeneity of glucose intolerance was partitioned into three basic
categories: 1) diabetes m~llitus (DM), 2) impaired glucose tolerance
(lGT), and 3) gestational diabetes (GDM). In addition, heterogeneity
within the diabetic syndrome was further partitioned into two basic DM
subclasses: 1) Type I, or insulin-dependent diabetes mellitus (100M), and
2) Type II, or noninsulin-dependent diabetes mellitus (NIDDM).
The Type I diabeti~ is ketosis-prone and requires exogeneous insulin
to sustain life. This subclass of diabetes classically occurs in juveniles
with abrupt onset of symptoms; it has been found, however, that the former
term for this disease, juvenile-onset diabetes, is inappropriate in that it
can be recognized and become symptomatic for the first time at any age.
IDDM appears to be heterogenous with respect to genetic and environmental
factors which precipitate the disease. In the majority of patients, genetic
determinants associated with histocompatibility antigens are thought to be
important. More specifically, studies have indicated a twofold to fourfold
increased risk of developing IDOM in individuals possessing certain human
leukocyte antigen (HLA) types on chromosome 6 (Ganda and Soeldner, 1977).
These HLA types appear to create a susceptibility for a gene-virus interac-
tion to trigger an islet-cell autoimmune reaction, destroying the beta
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cell insulin function. On the contrary, there is no statistically $;gnifi-
cant difference in risk of developing NIDDM between IIcontrol ll populations
and individuals possessing these same HLA types.
The Type Ii noninsulin-dependent diabetic is not ketosis-prone and is
not dependent on insulin for the prevention of ketonuria; ketosis may deve-
lop under certain circumstances, however, such as severe stress resulting
from infection or trauma. Patients with NIDDM are generally treated by
control of diet and oral agents, with occasional insulin utilization for
correction of persistent fasting hyperglycemia. In a majority of cases,
onset of NIDDM is after the age.of 40, and NIDDM was formerly termed
maturity-onset diabetes for this reason; as before, use of this terminology
was inappropriate since onset can occur at any age. The symptoms of NIDDM
are extremely heterogeneous in nature. Plasma insulin levels may range
from mild hypoinsulinemia, to normal, to above normal in cases associated
with insulin resistance. Patients often show very slow progression of
onset, and fasting hyperglycemia is not associated with many cases. It
must be noted, however, that the typical chronic complications associated
with diabetes, such as neuropathy and retinopathy, also oecor in NIDDM
patients. The cateogry NIDDM has been divided into two subclasses,
according to whether or not obesity is present. Obesity is associated with
etiologic factors such as insulin resistance resulting from tissue insulin
receptor malfunction (Beck-Nielson, 1978; Kolterman et al. J 1980), often
leading to p'lasma insulin levels which are elevated telative to normal.
NIDDM a9pears to have a stronger genetic basis than does 100M, as evidenced
by more frequent familial pattern of occurrence. The heterog~neous nature
of this genetic predisposition suggests an interplay between genetic
background and environmental modulation for expression of the genome (Ganda
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and Soeldner, 1977).
Individuals with plasma glucose concentrations which are intermediate
between those considered normal and those considered diabetic ar~ assigned
to the classification Impaired Glucose Tolerance (IGT). For psychological
reasons, previous terms such as chemical diabetes, latent diabetes> and
asymptomatic diabetes were abandoned. While individuals in this class are
not considered diabetic, they run a higher risk than the normal population
of develop:,~g diabetes. IGT ~s an intermediate stage in the natural deve-
lopment of NIDDM for some patients, whereas some individuals will spon-
taneously return to normal g'lucose tolerance.
The classification Gestational Diabetes Mel~itus (GDM) is reserved for
women who exhibit glucose intolerance for the first time during pregnancy.
GDM develops in approximately 1-2% of all pregnancies; deterioration in
glucose tolerance normally occurs during the third trimester of pregnancy
and is thought to result from complex metabolic and hormonal changes which
are not well understood at present (O'Sullivan, 1970). Associated with GDM
are increased perinatal morbidity and mortality (O'Sullivan et al., 1971),
and a higher risk of developing overt diabetes within 5-10 yrs after par-
turition (O'Sullivan and Mahan, 1964). Following termination of pregnancy,
the woman is reclassified into an approprate category of glucose into-
lerance based on her postpartum plasma glucose levels.
In addition to the clinical classifications out~ined above, two sta-
tistical risk classes of glucose intolerance have been established. The
category Previous Abnormality of Glucose Tolerance (PrevAGT) is restricted
to persons who now have normal glucose tolerance but who have previously
demonstrated impaired glucose intolerance or diabetic hyperglycemia. For
example, obese diabetics whose glucose tolerance returns to normal after
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loss of weight, and ge~tational diabetics whose glucose tolerance returns
to normal following parturition would be included under the classification
PrevAGT. The second statistical risk classification is Potential
Abnormality of Glucose Tolerance (PotAGT). This class would include per-
sons who have never exhibited glucose intolerance, but who are at a
substantially increased risk of developing diabetes mellitus. Individuals
at increased risk for development of 100M include: 1) persons with islet-
cell antibodies, 2) monozygotic twins of 100M diabetics, 3) siblings of
IDDM diabetics, and 4) offspring of lOOM diabetics. Persons who are at
increased risk for development of NIDOM included: 1) monozygotic twins of
NIOOM diabetics, 2) first-degree relatives of NIDDM diabetics (e.g.
sibling, parent, or offspring), and 3) members of ethnic or racial groups
among which high prevalence of diabetes has been observed. Although the
above are listed in decreasing order of apparent risk, the actual risk
associated with any of these circumstances is not well established as yet.
With respect to classification of subjects, the National Diabetes Data
Group (1979) recommended the following criteria for the diagnosis of diabe-
tes mellitus in nonpregnant adults. First, unequivocal hyperglycemia in
the presence of classic diabetic symptoms such as polyuria, polydipsia,
ketonuria, and rapid weight loss is considered diagnostic of diabetes.
Otherwise, dia~nosis is based on measurement of plasma glucose con-
centration. A ;asting venous plasma glucose concentration in excess of 140
mg/dl (normal value defind as <115 mg/dl) on more than one occasion consti-
tutes diagnosis. Under such circumstances, administration of an OGTT is not
required, because virtually all persons with a fasting venous plasma glu-
cose concentration in excess of 140 mg/dl would exceed the OGTT criteria.
Finally, diagnosis based on a 75 9 OGTT requires sustained elevation of
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plasma glucose concentration on more than one occasion; elevated glucose
concentration is defined as venous plasma glucose concentration in excess
of 200 mg/dl (normal value defi~ed as <140 mg/dl) for the 2-h sample and in
excess of 200 mg/dl (normai value defined as <200 mg/dl) for an additional
sample taken between dose administra~ion and 2-h. Subjects whose glucose
values are above those defined as normal but below those considered
diagnostic of diabetes are generally classified as IGT patients.
Specialized criteria for the diagnosis and classification of glucose into-
lerance in children and pregnant adults were also recommended by the
National Diabetes Data Group (1979); details of these criteria can be
obtained by the interested reader from the original report.
B) Abnormal Physiology in Diabetes Mellitus and Its Reversibility
The ultimate objective of medical research is to prevent disease, or,
in the absence of absolute prevention, to develop effective cures.
Unfortunately, the development of a-cell defects and their causes are not
well understood, and thus it is unlikely that prevention or absolute cure
of diabetes will be realized in the foreseeable future. A great deal of
effort is therefore being directed toward treatment of the disease, and in
particular toward developing improved insulin therapies in the hopes of
preventing the chronic complications associated with diabetes. Within this
context, a physiologic model of glucose metabolism provides a powerful tool
for ceveloping and assessing the effectiveness of insulin therapies.
Using the model of glucose metab~lism in normal, nondiabetic subjects
as a starting point, development of diabetic model(s) entails the iden-
tification, characterization, and modeling or remodeling of the metabolic
processes that deviate or cause deviation from normal behavior. Such
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abnormal physiology can be divided into two categories, primary and secon-
dary. The primary, or causal abnormal physiology of diabetes is deranged
pancreatic insulin response to glycemia. Other aberrant physiology,
generally considered secondary to the development of diabetes, includes
insulin resistance and reduced counterregulatory response to hypoglycemia.
The distinguishing feature of the secondary physiologic abnormalities is
the possibility of their avoidance and/or reversibility as a result of
improved glycemic control and insulin delivery.
In this section, the abnormal physiology associated with glucose meta-
bolism in diabetics will be discussed, together with evidence concerning
its reversibility. Since the present objective of diabetic modeling is to
develop a tool for assessing the efficacies of insulin therapies, emphasis
will be placed on abnormal physiology related to insulin-dependent, or Type
I diabetes mellitus.
1) Pancreatic Insulin Response to Glycemia
Deranged insulin response to glycemia is characteristic of diabetes
mellitus. Presented in Figure 85 are data correlated by Reaven and Miller
(1968) showing the relationships between glucose and insulin responses to
oral glucose for subjects with varying degrees of glucose intolerance. As
demonstrated in the upper plot, increased severity of glucos(~ intolerance
was clearly associated with a systematic increase in plasma glucose con-
centration. As evidenced in the lower plot, however, plasma insulin
responses exhibited a rather complex behavior. For subjects with impaired
glucose tolerance, insulin levels were substantially higher than normal; in
a more absolute sense, however, relative to the elevated glycemia accom-
panying the impaired glucose tolerance, insulin response was probably
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somewhat diminshed from normal. Although mOt~e severe diabetes wa~ charac-
terized by a greatly attenuated insulin response, mild diabetic glucose
intolerance was associated with an intermediate impairment of insulin
response (relative to glycemia) together with a deranged temporal patterning
suggestive of delayed pancreatic responsiveness. Similar glucose-insulin
relationships following OGTT administration have been reported by Seltzer
et al. (1967) and appear to be characteristic of the various degrees of glu-
cose intolerance.
NIDDM patients display a ;reat diversity of insulin responses to glu-
cose (Reaven, 1984). In response to an OGTT, insulin levels seem to
increase with progressive degrees of hyperglycemia up to a certain point,
but patients with the most severe NIDDM have the lowest insulin levels
(Reaven and Miller, 1979). Brunzell et al. (1976) have demonstrated that
the acute insulin response during the first few minutes after an intrave-
nous glucose challenge is abolished in NIDDM patients with fasting plasma
glucose levels in excess of 115 mg/dl. It is interesting, however, that
patients with NIDDM who have lost the acute insulin response to intravenous
glucose show relatively normal acute insulin response to other intravenous
secretagogues, such as isoproterenol (Robertson and Porte, 1973) and argi-
nine (Palmer et al., 1976), suggesting a primary defect in NIDDM is loss of
acute a-cell responsiveness to glucose. Although NIDDM patients with
severe fasting hyperglycemia show absolute hypoinsulinemia in response to
an OGTT, Lui et al. (1983) have demonstrated that the day-long circulating
insulin levels are within normal limits in these severely hyperglycemic
NIDDM patients. It is obvious from the above that the 'a-cell defects in
NIDDM are complex and result in a wide spectrum of insulin responses.
In Type I diabetes mellitus, the prediabetiG period prior to onset of
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clinically overt diabetes is characterized by appearance of islet cell
antibodies and activated T-lymphocytes together with a progressive loss of
acute early-phase insulin response to intravenous glucose (Srikanta et al.,
1983a; 1983b; 1984). IDOM usually results in an abrupt onset of overt
symptoms. Prior to diagnosis, insulin insufficiency can contribute to
catabolism of the a-cell and can thus cause an acute functional disturbance
of those cells not having been morphologically destroyed (I~enzel et al.,
1981). Initial insulin ther3PY often triggers a temporary remission with
increased capacity for endogenous insulin reponse (Park et al., 1974)
r2sulting from reversal of the functional disturbance of the intact a-cells
(M~nzel et al., 1981). Independent of this, however, the irreversible pro-
cess of morphological destruction of the a-cell progresses with duration of
diabetes. ~though the interpretatio~ of such data is somewhat controver-
sial (Polonsky and Rubenstein, 1984), several investigators (Block et al.,
1972; Vue et al., 1978; Menzel et al., 1981) using circulating C-peptide
immunoassay have shown that residual insulin secretion (RIS) ;s quan-
titatively insignificant for the majority of IDDM patients and is par-
ticularly difficult to observe in unstable patients or in diabetics for
whom the duration of the overt disease has exceeded several years. Thus,
in contrast to NIDDM, IDOM is generally characterized by abrupt onset of
symptoms and nearly complete failure of a-cell function.
2) Insulin Resistance
Insulin resistance is a common feature of diabetes mellitus. There
are two basic causes of insulin res:stance. The first involves tissue
resistance to the action of insulin in regulating glucose metabolism. The
second is associated with the presence of circulating insulin antibodies in
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insulin-tre~ted diabetics which result from the immunogenicity of conven-
tional exogenous insulins.
a) Tissue Resistance to the Action of Insulin
As was evidenced by the plasma glucose and insulin OGTT response cur-
ves of Figure 85, certain types of impaired glucose tolerance are charac-
terized by hyperglycemia in the presence of insulin levels that are higher
than normal. Such behavior is associated with tissue resistance to insulin
as excessive insulinemia fails to stimulate normal glucose disposal and
tolerance.
The euglycemic insulin clamp technique (DeFronzo et al., 1979) has
provided a means for assessing dose-response characteristics for the
effects of insul in on glucose disposal (Rizza et al., 1981). In the eugly-
cemic insulin clamp technique, plasma insulin is acutely elevated to a prede-
termined constant level by a primed-continuous infusion of exogenous
insulin, while plasma glucose is maintained constant at a euglycemic level
by means of a variable infusion of exogenous glucose. The glucose infu-
sion rate required to maintain euglycemia equals the sum of the dE!Cremtent
in endogenous glucose production rate and the increment in tissue ~11ucl)se
uptake rate and thus serves as an index of the overall f!ffect of insul in on
total-body glucose metabolism. ~se-respcnse curves are generated by
repeating the euglycemic insulin clamp at varicus plasma insulin levels and
plotting steady state glucose infusion rate as <1 funct~jon of steady state
plasma insul in concentration. Such a dos(~-respl)nse re'lationship for norrr.al
man (Rizza et al., 1981) is illustrated in the up~er plot of Figure 86. By
combining the eug"lycemic insulin clamp technique with simultaneous i~;otope
turnover measurement of endogenous 91 ucose producticn, the separat1e effects
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of insulin level on endogenous glucose production anc tissue glucose uptake
can be distinguished (DeFronzo et al., 1978) as shown for normals (Rizza et
al., 1981) in the lower panel of Figure 86.
Insulin resistance results in a shift from normal of the sigmoidal
dose-response curves for insulin stimulation of glucose metabolism. Since
insulin exerts its biologic action through binding to specific cell
membrane receptors (for review see Kahn, 1979), the effects of receptor
versus postreceptor defects on shifting of in vivo insulin stimulation of
glucose metabolism can be predicted (Kahn, 1978; Olefsky, 1981) as shown in
Figure 87. The first type of insulin resistance, as defined by theoretical
insulin dose-response .curves, is the pure receptor defect, termed decreased
sensitivity. The pure receptor defect is caused by a reduction in the
number of insulin receptors at the target tissue cell membrane. Since the
biologic acitivity of insulin is dictated by the quantity of receptor-
bound insulin, and this is generally an equilibrium-limited association, a
reduction in the number of receptors requires higher insulin concentrations
to affect the srme quantity of bound insulin. Because of the great excess
in the number of receptors normally available for binding at high insulin
concentrations, the maximal biologic response can be realized even in the
presence of a reduction in total receptors available for binding at a given
insulin concentration. The pure receptor defect is thus chdracterized by
a rightward shift in the insulin dose-response curve without change in the
maximal response (see Figure 87). The second type of insul'in resistance in
the pure postreceptor defect, termed decreased responsiveness. The pure
postreceptor defect is caused by a lack of proper intracellular metabolit
response to a given level of receptor-bound insulin. Such impaired
response could arise from abnormal intracellular enzyme levels. The pure
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tis~ue glucose utilization in normal subjects are
shown in the lower plot. Numbers of subjects are
indicated 1n parentheses. (From Rizza et al.~ 1981)
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A. Receptor Defect -- Decreased Sensitivity
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8. Post-Receptor Defect - Decreabed Responsiveness
c. Combined Deleet - Decreased Sensitivity and
Decreased Responsiveness
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Fig. 87 Theoretical shifts in the dose-response curves for the
biological action of insulin resulting from a pure
receptor defect (A), a pure postreceptor defect (B),
and a combined receptor and postreceptor defect (e).
(From Olefsky, 1981)
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postreceptor defect in characterized ily a proportionate reduction in
response at all insulin leve1s and an impairment of maximal response (see
Figure 87). Finally, a coexistence of receptor and postreceptor defects
would be represented by a rightward shift in the dose-response curve
together with a decrease in maximal response.
Because hyperglycemia in the presence of hyperinsulinemia is often
observed in NIDDM patients, insulin resistance in NIDDM has been exten-
sively studied (Ginsberg and Rayfield, 1981; Scarlett et al., 1982;
Mandarino and Gerich, 1984; Andrews et al., 1984) in an effort to elucidate
the complex interplay between the defects in insulin secretion and insulin
action which manifest the disease (Reaven, 1984; Skyler, 1984). Use of the
euglycemic insulin clamp method to generate in vivo ,insulin dose-response
curves in NIDDM subjects (Scarlett et al., 1982; Mandarino and Gerich,
1984) has demonstrated a decrease in insulin sensitivity suggestive of a
postreceptor defect, as shown by the data of Mandarino and Gerich (1984)
in Figure 88. As previously discussed, insulin action can be attributed
both to suppression of endogenous glucose production and to stimulation of
tissue (muscle and liver) glucose uptake. By use of [3_ 3H] glucose infu-
sions and isotope turnover analysis, Ginsberg and Rayfield (1981) and
Mandarino and Gerich (1984) have directly shown that the overall insulin
resistance in NIDDM is a result of both decreased insulin suppression of
hepatic glucose production and decreased insulin stimulation of tissue glu-
cose uptake.
An important aspect of insulin resistance concerns its reversibility.
Reaven et al.(1977) have shown that insulin insensitivity develops in nor-
mal dogs made diabetic with alloxan, but that this acquired insulin
resistance is reversed by treatment with exogenous insulin. Thus, it is
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Gerich, 1984)
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possible that the insulin resistance observed in NIDDM is secondary to
abnormal insulinemia. This possibility has been studied in insulin-
deficient NIDDM by use of insulin administration or oral hypoglycemic
agents to correct for insulin deficiency and improve glycemic regulation.
Hidaka et al.(1982) reported little improvement in in vivo insulin action
following 7 days of insulin treatment (4 subcutaneous injections of regular
insulin per day) in obese NIDDM 5ubjects. Scarlett et al. (1982), however,
indicated that 14 days of insulin treatment (2 injections of regular and
NPH purified pork insulin per day) essentially reversed the insulin
resistance in patients with NIDDM. Ginsberg and Rayfield (1981) found
improvement in insulin responsivene~~ :~tributable to both hepatic and
tissue contributions following 1-8 weeks of insulin therapy (singie injec-
tion of intermediate-acting insulin per day) in some of the NIDDM patients
studied, but results varied greatly over the group of NIDDM patients as a
whole, suggesting that the underlying causes of insulin resistance may be
heterogeneous with some defects being unresponsive to insulin replacement.
In a recent study, Andrews et al. (1984) reported that 1 month of insulin
treatment (3 subcutaneous injections of monocomponent insulin per day)
caused improvement in insulin action in a group of 13 NIDDM patients and
that insulin sensitivity no longer deviate~ significantly from a weight-
and age-matched group of normals, although this improvement varied con-
siderably from patient to patient. In addition, the observed improvement
in insulin action persisted for at least 2 weeks after cessation of insulin
therapy. Finally, Mandarino and Garich (1984) showed that prolonged
(~ mol administration of an oral hypoglycemic agent (tolazamide) resulted
in decreasing insulin resistance in a group of 18 NInOM patients, and this
decrease in insulin resistance was attributable to correction of post-
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receptor disorders associated with both the suppression of hepatic glucose
production and the stimulation of tissue glucose uptake. Similar results
have been reported by ~lterman and Olefsky (1984) for NIDDM subjects as a
result of prolonged (3-18 rna) treatment with the oral hypoglycemic agent
glyburide. Since oral hypoglycemic agents, in addition to stimulating s-
cell insulin secretion, can act directly on the lE!vel of cell metabolism
and its regulation by hormones (Levine, 1984), the reversal of insulin
resistance noted in the above studies could have in part resulted from fac-
tors other than enhancement of insulinemia. Nonetheless, although the
results to date are somewhat mixed, increasing evidence supports the notion
that the insulin resistance associated with insulin-deficient NIDDM can be
reversed with proper insulin replacement.
Although insulin resistance has been a well-recognized feature of
NIDDM, only recently has insulin resistance also' been recognized as a pro-
minent feature of Type I 100M. DeFronzo et ale (1982) used insulin clamp
methods to study insulin resistance in IDOM sUbjects. When euglycemic
levels of plasma glucose were maintained while plasma insulin concentration
was elevated to comparable levels (- 100 mU/ml) in both a group of Type I
diabetics (n = 8) and a group of nondiabetic controls (n = 36), insulin-
mediated glucose metabolism rose to 3.39 ± 0.30 rng/kg.min in the diabetic
group versus 7.03 ± 0.22 mg/kg-min in the control group; thus, response to
insulin was only 48% of normal in the diabetics. When the insuin clamp
experiment was repeated at hyperglycemic plasma glucose levels (- 170
mg/dl), insulin-mediated glucose metabolism was 4.77 ~ 0.18 mg/kg.min in
the diabetic group (n = 11) versus 12.14 ± 0.96 mg/kg.min in the control
group (n = 5); in this case, insulin response was only 39% of normal in the
diabetics.
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Revers et al. (1984) and Pernet et al. (1984) have employed euglycem;c
insulin clamp methods to construct dose-response curves for insulin stimu-
lation of glucose metabolism in Type I diabetics. Revers et al. (1984)
studied the insulin dose-response relationship in 5 well controlled Type I
diabetics (6 weeks of intensive conventional injection therapy, home glu-
cose monitoring 2-4 times daily and frequent adjustments in insulin dosage;
glycosylated hemoglobin of 7.2 ± 0.2%), 5 poorly controlled Type I diabe-
tics (conventional injection therapy, urinary glucose measured daily and
relatively fixed insulin dosage; glycosylated hemoglobin of 11.7 ± 0.6%),
and 21 age-matched normal subjects (glycosylated hemoglobin range of 5.5 -
7.0%); the dose-response curves for these three groups are shown in Figure
89. Insulin-stimulated glucose disposal in the well controlled diabetic
subjects was comparable to that in the normal subjects, with similar half-
maximally effective insulin levels and virtually identical maximal rates of
glucose disposal. In contrast, the dose-response curve for insulin stimu-
lation of glucose disposal in the poorly controlled diabetic subjects was
significantly right-shifted with a marked reduction in the maximal glucose
disposal rate. Thus, the insulin resistance observed in the poorly
controlled Type I diabetics was significantly right-shifted with a marked
reduction in the maximal glucose disposal rate. Thus, the insulin
resistance observed in the poorly controlled Type I diabetics was charac-
teristic of a combined receptor (decreased sensitivity) and postrec€ptor
(decreased responsiveness) defect (see Figure 87).
Pernet et al. (1984) used sequential graded euglycemic insulin clamps
to study the insu'"in dose-response curve for glucose metabolism in 6 Type I
diabetics (conventional insulin injection therapy; glycosylated hemoglobin
of 9.8 ± 0.5%) and 8 normal controls (glycosylated hemoglobin of 6.6 ±
325
~
e 400
"H~
"caE
'J
l&.I 3OO
l-
e
a::
..J
c(
en zoo
oQ.
en
is
w
en
o
(.)
:)
-J
CJ
100 1000 10.000
Fig. 89
INSlUN CONCENTRATION (pU/mD
Experimen~al Data (Mean ± SEM):
• Normal Subjects (n=21)
4 Well Controlled Diabetic Subjects (n=5)
• Poorly Controlled Diabetic Subjects (n=5)
Comparison of dose-response curves for insulin
stimulation of glucose metabolism in normal subjects,
well controlled Type I diabetics, and poorly controlled
Type I diabetics. Glucose disposal rate was based on
the steady state glucose infusion rate required to
maintain euglycem1a during graded insulin clamping:
(From Revers et al., 1984)
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0.2%); the reported dose-response data from this study is plotted in Figure
90. As shown in the figure, the dose-response curve for insulin-stimulated
glucose metabolism was significantly right-shifted for the diabetic group,
but the maximal stimulation at high insulin levels was comparable to that
in the normal subjects. The insulin resistance observed in this group of
Type I diabetics was thus characteristic of a receptor (decreased
sensitivity) type of defect. It should be mentioned that the glycosylated
hemoglobin levels in the IDDM subjects studied by Pernet et al. were inter-
mediate between the levels distinguishing the poorly and well ~ontrolled
100M subjects in the study of Revers et al. Thus, comparison of the dose-
response curves in Figures 89 and 90 could suggest that the postreceptor
defect is a consequence of a more poorly controlled diabetic state than is
the receptor defect.
With respect to the underlying causes of the insulin resistance
obse~ved in Type I diabetics, dose-response curves distinguishing betw2en
suppression of hepatic glucose production and tissue glucose uptake have
not been reported to date. Although normal inhibition (essential
suppression) of hepatic glu~ose production has been demonstrated in Tipe I
diabetics at high physiologic insulin levels () 100 mU/ml) (DeFronzQ et
al., 1982; Proietto et al., 1983; Revers et al., 1984), studies at low phy-
siologic insulin levels have not been performed, and thus the possibility
of a receptor defect (or decreased sensitivity) cannot be ex=luded. Since
hepatic glucose production was essentially suppressed at the high physiolo-
gic insulin levels employed in the studies of DeFronzo et al. (1982) and
Revers et al. (1984), the observed insulin resistance must be attributed
to a defect in tissue glucose uptake.
Since insulin-sensitive glucose uptake occurs in muscle and liver,
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Experi~ental Data (Mean ± SEM):
• Nonnal Subjects (n=8)
-Type I Diabetic Subjects (n=6)
Dose-response curves for insulin stimulation of glucose
metabolism in normal subjects and in Type I diabetics.
(Data from Pernet et a1 •• 1984)
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there are two underlying modes that could contribute to the observed insu-
lin resistance in tissue glucose uptake in the Type I diabetico In a
recent study at the Joslin Research Laboratory, Meistas et al. (1984) pro-
vided the first direct measure of insulin resistance across forearm in 100M
sUbjec~s. A group of 6 IDOM subjects receiving conventional insulin
therapy (CIT) were studied initially on CIT and again after 5 days of
intensive closed-loop insulin therapy on the artificial beta cell (ABC). A
group of 5 age- and weight-matched normal controls was also studied. The
euglycemic insulin clamp technique was combined with forearm glucose uptake
measurements such that both whole-body glucose metabolism rate and fOl~earm
glucose uptake rate could be simultaneously determined under comparable
conditions of euglycemic hyperinsulinemia in both the IDOM and normal sub-
jects. Results of the study are summarized in Table 35. The rate of
insulin-stimulated glucose metabolism (glucose infusion rate) was markedly
reduced in the 100M subjects (~48% of normal) and was not significantly
improved by 5 days of ABC therapy. Similarly, there was significant
resistance to insulin-stimulated glucose uptake by forearm in the IDDM sub-
jects (~39% of normal) that was also not significantly improved by the
intensive insulin therapy.
Although the above forearm data provides direct confirmation of muscle
insulin resistance in the Type I diabetic, it is interesting to extrapolate
the forearm values to whole-body muscle uptake to examine whether the
muscle insulin resistance entirely accounted for the observed whole-bcJy
resistance to insulin stimulation of glucose metabolism. The mean rate of
forearm glucose uptake in the 100M (CIT and ABC) studies was 0.21 mg/IOO ml
forearm/min, or 0.33 mg/IOO ml forearm/min less than that measured in the
normal subjects. Extrapolating this decrement in forearm glucose uptake to
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Table 35. Steady state data (mean ± SEM) of Mefstas et al. (1984) for combined
euglycem1c insulin clamp and forea~ glucose uptake studies in IDOM
and normal subjects.
PLASMA PLASMA GLUCOSE INFUSION RATE OF FOREARM
GLUCOSE CONe. INSULIN CONt. RATE GLUCOSE UPTAKE
SUBJECTS (mg/dlJ (mUll) (mg/kg/min) (mg/l0oml forearm/min)
IDDM (n-6)
CIT 84 :!: 4 78 :t 2 3.26 :J: 0.77 0.18 ± 0.07
ABC 90 :t 4 76 :t 4 3.90 :t 1.01 0.24 t 0.10
Normal (n-S) 6g :t 2 82 :t 3 7.49 :t 1.01 0.54 :t 0.22
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a whole-body muscle value (extrapolation of forearm data was deta.iled in a
previous section, Basal r~etabolism of Peripheral Tissues) y'ields a total
muscle resistance of 155 mgjmin in a 70 kg man, or 2.21 m~,/kg (body
weight)/min. From the glucose infusion data of Table 35 11 ho\,eve'r, the
total observed mE!an insul ~in resistance in the 100M subjects (CIl and ABC)
was 3.91 mg/kg/mi n rel ati ve to normal. Thus, decr,eased muscl (:~ glucose
uptake could only account fot" roughly 60% of the observed °insul in
resistanCle. Assuming that hepatic gluccse production was essentoially
sur:.ressed at the insul in levels of this study, the above e'Jideri1c l :! would
suggest a defect in li'ver insulin sensitiv~ity which, together with muscle
insulin re~)istance, ~is not significantly inlproved by 5 days o'fintensive
ABC insulin therapy.
One explanation far decreased muscle response to insul in stilnulation
of glu,cose uptake is the possibil ity that th,e muscle glycogen stOt~age capa-
city in diabetic:i is re'\atively saturated rnos,t of the time (Aoki 9 1984).
As disc.u:ised in a prev;clus $ection, the I1lajor' rout,: of gluCOSE! disposal in
muscle ti'~;sue is conversion to muscle gl.)'co£len. Normal sUbjects e~xhib;t a
large capacity to store 11ucose as muscle glycogen, and the muscle glycogen
; n turn i:~ depl eted for lise as an energj' sou\~ce fo~~' musel e ti ssue duri ng
exercise. The peripheral hyperinsulinemia associated with peripheral insu-
lin thera.pies together with high circulating glucose levE~ls in diabetics
could res;u'lt in enhanced nluscle glycogen formcttion caus'~ng effective
saturation of muscole glycogen storage ca.pacity. In such a case, mdscle
response to insulin-stimulated glucose uptake would be inhibited leading to
an observed resistance to the action of insulin. Unfortunlately, muscle
glycogen content has not been assessed in any of the insulin resistance
studies to appear" in the literature to date and thus may constitute an
important uncontrolled variable lending difficulty to the interpretation of
these studies.
Increasing evidence suggests that the insulin resistance observed in
poorly controlled Type I diabetics is reversible. Mayfield et ale (1983)
reported a significant decrease in the insulin dose needed to maintain
blood glucose control during the first 5-10 days of placing poorly
controlled 100M subjects on continuous subcutaneous irtsulin infusion pump
therapy. Furthermore, there was a correlation between the initial glycosy-
lated hemoglobin levels (HbAlc levels cGrrelate inversely with glycemic
control) in patients and the subsequent decrease in insulin dosage required
to maintain glycemic control, the insulin dose decreased 31.3 ± 4.1% in
patients with initial HbAlc > 11%, whereas in patients with initial HbAlc <
11% the insulin dose decreased only 8.6 ± 4.9%. Thus, patients most poorly
controlled by conventional therapy demonstrated the greatest apparent
reversal of insulin resistance.
Foss et ale (1982) recently reported that glucose processing
(oxidation and storage) in Type I diabetic patients was gradually restored
by 48-72 h of intensive ABC insulin therapy. In particular, a progressive
rise in carbohydrate oxidation rates in response to the ingestion of a
mixed meal was induced over the duration of the study. Since C02 produc-
tion acruss forearm does not significantly increase above basal during an
OGTT (Aoki, 1983a), the increase in carbohydrate storage was attributed to
restoration of hepatic glucose processing capacity. In a subsequent study,
Aoki et al. (1983b) measured forearm glucose uptaking during an OGTT in
Type I diabetics on CIT and after 72 h of ABC insulin treatment; the total
quantity of glucose taken up by muscle did not significantly change as a
result of the ABC insulin therapy and further enforced the notion that the
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restoration of glucose processing induced by 72 :1 of ABC treatment was
the result of improvement of a h~patic defect. At first, the above results
might appear inconsistent with interpretation of the forearm insulin clamp
studies of ~eistas et al. reviewed earlier. It must be noted that Foss et
ale and Aoki et al. were concerned only wi~h normalization of the quan-
tities of glu~ose processed by muscle and liver, respectively, following
OGTT administration, and not with the insulinemia required to affect these
results; after 72 h of ABC therapy, even though the total glucose pro-
cessing capacity had been restored to normal, the circulating plasma insu-
lin levels required to realize this improvement were still two-to-threefold
higher than those observed in normal subjects during the OGTT. In
contrast, Meistas et al. (1984) demonstrated that the rate of insulin-
stimulated glucose metabolism in both muscle and liver remained signifi-
cantly impaired in Type I diabetics after 72 h of ABC insulin therapy in
comparison to that observed in normals when each group was tested at com-
parable levels of euglycemic hyperinsulinemia. Thus, insulin resistance
was in evidence following 7~ h of ABC in all of the above studies, but
apparently the intensive closed-loop insulin delivery affected a partial
imprcvement in a hepatic glucose processing postreceptor defect such that
the elevated insulinemia evoked by ABC therapy was successful in nor-
malizing the quantity of glucose processed during the OGTT.
Beck-Nielson et al. (1984) recently studied insulin resistance in a
group of IDOM subjects changed from conventional injection therapy to con-
tinuous subcutaneous insulin infusion (CSII) treatment with a portable
pump. During eugylcemic insulin clamping (plasma insulin concentration of
about 80 mUll), insulin stimulation of glucose metabolism was 4.3 ± 2.0
mg/kg/min in a group of 11 IDOM subjects treated conventionally (diet and
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injection therapy, duration of diabetes 10.7 ± 5.6 yrj HbAlc of 8.9 ± 1.9%)
compared with 11.5 ± 4.0 mg/kg/min in a group of 10 normal controls. The
IDOM group was then placed on CSII pump treatment for 6 rno and the measure-
ments repeated; the CSII therapy resulted in improved glycemic control
(HbAlc decreased to 7.4 ± 1.2%) and insulin-stimulated glucose metabolism
increased about 80% to 7.5 ± 3.5 mg/kg/min during insulin clamping. Thus,
6 rna of CSII insulin treatment affected a significant reversal of the
tissue insulin resistance observed in the conventionally treated lOOMs.
The strongest evidence to date for the reversibility of insulin
resistance in Type I diabetics was provided by the studies of Revers et al.
(1984). As was previously shown in Figure 89, the dose-response curve for
insulin stimulation of glucose metabolism for the group of well controlled
100M subjects was virtually identical to that in the normal controls,
whereas significant insulin resistance was evidenced in the group of poorly
controlled lODM subjects. 10 assess the effect of diabetic control on
insulin resistance, Revers et al. studied one Type I diabetic at a time of
poor control and then 6 weeks ufter good control was established with careful
glucose monitoring and intensive multiple daily insulin injection therapy. As
illustrated in Figure 91, 6 weeks of intensive insulin therapy and good glycemic
control resulted in significant reversal of insulin resistance and normalization
of maximal insulin-stimulated glucose metabolism in this patient. The duration
of the above experiments suggests that a substantial period of good control
may be required for normalization of all of the varous modes of insulin
resistance in the Type I diabetic.
To summarize, insulin resistance is a prominent feature of both NIDDM
and IODM, and is associated with defects in both hepatic and peripheral
glucose processing. Evidence strongly suggests, however, that the insulin
334
500
IJJ
t-
<[ 400a:
-J
«~
~ ~ 300
a.,
(fJN
-~C,
L&J eft 200
mE
0"'"
o
::J
...J
C)
I I
100 1000
INSULIN CONCENTRATION (JjU/ml)
1
10.000
Fig. 91
Experimental Data:
-Normal Subjects (mean ± SEM, n=21)
• Type I Diabetic subject before insulin therapy
~ Type I Diabetic subject after 6 weeks of intensive
insulin management
Reversal of insulin resistance in a poorly controlled
Type I diabetic subject after 6 weeks of intensive
(conventional) insulin management. (From Revers et
a1., 1984)
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resistance observed in insulin-deficient NIDDM and poorly controlled 100M
is reversible with improved glycemic control and insulin management. The
time required and the degree of glycemic control and insulin management
necessary to affect normalization of insulin resistance are not as yet well
understood and will require further study.
b) Insulin Binding to Circulating Anti-Insulin Antibodies
Conventional insulins used for the treatment of diabetes are immunoge-
nic and cause the development of circulating antibodies to insulin as
orignally shown in the early studies of Berson et al. (1956). Insulin
antibodies bind plasma free insulin, and antibody-bound insulin is biologi-
cally inactive (Antoniades and Simon, 1972; De Pirro et al. 1980).
The capacity of antibodies to bind free insulin in diabetic patients
can be estimated from in vitro binding studies. Berson and Yalow (1959)
analyzed insulin antibody binding in plasma samples drawn from two groups
of insulin-treated diabetics, an insulin-resistant group of 5 subjects
categorized as such due to their extremely high daily insulin dosage
requirements (230 ± 70 U/day), and a nonresistant group of 5 sUbjects whose
insulin requirements were more typical (18 ± 4 U/day). Equilibrium cross-
competition binding between labeled and cold insulin was repeated at
various free insulin concentrations, and the resulting quantities of bound
and free insulin were determined. The experimental equilibrium binding
data was analyzed using the classical Scatchard plot; values for the ratio
of bound to free insulin concentration (B/F) were plotted against the con-
centration of bound insulin (B). The characteristic nonlinear shape of the
resulting Scatchard plots were ascribed to the presence of two distinct
classes of antibody binding sites (see De Meyts and Roth, 1975), a high
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affinity site of low capacity, and a low affinity site of high capacity.
For each class of sites,
k+
1
F + E1 *
B1
ki
k+
2
F + E2 * B2
k-
2
a chemical reaction equations may be written,
(206)
(207)
where F = concentration of free insulin (U/l)
Ei = concentration of empty binding sites (U/l)
B; = concentration of antibody-bound insulin (U/1)
kt = rate constant for insulin antibody association (l/Uomin)-l
k: = rate constant for insulin antibody dissociation (min)-l
1
From classical chemical kinetics, the opposing first and second order reac-
tions of Equations 206 and 207 may be expressed
(208)
(209)
Under equilibrium conditions, it follows that
(210)
(211)
and thus an equilibrium constant may be defined for each class of binding
site,
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k+ B1K1
1
= -- -k- FE!1
k+ 82K2
2
= -- -
k2 FEZ
(212)
(213)
Letting B~ denote the total concentration of binding sites of a particular
type, for a constant antibody level
(214)
(215)
SUbstituting Equations 214 and 215 into Equations 212 and 213 to eliminate
E1 and E2 respectivelYt the ratios of bound to free insulin for each class
of sites may be expressed
(216)
(217)
Since the total concentration of antibody-bound insulin B is simply given
by
(218)
it thus follows from Equations 216 and 217 that
(219)
From nonlinear experimental Scatachard plots of B/F versus B, Berson
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and Yalow used curve-fitting methods to determine values of the equlibrium
constants K1 and K2 and the maximum capacities of sites 81 and 82 for the
plasma samples of each individual studied. In addition, transient state
dissociation experiments were performed for the determination of the rate
constants kl and k2. Mean parameter values for the insulin resistant and
nonresistant groups are summarized in Table 36.
The parameter values listed in Table 36 together with Equations 218
and 219 were used to generate representative Scatchard equilibrium binding
plots for the insulin-resistant and nonresistant diabetic groups, respec-
tively, as presented in the upper panels of Figure 92& Although Scatchard
plots are particularly useful for analyzing equlibrium binding data, the
quantitative implications of insulin antibody binding are more readily
interpreted from plots relating bound insulin concentration and free insu-
lin concentration. Solving Equations 216 and 217 for bound insul;n~
respectively, yields
81
K1 BO=
1 1(- + K1)F
82
K2 BO=
1 2(- + K2)F
(220)
(221)
and successive substitution of these expressions into Equation 222 gives
K1 0 K2 08 = --- 81 +--- 82(.! + K1) (.! + K2)F F
(222)
Substitution of the parameter values of Table 36 into Equation 222 pro-
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Table 36. Insulin antibody binding parameters. Mean ± SEM values were calculated from
the individual plasma sample values reported by Berson and Yalow (1959) for a
group of 10 insulin-treated diabetics, with binding capacities segregated bet-
ween the subgroups af nonresistant (n-5) and insulin-resistant (n=5) subjects.
High-Affinity Site:
Low-Afffnity Site:
K1 - 10.3 ~ 4.0 l/U
ki. 0.0030 ± 0.0010 min-1
k; D 0.025 ± 0.014 l/U-mfn (calculated)
aO • { 0.46 ± 0.21 U/l nonresistant subgroup
1 14.5 ± 4.2 U/l resistant subgroup
K2 • 0.307 ± 0.096 l/U
ki · 0.11 ± 0.03 .in-1
k; • 0.029 ± 0.001 l/U·mfn (calculated)
80 • {7.6 ± 3.2 U/l
2 83. ± 18 U/l
Total Bindfng caPlct~:
80 80 • {S.l t 3.4 U/l1 + 2 8 22 /19 ± U
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Fig. 92 Scatchard binding curves (upper panel) and plot of
antibody-bound versus free insulin concentrations
(lower panel) for insulin-resistant and nonresistant
diabetics. Plots were generated from the binding
parameters of Table 36 obtained from the studies of
Berson and Yalow (1959).
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vided the means for generating plots of B versus F, and the resulting cur-
ves are presented in the lower panel of Figure 92. Additional plots
showing the fractions of free and bound insulin as functions of free insu-
lin concentration are included in Figure 93.
As indicated in Table 36 and the lower plot of Figure 92, the maximum
capacity to bind insulin, or the total concentration of antibody-binding
sites, was 8.1 and 98 U/l in the nonresistant and and resistant groups,
respectively. Although the maximum binding capacities were quite large,
saturation of binding sites at these high values was realized at supraphy-
siologic plasma free insulin concentrations (>10,000 mUll). Of more prac-
tical interest is the quantity of bound insulin expected over physiologic
ranges of plasma free insulin concentration (~10-100 mUll). It can be
interpolated from the lower plot in Figure 92 that increasing .plasma free
insulin concentration from 10 to 100 mUll would elevate the antibody-bound
insulin concentration from about 70 to 420 mUll in the more typical nonre-
sistant diabetic, or result in the equilibrium binding of 350 mUll of insu-
lin; the same case in the resistant diabetic would elevate the
antibody-bound insulin concentration from about It500 to 10,000 mUll, or
result in the equilibrium binding of 8,500 mUll of insulin. Since the
plasma volume in a 70 kg subject is about 3.36 1, the total increase in
bound insulin would be roughly 1.2 U in the nonresistant and 29 U in the
resistant cases, respectively. It is thus apparent that a sizeable quan-
tity of insulin may be antibody-bound over physiologic changes in plasma
free insulin concentrations in the insulin-treated diabetic. Furthermore,
it is apparent from the lower plot of Figure 93 that the majority of cir-
culating inslin would be antibody-bound at physiologic free insulin levels;
over the free insulin concentration range of 10-100 mUll, the mean fraction
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nonresistant diabetics. Plots were generated from
the binding parameters of Table 36 obtained from the
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of bound insulin would be about 0.85 in the nonresistant diabetic anc
roughly 0.98 in the insulin-resistant diabetic.
Although the presence of insulin-binding antibodies would not alt,er
the incremental insulin infusion rate required to affect d given change in
plasma free insulin concentration from one steady state level to anothe~'
(Scott et al., 1978), their presence would be expected to change the kine-
tics of the transition between steady states due to interaction of free
insulin through association with or dissociation from the antibody-bound
insulin pool. Berson and Yalow (1959) studied the kinetics of the rever-
sible binding of insulin to insulin antibodies. For each type of bitlding
site, di~sociation of insulin was first order in concentration of antibody-
bound insulin, and association of insulin was first order with respect to
both free insulin concentration and concentration of empty antibody-binding
sites (see Equations 208 and 209). From the kinetic studies of Berson and
Yalow (1959) and the resulting values of the antibody-binding rate
constants compiled in Table 36, it can be inferred that the time scales for
reversible insulin antibody binding are on the order of minutes with
respect to the low-affinity, high-capacity sites and on the order of hours
with respect to the high-affinity, low-capacity sites.
Considering the size of the antibody binding pool and the time scales
for reversible binding, it is not surprising that sluggish response of free
insulin concentrations to therapy has been noted in patients with anti-
insulin antibodies (Munkgaard Rasmussen et al., 1975). Such skewing of
plasma free insulin response to insulin infusions in diabetics with insulin
antibodies has recently been reported by clinical investigators. In stu-
dies of glucose counterregulation in 100M subjects, Bolli et ale (1983)
used a continuous 60-min insulin infusion of 28 mU/m 2/min to induce
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hypoglycemia in 6 IDOM patients uith no detectable insulin antibodies, 5
100M subjects with insulin antibodies, and a group of 10 nondiabetic
controls. Plasma insulin response of the diabetics without insulin antibo-
dies did not differ significantly from normal response as a result of the
insulin infusion. In contrast, the diabetics with antibodies exhibited a
significantly delayed response as shown in the upper plot in Figure 94.
Whereas the incremental increase in plasma free insulin levels affected by
the continuous insulin infusion was comparable in the diabetics independent
of the presence of insulin antibodies, both the plasma insulin increase
during the infusion and subsequent decrease following termination of the
infusion was much slower as a result of the presence of insulin antibodies,
suggesting the association of insulin with antibodies as plasma insulin
increased and its subsequent dissociation from antibodies as plasma insulin
decreased. Similarly, in using euglycemic insulin clamps to generate dose-
response curves to characterize insulin resistance in Type I di~betics and
normal subjects, Revers et ale (1984) reported that whereas steady state
insulin levels were achieved within 25 min in normal subjects, 90 min was
required to achieve steady state insulin levels in the diabetic subjects.
The importance of insulin antibody binding in the management of IDDM
patients has been highly controversial. As suggested by the above
discussion, since binding of insulin to antibodies is reversible and equ-
libration occurs over time scales of minutes to hours, the capacity to bind
insulin manifests sluggish response kinetics. Since insulin disappearance
is slowed by the presence of antibodies, and insulin dissociation is not
subject to glycemic feedback control, the presence of antibodies could
increase the likelihood of hypoglyemic episodes in diabetics (Harwood,
1960; Ichihara et al., 1977; Bolli et al., 1983). Although Dixon et ale
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(1975) have proposed that insulin antibodies may exert a favorable effect
on metabolic control of diabetics because of the reversible buffering capa-
city of the antibody-bound insulin pool, other invEstigators (Shima et al.,
1977; Vue et al., 1978; Aspl in et al., 1978; Gonen et al ~, 1979) have
reported no apparent relationship between antibody levels and the stability
and metabolic control of diabetics. Furthermore, antibody binding would
inhibit rapid insulin response to hyperglycemia, and such rapid response
may be required for improved insulin therapies to affect tight glycemic
regulation (Sorensen et al.~ 1982). With respect to the effects of insulin
~nt;bod;es on insulin dosage requirements, early studies (Berson and Yalow,
1959; Berson and Yalow, 1970) indicated a correlation between insulin
resistance and high antibody titers in diabetics. It is likely that the
insulin resistance in these patients was not due to the presence of cir-
culating insulin antibodies, hut rather that the high daily insulin
requirements of these (tissue) insulin-resistant diabetics caused their
development. Since insulin antibody binding is reversible, the presence of
antibodies should not alter the dosage requirements of diabetics, and more
recent studies (Asplin et al. t 1978; Kumar, 1979; Kurtz and Nabarro, 1980)
have cast doubt on any quantitative relationship between insulin require-
ments and circulating insulin antibodies in Type I diabetic patients.
Th~ immunogenicity of conventional insulins has been attributed to the
pioesence of impurities and the species of origin. Fineberg et ale (1983)
have recently studied the immunogen;city of purified pork insulins with and
without trace contamination of beef insulin relative to mixed pork-beef
insulins of lower purity. A group of 137 patients who had not previously
been treated with insulin were divided into groups according to the type of
insulin being administered, and serial assessm~nt of antibody development
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was monitored over the first year of treatment. Results of the study are
shown in Figure 95. As indicated, significantly less antibody development
was observed in the patients receiving the purifiLd pork insulins relative
to those receiving the less pure mixture of beef-pork insulin. In addi-
tion, even trace amounts of bovine insulin, which is more immunogenic than
porcine insulin, enhanced antibody development in comparison with uncon-
taminated porcine insulin. With the increasing availability of highly
purified insulins, several studies (Andreani, 1973; Bruni et al., 1973;
Schlichtkrull et al., 1974) have denlonstrated a decrease of antibody titers
in patients who changed from conventional to purified insulins, and it has
been suggested (Mustaffa et al., 1977) that all diabetics receiving insulin
for the first time, when~ver possible, should be treated with a highly
pUl·ifi.ed insul in.
In summary, the immunogenicity of conventional insulins causes the
development of circulating antlbodies that bind insulin. Antibody levels
vary greatly from patient to patient as evidenced by wide ranges in plasma
binding capacities. Since insulin antibody binding is reversible, the pre-
sence of circulating antibodies causes sluggish insulin response ki~etics
but does not alter dosage requirements. Evidence suggests that the new
purified insulins are significantly less immunogenic than conventional
insulins of the past. Recent progress in purification methods together
with the imminent availability of human insulin through recombinant DNA
technologies offers the promise of insulins that will be essentially nonim-
munogenic.
3) Impaired Counterregulation of Hypoglycemia
Patients with IDDM commonly exhibit blunted or absent glucagon respon-
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ses to hypoglycemia (Gerich et al., 1973; Benson et al., 1977; Maher et
al. s 1977; ~einbaum and Shamaon, 1983), the severity of which largely
segregates with the presence of autonomic nueropathy (Hilstead et al.,
1981). Although glucagon provides the primary stimulus for normal glucose
recovery from hypoglycemia, epinephrine compensates largely for deficient
glucago~ response in IDOM subjects (Cryer and Gerich, 1983).
As previously discussed, release of antibody-bound insulin can prolong
the duration of recovery from hyperinsulinemia and promote hypoglycemia in
diabetics. This situation is further complicated by abnormal glucagon
counterregulatory response. Bolli et al. (1983) recently studied the
abnormal glucose counterregulation in IODM. Three groups of diabetic
patients were studied: Group A - 5 diabetic patieuts, duration of diabetes
less than one month; Group B - 11 diabetic patients, duration of diabetes
1-5 years; Group C - 5 diabetic patients, duration of diabetes 14-31 years
and presence of autonomic neuropathy. A group of 10 age- and weight-
matched nondiabetics was also studied for comparison. Resulting plasmd
free insulin, glucose, and counterregulatory hormone responses to insulin-
induced hypo~lycem;a (28 mU/m 2 .min infusion for 60 m1n) are presented in
Figure 96. In patients with recent-onset diabetes (Group A), insulin, glu-
cose, and glucagon response did not differ from the nondiabetics. In
patients with diabetes of longer duration, insulin response was more
sluggish due to the presence of insulin antibodies, glucagon response was
significantly diminished, and glycemic recovery from hypoglycemia was pro-
longed, and these effects became more pronounced with duration of diabetes
(compare Groups B and C). When glucagon was subsequently infused during
hypoglycemia in diabetics with impaired glucagon responses in order to
simulate normal glucagon responses, glucose recovery was normalized in
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responses to insulin-induced hypoglycemia (28 mU/m2/min
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(open circles). (From Bolli et al., 1983)
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patients without significant antibody levels; thus, the impaired «-cell
secretion was the predominant mechanism for the delayed glucose recovery in
these patients.
Since impaired glucagon response is associated with duration of diabe-
tes, and in particular with the chronic complication of autonomic neuro-
pathy, the question arises whether good glycemic control and intensive
insulin management could normalized «-cell function. Kawamori et al.
(1980) have reported that pancreatic glucagon response to intravenous argi-
nine is perfectly normalized in insulin-deficient NIDDM and IDOM subjects
during intensive ABC insulin delivery. Bolli et ale (1984a) observed that
counterregulatory response remained normal in 5 100M patients over the
first year of insulin injection therapy with intensive management and good
glycemic control (HbAl of 7.9 ± 0.2%); in contrast, however, 9 months of
improved glycemic control (intensive injection therapy) ins~ituted in 7
100M patients of long duration" (9 ± 0.5 yr) and initially poor glycemic
control (glycosylated hemoblobin of 12.4 ± 0.2%) failed to improve glucose
counterregulation in the presence of improved glycemic control
(glycosolated hemoglobin of 7.9 ± 0.02%). Since NIDDM sUbjects (Boden et
a1., 1983), and newly-diagnosed 100M subjects have normal glucagon
response, and this normalization appears maintainable with good insulin
management, new diabetics may experience reduced risk of hypoglycemic
complications in the future. Because «-cell response to arginine can be
normalized in the presence of adequate insulin in IDDM subjects, it would
appear that inadequate counterregulatory response results from a reduced
sensitivity specific to glucose in 100M of long duration. Initial evidence
concerning reversal cf this «-cell defect in diabetics of long duration is
not promising, particularly if autonomic neuropathy is evident, but further
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study will be required. Nonetheless, standardized tests for adequate glu-
case cQunterregulation in Type I diabetics have been recently developed
(Bolli et al., 1984b) and can be used to predict accurately and safely
those patients who are at risk of developing severe hypoglycemia during
intensive insulin therapy.
C) Formulation of the a-Cell Deficient, Metabolically-Normalized Type I
Diabetic Model, and the Rationale for Its Use to Design and Assess
Improved Insulin Therapies
Using the model of glucose metabolism in normal, nondiabetic man as a
starting point, the first consideration in diabetic modeling concerning
fixing the concentration scales used to calculate normal metabolic source
and sink rates. In the nondiabetic model, metabolic rates were formulated
in terms of local organ glucose and insulin concentrations that were nor-
malized with respect to basal values. Upon model initialization, all meta-
bolic rates were assumed to occur at their respective fixed basal rates by
definition, while the corresponding basal organ glucose and insulin con-
centrations were allowed to float over a narrow range such that model ini-
tialization conditions could be matched to specified basal experimental
conditions. Those initial basal state glucose and insulin concentrations
requried for calculation of metabolic rates were stored for subsequent
reference (see Table 31), as they in turn defined the basis for the nor-
malized concentration scales used in the metabolic rate formulations.
Before starting to model the insulin-treated diabetic, it was
desirable to fix the basal glucose and insulin concentrations used to
calculate normal metabolic response. This was simply accomplished by
adopting a reference set of organ concentrations deemed representative of
the basal postabsorptive state in normals. These values were obtained by
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running the normal model initialization routine with the following spe-
cified basal state initial conditions derived from measurements accumulated
at the Joslin Research Laboratory for 267 normal adult males: 1) mean
peripheral venous blood glucose concentration equaled 75.3 mg/dl
(correspon~ing to GpV = 89.6 mg/dl); 2) mean peripheral venous plasma insu-
lin concentration equaled 12.9 mUll (IpV = 12.9 mUll). The resulting set
of reference basal organ glucose and insulin concentrations is listed in
Table 37. These reference values were used as the basis for fixing the
concentration scales defining normal metabolic response to local organ
solute concentrations in all subsequent diabetic modeling.
Probably the most obvious aspect of diabetic modeling concerns altera-
tion uf normal pancreatic insulin response to glycemia. Since the purpose
of diabetic modeling was to provide a basis for insulin therapy assessment,
modeling efforts were focused on a physiologic representation of IDOM. The
irreversible loss of a-cell function typical of Type I diabetes was simply
evoked by removing the model pancreas from the normal model of glucose
metabolism, or more specifically, the rate of pancreatic insulin release
(rpIR) as a metabolic source for insulin in the liver insulin mass balance
fornlulation (Equation 20) was set equal to zero.
Although present modeling will be restricted to IDOM, NIDOM subjects
experience the same chronic diabetic complications as 100M subjects, and
evidence suggests that insulin administration may be beneficial in
improving the regulation of glycemia in NIDOM. Development of a physiolo-
gic model for assessing insulin therapies in the Type II diabetic would be
very difficult due to the diverse range of abnormal pancreatic insulin
responses which characterize NIDOM. A possible approach to modeling
pancreatic insulin release in the Type II diabetic would be to use para-
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Table 37. Reference normal basal state glucose and insu1n concentrations used
to fix the concentration scales defining normal metabolic source and
sink rates.
REFERENCE NORMAL BASAL CONCENTRATIONS USED FOR CALCULATION OF
G~ • 101 lI19/dl Hepatic Glucose Uptake, rHGU
Hepatic Glucose Production. rHGP
B 96.8 mg/dl Perfpher~l Glucose Uptake, rpGUGpl II
til: • 91.9 l119/dl Pancreatic Glucagon Release, rprR
I~ • 21.4 DUll Hepatic Glucose Uptake, rHGU
Hepatic Glucose Production, ~GP
B 5.30 dill Peripheral Gl~tose Uptake, rpGUIpi •
~ • 15.2 1ItI/1 Pancreatic Glucagon Release, rprR
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meter adjustment of the normal pancreas model so as to match the abnormal
diabetic insulin response to a standard glucose input such as an IVGTT.
To this point, adaptation of the normal model to a representation of
Type I diabetes included two major steps: 1) removing the model pancreas
to represent C-peptide negative endogenous reponse to glycemic; and 2)
fixing absolute concentration scales on the metabolic source and sink func-
tions such that diabetic response to any particular combination of local
glucose, insu'iin, and glucagon concentrations would be the same as normal
response under similar conditions. The resulting diabetic model could th~s
be specifically termed a a-cell deficient, metabolically-normalized Type I
diabetic model. This is a specialized representation, however, because as
discussed previously, Type I diabetic patients commonly exhibit metabolic
abnormalities secondary to a-cell dysfunction. An important issue must
therefore be addressed: is a metabolically-normal model of Type I diabetes
a valid basis upon which to design and assess improved insulin therapies?
It was apparent from a review of the literature that the abnormalities
associated with 100M metabolism could be quantitatively significant, but
that these aberrant factors were not well characterized and could vary over
an extremely wide range from individual to individual. Tissue response to
insulin in IDDM subjects ranged from normal to observed responses charac-
teristic of significant receptor and/or post-receptor defects, and evidence
suggested the contribution of both muscle and liver defects to the overall
observed insulin resistance. The presence of circulating insulin antibo-
dies was reported to cause sluggish plasma insulin response kinetics in
insulin-treated diabetics, and antibody-bound insulin could represent up to
98% of the circulating insulin. Blunted glucagon response to hypoglycemia
was evidenced in IDOM subjects, and this abnormality was associated with
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duration of diabetes and in particular with the presence of chronic autono-
mic neuropathy. From a modeling standpoint, one could thus envision a
whole spectrum of Type I diabetic models encompassing varying degrees and
combinations of metabolic abnormalities, ranging from an ideal
metabolically-normal representation to that of an insulin-resistant,
antibody-laden, glucagon-deficient Type I diabetic.
The present objective of diabetic modeling is to provide a basis for
designing and assessing improved insulin therapies, and in part;cula.~ for
developing an insulin infusion algorithm for closed-loop insulin delivery
based on blood glucose measurement. The widespread availability and com-
petitive pricing of the new highly nonimmunogenic biosynthetic human insu-
lins is imminent. These biosynthetic human insulins should prove even less
immunogenic than the highly purified pork insulins available presently.
No significant development of antibody levels would thus be anticipated in
newly-diagnosed diabetics initially placed on these new nonimmunogenic
insu1ins. With respect to the population of diabetics previously treated
with conventional insulins, the insulin antibodies produced in response to
the conventional insulins bind bovine, porcine, and human insulins without
distinction (Goldman et al., 1979). But evidence to date has demonstrated
that antibody titers decrease in diabetics changed from conventional to
purified insulins, and thus abnormalities assotiated with the presence of
insulin antibodies should be alleviated in those patients presently exhi-
biting high antibody titers on conventional insulins. Thus, abnormalities
presently associated with the presence of insulin antibodies will soon be
reduced to background phenomena of no quantitative significance in the
insulin-treated diabetic and thus will not constitute an issue of impoto-
tance in the development and application of new insulin delivery systems
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(Soeldner, 1984). Therefore, for the purposes of algorithm design, the
need for inclusion of antibody binding in a Type I diabetic model is not
indicated.
The issue of tissue insulin resistance is more complicated. In the
literature to date, the prominance of tissue insulin resistance has been
loosely associated with lack of effective glycemic regulation in diabetic
patients (as indicated by glycosylated hemoglobin levels), and normal insu-
1in sensitivity represents a.n end state affil iated with IIgood li glycemic
control. Sirce essential normalizatio~ of insulin sensitivity has been
induced by 6 weeks of intensive CIT, i.e. home glucose monitoring 2-4 "times
daily and frequent adjustment of insulin dosage (see Figure 91), it seems
reasonable to assume that end state normalization of tissue insulin sen-
sitivity will be realized by the more precise glycemic regulation offered
by closed-loop insulin management.
Unfortunately, insufficient experimental data exists to identify the
precise mechanisms underlying tissue insulin resistance, or the factors
which cause its apparent reversal during improved glycemic regulation.
Most likely, chronic insulin deficiency would be associated with post-
receptor defects related to the maintenance of proper intracellular enzyme
levels, whereas chronic hyperinsulinemia would be associated with receptor
down regulation. Since neglect of insulin resistance during design of an
insulin infusion algorithm would result in a device that administers the
minimal insulin dosage concommitant with glycemic normalization, such an
algorithm would provide the best promise for the reversal and/or avoidance
of insulin resistance in the Type I diabetic. Indeed, one could surmise
than an algoirth designed to compensate for insulin resistance in seeking
glycemic normalization would likely induce excessive hyperinsulinemia which
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in turn would be detrimental to the reversal of insulin resistance.
Although pulsatile basal insulin delivery will not be encompassed in
the present modeling studies, whether this will prove important in the
maintenance of normal tissue insulin sensitivity in diabetics remains to be
determined, however such action was clearly not mimiced during nor-
malization of tissue insulin resistance induced through intensive CIT.
Since basal pulsatile insulin delivery has a greater hypoglyc~mic effect
than continuous insulin delivery (Mathews et al., 1983), pulsed basal
insulin delivery could further reduce basal insulinemia, and thus fhight
possibly affect a more rapid and complete normalization of tissue insulin
resistance, particularly with respect to effects of receptor down
regulation.
Finally, impaired glucagon response to hypoglycemia will not be incor-
porated into the Type I diatJetic model during al gorithm development for a
number of reasons. First of all, the severity of impaired coun-
terregulation normally observed in insulin-treated diabetics is largely
attributable to prolonged hyperinsulinemia associated with release of
antibody-bound insulin which serves to defeat glucagon effectiveness. As
previously discussed, such problems related to insulin antibodies are ant;-
clpated to be of negligible importance in the near future. Furthermore,
although the reversibility of impaired glucagon response by intensive CIT
has not been demonstrated, it is possible that precise closed-loop insulin
delivery may be able to affect such a normalization, particularly since
normal glucagon response can be maintained in ne~ly-diagnosed diabetics
through careful CIT management, and thus impairment of glucagon response
appears to be secondary to a-cell deficiency. Finally, since neglecting
tissue insulin resistance will resu~t in minimal closed-loop insluin dose
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delivery, this will help lessen the likelihood of severe hypoglycemia and
the need for acute counterregulatory capacity.
Because of the above reasons, a B-cell deficient, metabolically-
normalized Type I diabetic model will be employed for the design and
testing of an insulin infusion algorithm for closed-loop glycemic regula-
tion. The strategy for diabetic modeling will thus be to neglect the
abnormalities associated with diabetic physiology secondary to beta-cell
dysfunction for the purposes of designing an in~ulin infusion algorithm.
Once the closed-loop insulin delivery system has been designed, however,
its effectiveness in regulating glyce~n·~a in the presence of such diabetic
abnormalities will be studied. This will entail introducing representative
metabolic abnormalities, including tissue insulin resistance, antibody
binding, and impaired glucagon response to hypoglycemia into the Type I
diabetic model and simulating the OGTT under closed-loop control. Results
of these simulation studies will provide a basis for assessing performance
of the resulting algorithm in the presence of diabetic metabolic abnor-
malities and may indicate possible compensatory algorithm modifications.
In the next section, modeling and simulation of diabetic abnormalities will
be explored using available data for diabetics administered the OGTT during
ABC insulin delivery.
D) Simulation Studies with the Type I Diabetic Model
1) ~1odel Initial ization and the Postabsorptive Steady State in Diabetics
In a meta~olic sense, the postabosorptive steady state in the insulin-
treated diabetic is not internally defined, as it is manipualted by an
external variable, namely the provision of exogeneous insulin. This is the
primary reason that a reference set of normal basal state glucose and insu-
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lin concentrations (Table 37) had to be adopted for computing metabolic
rates during diabetic model simulations, as these values could not be
define1 upon model initializaiton as was the case for normal model simula-
tions (see Table 31).
Initialization for Type I diabetic model simulations is outlined in
Table 38. For diabetic modeling, the reference set of normal basal state
concentrations (Table 37) was loaded and the pancreatic insulin release
rate (rpIR) was set to zeroo The insulin model mass balance equations used
in diabetic model simulations were the same as those used in normal non-
diabetic simulations (Equations 17-23) except Equation 18a was substituted
for Equation 18 to provide for'intravenous insulin delivery (rIVI).
Equating the time derivatives to zero (steady state) in the modified set of
insulin model mass balance equations yielded a set of 7 equations in 8
unknowns (7 insulin concentrations and rIVI); thus, specification of the
initial steady insuin delivery rate rIVI allowed calculation of all initial
insulin concentrations in the insulin model. Next, the glucose model mass
balance equations (Equations 9-16) were employed to calculate the initial
glucose concentrations. Equating the glucose model mass balance time deri-
vatives to zero (steady state) resulted in a set of 8 equations in 8
unknowns (the respective glucose concentrations). In nondiabetic modeling,
under basal conditions the rates of basal glucose metabolism were fixed
with the sum of the metabolic sinks equaling the rate of hepatic glucose
production; because the sources and sinks were fixed and cancelled from the
set of equations, the glucose concentrations could not be uniquely deter-
mined, and thus a glucose concentration had to be splcified for initializa-
tion (mathematically, because the fixed sources equaled the sinks, the
resulting set of equations was not linearly independent but formed a rank 1
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Table 38. Summary of initialization procedure for Type I diabetic model simu··
lations
Ref€rence set of normal basal state concentrations (Table 37) are loaded for
subsequent computations of metabolic source and sink rates:
GB = 101.0 mg/dl IS = 21.43 mUllL L
B 86.81 mg/dl B 5.304 mUllGpI = IpI =
GB = 91.89 mg/dl IB = I5.I!> mUllH H
Pancreatic insulin release rate is set to zero:
r pIR = 0 mU/min (model pancreas removed)
Insulin Model
Mass Balances:
r IVI = [input rate of peripheral venous insulin delivery] (See Eqn. 18a)
r IVII =
H I I I I IQH - QL{l-FLIC ) - QK(1-FK1C ) - Qp(l-FpIC ) - QS
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Table 38. (Continued)
Gl ucose ~'odel
Mass Balance:
GH = [Guess Arterial Glucose Conc.]
Initialize Glucagon Model:
I GCompute MprR,MprR
= G _ rBGU
H Q~
= G _ rGGU
H Q~
ICompute MpGU
(1 +
GK = [Guess Kidney Glucose Conc.l
compute rKGE
G =G _ rKGEK H -Q~
[Check Kidney Glucose Cone.l
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Table 38~ (Continued)
GL ~ [Guess liver Glucose Cone.]
Compute f HGP ' rHGU
1 G GGl = - (QAGH + QGGG + rHGP - r HGU ' [Check liver Glucose Cone.]Q~
1 G G G GGH = --- (QBGBV + QLGL + QKGK + QpGpV - r RBCU ) [Check Artp.rial GlucoseQ~ Cone.]
GpV
I B GMpGU rpGU Tp )(1 +
Metabolism: (Initialize using values computed on last glucose model mass
balance iteration)
IMHGP
IMHGU
ra 1MHGP -f =2 2
Glucagon Model
N I Gf = MpfRMpfR (Computed during glucose model mass balance iteration)
364
matrix meaning there was a subset of 7 linearly independent equations). For
diabetic modeling, since the concentration scales on the metabolic source
and sink functions were specified a priori, the steady state metabolic
rates now became functions of the initial glucose model concentrations.
Thus, having computed all of the respective insulin concentrations, only
one unique set of glucose concentrations would satisfy the steady state
glucose model mass balance equations. The series of calculations required
in solving for the initial glucose model concentrations is outlined in
Table 38. As indicated, the process involved iterative solution due to the
fact that some of the metabolic rates were nonlinear functions of local
glucose concentration. Since the rate of pancreatic glucagon release was a
function of arterial glucose concentration, and plasma glucagon con-
centration in turn affected hepatic glucose production rate, the glucagon
model was initialized from steady state consideration of its normalized
mass balance equation (193) during iteration of the glucose model con-
centrations.
In the absence of exogeneous glucose input (oral or intravenous
loading), the steady state glucose and insulin levels are dependent on the
rate of insulin delivery to the Type I diabetic. Presented in Figure 97
are the steady state peripheral venous plasma glucose and insulin con-
centrations resulting from various rates of continuous intravenous insulin
infusion as predicted from the Type I diabetic model initialization proce-
dures outlined above. It can be seen from Figure 97 that normalization of
plasma glucose to a value of 90 mg/dl would require an insulin infusion
rate of 20 mU/min with a resulting peripheral plasma insulin concentration
of about 23 mUll. Thes2 numbers are representative of those observed to
maintain such fasting normoglycemia in patients on ABC therapy. It should
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be noted that the steady state peripheral ~nsulin level required to main-
tain fasting ~ormoglycem;a in the diabetic is roughly double that observed
under basal state conditions in the nondiabetic. This is the consequence
of peripheral routing uf insulin delivery to the diabetic, as nonportal
insulin input alters the relative steady state organ insulin levels com-
pared with normal. In the normal subject, pancreatic insulin secretion
into the portal vein results 1n a positive portal :peripheral insulin gra-
dient. In contrast, peripheral insulin therapy causes a reversal in the
normal portal :peripheral insulin gradient, and the fasting peripheral
hyperinsulinemia required to maintain basal glycemia in the diabetic
reflects the general level of insulinemia necessary to elevate sufficiently
hepatic insulin such that excessive hepatic glucose production is avoided.
An interesting aspect of conventional insulin therapy arises from the
above discussion. Since CIT provides for a relatively constant level of
insulinemia over the course of a day, CIT results in peripheral hyperin-
sulinemia during fasting, and peripheral hypo;nsulinemia during postpran-
dial periods. Although peripheral closed-'Ioop insulin delivery can provide
for normalization of insulinemia during postprandial glucose excursions,
such devices will still not circumvent baseline peripheral hyperin-
sulinemia. Whether such chronic elevation of tissue ins 1in levels will
prove adverse to complete reversal of insulin resistance or possibly pro-
mote development of diabetic pathologies remains to be determined. A
possible solution to the problem of basal peripheral hyperinsulinemia is
intraportal insulin delivery to diabetics, but intraportal access would
involve considerable additional risk to the patient. Another potential
solution is the possibility that pulsatile baseline insulin delivej'r could
lower the mean level of insulinemia required to maintain fasting nor-
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moglycemia in the insulin-treated diabetic (Mathews et al., 1983) and thus
could be incorporated into a closed-loop insulin delivery system.
2) Simulation Studies
Although the Type I diabetic model incorporating normal metabolism
will be employed for the design and assessment of closed-loop insulin deli-
very systems, a number of preliminary Type I diabetic simulation studies
were conducted and will be reviewed in this section. These diabetic model
simulations were undertaken to demonstrate the model·s capacity for pre-
dicting observed diabetic response and to illustrate methods of modifying
the metabolically-normalized Type I diabetic model for simulating various
diabetic metabolic abnormalities.
a) The OGTT on C~nventional Therapy or Continuous Basal Insulin Delivery
The first simulation study using the Type I diabetic model (normal
metabolism) was designed to explore the effectivness of constant basal
insulin levels in regulating postprandial glycemia. For this study, a
standard 100g OGTT was simulated by employing the rate of gut oral glucose
~bsorption function previously derived from consideration of nondiabetic
response profiles (see Figure 81) as an input to the gut compartment mass
balance equation in the glucose model (Equation 12a). During the OGTT
simulation, the rate of peripheral insulin delivery (rrVI in Equation 18a)
was fixe" Jt a constant value; this would represent either a continuous
rate of intravenous insulin absorption from a local injection site during
CIT or the basal continuous insulin delivery rate provided by a simple
open-loop insulin pump system.
Results of the simulation study are presented in Figure 98. So that
the results could be directly compared with the nondiabetic response profi-
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les of Figure 81, the peripheral insulin delivery rate was selected from
model initialization considerations such that the fasting diabetic glycemia
matched that of the normal group used as the basis for the previous non-
diabetic OGTT simulation studies (peripheral blood glucose concentration of
75 mg/dl); the resulting fixed insulin delivery rate was 23 rnU/min and
resulted in a peripheral plasma (free) insulin level of 27 mUll in the
diabetic.
As shown in Figure 98, the peripheral route of insulin delivery
resulted in the normalization of fasting glycemia at the expense of basal
peripheral hyperinsulinemia in the diabetic relative to that observed in
normals. During the oral glucose challenge, however, circulating insulin
levels generated from pancreatic insulin responsE in normal subjects greatly
exceeded the insulinemia resulting from baseline insulin delivery to the
diabetic. The lack of insulin response to glycemia lead to impaired glu-
cose disposal and hyperglycemia in the diabetic as illustrated in the upper
plot of Figure 98.
Since continuous peripheral basal insulin delivery would not unmask
uiabetic abnormalities cssociated with tissue insulin resistance or insulin
antibody hinding, the simulated ineffectiveness of this mode of therapy in
providing for good postprandial glycemic regulation should be represen-
tative, and the duration and magnitude of the glycemic excursion shown in
Fi~ure 98 are comparable with glycemic behavior observed in Type I diabe-
tics during OGTTs on CIT~ In a sense, however, the $imulation study
reflected a best case of continuous peripheral insulin delivery, since per-
fect fasting normoglycemia and correspondingly high continuous insulin
levels were considered. In most cases such an open-loop form of insulin
delivery would not be tuned so precisely to alleviate the likelihood of
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hypoglyemic episodes, and thus fasting hyperglycemia and lowe~ average cir-
culating insulin levels are more commonly observed in patients on conven-
tional therapy. In such cases, hyperglycemic response to an OGTT ;s more
severe owing primarily to the initial fasting hyperglycemic offset.
In order to assess the importance of the site of insulin delivery, an
analogous OGTT simulation was run using a fixed continuous intraportal
insulin infusion rate. For this simulation, the liver compartment mass
balance equation in the insulin model (Equation 20) was modified to include
a source term for intraportal insulin delivery
Intraportal Insulin Infusion: (modification of Equation 20)
(20a)
where: r IPI = rate of intraportal insulin infusion (mU/min)
Specification of the initial intraportal insulin infusion rate allowed uni-
que determination of the initial insulin concentrations in the insulin
model, although the diabetic model initialization procedure outline in
Table 38 had to be modified with resepct to the order in which the steady
state insulin model mass balance equations were solved. The rate of intra-
portal insulin infusion was adjusted (by trial and error) until the fasting
diabetic glycemia matched that of the normal group used as the basis for
the previous OGTT simulations (peripheral blood glucose concentration of 75
mg/dl): the resulting fixed intraportal insulin delivery rate was 19 mU/min
and resulted in a peripheral plasma (free) insulin level of 13 mUll.
As shown in Figure 98, the intraportal, in contrast to the peripheral
route of insulin delivery, did not require basal peripheral hyperin-
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sulinemia for the normalization of fasting glycemia. During the oral glu-
cose challenge, the magnitude of the glycemic excursion was similJ~~ whether
insulin was delivered peripherally or intraportally, with lack of insulin
reponse to glycemia resulting in elevated glucose levels relative to nor-
mal. Thus, with respect to continuous basal insulin delivery, the only
apparent advantage to intraportal over peripheral delivery would be the
elimination of fasting peripheral hyperinsulinemia. Furthermore, insulin
response to glycemia ;s necessary for avoidance of postprandial hyperglyce-
mia, independent of the route of insulin delivery.
b) The OGTT on Artificial Beta Cell Insulin Delivery
Available data for Type I diabetics on ABC therapy during the standard
100g 06TT provides a basis for studying the simulation of insulin
resistance. In this section, insulin resistance due to tissue insen-
sitivity and antibody binding will first be addressed separately, and then
in combination.
i) Simulation of Tissue Insulin Resistance
Following 72 h of ABC therapy, Foss et ale (1982) administered 100 9
OGTTs to 5 Type I diabetic subjects. The ABC is a closed-loop insulin
delivery system; peripheral blood glucose concentration is meaured on a
continuous basis and a variable intravenous insulin infusion is adjusted
based on the glucose measurement as determined from an infusion algorithm.
In order to study insulin resistance, the glucose and insulin models were
first decQupled to allow isolation of contributing factors. For the study
of tissue insulin resistance, the rate of intravenous insulin infusion (rIVI
in Equation l8a) was adjusted (by trial and error cubic spline fitting)
such that the time course of peripheral plasma (free) insulin concentration
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in the insulin model matched that reported in the Type r diabetics
following OGTT administration as shown in the lower plot of Figure 99.
Therefore, by matching the plasma free insulin levels, factors associated
with the presence of insulin antibody binding were directly circumvented.
Furthermore, by having properly fixed the insulin response levels in the
insulin model, metabolism in the glucose model could then be studied inde-
pendent of interactive changes in insulin concentrations in the insulin
model.
For simulation of the 100 g OGTT, the gut glucose absorption rate
function (Figure 81) was input to the gut compartment mass balance equation
in the glucose model (Equation 12a) as described previously. As shown in
the upper plot of Figure 99, use of normal metabolism in the glucose model
lead to predicted glycemic response that was significantly lower than that
actually observed in the diabetic subjects. Since the circulating insulin
levels resulting from ABC insulin delivery were roughly three times higher
than those normally observed in nondiabetics during the OGTT (see lower
plot of Figure 99), it was not particularly surprising that normal insulin
sensitivity in the met&bolic functions of the glucose model caused
excessive glucose disposal and hypoglycemia.
Since insulinemia had been fixed at the observed level, the above
results suggested the presence of tissue resistance to the action of insuin
in stimulating glucose disposal in the TYr~ I diabetics, a conclusion sup-
ported by the data of Meistas et ale (1984) which directly demonstrated
such resistance in Type I diabetics after 5 days of ABC therapy~ Further
simulation studies were thus undertaken to determine if introduction of
tissue insulin resistance into the glucose model physiology could account
for the observed diabetic glycemic response of Figure 99.
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Fig. 99 Comparison between model predictions and experimental data
for Type I diabetic response to the standard 1009 OGTT
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Figure 81)
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For simulating tissue insulin resistance, three possible glucose model
functions ~ould be considered: 1) the insulin multiplier of peripheral
glucose uptake rate, M~GU (Equation 51, Figure 13); 2) the insulin steady
state insulin multiplier of hepatic glucose production rate, M~~ (Equation
58, Figure 19); and 3) the steady state insulin multiplier of hepatic glu-
cose uptake, M~~U (Equation 95). To simplify matters, only the most dominant
function, the insulin sensitivity of peripheral glucose uptake, was altered
for simulating tissue insulin resistance. This strategy was adopted
because, as previously shown during the development of the nondiabetic
model, simultaneous adjustment of more than one metabolic function to fit
model predictions with observed glycemic response is quite arbitrary, as
the partitioning of effects between different sources and sinks can assume
a multitude of symmetric compensatory baldnces.
Two types of peripheral tissue insulin resistance were considered, the
pure receptor defect (a shift in the interstitial insulin concentration
affecting half-maximal response) and the pure postreceptor defect ( a pro-
portional decrease in response at all interstitial insulin concentrations).
Each of these respective shifts in the insulin multiplier of peripheral
glucose uptake rate (M~GU) could be realized by variation of a single func-
tion parameter. The general mathematical form for the function M~GU was
expressed by
M~GU = E {A + B tanh[C(I~I+ D)]}
where, for norma1 metabolism (Equation 51) ,
A = 7.03
'3 = 6.52
C = 0.338
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(223)
D = -5.82
E = 1
Thus, the pure postreceptor defect causing a proportionate decrease in
response at all insulin levels was represented by varying parameter E in
Equation 223, whereas the pure receptor defect causing a shift in the insu-
lin concentration affecting half-maximal response was represented by
varying parameter D. Having fixed the time course of the insulin model
concentrations, OGTT simulations were repeated while varying the degree of
each respective mode of insulin resistance until the best least-squares fit
was attained between model predictions and experimentai data for th€ time
course of peripheral plasma glucose concentration. These one-dimensional
least-squares fits were cbtained by use of the IMSL library computer
subroutine ZXSSQ. The resulting paramet2r values were E = 0.19 i-or the
postreceptor shift and 0 = 24.9 for the receptor shift, respectively, in
Equation 223.
The resulting shifts in peripheral tissue insulin sensitivity are pre-
sented in Figure 100, and their respective efficacies in providing for
matching of model predictions and observed plasma glucose response are com-
pared in the upper plot of Figure 99. As demonstrated in Figure 99,
although the pure receptor defect shift in the insulin sensitivity of
peripheral glucose uptake could generally account for the magnitude of the
cbserved glycemic response, the pure postreceptor defect shift was most
~ffective in accounting for both the magnitude and time course of the
observed glycemic response with model predict10ns falling within the
experimental error range at all times during the OGTT.
The magnitudes of the shifts ill the ins~lin dose-response curves of
Figure 100 were quite slgnificant. Even though the insulin multiplier of
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Fig. 100 Tissue insulin resistance curves resulting from pure receptor
and postreceptor shifts 1n the effect of insulin on the
rate of peripheral t"issue glucose uptake in ~he glucose
model. Magnitudes of the respective shifts were obtained
by least-squares fitting of model predictions and
experimental data for glycemic response of Type I diabetics
during OGTTs (see Figure 99).
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peripheral glucose uptake rate (M~GU) was modeled as a function of peripheral
interstitial insulin concentration (I pI )' an upper scale in the plot of
Figure 100 was included to indicate the peripheral plasma insulin con-
centrations (IpV) that would correspond to these interstitial insulin
levels under steady state conditions. From the data of Meistas et al.
(1984) previo~sly presented in Table 35, insulin-stimulated forearm glucose
uptake was only about 39% of normal at a steady-state peripheral plasma
insul in concentration of approx'imately 80 mUll in the group of 6 Type I
diabetics studied. The postreceptor defect response curve in Figure 100
yielded an insulin-stimulated peripheral glucose upta~e of roughly 20% of
normal at all steady state peripheral plasma insulin concentrations
including the value of interest here, 80 mUll (IpV= 80 mUll). The apparent
discrepancy between the above results can be attributed to two possible
factors: 1) the data of Meistas et ale also indicated a defect in liver
insulin sensitivity, thus having simply attributed all insulin resistance
to peripheral tissue glucose uptake in the model simulation studies would
lead to overestimation of its respective contt'ibution to the total
resistancc; and 2) as indicated in the earlier review of tissue insulin
resistance in Type I diabetics, the observed insulin dose-r~sponse curves
appear to vary greatly from study to study.
An interesting aspect of ABC insulin delivery arises in analyzing the
results of this simulation study of tissue insulin resistance. As was
shown in Figure 99, ABC insulin delivery resulted in insul inemia roughly
threefold higher than that observed during normal response to an OGTT
challenge. But examining the dose-respcnse curves in Figure IuD, the post-
receptor defect shift which could account for the observed OGTT glycemic
response data saturated its maximal stimulation of glucose uptake at
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corresponding plasma insulin levels significantly lower than those evoked
by ABC therapy (the same saturation level observed in normals). It is thus
quite possible that such excessive insulinemia (IpV > ~150 mUll) is
unjustified because it can not provide effective compensation for this
underyling mode of insulin resistance to the stimulation of glucose dispo-
sal. Furthermore, such high insulin levels could prove quite detrimental
to the normalization of tissue insulin action, and thus the very character
of present lIintensive" ABC insulin therapy might defeat the goal of
reversing tissue insulin resistance in Type I diabetics.
ii) Simulation of Insulin Antibody Binding
In order to study th~ effects of insulin antibody binding, the glucose
and insulin models were again decoupled. As previously discussed, the rate
of peripheral insulin delivered by the ABC is determined by an infusion
algoritnm based on measurement of peripheral blood glucose concentration.
For the study of insulin antibody binding, a cubic spline fit of the time
course of plasma gluc0se concentration was obtained from the data reported
by Foss et ale (1982) for 5 Type ~ diabetics administered 100g OGTTs, as
showr in the upper plot of Figure 101. This glucose profile (after con-
version from plasma to bloud ~lutos~ concentration) was input to the ABC
infusion ~lgorithl(i :0 determine the resulting rate of insulin delivery
during the OGTT. The resulting ins~~in infusion rate is shown in Figure
102; although details of the mathematical form of the insulin infusion
algorithm will be deferred to future discussion of closed-loop insulin
delivery, the parameters of the ABC (Biostator) algorithm employed in
generating the insulin delivery profile of Figure 102 ere listed in its
caption for reference. The insul in del iver.y rate shown in Figure 102 was
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Fig. 101 Simulation studies of the effects of introducing insulin
antibody binding on prediction of insu~~in response kinetics.
A cubic spline fit of the experimental glucose response
data (upper plot) was used to determine the rate of insulin
delivered by the ABC as shown in Figure 102, while the
antibody binding capacity was varied in the insulin model.
(Data for 5 Type I diabetics from Foss et al., 1982)
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in turn used as the input to the insulin model (r'IVI in Equation 18a) for
studying the effects of insulin antibody binding on the predictions of
plasma insulin response. Thus, by having determined the proper closed-loop
insul in infusion rate from a fit of the glycemic response data, factors
associated with tissue insulin resistance in the glucose model were circum-
vented, since the insulin delivery in these simulations was not interactive
\-lith changes in predicted glycemic response (or with the gl ucose model at
d 11 )•
As shown in the lower plot of Figure 101, use of the insulin model
without including the effects of antibody binding (Curve A) resulted in a
predicted plasma (free) insulin response that was less sluggi~h than that
observed in the diabetic subjects. Therefore, additional simulation stu-
dies were undertaken tu determine if the inclusion of insulin antibody
binding in the insulin model could account for this discrepancy between
predicted and observed insulin response kinetics.
Since plasma free insulin concentrations vary from organ to organ, an
exacting approach to modeling of insulin antibody binding would be to deve-
lop a distributed binding model in which antibodies would flow and mix in
the circulation and partially equilibrate bound insulin levels in reSponse
to local free insulin concentrations. Such a distributed binding model
coupled with the existing insulin mode'i would have been extremely complex.
To explore the first order effects of antibody binding, a simplified lumped
binding model was instead employed. For the lumped model, it was assumed
that the plasma circulation time is reasonably small yoelative tu charac-
teristic antibody binding times; this was a reasonable a~sumption, since
the longest local organ plasma space residence time (plasmQ volume d~vided
by plasma f1o\'/ rate) in the insul in model was 0.7 min (jJeriphera'l
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compartment) whereas insulin antibody binding occurs over time scales of
minutes to hours. Thus, for a lumped insulin antibody binding model, plasma
free insulin was assumed to exchange with a single uniform antibody binding
pool at a rate determined by the instantaneous mean mixed whole-body plasma
free insulin level.
The insulin antibody binding model was formulated as follows. At each
time step of numerical integration, a mean mixed whole-body plasma free
insul·in concentration was computed from the local plasma (free) insulin
concentrations in the insulin model, given by
F =
where:
~ Vi V
1
F = mean plasma free insulin concentration (mUll)
I;V = plasma free insulin concentration in the ith insulin
model compartment (mUll)
'iV = ~lasma equilibration volume of the ith insulin
model compartment (1)
(224)
From Equations 208 and 209, the mean rates of insulin antibody binding to
each class of binding site per unit volume of plasma would thus be
dB!
-- =
dt
dB2
--=
dt
(225)
(226)
Using Equations 214 and 215 to eliminate E1 and E2 from Equations 225 and
226, respectively, yields
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dB!
k;Brr - kiBl-
~
-- = kI FBIdt
dB 2 k;B~ - k2B2- k;rB 2-- -dt
(227)
(228)
Thus, the total mean rate of free insulin binding to the antibody pool per
unit volume of plasma was given by
= dB = dB! +
dt dt
(229)
where: rAIB = mean rate of free insulin binding to antibodies
[(mU/min)/l plasma]
Finally, a sink term was subtracted from each plasma space mass balance
equation in the insulin model (EquatiJns 17-22) to account for free insulin
binding to the antibody pool t where'each sink term was expressed
(230)
where: irAIS = rate of free insulin binding to antibodies in the ith
insulin model compartment (mU/min)
iBecause insulin antibody binding is reversible, the values of rA1B could
be positive or negative depending on whether free insulin was associating
with or dissociating from the ~ntibody pool, respectively.
For simulation studies incorporating the insulin antibody binding
model modifications in the insulin model t the rate constants k;t kit k;
and k2 in Equations 227 and 228 were assigned the experimentally-
determined values compiled in Table 36 from the studies of Berson and Yalow
(1959). The capacity of the antibody binding pool> representing the
in vivo antibody titer levels, was determined by specifying the values of
384
the binding capacity parameters B1 and B~ in Equations 227 and 228
(values listed in caption of Figure 101).
The effects of varying the insulin antibody binding capacities on the
insulin model predictions of plasma insulin response to ABC insulin deli-
very during the OGTT are shown in the lower plot of Figure 101. As pre-
viously discussed, exclusion of insulin antibody binding (equivalent to
letting B~ = B~ = 0) resulted in predicted plasma free insulin response
kinetics that were faster than those observed in the experimental study
(Curve A). Next, antibody binding capacities reported by 8erson and Yalow
(1959) for nonresistant (Curve B) and resistant (Curve C) groups of diabe-
tics (see Table 36) were employed. Incorporation of insulin antibody
binding into the insulin model resulted in slowing the predicted free
insul;n response kinetics, with the nonresistant and r·esistant response
curves appearing to bracket the observed response behavior. Finally, the
values of the binding capacities BO and BO were varied in order to1 2
obtain the best least-squares fit (library computer subroutine ZXSSQ) of
model predictions with experimental data for the time ccurse of peripheral
plasma free insulin con:entration response. The resulting binding capaci-
ties were intermediate between those reported for nonresistant and
resistant diabetics (see caption of Figure 101), and the prediction of
plasma free insulin response agreed well with the experimental dd~a as
shown by Curve C in the lower plot of Figure 1010 In order to show :he
extent of insulin binding during this simulation, the mean levels of plasma
free and total (bound plus free) insul irl concentration are plotted as a
function of time in Figure 103; as shown, the majority of circulating
insulin was predicted to be in bound form as would be anticipated in the
presence of significant antibody titers.
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iii) Combined Simulation of Tissue Insulin Resistance and Insulin Antibody
Binding
Since the glucose and insulin model~ were essentially decQupled in the
above simulations of tissue insulin resistance and insulin antibody
binding, a final diabetic simulation study was conducted combining these
effects with the gluccse and insulin models coupled. For this
simulation,the metabolically-normal Type I diabetic model was employed,
except that tissue insulin resistance (the postreceptor defect of Figure
100, corresponding to Curve B in Figure 99) was introduced into the glucose
model, and insulin antibody binding (antibody titers corresponding to
response Curve C in Figure 101) was included in the insulin model. The
100g OGTT was again simulated, but the rate of insulin delivered by the ABC
and used as the input to the insulin model was determined from interactive
mea5urement of the peripheral blood glucose values generated by the glucose
model.
Results of this simulation are presented in Fi~ure 104. As shown in
the figure, model predictions agreed well with the experimental data of
Foss et al. (1982) when the diabetic abnormalities of tissue insulin
resistance and insulin antibody binding were included in the Type I diabe-
tic model.
For reasons previously stated, no diabetic metabolic abnormalities
will be incorporated into the Type I diabetic model during design of a
closed-loop insulin infusion algorithm. However, once this algorithm is
designed, it will be very useful to assess its effF,iiveness if employed in
a Type I patient who is not initially in a metabolically-normalized state.
Since introduction of the above diabetic abnormalities into the Type I
diabetic model was successful in predicting the data of Foss et al _, the
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potential interaction of these diabetic abnormalities with the newly-
designed infusion algorithm can also be studied through model simulations.
Thus, the above methods of modeling insulin resistance, together with the
capability of representing blunted glucagon response to hypoglycemia by
setting M~rR equal to unity in Equation 155 of the glucagon model, will
will provide d valuable means for simulating diabetic abnormalities and
testing algorithm performance in the metabolically "uncontrolled" Type I
diabetic.
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VI. DESIGN AND ASSESSMENT OF AN OPTIMAL GLUCOSE-CONTROLLED
INSULIN DELIVERY SYSTEM
A) Optimal Control
1) Background
The present review is concerned with the algorithms for the com-
putation of glucose-controlled insulin delivery that have evolved in con-
junction with the development of various closed-loop systems~
Continuous in vivo determination of blood glucose concentration was
made possible in the early 19605 through the invention and development of
the double-lumen catheter (Weller et al., 1960) and the establishment of a
continuous glucose analyzer for the laboratory, the Autoanalyzer (see
Bannafe, 1977). Using these methodologies, Kadish (1963) pioneered clini-
cal application of glucose-controlled insulin delivery; blood glucose was
continuously monitored, and an. insulin infusion system delivering 100
mU/min was actuated whenever the measured blood glucose concentration
exceeded 150 mg/dl. Although this simple "on-offn ~ontrol system failed
to produce glycemic normalization, its realization was a notable achi~ve­
ment for its time.
Glucose-controlled insulin delivery has sUbsequently been advanced to
a significantly higher state of sophistication by a number of groups of
investigators, including Albfsser et al. in Canada, Kraegen et al. in
Australia, Clemens et al. in the United States (in close collaboration with
medical researchers in Europe), and Shichir1 et ~l. in Japan.
Albisser et ale (1974a) developed a bedside closed-loop insulin deli-
·v~ry system suitable for clinical applications. This system employed an
algorithm for computer-controlled insulin delivery based on a hyperbolic
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tangent functionality of blood glucose concentration (Albisser et al.,
1974a; 1974b), given by
IR(k)=
IR
max {l-tanh[S(G (k)-B)]} kT~«k+l)T; k=O,1,2, •••
2 p
(231)
where IR(k) = i~sul;n infusion rate (mU/m;n)
Gp(k) = projected blood glucose cone. (mgjdl)
T = sampling interval = 1 min
with parameters
IRmax = maximum insulin infusion rate (mUjmin)
B = tlood glucose con~. for half-maximal infusion rate (mg/dl)
S = sensitivity of infusion response to deviations in blood
glucose cone. (dl/mg)
The hyperbolic tangent formulation was selected because it offer~d the
theoretical advantage of closely resembling sigmoidal dose-response curves
observed for steady state glucose stimulation of pancreatic insulin secre-
tion (Grodsky, 1972). As indicated in Equation 231, the insulin infusion
rate was based on a IIprojected ll glucose concentration, ~xpressed by
where Gm(k) = measured blood glucose concentration (mg/dl)
DF(k) = difference factor (mg/dl)
(232)
Thus, the present measured glucose concentration was modulated by a
"difference factor," a rate-sensitive function defined by
dG,n(i<)
dtDF(k)=K1(exp (-- )-1]K2
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(233)
where K1 = parameter (mgjdl)
K2 = parameter (mgjdl omin)
and, for noise suppression, the derivative term was computed from an
arithmetically weighted a~erage of the rates of change over the previous 4
min of monitoring (Broekhuyse et al., 1981),
1 4 G (k+i-4}-G (k+i-5)
__ Ii~m m )
10 i =1 T
4Gm(k)-Gm{k-l)-Gm(k-2)-Gm(k-3)-Gm(k-4)
=----------------
10 T
(234a)
(234b)
In effect, the difference factor introduced anticipatory derivative action
into the infusion algorithm, and the resulting use of projec~ed glucose
values was found to improve glycemic regulation. Botz(1976) introduced an
improved relationship for the difference factor, given by
(235)
where K1 ·· parameter (d1
2omin 3jmg 2)
K2 = parameter (min)
Use of this difference factor formulation improved glycemic regulation
(Botz, 1976) and it has subsequentl y been employed by A1 bi sser and
call eagues.
Kraegen et al.(1975,1977,1979) developed a bedside glucose-controlled
insulin infusion system which has been applied to clinical research. The
insulin infusion algorithm imcorporated into this device was that origi-
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nally proposed by Jrl bisser et al. (Equations 231-233), except the rate of
change of glucose concentration was computed from a geometrically weighted
average of the rates of change over the previous 4 min of monitoring
(Kraegen et al., 1977),
dGm(k) 1 4 4· G (k+l-i )-G (k-i)
__ = _ L 2 -1 t m m)
dt 15 ;=1 T
8Gm(k)-4Gm(k-l)-2Gm(k-2)-Gm(k-3)-Gm(k-4)
=--------------------
15 T
(236a)
(236b)
This relationship was used instead of the arithmetically weighted average
employed by Albisser et al. (Equation 234) in order to achieve a better
compromise between speed of response and immunity to artifactual noise.
To date, the only commercially available clos~d-loop insulin infusion
dey; ce is the B'i ostator® G1 ucose Controll ed Insl!l in Infus i on System (GC I IS)
developed by Miles Laboratories in close conjunction with medical
researchers in Europe (Pfeiffer et al.,1974; Clemens and Chang,1976;
Clemens et al.,1976). The Biostator GCIIS is a bed~ide unit which has been
used extensively for clinical research applications. Clemens et ale deve-
loped a series of insulin infusion algorithms throughout the evolution of
the Biostator GCIIS. The original algorithm utilized projected glucose
values with a biquadratic control functionality (Clemens and Chang,1976;
Clemens et al.,1977; Clemens and ~~yers,1977), given by
IR(k) =
Gp(k)-B 4
R( )
Q
IR(k)<IRmax
kTd«k+l)T; k=O,l,2 ••• (237)
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where IR(k) = insulin infusion rate (mU/min)
Gp(k) = projected blood glucose con~. (mg/dl)
T = sampling interval = 1 min
with parameters
IRmax = maximum insulin infusion rate (mU/min)
R = basal insulin infusion rate (mU/min)
B = basal blood glucose conca (mg/dl)
Q= sensitivity of infusion response to deviations in blood
glucose cone. (mg/dl)
The projected glucose concentration Gp(k) was defined as in Equation 232,
but the difference factor DF(k) was calculated according to
where
KR d9m(k) 2 dGm(k) d9m(k) )0-~ ) + K( )
10 dt dt dt
DF(k) = {
KF d9m(k) 2 d9m(k) dGm(k) <0--( )+K( )
10 dt dt dt
KR = parameter for rising glucose conc. (min 2.dl/min)
KF = parameter for falling glucose conc. (min 2.dl/min)
K = fixed parameter = 6 min
(238)
and dGm(k)/dt was determined from Equation 234. Clemens et al used a
biquadratic formulation for insulin infusion instead of the hyperbolic
tangent functionalities of earlier algorithms because the control constants
could be selected more directly in physiologically meaningful terms, such
as basal glucose level and basal insul in infusion rate. In addi tion, use
of Equation 238 for the calculation of the difference factor allowed for
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altering the insulin infusion response depending on whether glucose was
rising or falling.
Experience gained with the original Biostator GCIIS infusion algorithm
led to the evolution of the presently employed control equations. The
major change from the previous formulation was the introduction of explicit
derivative control directly into the insulin infusion equation and the eli-
mination of the use of projected glucose values. The present insulin infu-
sion algorithm (Clemens,1979a; Clemens,1979b; Biostator GCIIS Operation
Manual ~©1980) is given by
IR(k) =
IR(k) ~IRmax
kT (1:< (k+l) T;k=O, 1,2••• (239)
A A
RfG( k) -8+1 )2. G(k)-B+1>O
IR1(k) =
Q Q (240)A
0 G( k) -B+1,0
Q
fKR )(~ ) (dG(k) ) (G(k) - B )
10 100 dt
= { ~H_~_HdG(k))(G(k)-B)
10 100 dt
o
G(k)-8>0 and dG(k»O
dt
G(k)-B>O and dG(k) (0
dt
G( k) -B ,0
(241)
where IR(k) = insulin infusion rate (mU/min)
A
G(k) = estimated present blood glucose conc. (mg/dl)
T = sampling interval = 1 min
l4/i t h pa rameters
IRmax = maximum insulin infusion rate (roU/min)
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R = basal insulin infusion rate (mU/min)
B = basal blood glucose conc. (mg/dl)
Q = sensitivity of infusion response to devia:ions in blood
glucose conc. (mgt dl )
KR = parameter for rising glucose cone. {d1 2omin/mg 2)
KF = parameter for falling glucose conc. (d1 2omin/mg 2)
For noise reduction, a linear regression fit over the previous five
measured blood glucose concentration values (Gm) was utilized; the slope of
the resulting regression line provided an estimate of the rate of change of
glucose concentration,
dG(k) 2G
m
(k)+G
m
(k-I)-G
m
(k-3)-2G
m
(k-4)
--=--------------
dt 10 T
(242)
from which the present glucose' concentration values was in turn estimated
by
~ Gm(k}+Gm(k-I}+Gm(k-2)+Gm(k-3}+Gm(k-4)
G(k) = -----.---..----
5
dG( k)
+ 2 t )
dt
(243)
The reported rational e fo~~ impl ernenti ng deri vat; ve act; on more di rectl y
into the infusion algorithm was that the usage of projected glucose values
was no longer needed to compensate for the Biostator's glucose measurement
response time which, including the time required for blood transport from
the patient, had been reduced from about 4 to 5 min in earlier units to
less than 1.5 min in the more recent models (Clemens, 1979b). In general,
derivative control action is primarily introduced into controll~r design to
provide effective anticipatory action with respect to the inherent response
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time of the process under regulation (in this case the time required for in
vivo glycemic response of the diabetic patient to manipulation of the insu-
lin infusion rate), although its secondary purpo$e may be to provide anti-
cipatory compensation with respect to response time of the measurement
signal. Since it is not clear that the implicit derivative action pre-
viously realized through the use of projected glucose values solely acted
to affect measurement response time compensation, the contribution of
reducing the Biostator CGIIS measurement response time to under 2 min in
pursuing the achievement of good closed-loop glycemic regulation may have
been overstated.
Shichir; et al. originally developed a glucose-controlled insulin
delivery system (Kawamori et a~., 1978; Goriya et al., 1979) that, in simi-
larity to all other bedside-type units to date, used doubl~-lumen catheter
technology for withdrawal of a continuous stream of heparinized blood which
in turn was fed to a glucose analyzer reporting measurements at 1 min
intervals. More recently, Shichiri et ale (1983; 1984) reported on the
development and initial testing of a wearable closed-loop insulin delivery
system'that utilized a needle-type glucose sensor inserted into the sub-
cutaneous tissue. The insulin infusion algorithm employed in the above
systems was given by
A
K G(k}+K (dG(k) )+K
P d dt c
IR(k) =
IR(k)<IR
max
kT(t«k+l)T;k=O,1,2 ••• (244)
IR( k) )IR
max
where IR(k) = insulin infusion rate (mU/min)
A
G(k) = estimated present blood glucose conc. (mg/dl)
T = sampling interval = 1 min
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with parameters
IRmax = maximum insulin infusion rate (mU/min)
K = coefficient for proportional action (mU-dl/mg-min)p
Kd = coefficient for derivative action (mUodl/mg)
Kc = constant for basal insul in infusio; r~ate (mU/min)
In order to compensate for time delays in the analysis of glucose con-
centration, the insulin infusion rate was calculated on the basis of esti-
mated present glucose concentration values. For this purpose, a hyperbolic
tangent curve was fit by least squares methods to the previous 10 min of
measured glucose concentrations (Gm) and the estimated present glucose con-
centration was calculated by
where
A
G(k)
10
.L (~(k-i)-Gm(k) )tanh(iTw)
=G
m
(k) + C=l 10 )tanh(m w)
L (tanh(iTw))2
;=1
m = glucose measurement delay (min)
t ( . -1)w = parame er mln
(245)
and the rate of change of glucose concentration was in turn given by
= G(k)-G(k-l)
T
(246)
As indicated in Equation 244, the infusion algorithm derectly employed pro-
portional {P} action based on glucose concentration plus derivative (0)
action based on the rate of change of glucose concentration; Shichiri et
al. selected a b~sic PD control structure because analysis of experimental
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data in the perfused rat pancreas (Basabe et al., 1970) and with intrave-
nous glucose infusions in normal man (Cerasi et al ~) 1974) suggested that
the dynamics of nat~ral pancreatic insulin secretion were based on both
proportional and derivative responses to glycemia. Fischer et ale
(1978;1980) arrived at a mathematically identicai PO algorithm for insulin
delivery through analysis of in vivo glucose-insulin relationships
following oral and intravenous glucose tolerance tests in normal sUbjects.
The performance of a controller resides not only in the appropriate-
ness of its mathematical structure in relation to the process being regu-
lated, but also in adjustment of its parameters (tuning). For the various
algorithm structures reviewed above, tuning parameter values have been
attained through trial and error clinical experimentation until desired
results were obtained. It is thus difficult to assess if such ad hoc
tuning methods have resulted in full realization of a given algorithm's
performance. For example, Christensen et al. (1981) performed repeated
oral glucose tolerance tests (OGTTs) in diabetic subjects in order to
"optimize" the tuning parameters of the Biostator GCIIS infusion algorithm
(see Equations 239-241); results of the study indicated that d modified set
of tuning parameters enabled normal glucose tolerance to be achieved while
sUbstantially reducing the amount of insulin delivered (by more than 50% in
Jme patients) when compared to the amount of insulin delivered using the
tuning parameters originally recommended by the manufacturer.
In this chapter, two important issues are addressed during formulation
of an optimal controller for closed-loop glycemic regulation: 1) an
appropriate mathematical structure for the optimal controller algorithm,
and 2) tuning of the controller for optimal performance. Optimal
controller design and tuning are derived through consideration of the dyna-
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mics of the process being regula~ed, glucose metabolism in the ;nsulin-
dependent diabetic, via use of simulation studies.
Several groups have previu~51y used simulation studies to approach
problems concerned with closed-loop insulin delivery. Sorensen et ale
(1982) and Cabelli and Ruggeri (1983) have both utilized models of glucose
metabolism in diabetic man challenged with oral glucose to study peripheral
versus the more physiologic portal routing of glucose-controlled insulin
delivery. Broekhuyse et al. (1981) compared closed-loop insulin infusion
algorithm responses by inputting the same blood glucose profiles to a
number of the established mathematical algorithms and calculating the
resulting insulin infusion rate output profiles. The effects of parameter
tuning in changing or improving algorithm performance were not considered
in any of the above studies.
To date, Swan (1982) has been the only investigator to apply optimal
control analysis to the problem of closed-loop glycemic regulation in the
diabetic. Swan used methods of variational calculus to determine the insu-
lin delivery action that would minimize the time required to drive blood
glucose concentration from an initial value to a desired steady state
level. There were a several serious drawbacks to the analysis, however.
First, the mathematical approach yielded an algo~ithm for insulin infusion
rate as a linear combination of not only blood glucose level but also
plasma insulin concentration as a function of time; t~.us, implementation of
such a control principle would not re practical since mo~itoring of plasma
insulin would be required. Second, the problem ~ddr·essed was now to drive
glucose level to some prescribed value in the absence of exogenous glucose
input, eithe~ orally or intravenously introduced into the body; therefore,
the solution did not determine the most effective way to minimize the
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impact of glucose loading on changes in glycemia (the IIregulatorll problem)s
but rather provided an optimal method for changing glucose levels from one
value to another in the absence of a glucose challenge (the IIservoll
problem). Finally, an extr-emely simp'lified linear two-compartment mathe-
matical model was employed for prediction of in vivo glucose and insulin
dyndmics (see Ackerman et al., 1969). As acknowleged by Swan, a need
existed for future application of optimal control analysis utilyzing a more
realistic physiologic model of in vivo glucose metabolism. Such was the
objective of the present study.
2) Optimal Controller Development
a) Basic Control Structure
Under basal steady state conditions, exogenous glucose input from the
gut is zero, and blood glucose concentration in the insulin-dependent
diabetic is maintained at a de~irable basal level by means of basal insulin
delivery. The basic problem was to develop an optimal controller for mini-
mizing the impact of unknown rates of gut glucose input resulting from glu-
case ingestion on deviations in blood glucose concentration from its basal
or setpoint level. Such would be t:onsidered a UregulatorU problem in
, control terminology.
Internal ~Ddel Control (IMC) is a modern control methodology that
allows for a ver'y transparent and rational approach to optimal controller
design (for review, see Garcia and Morari, 1982). IMC structure was
employed for the basic closed-loop control configuration, as shown ;n
Figure 105. Variables corresponding to the figure were defined as follows:
y(t) = observed variable (mg/dl)
= deviation in g1ucose conc. G(t) from its basal value Gb
= G(t)-Gb
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Fi g. 105 Basic IMC structure for blood glucose regulation.
402
m(t) = manipulated rariable (lJU/kg .min)
= deviation in insulin infusion rate IR(t) from its
basa1 rate IRb
.. IR(t ) - IRb
l(t) ~ load (mg/min)
= rate of gut absorption of oral glucose
d(t) = disturbance (mgjdl)
= contribution of gut glucose loading to y(t)
....
y(t) = internal model prediction of y(t) for l(t)=d(t)=O (mg/dl)
Ysp ~ setpoint (mg/dl)
= desired value of y(t)
= a mg/dl
d(t) = estimated disturbance (mgjdl)
....
= y(t)-y(t)
e:(t) = error signal (mg/dl)
= Ysp-d(t)
Since control analysis is facilitated by use of time domain Laplace trans-
formation (denoted by variable.s), glucose concentration y(t) and i~sulin
infusion rate m(t) were defined as deviation values such that all of the
control variables in the loop assumed a value of zero at basal steady
state. In the Laplace domain, the following transfer functions were
defined (see Figure 105):
Gm(s) = ~nternal model transfer function
= y(s)
m(s)
Gc(s) = controller transfer function
= m(s)
e(s)
Gp(S) = process transfer function
= y(s) for 1(s )=d (s )=0
m(s)
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Gl (t) = load transfer function
= d(s)
1(s )
As shown in Figure 105, IMC structure incorporates an internal mod~l to com-
-pute y(t), a prediction of what the observed variable y(t) would be as a
result of changes in the manipulated variable m(t) under unloaded con-
-ditions. By subtracting y(t) from the actual observation y(t), the
-
resulting feedback signal d(t) is an estimate of the disturbance d(t), the
deviation in y(t) attributable to the presence of a load l(t). An error
signal e(t) is taken as the difference between the setpoint Ysp and d(t),
and the controller changes the value of the manipulated variable m(t) on
the ~asis of this error signal.
The dashed box in Figure 105 represents the insulin-dependent diabetic
under closed-loop glycemic regulation, whose observed glycemia at any given
time is determined by external.changes in insulin infusion rate and the
presence, if any, of oral glucose loading. For the purposes of designing
and a~sessing an optimal controller in the present work, a physiologic
model of the Type I (insulin-dependent) diabetic was employed to simulate
in vivo glycemic response. The Type I diabetic model was obtained by
removing endogenous pancreatic insulin release from the physiologic model
of glucose metabolism and its regulation by insulin and glucayon as origi-
nally formulated for a normal 70 kg man. Since reversible diabetic abnor-
ma1ities such as insulin resistance, insulin antibody binding, and impaired
glucose counterregulation were not considered, the model was representative
of a well-controlled, metabolically-normalized subject. Details of the
formulation and verification of the physiologic models of glucose metabo-
1ism in nornal and Type I diabetic man are presented in Chapters II and V.
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For interfacing of the Type I diabetic model with the control struc-
ture of Figure 105, observed glucose concentration was assumed to be that of
peripheral ve~ous blood, insulin infusion was routed intravenously, and the
load corresponded to the rate ~f gut glucose absorption into the blood.
For calculation of deviation variables, a basal peripheral venous blood
glucose concentration Gb of 75 mg/dl was employed, as this represented the
mean value of measurements accumulated from 267 ideal weight normal adults
at the Joslin Research Laboratory, Boston; the basal insulin infusion rate
IRb to maintain the specified basal glycemia was 320 ~U/kg.min.
b) Process Characterization and the Internal Model
The internal model provides a simple input-output approximation of the
process response to changes in the manipulated variable under unloaded con-
ditions, or (see Figure 105)
(247)
The first step in designing the IMC control loop was to characterize the
process transfer function Gp(s) for use in the internal model.
The process transfer function relates in vivo glycemic response to
changes in insulin infusion rate in the absence of glucose loading. In
order to derive a suitable mathematical form for the process transfer
function, open-loop "experiments" were performed with the diabetic model;
step changes in the insulin infusion rate m(t) were input into the diabetic
model and profiles for the time course of glycemic response y(t) were
generated. A typical glycemic step-response profi1e is plotted in Figure
106. As commonly observed for many processes (Cohen and Coon, 1953), the
step response curve had a sigmJidal shape that could be adequately approxi-
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Fig. 106 Simulation of blood glucose concentration response to a step
change in insulin infusion rate in the absence of glucose
loading. Results were used to characterize the process of 1n
vivo glycemic regulation.
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mated by the response of a first-order system with dead time:
G(s) ~-~=
~ + 1
where K = gain
T = response time constant
o = dead time
(248)
the parameters of which may be estimated from the sigmoidal step response
~u~ve according to (see Figure 106)
K = steady state output = y(t+~)
steady state input m(t+~)
T = y(t+m), where S is the slope of the inflection point
S
tangent line
o = the abscissa intercept of the inflection point tangent line
Since in vivo regulation of glucose was known to be nonlinear with respect
to insulinemia, step response curves were generated for insulin infusion
step increases and decreases of varying magnitudes; resulting parameter
values are summarized in Table 39. As would be anticipated, negative gain
values were attained, indicating inverse steady state relationships between
glucose concentration and insulin infusion rate, i.e. step increases in
m(t) yielded decreases in y(t+~), and vice versa. For large step inputs,
the observed magnitutde of the response gain ~ decreased, presumably
reflecting nonlinear saturation of insulin-stimulated glucose disposal at
plasma insulin concentrations sUbstantially removed from basal, whereas
values of Land 0 remained relatively constant, implying similarity in the
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Table 39. First-order response parameters for insulin infusion step changes
of varying magnitudes as obtained by fitting of blood glucose
concentration step response profiles as depicted in Figure 106.
m(t +cD) K 0 T
( lJU/kg ef11i n) (mg/dl) ()JU/kg -min)-l (min) (min)
-200 -C.22 12 95
200 -0.21 10 92
400 -0.18 9.2 88
800 -0.09 7.9 75
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response dynamics. ~r subsequent analysis, the linear model of Equation
248 was employed with the following fixed parameter values:
Kp = -0.21 (mg/dl)(~U/k9·min)-1
Tp = 90 min
0p = 10 min
where the subscript p has been used to denote applicability to the process
trans fer funct ion. The~e parameter va1ues refl ect 1; nea r'i za t ; on about the
basal steady state (see Table 39), and this was assumed to be a valid first-
order approximation over the operational ranges of interest.
The process transfer function thus established provided the internal
model transfer function needed for It·1C ;ntpl ementation:
(249)
- 0 s
K e pp
T S + 1p
-Y(5)
m(s)
- -
-- ---
G (5)
m
Inversion of this expression from the Laplace domain yielded the equivalent
-internal model function relati~g y(t) and m(t) in real time, given by
-dy{t) ...
+ y( t) = Kpm (t - 0p ) (250)
3) Optimal Controller
Under the assumption that 9m(S)=Gp(s) and that Gp(s) is stable, it can
be derived from optimal control theory that the sum of the squared errors ;s
minimized for the regulator problem when the controller transfer function
is given by the inverse of the process transfer function (Garcia and
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t~o rar i, 1982),
(251~
Because Gc(s) must be stable, however, the following process transfer func-
tion factorization is introduced:
(252)
where G+(s) contains the time delays (their inversion would require a pre-
diction) and the zeros outside the unit circle (their inversion wou"id yield
an unstable controller)(see Garcia and ~~rari, 1982). The optimal reali-
zable controller is thus given by
(253)
For the precess of glucose regulation in the diabetic, the process
transfer function was given by
- <5 s
K e P
= P
T S + 1p
which upon factorization yielded
(254)
(255)
(256)
Here, G+(s) factored out the effect of the dead time 0p in the glycemic
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response to changes in the insulin infusion rate; inversion of G+(s) would
have required the controller to have future knowledge (from time t to time
t+op) of the time course of the insulin infusion rate. Although G+(s) con-
tains the part of the process that limits achievable control quality, such
limitations, inherently arising from the physical system under regulation,
cannot be removed by any control system.
Finally, from Equations 253 and 255, the optimal controller was given
by
TpS + 1
G
c
(s) =
Kp
which upon inversion from the Laplace domain yielded
= _1:p dE(t) 1
m(t) +- e(t)
Kp dt ~
(257)
(258)
Interestingly, by deriving the optimal controller via consideration of the
inherent dynamics of in vivo glycemic regulation, the resulting optimal
controller function incorporated proportional and derivative action with
respect to the error signal e(t). The PO controller as given by Equation
258 is tuned for optimal performance within the IMC structure utilizing
parameters directly provided by process characterization. Because the
error signal fed to the IMC controller [E(t)=Ysp-d(t)] differs from that
employed in classical feedback control [i~ general, E(t)=y(t)-ysp]' tuning
of the PO controller in Equation 258 does not directly relate to selection
of tuning parameters for a classical PO controller such as the one used by
Shichiri et al. (see Equation 244).
For application of the optimal controller (Equation 258) to blood glu-
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case regulation, the following constraint was imposed:
( 259)
Regulation of in vivo glucose metabolism is a nonlinear process with
respect to insulinemia; in particular, the incremental effectiveness of
elevating peripheral insulin levels above about 100 ~U/ml in stimulating
increased glucose disposal rates diminishes rapidly (Mtndarino and Gerich,
1984). Application of the linear controller of Equ~tion 258 scheduling
insulin delivery strictly on the basis of observed glycemia could thus
induce circulating plasma insulin levels exceeding normally effective phy-
siologic ranges, and the resulting exposure of the diabetic to such inef-
fective hyperinsulinemia could be detrimental to the maintenance of normal
in vivo insul in responsiveness. In normal subjects, administation of a
100g OGTT (a rather large dose of oral glucose relative to normal mealtime
intake) elicits a mean maximal venous plasma insulin concentration of about
100 ~U/ml (Soeldner and Park, 1977); a value of mmax was thus imposed to
constrain controller action such that peripheral venous insulin
concentration would not exceed 100 ~U/ml in the diabetic under closed-loop
glycemic regulation. The maximum controller action mmax was assigned a
value of 905 ~U/kg.min, as this was the incremental infusion rate from
basal predicted by use of the diabetic 'Dodel to result in a venous plasma
insulin concentration of 100 ~U/ml~ Sinc6 m(t) represents the deviation in
insulin infusion rate IR(t) from its basal rate 1Rb' the minimum controller
action mmin was -320 ~U/kg.min (-IRb) such that IR(t) was limited to values
greater than zero.
d) Summary of the Optimal IMC Equations
To summarize, process characterization and optimal control con-
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siderations yielded the following relationships for implementing optimal
IMC control of blood :lucose concentration in the insulin-dependent
diabetic:
Interna1 Model
....
T dy(t) + y(t) = K m(t-o )
P dt P P
Optimal Controller
(260)
(261)
rnmax = maximum
mmin = minimum
Kp = process
Tp = pro~ess
0p = process
where y(t) = deviation in blood glucose cone. G(t) from its basal
val ue Gb (mg/dl)
.... = G( 1:) - Gb
y(t) = estimate of y(t) in the absence of glucose loading (mg/dl)
m(t) = deviation in insulin infusion rate IR(t) from its basal
rate IRb (~U/kg.min)
= IR( t) - IRb _
e(t) = error signal = Ysp- (y(t)-y(t) )
and Ysp = setpoint = 0 mg/dl
Gb = basal blood glucose conc. = 75 mg/dl
IRb = basal insulin infusion rate = 320 ~U/kg.min
allowed value of m(t) = 905 ~U/kg.m;n
allowed value of m(t) = -320 ~U/kg.min
gain = -0.21 (mg/dl)(~U/kg.min)-l
response time constant = 90 min
dead time = 10 min
The value of the maximal contraint imposed on Equation 261 was selected to
limit peripheral venous plasma insulin concentration to 100 ~U/ml.
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C) Simulation Studies to Assess Optimal IMC Performance
Simulation studies using the Type I diabetic model were undertaken to
assess optimal IMC performance in regul~ting glycemia during oral glucose
loading. For cqrnputer simulations, the simultaneous first-order differen-
tial equations of the IMC internal model (Equation 260) and the diabetic
model (see Chapter V) were solved numerically using fourth-order Runge-
~tta integration with a time step of 0.1 min.
Intestinal absorption of glucose occurs via active transport of glu-
cose across the intestinal mucosa, a process that may be rate-limited by
intralumenal diffusion and/or carrier availability (Wilson, 1962; Csaky,
1975). Initiation of gastric emptying of a large glucose load can lead to
effective saturation of the intestina1 absorption mechanism (Langerlof et
al., 1976). The maximal rate of gut glucose absorption in man is dbout 800
mg/min, based on analysis of intestinal perfusion data (Hillman, 1977),
interpretation of in vivo double tracer studies (Radziuk et al., 1978; Pilo
et al., 1981), and simulation studies using physiologic models of glucose
metabolism (Cobell; et al., 1983; see simulation of the 100g 0611 in
Chapter IV). Thus, a viable closed-loop insulin delivery system must
acceptably minimize blood glucose variations ca~sed by gut glucose loading
rates which may arbitrarily vary with time over a range of a to 800 mg/min.
Presented in Figure 107 are results of simulation studies to evaluate
optimal controller regulation of gut glucose step loading. Simulations
were performed for gut glucose load rate step inputs of 100, 400, and 800
mg/min (upper panel). The optimal controller action regulated glycemia
within a narrow range (center panel), with blood glucose concentration
peaking at a value of about 120 mg/dl in response to the maximal gut load
rate of 800 mg/min. For gut load rates in excess of 400 mg/dl, a nonzero
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steady state offset from basal glycemia resulted. fhe observed offset
implied that use of a fixed gain, a linear approximation, did not precisely
compensate for nonlinearities of actual in vivo glucose responS2 under con-
ditions most removed from basal. Although logic providing for on-line gain
adjustment (nonlinear control) could have been introduced to eliminate the
steady state glycemic offset, introducing the additional complexities of
such an approach was deemed unjustified since maintenance of blood glucose
concentration below 100 mg/dl would be quite acceptable under such ~xtreme
load conditions. Simulated plasma insulin response profiles resulting from
optimal controller action are presented in the lower panel of Figure 107.
The maximal step loading just saturated controller insulin delivery as evi-
denced by plateauing of the resulting plasma insulin concentratin response
at a value of 100 ~U/ml. It is interesting that, at lesser gut load rates,
interaction of the process dead time and controller derivative action pro-
duced transient ascillations (period ~ 11 min) in plasma ins~lin level that
damped with time. Regular oscillations have been observed in plasma insu-
lin concentrat7on profiles in normal man; these oscillations have a mean
periorl of 13 min with a mean amplitude of 1.6 ~U/ml under basal conditions
(Lang et al., 1979) and persist with the same period but increased ampli-
tude during intravenous glucose loading (Mathews et al., 1983). However,
neither the phys10logic importance of this phenomenon nor its driving force
have as yet been fully elucidated (Verdin et al., 1984).
Although closed-loop insulin delivery is primarily directed toward
minimizing hyperglycemic excursions following oral glucose ingestion,
hypoglycemic excursions are potentially dangerous, and thus the regulatory
characteristics of the controller must also avoid inducement of hypoglyce-
mia. In order to assess optimal controller effectiveness in averting
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Iserious hypoglycemia, a worst case scenario was simulated as shown in
Figure 108. A continuous maximal rate of gut glucose loading was first
imposed for a period of 150 min to elicit high levels of circulating insu-
lin, then the glucose loading was acutely withdrawn. Upon termination of
glucose loading, blood glucose concentration began to decrease rapidly.
Controller action quickly modulated insulin delivery, however, such that
the resulting maximum glycemic undershoot was only about 15 mg/dl below
basal glucose concentration, thus maintaining absolute blood glucose levels
above 60 mg/dl. Since hypoglycemic excursions to 60 mg/dl are commonly
observed in normal subjects following oral glucose, (Soeldner and Park,
1977), the above simulation study suggested that implementation of the
optimal controller would not evoke hyperglycemia in excess of acceptable
limits.
Having assessed controller performance with respect to the extremes of
step loading, it was desirable to study how optimal closed-loop insulin
delivery would control glycemia during a more physiologic temporal pat-
terning of gut glucose loading. For this purpose, optimal controller regu-
lation of the 100g OGTT was simul~ted (Figure 109). The gut glucose
absorption rate profile employed for OGTT simulation (upper panel) was that
originally derived from the study of glucose-inSUlin relationships observed
in normals using the physiologic model of glucose metabolism in normal man
(see simulation of the 100g OGTT in Chapter IV). In Figure 109, simulated
blood glucose and plasma insulin profiles resulting from optimal controller
action are compared with clinical data correlated frum l~Og OGTTs admi-
nistered to a population of 145 ideal weight normal adult males at the
Joslin Research LaboratorYt Boston. Optimal closed-loop insulin delivery
resulted in glycemic regulation comparable to that observed in normal man.
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In addition, controller action generated a plasma insulin-response that was
quite similar to that normally resulting from endogenous pancreatic insulin
release in the nondiabetic. (It should be noted that the offset between
basal steady state insulin levels results because in normal man, the
pancreas maintains ba~al glycemia by means of intraportal insulin release,
whereas in the diabetic, basal glycemia is maintained by peripheral insulin
delivery.) The similarity between optimal control and normal in vivo gly-
cemic regulation was extremely interesting, interpretable in one of two
ways: 1) assuming the normal pancreas represents a natural biological
optimal controller, the physiologic model employed in the present study
must have been a good representation of in vivo glucose metabolism, as its
use for process characterization dictated optimal control behavior; or con-
versely, 2) assuming the physiological model was a good representation of
in vivo glucose metabolism, the pancreas must have evolved as an optimal
biological controller for the process of glucose metabolism.
4) Discussion
Through application of IMC methods, an optimal control scheme for
blood glucose regulation was derived from consideration of characterizing
the process of in vivo glycemic response to changes in insulin infusion
rate. The resulting IMC structure offers mathematical simplicity, as its
implementation only requires on-line integration of the linear first-order
ordinary differential equation which constitutes the internal model
(Equation 260) and calculation of insulin delivery rate from the PD
controller (Equation 261). The effectiveness of optimal IMC was
demonstated through simulation studies, and results suggested that optimal
IMC is quite similar to the physiologic control provided by normal
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pancreatic action in the nondiabetic.
In reviewing development of the algorithm of Albisser et al.
(Equations 231-234) and the work of Clemens et al. leading to the control
equations presently employed in ~he Biostator GCIIS (Equations 239-243), it
became apparent that selection of the basic controller functionalities used
in these control systems was loosely based on a combination of physiologic
reasoning and experience gained from clinical trials. The insulin infusion
algorithms that evolved as a result are rather complex, highly nonlinear
formulations incorporating a number of tuning parameters for which values
were attained by ad hoc means through clinical experimentation. The
approach of Shichiri et a1. was somewhat different and led to development
of a PO controller (Equation 244) which resembles that obtained in the pre-
sent study. Shichiri et al, derived the PD control functionality and based
its tuning on analysis of glucose-insulin relationships observed during.
glucose loading in normal man. It is interesting that similar controller
functions were attained by Shichiri et al. from studying the behavior of an
assumed functional optimal controller, the pancreas, and from the present
work applying optimal control analysis to the system being regulated, in
vivo glucose metabolism.
Whether optimal performance has been attained from the controllers
reported in the literature to date is unclear. Broekhuyse et ale (1981)
input the same glucose profile to a number of established insulin infusion
algorithms (including those of Albisser at al., Clemens et a1o, and the PO
controller of Fischer et al.) and reported similarity between resulting
insulin infusion responses despite the apparent diversity of the various
algorithm functionalities. The optimal controller derived in this chapter
thus may not provide for radical improvement in achievable b100d glucose
421
regulation in the context of present applications, although its mathemati-
cal simplicity relative to most other algorithm formulations is certainly
an attractive feature.
Emphasis must be placed, however, on the notion that existing applica-
tions of glucose-controlled insulin delivery (e.g the Biostator GCIIS) may
reflect relatively ideal conditions compared with those which may be
encountered in extending closed-loop insulin delivery to long-term implan-
table applications. In particular, glucose sensors used in present bedside
systems provide minute-to-minute measurements, have response times on the
order of one minute, and are quite accurate (if calibrated on a frequent
basis). In tontrast, implantable glucose sensors suitable for long-term in
vivo applications will prqbably exhibit less ideal performance charac-
teristics, thus requiring suitable control systems to function in the pre-
sence of less ideal glucose monitoring. Adaptation of the literature
algorithms for use with less ideal sensors is not straightforward. In the
best case, trial and error parameter readjustment may provide adequate com-
pensation for some types of sensor nonidealities. It is quite possible,
however, that the basic functional structures of these algorithms might be
incompatible with certain types of sensor-induced feedback dynamics, in
which case instabilities could develop and simple parameter readjustment
would not prove satisfactory. In addition, since it is a good assumption
that the normal pancreas can monitor blood glucose in a manner approaching
ideality relative to man-made sensors, analysis of glusose-insulin rela-
tionships in normal man cannot be extended to provide insight into methods
of coping with problems associated with control in the presence of nonideal
glucose monitoring. IMe provides a straightforward approach to con-
sideration of nonideal glucose measurement effects, however, and the power
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of this approach will be demonstated in the next section as analysis is
extended to explore optimal control in the presense of nonideal glucose
sensing.
B) Effects of ~~asurement Characteristics on the Quality of Control
1) Bac kground
Problems associated with development of a suitable glucose sensor have
retard;d progress towards a totally implantable glucose-controlled insulin
delivery system, It ~s likely that the ultimat~ performance of implantable
systems will be limited by the operational characteristics of the sensor
component. We begin with a brief overview of glucose sensors, their
measurement characteristics, and other problems related to in vivo glucose
monitoring.
There are basically three types of glucose sensors under development,
enzymatic, electrocatalytic, a~d affinity. The enzymatic glucose sensor is
based on the oxidation of glucose by disolved oxygen in the presence of
glucose oxidase:
glucose oxidase
glucose + 02 + H20 ----------------+ H202 + gluconic acid (262)
Glucose measurement is mad~ by virtue of decreases in pOZ' increases in pH,
or production of hydrogen peroxide. The electrocatalytic glucose sensor
employs a platinum anode to catalyze the direct electrochemical oxidation
of glucose:
platinum
Anode: C6H1206 ---------+ C6H1006 + 2H+ + 2e (263)
Cathode: 10 + H20 + 2e2 2
platinum
--------- + 20H
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(264)
Measurement of glucose is based on the potential difference and current
flow between a worKing electrode and ieference or counter electrodes. The
affinity sensor is based on the competitive binding of glucose and
fluoroscein-labeled dextran with specific receptor sites on immobilized
concanavalin A. Measurement;s made by optical detection of the unbound
dextran label (Schultz et al., 1982).
At present, the enzymatic sensor is the most highly advanced and has
been utillzed in all of the bedside-type glucose-controlled insulin deli-
very systems to date. The most widely used and comercially successful
enzymatic sensor has been the Clark-type glucose sensor (Clark, 1970) which
employs polarographic detection of hydrogen peroxide oxidation catalyzed by
a platinum electrode. This is the type of glucose sensor used in the
Biostator GCIIS glucose sensing module (Santiago et al., 1979; Oberhardt et
al., 1982). Other configurations of glucose oxidase sensors suitable for
direct intravascular or subcutaneous applications are under development,
including the needle-type sensor of Shichiri et ale (1983), the catheter-
tip sensor of Clark and Duggan (1982), and the implantable oxygen electrode
design of ~ndo et al. (1982).
In general, the enzymatic glucose s€nsor offers good accuracy and
rapid response characteristics. In reviewing a number of enzymatic sen-
sors emplying various detection methods, Thevenot (1982) concluded that in
vitro glucose determinatins seemed relatively easy to perform with an
accuracy of 2-5% over glucose concentration ranges of physiologic interest.
Guilbault (1982) compared in vitro response times of various enzymatic glu-
cose sensors and reported values generally ranging between 1-10 min. It
should be noted, however, that data such as the above reflect in vitro
measurement characteristics, and thus may not be achievable under less
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ideal in vivo conditions where, for example, local glucose availability
(glucose is consumed by sensors), oxygen availabilty, or changes in p02
could effect sensor response. The major problem with the immobilized
enzyme glucose sensor is that of long-term stability, as glucose oxidase i~
subject to mechanical, chemical, and enzymatic denaturation (Thevenot,
1982). Stability problems make enzy~matic sensors susceptible to measure-
ment drift. To date, long-term stability of enzymatic sensors has not been
adequately studied in human fluids or tissues at 37° C. Experience with
the Biostator GCIIS sensor, however, has indicated a limited sensor life-
time of up to 200 h a.nd a need for frequent calibration (Oberhardt e-:: al.,
1982). Shichiri et al. (1983) reported that output current from their
needle-type glucose sensor decreased 24% over 168 h of incubation in
albumin-saline solution. Obviously, future improvements will be necessary
before chronic implantation of enzymatic glucose sensors becomes feasible.
Electrocatalytic glucose sensors are being developed by a number of
groups, including Lewandowinski et ale (1982), Richter et al. (1982), and
Lerner et al. (1981; 1982). The electrochemical approach to glucose
sensing offers a great advantage over enzymatic se~sors with respect to the
promise of long-term stability. In particular, the platinum electrode sur~
face of the electrocatalytic sensor can be rejuvenated' in situ by dedi-
cating a portion of the elctrode potential cycling to surface oxidation to
prevent surface poisoning, thus preserving catalytic activity (Richtei' et
ale, 1982; Lerner et al., 1982). The major problem with electrocatalytic
sensors, however, is their susceptibility to interference in glucose
measurement caused by co-reaction of physiologic agents, primarily amino
acids and urea. For the sensor of Lerner et "ale (1982), a physiologic
change in amino acid concentration from 35 to 65 mg/dl caused a 25%
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variation in glucose determination at 50 mg/dl of glucose, and 10%
variation in glucos£ determination at glucose concentrations greater than
about 125 mg/dl. Richter et ale (1982) reported an error of approximately
20% resulted from variation of urea concentration over a physiologic range.
With respect to response time, the electrocatalytic sensor design of Richter
et al. (1982) required about 17 min (20 cycles) to yield a steady state
response following a step change in glucose concentration. To date, dyna-
mic response data for other electrocatalytic sensors have not been reported
in the literature.
The affinity sensor using opti~al glucose detection is being developed
by Schultz et ale (1982). In vitro feasibility studies with a prototype
design demonstrated reasonable glucose sensit~vity over physiologic con-
centration range5 with a measurement response time on the order of 10 min.
The affinity sensor offers a promising approach t but future work will be
required to produce a viable implantable glucose sensor using this tech-
nology.
Independent of the approach employed for glucose sensing, certain
other issues complicate in vivo glucose monitoring. Sensor placement in
the subcutaneous or intraperitoneal environment may be advantageous over
intravascular placement to avoid tile hazards of intravascular thrombosis,
and glucose concentration measurements at these possible sensor implant
sites have suggested their feasibility (Wolfson et al., 1982). Relative to
the vascular environment t however, absolute glucose concentrations are
lower and dynamic response times are increased at these alternative moni-
toring sites. Shichiri et al. (1983) reported that glucose concentrations
in subcJtaneous tissues (forearm or abdomen) were 10% lower but highly
correlated with blood glucose cotlcentrations in the range of about 50-400
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mg!dl. Furthermore, the mean rise time in output of the needle-type glu-
cose sensor (intrinsic response time of 29 s) inserted into subcutaneous
tissue was 5.1 min relative to changes in blood glucose concentration.
Thus, extravascular sensing can add effective response time to glucose
monitoring relative to that achievable by direct vascular access.
Biocompatibility issues may also influence the quality of ;P vivo glucose
monitoring, as so-called "protein fixation" (Sh;chir; et al., 1984) and
fibroblast encapsulation could reduce sensitivity and increase response
time of the implanted sensor. Shichiri et ale (1984) noted protein fixa-
tion on membranes of sensors kept in subcutaneous tissue for 72 h, and
reported that 96 h of imp1antation prolonged the in situ sensor response
time from 5.1 to 13.5 min relative to blood glucose concentration changes.
Although the quality of achievable in vivo glucose monitoring has yet
to be determined by future research, it appears likely that glucose-
controlled insulin delivery devices will have to rely on nonideal glucose
measureme~ts. ~ date, the only study to assess the effects of nonideal
glucose measurement on closed-loop glycemic regulation was report~: by
Sorensen et al. (1982). Using a physiologic model of glucose metabolism
developed by Guyton et al. (1978; Guyton, 1973) as adapted for oral glucose
loading by Hillman (1977), simulations of OGTTs were repeated while glucose
measurement dead time was varied from 1.5 to 30 min. An insulin infusion
algorithm from the literature, the hyperbolic tangent infusion algorithm of
Albisser et al.(see Equaticns 231-232,234) using projected glucose values
as proposed by Botz (see Equation 235), was employed for calculation of
insulin infusion rate. Results indicated that increased meaSl-~ement dead
time decreased the quality of glycemic regulation as initial delays in
insulin response allowed greater hyperglycemic excursions. It should be
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noted, however, that the issue of optimal it.y was not addressed in the above
study, neither with respect to the basic form of the infusion algorithm nor
with reSpEct to its tuning.
The purpose herein is to extend the previous discussion of optimal
control in order to examine in a very broad sense Lhe degree to which non-
ideal glucose sensor characteristics limit the quality of achievable glyce-
mic regulation.
2) Optimal IMC With Nonideal Process Observation
Analysis of optimal IMC impl imentation is now ext~nded to incorporate
the possibility of nonideal process observation. As shown in Figure 110, a
glucose sensor process transfer function Gs(s) is inserted into the basic
IMC structure to characterize the relationship between actual deviations in
blood glucose concentration from basal y(s) and that measured by the glu-
cose sensor Ym(s),
(265)
Optimal control analysis parallels that presented earlier if a new
.. process 11 is defi ned as fo 11 ows :
(266)
. *Here, the "process" Gp(s) relates changes in insulin infusion rate m(s) to
measured glucose response Ym(s) under unloaded conditions (l(s)=d(s)=O),
and thus includes consideration not only of the actual process being regu-
lated but also of toe characteristics of the glucose sensor used to observe
i t~
Using variables as defined previously but employing a superscript *
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Fig. 110 Extension of basic IMC structure to include a glucose sensor
measurement element. (Compare with Figure 105)
*notation to imply reference to "process" Gp(s) (compare Figures 105 and
110), the internal model transfer function becomes
G (s)
m
~
= y (s)
m(s)
(267)
and, in analogy to previous optimal controller development, is approximated
by
*G (s) ~ G (5)
m p
The optimal controller is given by
(268)
= m(s)
*E (s)
(269)
(270)
*and represents the portion of Gp(s) which upon inversion yields a stable,
realizable controller.
The above approach accounts for stability and optimality of control in
the presence of nonideal process observation. For the ideal glucose
sensor,
= 1 (271)
and the analysis reduces to the case of optimal control presented earlier.
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3) Simulation Studies to Assess Effects of Nonideal Measurement
on Optimal IMC Performance
Simulation studies wer'e undertaken using the iype I (insul in-dependent)
diabetic model under 100g OGTT loading to assess the effects of glucose
sensor measurement characteristics on optimal IMC glycemic regulation. For
these simulation studies, glucose measurement characteristics were defined
by selection of the glucose sensor transfer function Gs(s), and the inter-
nal model and controller transfer functions were appropriately modified to
achieve stable, optimal control. The purpose here was to evaluate how the
quality of optimal glycemic regulation degrades as closed-locp control is
increasingly driven by the sensor response Gs(s) rather than the real pro-
cess response Gp(s).
a) Sensor Dead Time
The glucose sensor transf~r function corresponding to a system with
measurement dead time is given by
where Os = sensor dead time (min)
(272)
The internal model transfer function in this case becomes
(273a)
-°sHe S )
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(273b)
(273c)
and thus the internal model incorporates the sum of the proc€ss and sen~or
dead times. Factorization of Equation 273c yields
* KpG_(s) =-~-
T S + 1P
from which the optimal controller is then given by
(274)
(275)
= (276)
The resulting optimal controller is the same as that ~reviously derived
for the case of ideal process observation (Equation 257), since sensor dead
time, like process dead time, only contributes to the noninvertible portion
*of the process factorization G+(s). Inverting the above equations from the
Laplace domain to real time gives the following IMC relationships:
Gl ucose Sensor
Internal ~1odel
-*
T dy (t) + y(t) = Km(t-IS -IS)
P dt P P s
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(277)
(278)
Optimal Controller
m(t) Ln=_.-
*dE (t)
dt
1
+--
Kp
*e: (t) (279)
Simulation studies were performed to assess the effects of glucose
sensor dead time on the quality of achievable glycemic regulation as shown
in Figure 111. The diabetic model was employed to s'imulate blood glucose
and plasma insulin responses during the 100g OGTT whi-le glucose sensor dead
time Os was varied from 0 to 60 min in the optimal IMC equations. Results
of the study showed' that increasing the sensor dead tim\: increased the
delay in the initial response of insulin to rising blood glucose con-
centration causing larger and larger hyperglycemic excursions. Sensor dead
time variation did not contribute to inducement of significant hypoglycemic
excursions, however. As could be anticipated, for sensor dead time values
much less than the process response time,
or
(280)
(281)
the impact of sensor dead time on degrading the quality of blood glucose
control was quite minimal.
b) Sensor Response Time
A glucose sensor may not instantaneously respond to a step change in
surrounding glucose concentration, but rather may require a finite time for
its output to reflect fully a step input. With respect to sensor design,
response time is associated with the time required for diffusion of glucose
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across membranes coupled with intrinsic sensor measurement response kine-
tics. In addition, an apparent sensor response time can be induced by
external factors, such as in vivo protein fixation to sensor membranes or
tissue en~apsulation of the s~nsor implant causing additional transport
resistance. Furthermore, as previously discussed, subcutaneous sensing
increases sensor response time relative to that obtained by direct vascular
access.
In order to study the effects of glucose sensor response time on
closed-loop glycemic control, a simple first-order response model was
employed for the glucose sensor transfer function:
where
Gs(s) = __I_
T S + 1s
TS = sensor response time constant (min)
(282)
Output from such a sensor would reflect 63% of a step change input in one
time constant TS • The interna'i model transfer function in thi s case beco-
mes
(283a)
(283b)
(283c)
Factorization of Equation 283c yields
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from which the resulting optimal controller is given by
(284)
(285)
= (TpS + 1)(TSS + 11
Kp
(286)
Inversion of the above expressions from the Laplace domain to real time
yields the following IMC relationships:
Gl ucose sensor
dy (t)
T
S
m + y (t) = y{ t)
dt m
Internal Model
d2; (t ) dy(t ) ""*
LpTS dt2 + (Tp+TS ) dt + Y (t) = Kprn(t- 6p)
(287)
(288)
Optimal Controller
2 * *TpTS d £ (t) (Tp+TS ) d€ (t) 1 *
m(t)= -- + + - £ (t'J (t) (289)2 m nli n-m '31 maxKp dt Kp dt Kp
The above equations represent a rigorous treatment. Because the sen-
sor response time transfer function Gs(s) does not contribute to the nonin-
vertible factorization G:(S) of the process transfer function G;(S)s the
optimal controller of Equation 289 provides complete mathematical compen-
sation for the presence of sensor response time. Thus, use of the above
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IMC relationships for sensors with finite response times ts yields blood
glucose regulation identical to that obtained for the ideal case of instan-
taneous sensor response time (ts=O).
Although rigorous treatment can provide complete, ideal compensation
for sensor response time, this introduces second-order derivative terms
(dencted by dashed underlines) into the internal model (Equation 288) and
controller (Equation 289). In practical applications, use of second-order
derivative terms in the control loop equations may not be desira~le due to
problems associated with their accurate on-line calculation in real systems
and because use of the second-order derivative terms makes control action
particularly sensitive to sensor modeling inaccuracies such as inexact
matching of true sensor response time and that assumed for the sensor in
the control equations (note that TS multiplies Tp in the second-order deri-
vative terms of the above IMe control equations).
Since implementation of the ~econd-order IMC sensor response compen-
sation equations could present practical difficulties, studies were under-
taken to exami~e the quality of subuptimal blood glucose regulation that
would result with first-order response time compensation. Results of simu-
lations to assess the effects of first-order sensor response time compen-
satio~ on blood glucose regulation during the 100g OGTT are presented in
Figure 112. Sensor response time TS was varied from 0-120 min in Equations
287-289 while the second-order derivative terms in the IMC internal model
(Equation 288) and controller (Equatior 289) were neglected; it may be noted
that the presence of sensor response time TS thus entailed use of an effec-
tive response time of Tp+TS in the resulting first-order control loop
equations. Unlike the case of sensor dead time (see Figure 111) which
caused a pure lag in initial insulin response, increased sensor response
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response time TS was vari ed from 0-120 mi n in the g1 ucose sensor
(Equation 287). and in the IHe internal model and controller
(Equations 288 and 289, respectively; second-order derivative
terms neglected).
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time caused sluggish but imm~diate insulin r~sponse upon onset of rising
glycemia; as a consequence, even sensor response times on the order of the
process response time Tp only resulted in modest hyperglycemia. As sensor
response time TS approached the process response time Tp' however, oscilla-
tions in blood glucose concentration reflecting second-order respon3e
interactions began to appear upon recovery to steady state. Such oscilla-
tions would not be desirable due to their observed penetration into
hy~oglycemic regimes. Finally, for sensor response times much less than
the process response time, or
<T
S
.. 9 mi n (290)
the effects of glucose sensor response time on achievable glycemic regula-
tion were of minimal significance.
As discussed previously, increased sensor response time could result
from factors such as tissue encapsulation of the sensor implant. Under
such conditions, the actual change in measurement response might not be
anticipated, in which case no modification of the control equations would
be made. Thus, simulation studies were repeated where sensor response time
TS was again varied from a to 120 min in the glucose sensor (Equation 287),
but no compensat~ry modifications of the control equations was taken, i.e.
the value of TS in the internal model (Equation 288) and controller
(Equation 289) was set to zero for all sensor response time variations~
Results of simulations to assess the effects of sensor response time on
uncompensated closed-loop glycemic regulation during the 100g OGTT are
shown in Fi gure 113. Compari son of Fi gures 112 and 113 c1 earl y
demonstrated the relative effectiveness of partial (first-order) compen-
sation for glucose sensor response time in reducing the magnitudes of
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Fig. 113 Simulation studies to determine the effects of sensor response
time on glycemic regulation during the 100g OGTT in the absense
of control loop compensation. Here, the simulations of Figure
112 were repeated, excelJt TS was set· to zero ; n the i nterna1
model and controller (Equations 288 and 289, respectively) for
all va,·iations in glucose sensor response time.
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resulting hyperglycemic and hypoglycemic excursions. Of particular impor-
tance were the dangerously F1.",rge hypoglycemic oscillations caused by sensor
response times approaching the process response time if no control loop
compensation was adopted. Of course, for the conditions of Equation 290,
lack of compensation was not important, and good glycemic regulation was
maintained; this result could be anticipated from Equation 283c, because
- 0 S
K e Pp
T S + 1p
(291)
c) Systematic Sensor Measurement Error
A serious concern with development of a sensor suitable for long-term
applications is the problem of systematic measurement error arising, for
example, through error in the calibration curve or drift. To study
measurement error effects, the following glucose sensor transfer function
is defi ned:
Gb(y-l )1----
y(s)
(292)
where y =measurement error parameter (dimensionsless)
Gb = basal blood glucose concentration (= 75 mg/dl)
Inversion of this expression from the Laplace domain to real time yields
Gl ucose sensor
(293)
It can be seen from Equation 293 that the dimensionless parameter y produces
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a measurement error proportional to the absolute magnitude of the true
blood glucose concentration. In general, the presence of systematic
measurement error would not, from a control perspective, be detected. In
this ca5e, the internal model and optimal controller equations would
remain as originally derived without consideration of nonideal process
observation (Equations 260 and 261, respectively).
Simulation studies to assess the effects of systematic measurement
error on blood glucose regulation during the 100g OGTT are presented in
Figure 114. Here, the diabetic model was employed for preaiction of blood
glucose and plasma insulin respcnse profiles while the magnitude of sensor
measurement error was altered by varying the value of y from 1.30 tu 0.70
(±30% range in error). Variation in systematic measurement error resulted
in proportional offset in the blood glucose response profiles, with the
inconsistency in spacing between adjacent blood glucose profiles simply
reflecting effects of system nonlinearities. Although decreases in
measurement sensitivity (y(1.0) induced roughly proportional increases in
hyperglycemia, of concern were the more potentially hazardous effects of
increased measurement sensitivity (y)1.0) which caused hypoglycemic offset
from normal. Although decreases in sensitivity might be more commonly
anticipated, in reality such may not always be the case; indeed, enzymatic
glucose sensors are prone to initial periods of increasing measurement sen-
sitivity presumably attributable to establishment of diffusion channels
within the enzyme matrix (Guilbault and Lubrano, 1973).
An interesting approach to dealing with sensor drift is suggested by
the simulation results shown in Figure 114. At basal steady state, the
controller drives the measured glucose concentration deviation Ym(t) to its
setpoint value of zero, thus generating basal offset in actual blood glu-
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Fig. 114 Simulation studies to assess the effects of systematic sensor
measurement error on glycemic control during the 100g OGTT. A
measurement error of ±30% w~s introduced by variation of parameter
y from 1.30 to 0.70.
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case concentration in the presence of measurement drifto Under drift con-
ditions, however, insulin concentration under basal conditions also changes
as shown in the lower plot of ~gure 114, thus r2flecting changes in the
actual steady state rate of insulin delivery. It might th~s be possible to
implement logic 'into the control system to warn of apparent measurement
drift and to alert the pcltient of the need for sensor recalibration; such a
warni ng waul d be i ssued ,~hen the system 1ogi c confronts the paradox of
departure from normal basal baseline insulin infusion rate to produce
"apparent" basal glycemiil. Conceivably, an effective automatic recalibra-
tion procedure could be initiated based on logical interpretation of
changes in m(t) from zero when Ym(t) equals zero.
d) Sensor sampling Interval and Digital Control
To this point, only continuous glucose measurement has been con-
sidered, and simulations of "continuous" time entailed use of numerical
integration methods (fouT'th-order Runge-Kutta integration) based on a time
step of 0.1 min (a time step deemed satisfactory for approximat"ing con-
tinuous dynamics from previous experience with modeling of in vivo glucose
regul ation) • Due to oj ntl'~i nsi c sensor measurement characteri sti cs and/or
the possible need to conserve power expenditure of an implantable unit,
however, it may be necessary or desirable to sample blood glucose con-
centrati on at speci fi c t'imes ~ather tha.n on a conti nuous bas is.
A glucose sensor pr~~iding discrete blood glucose concentration values
is defined as follows:
ym(kT) =y(kT) k = 0,1,2 ••• (294)
where T = sampl i ng i nterva1 (mi n)
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Discrete time IM~ was analyzed by first considering the analogous con-
tinuous time system and then digitalizing the resulting control equations.
l~e analogy between discrete and continuo~s system analysi~ holds if the
effect of discrete sampling is considered aqu;valent to introducing an
induced measurement dead time of T into a continuous system. Thus, the
continuous system glucose sensor analogy to Equation 294 is given by the
transfer function
() - TsGs s = e (295)
Given this glucose sensor transfer function, optimal control analysis was
identical to that previously described for the case of sensor dead time
(compare the equivalence of the glucose sensor transfer functions of
Equations 295 and 272 with dead times of T and os' respectively). Thus,
the resulting continuous tinle internal model is given by
-kdy (t)
Tp dt
~
+ y (t) = K m{t-o -T)p p (296)
and the optimal controller by
*
___t p de: (t) 1
m(t) --- +--
Kp dt Kp
*
€ (t) (297)
Digitalizing Equations 296 and 297 by using finite differences for approxi-
mating derivatives, the following set of relationships for discrete time
IMe implimentation result:
Gl ucose sensor
ym(kT) = y(kT)
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k = C,l,2 ••• (298)
Internal ~1odel
-k -It
T Y (kT)-y (kT-T) + ;(kT) = K m(kT-c5 -T)
P T P P
k=O,1,2 ••• (299a)
-k(or) y (kT) =
-It
Tpy (kT-T) + TKpm(kT-C'p-T)
Tp + T
k = 0,1,2 ••• (29gb)
Optimal Controller
* *
__ Tp € (kT) - € (kT- T) 1 *
m(kT) + -€ (kT) mmin ~(kT) ~max ;k=0,1,2••• (300)
Kp T Kp
Finally, for coupling of discrete time control with the continuous process
of in vivo glycemic regulation, the digital controller output m(kT) is
converted to a continuous output m(t) via a zero-order hold:
m(t) =rt(kT) kT < t < kT+T; k=O,1,2 ••• (301)
Simulation studies to assess the effects of discrete sampling on glyce-
mie regulation during the 100g OGTT are shown in Figure 115. The diabetic
model was used to predict blood glucose and plasma insulin responses while
the discrete glucose sampling interval T was varied from a to 60 min in
the digitalized IMC equations. It should be noted that blood glucose
responses for the case of sensor sampling would actually vary, particularly
for large values of T, depending on alignment of sampling times relative to
administration of the oral glucose challange at time t=O. The simulations
in Figure 115 represented a worst case with respect to hyperglycemic excur-
sions, because sampling was adjusted such that a glucose measurement was
taken at time t=O for all specified sampling intervals T. As shown in the
lower panel of Figure 115, this approach maximized the delay in the initial
insulin response to rising glucose concentration in all cases. The
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Fige 115 Simulation studies to assess the effects of measurement sampling
interval on discrete time glycemic control during the 100g OGTT.
The interval T of discr~te glucose sampling was varied from
5-60 min in the digit~l IMe Equations 298-300. Included for com-
parison are results for T+O, or the case of continuous measurement.
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hyperglycemia resulting from discrete sampling interval values T was simi-
lar to, but modestly lower than that obtained ~r continuous time control
with equivalent sensor dead time values ~ (compare Figures 115 and 111).
The reason for the slightly improved blood glucose regulation in the case
of discrete sampling can be exp'iained as follows. For equivalent values of
T and ~St initial plasma insulin response to oral glucose is comparably
delayed (compare lower plots in Figures 115 and 111). In the case of digi-
tal control, at time t=T, sampling of the present elevated glucose con-
centration immediately initiates a step increase in insulin infusion rate,
whereas for the case of sensor dead time, at time t=~ the del~yed initial
rise in blood glucose concentration just begins to initiate increased insu-
lin delivery. Thus, digital control results in a faster initial plasma
insulin response than does the system with equivalent sensor dead time, and
this provides for the observed improvement in hyperglycemic regulation. As
shown in Figure 115, for values of the sampling interval T much less than
the process response time Tp' or
T ~ 9 min (302)
the resulting discrete time closed-loop glycemic control was comparable to
that obtained for continuous time optimal control (T+o).
e) Coupling of Nonideal Sensor Characteristics
In this section, analysis is extended to consider coupling of the
above sens~r nonidealities. Generalized step responses for sensors
operating in continuous time and discrete time mode~ respectively are
depicted in Figure 116. The continuous time glucose sensor (center panel)
is represented by coupling of dead time ~ with a first-order response time
448
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Fig. 116 Generalized sensor step responses depicting the coupling of dead
time Os and fi rst-order response time Ts for a conti nuous time
sensor (center panel). and extention to digital operation with
superposition of sampling interval T for the discrete time sensor
(lower panel).
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LS. For the discrete time glucos~ sensor (lower panel), measurement output
used for control purposes is sampled at time intervals T.
Extention of earlier analysis to consider coupling of sensor dead time
as and response time TS in conti nuous time ; s stra i ghtforward. In thi s
case, the glucose sensor transfer function L~comes
- 0 S
e s
Gs(s) =---
or S + 1s
The internal model is given by
-0 S -0 S
K e Pes
:: ~ PH)
(303)
(304a)
(304b)
- ( 6p+6s )s
= K..;.-p_e _
(TpS + 1)(T~S + 1)
Factorization of Equation 304c yields
(304c)
(305)
(306)
Because the presence of sensor dead time 6s contributes only to G:(s)t the
*
. optimal controller (givpn by the inverse of G_(s)) is the same as that pre-
viously derived by consideration of sensor respotlse time TS alone (Equation
450
286). Inverting the relevant expressions from the Laplace domain to real
time gives the following IMC relationships:
Gl ucose Sensor
dy (t)
m + y (t) = y( t- 0 )
dt m s
In terna1 ft\lde1
d2y(t) dy(t)-
+ (Tp+<S) + yet) =
dt 2 dt
(307)
(308)
Optimal. Controller
T TS d
2t (t ) (-rp+TS ) d t (t ) 1 *m(t)= _P- + + -E (t)
Kp dt
2 Kp dt Kp
m · ~(t) qn (309)mln max
Although the internal model (Equation 308) incorporates consideration
of the presence of both dead time Os and response time TS in the glucose
sensor measurement signal, the optimal controller (Equation 309) can pro-
vide compensation only for the presense of response time TS. If the
second-order derivative terms in the above internal model and controller
equations are retained, complete compensation for sensor responsr time TS
is provided and the resulting quality of blood glucose f'egulation depends
only on the sensor dead time ~; in this case, the quality of achievable
control may be ascertained directly from results of the sensor dead time
simulation studies presented in Figure 111.
As discussed previously, omission of the second-order derivative terms
in the control loop equations may be desirable for practical applicatioris.
If partial (first-order) sensor response time compensation is employed in
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the IMC equations, the quality of blood glucose control is affected not
only by the sensor dead time ~, but also by the magnitude of the sensor
response time TS. Simulation studies to assess the effects of such
coupl i ng of sensor dead time Os and sensor response time TS on blood g1 u-
case regulation during the 100g OGTT are shown in Figure 117. For these
simulations, values of ~ and TS were varied in Equations 307-309, but the
second-order derivative terms (denoted by dashed underlines) were neglected
in the IMC internal model (Equation 307) and controller (Equation 309).
Within limits of the assumption that the process of in vivo glucose regula-
tion is linear, it would be expected that coupling of sensor dead time and
sensor response time would result in a superposition of the effects
observed for each of these cases considered individually (see Figures 111
and 112, respectively~. As shown in the lower plot of Figure 117, initial
plasma insulin response to rising blood glucose concentration was delayed
by a time period corresponding'to Os (compare lower plot of Figure 111),
and following this initial delay period, the initial dynamic insulin
response was slo\'iec! due to the presence of sensor r'~sponse time s (compare
lower plot of Figure 112). The coupling of Os and TS °in Figure 117 thus
resulted in peak hyperglycemia reflecting the sum of the effects shown in
the upper plots of Figures 111 and 112. With respect to recovery of blood
glucose to its basal level, however, such superposition effects become dif-
ficult to anticipate due to the more complex dynamic interactions involved.
As shown in the upper plot of Figure 117, for coupling of os=ts=40 min,
which evoked combined sensor response time dynamics on the order of the
process response time Tp (=90 min), an unacceptable blood glucose nddir of
45 mg/dl resulted during the recovery period; this behavior is not predic-
table a priori by apparent superpositioning of the results presented in
452
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Fig. 117 Simulation studies to assess the effects of coup~fng sensor dead
time and sensor response time on blood glucose regulation during
the 100g OGTT. Va1ues of 6s and TS were va ri ed from 0-40 mi n ; n
Equations 307~309 (second-order derivative terms neglected).
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Figures 111 and 112. For values of Os and TS of 20 min or less, however,
coupling of these sensor characteristics led to acceptably small hypoglyce-
mic excursions during blood glucose recovery to basal steady state.
Finally, for coupling of sensor dead time and response time such that the
induced measurement ~.ill"r'li~s occ.ur on tlrne scales much less than the pro-
cess response time Tp' or
~ + < 9 ·Us TS " ml n (310)
the resulting blood glucose control approaches that obtained for ideal glu-
case sensing.
Presented in Figure 118 is a comparison between true blood glucose
concentration (equivalent to y(t)+Gb) and the blood glucose concentration
sensor reading (equivalent to Ym(t)+Gb) for the case of 0s=Ts=20 min in
Figure 1170 Because of the sensor dead time Os, the initial rise in blood
glucose concentration was first detected 20 min after its actual
occurrence, resulting in a 20 min delay in the initial controller response
(see lower panel of Figure 117). In addition to the pure measurement delay
associated wi th os' the sensor response time TS resul ted ina sensor
reading that was dynamically sluggish and attenuated in magnitude relative
to the true blood glucose response.
For a 91 ucose sensor with dead time Os and response time TS operati ng
in a discrete time mode (see Figure 116), output from the senor as given by
Equation 307 is sampled at time intervals T. The proper IMC equations for
use in this case may be derived simply by digitalizing the above rela-
tionships for the generalized conti~uous time glucose sensor (Equations
307-309), recognizing that such digitalization adds an induced dead time T
to the internal model (Equation 308). The following discrete time IMC
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Figure 117.
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relationships result:
Gl ucose Sensor
Internal Model
kT<t<kT+T; k=O,1,2 •••
(311)
(312)
'-'* -k --okY (kT)-2y (kT-T)+y (kT-2T)
TpTS 2T
= ICm(kT-o -0 -T)
-p p s k=0,1,2 ••. (313a)
-It -Ie
K m(kT- 0 _0 - T) + 2y (kT- T) -y (kT- 2T ) + (T +T )y-k (kT- T)~ p p s T_ _ _ _ _ p s
(or) y (kT)= ------------------
Tp TS
T
(313b)
Optimal Controller
* k * * *
__ TpTS € (kT)-2€ (kT-T)+€ (kT-2T) (Tp+TS ) € (kT)-£ (kT-T)
m(kT) +~---------
_ ~p_ _ T2 _ _ _ _ Kp T
k=O,1,2 ••• (314)
and the digital controller output m(kT) is converted to continuous time
output m(t) by Equation 301.
The generalized discrete glucose sensor model introduces a dead time
of 6s+T and a response time of TS into the measurefllent signal, and the pre-
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sence of these sensor characteristics is fully reflected in the IMC inter-
nal model formulation (Equation 313b). The optimal controller (Equation
314), however, provides compensation only for the presence of response time
TS. For cases in which' T5=0, or if the second-order derivative terms
(denoted by dashed underlines) in the above internal model and controller
are retained to compensate fully for the presence of TS>O, the quality of
achievable blood glucose regulation depends only on the effective digital
sensor dead time cSs+T; the effects of coupl ing Os and T on blood gl ucose
control can be approximately predicted simply by superimposing results pre-
sented for Os and T in Figure~ 111 and 115, respectively.
If, for practical applications, the second-order derivative terms are
neglected in the digital IMC internal model (Equation 313b) and optimal
contro~ler (Equation 314), thus providing only partial or suboptimal
(first-order) compensation for the presence of sensor response time 1"s>O,
the resulting blood glucose regulation is affected by coupling of TS with
the sensor's effective dead time Os+T. For cases in which Os=O, coupling
of TS with induced dead time T would be closely approximated by the results
presented in Figure 117 for the coupling of ts with dead time Os in the con-
tinuous time domain. Thus, only the effects of fully CQuplipg ~ and T in
the presence of LS with first-order IMC compensation remains to be eluci-
dated. Presented in Figure 119 are simulation studies to assess the Jffects
of coupl i n9 sensor dead time os' sensor response time l"s, and di g; ta 1
control (sampling interval T) on blood glucose regulation during the 100g
OGTT. Values of OS' LS' and T were vared in Equations 311-314, but the
second-order derivative terms (denoted by dashed underlines) in th'~ digital
IMC internal model (Equation 313) and controller (Equation 314) were
neglected. The results in Figure 119 may be viewed as reflecting the 5uper-
457
250
Os; "rs ;T: (mi n)
-0 40;40;40
" 2000>(: 20;20;20
10;10;10
u 150z 5;5;50
u 0;0;0
w
V>
0 100u
:)
.-J
~
0 500
a
-1
m
0 I
120 l
os; Ls;T: (min)
" 100:::l(
u 80 5;5;5
z 10;10;100
u 20;20;20
z 60
-..J 40;40;40
:) I(j)z 40<1:
:L _J(j) 20<t
.-J
£1.
0
-50 50 100 150 200 253 303
TIME (Min)
Fig. 119 Simulation studies to assess the effects of cOJpljng sensor dead
timet sensor response time. and digital IMC control on blood glu-
cose regulat·~on during the 100g OGTT. Values of 6s, Ts, and T were
varied from 5-40 min in Equations 311-314 (second-order derivative
terms neglected). Included for comparison are results for ideal
continuous glucose measurment (6s=TS=O; T-+O).
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position of digital sampling T on the results obtained in Figure 117 for
coupling of Os and ts in continuous time. As shown in the lower plot of
Figure 119, coupling of Os and T in the glucose sensor causes an initial lag
in insulin response to rising blood glucose concentration corresponding to
a total delay time of Os+T. Thus, the addition of sampling interval T to
the coupling of Os and ts (as shown in Figure 117) further degrades the
quality of achievable blood glucose regulation. The peak hyperglycemic
excursions observed in the upper plots of Figure 119, however, are approxi-
mated nicely by superimposing the effects of digital sampling (as shown in
the upper IJI at of Fi gure 115) on the effects of coupl i ng Os and TS in con-
tinuous time (as shown in the upper plot of Figure 117); here, superposition
refers to using the blood glucose response profile obtained for the ideal
continuous sensor as the base case and superimposing the deviation effects
caused by introduction of respective sensor nonidealities. With respect to
inducement of hypoglycemia during recovery of blood glucose to its steady
state basal level, the contribution of digital control per se led only to
minor amplification of the magnitudes of the hypoglycemic excursions
observed in Figure 117. Finally, for the coupling of OS' TS' and T, if the
induced measurement dynamics correspond to time scales much less than the
process response time tp' or
(315)
the quality of achievable blood glucose control approaches that obtainable
with the ideal glucose sensor.
Presented in Figure 120 ;s a comparison between true blood glucose
concentration and the digital blood glucose concentration sensor readings
for the case of 0s=Ts=T=20 min in Figure 119. With respect to sensor
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response to initial rising blood glucose concentration, the sensor dead
time ds caused sensor output at t=20 min to remain at basal concentration.
Because of digital sampling, the first sensor reading to reflect a rise in
blood glucose concentration occurred at t=40 min. Thus, controller
response to initial rising blood glucose concentration resulted 40 min
after its actual occurrance (see lower panel of Figure 119). This
illustrates the notion that digital sampling per se induced a measurement
dead time equal to the sampling interval i, as the sensor response delay
was effectively ds+T=20+20=40 min in Figure 120. As suggested in Figure
120, the presence of sensor response time TS caused the digitalized sensor
response to be dynamically sluggish and attenuated in magnitude relative to
the true blood glucose response being monitored.
The effect of sy~tematic sensor measurement error was not considered
in the above analyses of sensor measurement characteristic couplings.
Because the IMC structu~~e is designed on the basis of variables for which
values are defined in terms of deviations from basal steady state, the
introduction of systematic sensor measurement error in the absence of
control loop compensation simply offsets resulting blood glucose response
profiles as was demonstrated earlier (see Figure 114). Thus, introduction
of systematic sensor measurement error was not explicitly explored ;n the
context of coupling sensor measurement characteristics, as its inclusion
would simply lead to a predictable offsetting of the response behav10rs
generated in the above coupling studies.
f) Sensor Measurement Noise and Its Filtering
Measurement noise is an important consideration when implementing
closed-loop control because superposition of noise on the measurement
461
signal is particularly detrimental to accurate calculation of derivatives
in the control loop equations. It is therefore necessary to minimize
interactions of noise signals by application of effective noise filtering.
In order to study measurement noise eff~cts, a discrete time glucose
sensor is defined as follows:
Ym(kT) = y(kT) + u(kT) k=O,1,2 ••• (316)
where u(kT) = zero-mean, random measurement deviates (mg/dl)
Here, a sensor with measurement noise is simulated by superposition of zero
mean random deviates u(kT) on the true sampled glucose concentration values
y(kT). The zero-mean random deviates u(kT) are defined statistically by a
gaussian distribution with a standard deviation (sd) given by
sd = a (y (kT) + Gb ) k=O,l ,2 ••• (317)
where a = measurement noise parameter (dir.1ensionless)
Gb = basa1 setpoint blood glucose conc. (= 75mg/dl)
Thus, the standard deviation of the noise is assumed proportional to the
(instantaneous) true blood glucose concentration, and the relative contri-
bution of the noise component to the measurement signal is altered by
vary; ng the val ue of parameter a.
A measurement noi se fi 1ter is; nserted into the IMC st.~ucture as shown
in Figure 121. The purpose of the filter is to provide a relatively no;se-
A
free measurement estimate ym(kT) from the noise-contaminatej measurement
--signal ,)'m(kT). Although "filters" are commonly inserted into the d(t)
feedback loop of the IMC structure in the control literature (see Garcia
and Morari, 1982), such filters provide a freedom to the designer to adjust
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Fig. 121 Schematic depiction of discrete time IMC structure indicating in-
sertion of a filter block for filtering measurement noise u(kT)
introduced by the glucose sensor.
closed-loop response so as to achieve a desired behavio~. The objective
here, however, is simply to fi1ter noise from the measurement signal
without modifying the basic characteristics of optimal controller regula-
tion of blood glucose.
For present purposes, a simple first-order response filter (single
exponential smoothing)(see ~ppel, 1968) is employed, which in discrete
time form ;s given by
;, (kT) - ;, (kT-T) A
Tf~_m_--_m_- + ym(kT) = ym(kT)
T
k=O,1,2 ••• (318a)
Tf;~(kT-T) - TYm{kT)
Tf + T
k=O,1,2 ••• (318b)
where Tf = noise filter time constant (min)
Equation 318a can be recognized as the discrete time repres~ntation of
a simple first-order response model with time constant Tf. Thus, insertion
of the filter into the IMC structure as shown in ~gure 121 introduces a
response time Tf analogous to that introduced by previous consideration of
a gl ucose sensor wi th response time T
S
• For noi se fi 1teri og, however, the
Ir~C internal model and controller are not modified to compensa~~e for the
presence of the filter in the measurement loop; the purpose for the filter
is to provide an inverse for the noise component u(kT) in the measurement
signal, and thus inclusion of IMC compensation for the filter would simply
serve to reintroduce the noise component and counteract filter effec-
tiveness. For the glucose sensor and noise filter described above, the
following IMC relationshi~s are employed:
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Gl ucose Sensor
ym(kT) = y(kT) + u(kT)
Noise Filter
A TfYm(kT-T) + TYm(kT)
ym(kT) =-------
Tf + T
Internal Model
Optimal Controller
k=O,1,2 •••
k=O,1,2 •••
k=O,1,2 •••
(319)
(320)
(321)
* *T E (kT)-€ (kT-T) 1 *
m(kT)= -E ---- + -€ (kT) mmin ~(kT) ~min ;k=O,1,2 ••• (322)
Kp T Kp
where the error signal is given by (see Figure 121)
* A ~
€ (kT) = YsP - (ym(kT) - Y (kT) ) k=O,1,2 ••• (323)
and the digital controller output m(kT) is converted to continuous time
output m(t) by Equation 301. Here, the internal model and controller
(Equations 321 and 322) are the digital IMC control equations (Equations
29gb and 300) previously derived for application to systems with discrete
sampling int . val T.
The quality of blood glucose regulation achieved by application of
the above IMC equations is affected by the contribution of measurement
noise u(kT) via parameter a, the discrete time sampling interval T, and the
filter time constant Lf. It should be noted that control generated by the
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above approach does not represent optimality because optimal filtering with
respect to the noise input u(kT) is not con5idered. Optimal filtering
refers to application of filter designs, such as the Kalman filter, that
provide for interactive gain adjustment such that the noise contribution is
minimized as a function of time (for details, see Maybeck, 1982).
Specification of the filter time constant Tf in the present study, however,
is equivalent to using a fixed filter gain. Application of optimal adap-
tive noise filtering to the problem of blood glucose control presents spe-
cial difficulties due to the presence of the u'1easured rate of oral
glucose loading that drives the system response. Because of this
unmeasured input, extended-adaptive Kalman filtering methods of optimal
estimation must be employed. Such methods are based on use of a stochastic
(Markov) system model for prediction of the time-varying parameter to be
estimated (Stephanopoulos and San, 1984), the system model being driven by
a noise source for which the variance undergoes adaptive changes in
response to observation noise (Jazw;nski, 1970). The effectiveness of this
estim&~ion approach has been recently demonstrated for on-line control
of bioreactors based on noise-contaminated data (Stephanopoulos and San,
1984; San and Stephanopoulos, 1984). The purpose of the present study,
however, is to determine the effectiveness of a' simple first-order response
filter, and thus to determine the need, if any, for use of more sophisti-
cated optimal filtering methods.
As stated previously, measurement noise primarily interacts with deri-
vative controller action. For the case of blood glucose regulation, an
important consideration with respect to measurement noise interaction is
its possible inducement of baseline hypoglycemic drift. Under basal steady
state conditions, derivative controller action is normally zero reflecting
466
a constant blood glucose level. The presence of artifactual measurement
noise, however, can randomly drive the controller output about a mean
(time-averaged) value independent of actual in vivo changes in blood glu-
cose concentration. If measurement noise causes random insulin infusion
rate deviaticns from basal with magnitudes exceeding the basal insulin
infusion rate IRb as shown in Figure 122, controller output is clipped
because the insulin infusion rate IR(t) must be constrained such that its
value is greater than zero. As a result of clipping the controller output,
the time-averaged insulin infusion rate lies above the normal basal insulin
infusion rate (the area represting IR>IRb (or m>O) becomes greater than the
area representing IR<IRb (or m<O) with time in Figure 122). When the time-
averaged insulin infusion rate exceeds the normal basal insulin infusion
rate in the absence of glucose loading, hypoglycemia is induced. For
example, in the worst case the insulin infusion rate would be randomly dri-
ven between zero and its maximum value of 1275 ~U/kg.min (evoking both
minimum and maximum constraint clipping), resulting in a time-averaged
insulin infusion rate approaching 637 uU/kg-min; this value represents
about twice the normal basal insulin infusion rate of 320 ~U/kg~in and
would cause a predicted time-averaged blood glucose concentration below 40
mg/dl. Thus, one objective of noise filtering ;s to avoid basal hypoglyce-
mic drift. Of course the other objective is to minimize the adverse
effects of noise interaction with controller regulation of blood glucose
during oral glucose loading.
Simulation studies were undertaken to assess the effectiveness of
first-order response noise filtering. For these studies, psuedo-random
zero-mean gaussian deviates were generated using the IMSL library computer
subroutine GNML. The standard deviation of these gaussian deviates was
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Fig. 122 Illustration depicting how basal state noise-driven deviations
in insulin infusion rate can lead to clipping of controller
output causing inducement of hypoglycemia.
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Ivaried via parameter a as defined by Equation 317, and the resulting zero-
mean random gaussian deviates representing measurement noise u(kT) were
superimposed on the discrete blood glucose concentration values according
to Equation 316 to generate a simulated sensor measurement output Ym(kT)
contaminated with noise. The general approach taken was to examine
tolerance of representative operating systems (T, Tf fixed) to increases in
the measurement noise (via increasing parameter a) as assessed with respect
to resulting basal hypoglycemic drift and control of oral glucose loading
during the 100g OGTT.
The effectiveness of the first-order respo~se noise filter resides in
the property that high frequency components of the input signal are atte-
nuated to a greater extent than the low frequency component5 of the input.
signal upon passage of the signal through the filter. The resulting noise
suppression for a fixed level of noise input thus increases as the ratio
T/Tf decreases. For a given sampling interval T, a design compromise must
be reached between achievable noise suppression (favoring large values of
Tf) and avoidance of sluggish filter response in tracking of the input
signal (favoring small values of Tf). For practical applications of single
exponential smoothing, a ratio T/Tf=O.2 represents a reasonable compromise
(Koppel, 1968). Simulation studies were conducted to examine the noise
tolerance of two representative system designs: 1) a discrete time IMe
system with sampling interval T=l min and a first-order responsa filter
with time constant Tf=5 min; and 2) a discrete time IMC system with
sampling interval T=4 min and a first-order response filter with time
constant Tf=20 min. Filters with time constants Tf>20 min were not con-
sidered on the basis of the simulation results presented in Figure 113 which
demonstated that introducing sensor response time TS greater than about 20
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min into the measurement signal (a case analogous to introducing filter
response time Tf into the measurement signal) leads to unacceptable blood
glucose regulation in the absence of IMC control loop compensation.
Presented in Figures 123-126 are results of simulation studies to
assess the noise tolerance characteristics of a digital IMC structure
employing a sampling interval T=l min coupled with a first-order response
filter with time constant Tf=5 min. The quality of IMC blood glucose regu-
lation provided by Equations 319-322 was studied with respect to basal base-
line drift (Figures 123 and 124) and during the 100g OGTT (Figures 125 and
126) as the magnitude of the measurement noise was varied (via parameter a)
in Equation 317. As shown in the upper plot of Figure 123, introduction of
2.5% measurement noise (OFO.025) caused a small drift in basal blood glu-
cose concentration from main~enance at the desired setpoint concentration
of 75 mg/dl to a time-averaged concentration of about 73 mg/dl.
Introduction of 5% measurement" noise (OFO.05) further decreased the basal
time-a~eraged blood glucose concentration to roughly 67 mg/dl. As indi-
cated in the lower panel of Figure 123, the observed depression of basal
glucose levels coincided with increased interaction of noise with
controller insulin delivery as the measurement noise level was elevated.
At the 5% measurement noise level, the filter1s effectiveness was readily
demonstrable, however, as its removal from the IMC structure resulted in
rapid, unacceptable depression of basal blood glucose concentration caused
by excessive noise-induced controller action~ In the absense of measure-
ment noise (a~O), the dead time T induced by digital control and the
(uncompensated) measurement response time Tf introduced by the filter only
caused modest degradation i~ blood glucose control during the 100g OGTT
from that obtainable under ideal conditions (see upper panel of Figure
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Fig. 123 Simulation studies to assess the basal state noise tolerance
characteristics of digital IMC (Equations 319-322) with sampling
interval T=l min and first-order response filter with time
constant Tf=5 min. Gaussian measurement noise of 2.5-5% was
introduced by variation of parameter a from O.025~O.05 in
Equation 317.
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Fig. 124 In the upper panel t true blood glucose concentration ;s compared
with its sensor measu,·~ement for the case of <FO.05 in Figure 123.
In the lower panel, true blood glucose ;s compared with that
obtained by filtering of the measured values with Tf=5 min.
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Fig. 125 Simulaticn studies to assess the noise tolerance characteristics
of the" digital IMC system of Figure 123 (T=l min; Tf=5 min) during
the 100g OGTT. Measurement noise was varied from 0-5% by variation
of parameter a in Equation 317. Included for comparison are results
for the case of ~deal continuous measurement (T-+o; Tf-+O; (FO).
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with its sensor measurement for the case of OFO.05 in Figure 125.
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obtained by filtering of the measured values with Tf=5 min.
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123). Presented in Figure 121 are comparisons between 1) true and measured
(Y
m
+G b) blood glucose concentration (upper pane1), and 2) true and filtered
...
(Y
m
+Gb ) blood glucose concentration (lower panel) for the case of 5%
measurement noise (OFO.05) in Figure 123). The filter effectiveness is
clearly demonstrated by noting the large scatter in the measured (upper
panel) relative to the filtered (lower panel) values. (It should be noted
to avoid misinterpretation of results that, for clarity, the blood glucose
concentration scale employed in Figure 122 is expanded relative to that
used for presentation of earlier sensor measurement interaction studies.)
Introduction of measurement lIoise resulted in increased hyperglycemia
during the OGTT (Figure 125) as noise interactions interfered with
controller action in determining insulin delivery rate. During the period
of blood glucose recovery to its steady state basal level, however,
measurement noise did not induce hypoglycemic excursions in exce~s of those
oberved in the baseline drift studies of Figure 123. To illustrate filter
effectiveness, presented in Figure 126 are comparisons between 1) true and
measured blood glucose concentration (upper panel), and 2) true and
filtered blood glucose concentration (lower panel) for the case of 5%
measurement noise (OFO.05) in Figure 125.
The above simulation studies were repeated to assess the performance
characteristics of a digital IMC system utilizing a samplin9 interval of
T=4 min coupled with a first-order response filter with time constant Tf=20
min; results are presented for basal hypoglycemic drift and 1009 OGTT
loading studies in Figur~s 127-128 and 129-130, respectively. Under basal
conditions (Figure 127), the uncompensated filter response time tf of 20
min induced oscillations (period -120 min) in basal glucose concentration
reflecting second-order control loop interactions. The mean time-averaged
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Fig. 127 Simulation studies to assess the basal state noise tolerance
characteristics of digital IMC (EquJtions 319-322) with sampling
interval T=4 min and a first-order response filter with time
constant Tf=20 min. Gaussian measurement noise of 5-15% was intro-
duced by variation of parameter a from 0.05-0.15 in Equation 317.
476
160 ]
"'0 140 - actual
"c:» o sensor· measurementr: (T=4 min,a=O.15)
120
u
z
0
u
100
w CJ [J 0°(j) DO o 0 000
u CJ
::> 80 0
-1 -o~--~ o Cb o
0 0 0000 60 QIJo 0
o 0 0 0
0 0 0 0 CO 0 00-.J 0
m 00 o 0
40
160
-0 140
- actual"-0>
£ <> fi 1tered (Tf=20 min)
120
u
z
0
u
100
w(j)
0
u
~ 80 0
-I ~~ ~%<>o~<b<po -(9
0 P::>OO ~
0 60 °00
-I
CIJ
40
-50 50 100 150 200 250 300
TIME (Min)
Fig. 128 In the upper panel, true blood glucose concentration is compared
with its sensor measurement for the case of aFO.15 ;n Figure 127.
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Fig. 129 Simulation studies to assess the noise tolerance chardcteristic5
of the digital IMC system of Figure 127 (T=4 min; Tf=20 min) during
the 100g OGTT. Measurement noise was varied from 0-15% via
variation of parameter a in Equation 317. Includert for com~arison
are resu"lts for the case of ideal continuous measurement (T-+O;
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Fig. 130 In the upper panel, true blood glucose concentration is compared
w'ith its sensor measurement for the case of a=0.15 in Fi gure 129.
In the lower panel, true blood ~lucose is compared with that
obtained by filtering of the measured values with Tf=20 min.
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blood glucose concentration decreased with superposition of measurement
noise; for measurement noise of 15% (OFO,15), however, baseline hypoglyce-
mia below 60 mg/dl was not observed. In contrast, removal of the filter
with 15% measurement noise caus~d rapid baseline drift to unacceptable
hypoglycemic levels. To illustrate filter effectiveness, presented in
Figure 126 are comparisons between 1) true and measured blood glucose con-
centration (upper panel), and 2) true and filtered blood glucose con-
centration (lower panel) for the case of 15% measurement noise (OFO.15) in
Figure 125. As shown in Figure 129, the sampling interval T=4 min coupled
with the uncompensated filter response time Tf=20 min in the measurement
signal caused a significant increase in peak hyperglycemia during the 100g
OGTT relative to that obtainable under ideal conditions. The filter,
however, provided for acceptable minimalization of further degradation in
the quality of blood glucose regulatio~ as the measurement noise content
was increased to 15%. To demonstrate the filter effective, in Figure 130
measured (upper panel) and filtered (lower panel) blood glucose con-
centration values are compared with true blood glucose response for the
case of 15% measurement noise (OFOo15) in Figure 129. It may be noted from
the 10~er panel of Figure 130 that, although the filtered response wa~
relatively noise free, passage of the blood glucose response signal through
the filter resulted in a filter output signal that was dynamically sluggish
and attenuated in magnitude relative to the true blood glucose response
being monitored; this was attributable to the presence of response time
Tf~20 min in the digital filter.
Because filter effect;~eness is primarily dictated by the ratio TI Tf'
it is interesting that the latter system (T=4 min; Tf=20 min) tolerated
roughly 15% noise, whereas the former system (T=l min; Tf=5 min) tolerated
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only about 5% noise. The explanation for this behavior may be attributed
to the notion that noise primarily interferes with derivative term calcula-
tions in the control loop equations; since first-order derivative term
calculation errors are proportional to lIT, passage of a given amount of
noise-induced error through the filter results in less relative control
loop i~teraction as the sampling interval T increases.
The above results suggest that simple first-order response noise
filtering would provide acceptable performance under quite limited con-
ditions. Because introduction of the filter and thus uncompensated
response time Tf into the measurement signal impacts on achievable blood
glucose control, use of filter time constants Tf>20 min would not be
desirable. This restriction limits applications to systems employing
sarrlpling intervals T<;4 min, such that T/Tf-:'O.2. As shown in Figures 127
and 129, for a system with T=4 min and Tf=20 min, 15% noise tolerance ;s
achievable at the expense of basal hypoglycemic drift approaching 60 mg/dl
and increased hyperglycemia during oral glucose loading. Although
decreasing the filter time constant to Tf=5 min improves blood glucose
response characteristics as shown in Figures 123 and 125, this restricts
the sampling interval T to 1 min or less and decreases acceptable noise
tolerance to only about 5%. Furthermore, it must be noted that super-
position of additional sensor measurement nonidealities (.cS,TS) was not
cons;dereu in the above studies. and inclusion of these effects would cause
additional degradation of observed blood glucose regulation when coupled
with first-order response filter insertion into the IMC structure. It may
thus be concluded that for real sensors producing measurement noise in
excess of 5%, the potential benefits to be gained from designing more
sophisticated optimal filtering schemes WJuld be justified. For glucose
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sensors with measurement characteristics approaching ideality (T(1 min;
T+OS+TS(9 min), use of simple first-order response filtering is satisfac-
tory for dealing with measurment noise of 5% or less~
4) Discussion
As illustrated in the first part of this chapter, IMe provides a
simple and effective approach to closed-loop insulin delivery that results
in optimal blood glucose regulation simliar to that observed ;n the non-
diabetic. For initial treatment, however, ideal blood glucose measurment
was assumed. Because glucose sensors suitable for long-term in vivo
implantation will likely provide for nonideal glucose monitoring, IMe ana-
lysis was extended to explore blood glucose regulation in the presence of
glucose :~nsor nonidealities.
IMC offers ~ very straightforward approach to consideration of glucose
sensor measurement nonirlealities. In general, the internal model directly
incorporates all information ;~ith respect ot the measurement response dyna-
mics resulting from the presence of the glucose sensor, and the optimal
controller is taken as the inverse of that portion of the internal model
transfer function whi~h, upon factorization, leads to stable, realizable
control.
Because introduction of blood glucose measurement dead time cannot be
compensated by controller design modification, direct inclusion of sensor
dead time 6s (Figure Ill) or indirect inducem~nt of dead time T caused by
digital control (Figure 115) significantly degrades achievable bl~od glu-
cose control &s effective measurement dead time approa~hes the process
response time Tp. Although optimal controller design ;s not affected by
meas~rement signal dead time, inclusion of measurment dead time in the IMC
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internal model is important because it provides for stable operation.
Unlike measurement dead timet th~ presence of sensor response time TS
can be fully compensated by optimal controller design; thus t the effects of
sensor response time can be cancelled out of the IMC loop signals and blood
glucose control obtainable under ideal measurement conditions (TS~)
results. Such IMC compensation, however, introduces second-order deriva-
tive terms into the internal model and controller equations. If, for prac-
tical reasons, only suboptimal first-order IMC response time compensation
is employed, acceptable blood glucose control results as sensor response
time approaches the process response time Tp (see Figure 112). For cases
in which unanticipated sensor response time arises from factors such as
tissue encapsulation of the sensor implant, lack of IMC compensation leads
to unacceptable blood glucose control for induced response times greater
than about 20 min (see Figure 113).
The presence of systematic sensor measurement error causes an offset
in blood glucose levels under IMC closed-loop regulation (Figure 114).
An overestimate of glucose concentration causes hypoglycemic offset and is
thus potentially hazardous. Concomitant with basal blood glucose offset
induced by systematic measurement error, how~ver, is altered basal insulin
delivery rate; it may thus be possible to implement system logic to detect
such conditions.
Coupling of sensor nonidealities (Figures 117 and 119) leads to super-
position of the effects observed by consideration of Ilonidealities indivi-
dually. Of particular note is the constraint of Equation 315 which
indicates that blood glucose control approaches that attainable with an
ideal sensor if the sum of the nonideal sensor measurement characteristic
times (os+Ts+T) is much less than the process response time TD- It is
.
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~lear that present bedside systems such as the Biostator GCIIS operate
within limits of ideal glucose observation. With respect to realizable
glucose sensors for long-term in vivo implantation, howev(r, the above
constraint will be difficult to meet. For such systems, realization of
good blood glucose control will necessitate use of effective control loop
designs in order to minimize the impact of sensor no~idealities.
IMC of blood glucose in the presence of meausurement noise was briefly
addressed. Results suggest that acceptable 5% noise tolerance may be
obtained using simple first-order response noise filtering for systems with
sensors providing otherwise ideal measurement characteristics (as defined
by Equation 315)& For sensors with measurment noise in excess of 5%,
design of more sophisticated optimal filtering schemes would be potentially
beneficial, as introduction of the first-order response filter into the IMC
measurment signal, due to filter response time Tf' degrades observed blood
glucose regulation as the value of Tf is increased.
Finally, it may be noted that the results obtained in studying the
effects of sensor nonidealities on blood glucose regulation have rather
widespread applicability with respect to problems associated with closed-
loop insulin delivery in general. This is because the generalized glucose
measurment models employed in the present work can be used to approximate
consideration of parallel design problems. For example, relative to vascu-
lar glucose sensing, placement of a glucose sensor with a needle
configuration in subcutaneous tissue leads to inducement of approximately a
5 min response time and roughly a 10% decrease in glucos', concentration
measurement (Shichiri et al., 1984); such effects of subcutaneous sensor
placement may be readily analyzed in terms of results presented herein.
Furthermore, in addition to closed-loop electromechanical systems, research
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efforts are pre~ently b~ing directed toward therapies based on transplan-
tation of insulin-secreting tissue,- One: of the most promising apPY'oaches
to tissue transplantation therapy is the hybrid artificial or bio~rtificial
pancreas (for revi~wt ~ee Reach, 1984)>> The hybrid ar~ti·ficj\.~'i paf1creas
consists of intact pancreatic islets or individual beta-cells protected
from tissue rejection by semipermeable membranez; the membr~ne pore size is
selected such that glucose and insulin may freely pass through, but passage
of larger entities such as gamrna glQbulins and lymphocytes 'is blocked. The
device is implanted as an arteriovenous shunt t and fluctuation of blood
glucose levels stimulates insulin release via normal biological feedback
response from the insulin-secreting tis~ue. Due to the presence of the
protective membrane and the volume associated with the tissue chamber, dif-
fus~v~ and/or convective delays in glucose and insulin transport will
degrade device performance, and consideration of such effects on device
response is presently under investigation (Sparks et al. t 1982; Weinless
and Colton, 1983; Reach et al. t 1984).
Insight into design requirements for provision of good blood glucose
regulation by the hybrid artificial pancreas can be attained by drawing
analogies between such biological feedback systems operating with tranport-
induced dynamic nonidealities and the IMC system operating with
measurement-induced dynamic nonidealities. The hybrid pancreas may be
modeled in terms of transfer functions accounting for 1) the dynamics of
glucose transport from the blood into the beta-cell chamber, and 2) the
dynamics of insulin transport from the beta-cell chamber into the blood.
Using first-order lag models to represent these transport dynamics, the
following relationships are defined:
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Yc(S) e 9
Gg(s) = =
y(s) TgS + 1
- 0- S
m(s) e 1
Gi (5) = =
mc(s) T- s + 11
(324)
(325)
where Gg(s) = tranfer function for glucose transport from the blood
into the beta-cell c~amber
G1(s) = transfer function for insulin transport from the beta-
cell chamber into the blood
yc(s) = glucose concentration 1n the beta-cell chamber (mg/dl)
Y(5) = blood glucose concentration (mg/dl)
6g = glucose transport delay time (min)
Tg = glucose transport response time constant (min)
m(s) = rate of insulin release into the blood (J,lU/kg -min)
me(s) = rate of insulin release from the beta-cells (IJU/kg~in)
o. = insulin transport delay time (min)
1
T. = insulin transport response time constant (mU/kg~in)
1
*For the hybrid artificial pancreas, a lumped process transfer function Gp(s)
may be defined in a manner similar to that used earlier for consideration
of glucose sensor nonidealities, 1.e~
(326a)
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where, as before, Gp(s) represents the process transfer function for in
vivo blood glucose response to changes in insulin delivery rate. Unlike
the IMC structure which can be modified to compensate for deviations bet-
*ween G (s) and G (s), intrinsic beta-cell insulin response to glucosep p
stimulation linking yc(t) and mc(t) in Equation 326a cannot be altered to
compensate for the presence of transport-induced nonidealities in the
biological feedback loop configuration. Thus, for the hybrid pancreas to
provide blood glucose regulation approaching that observed in normal man,
*device design must minimize the deviations between Gp(s) and Gp(s) such
that
(327)
This condition is approached if the total characteristic time associated
with glucose and insulin transport dynamics in the device is much less than
the process res pose time Tp' or
< 9 ·~ + T + O. + T,. __ ml n9 9 , (328)
To summarize, because the biological controller (the beta-cell) is fltuned fl
for optimal performance in the absence of response constraints introduced
by superposition of the hybrid pancreas configuration, the device design
must introduce response nonidealities that, in combination t interfere with
the feedback loop response dynamics on time scales much less than the
response time Tp for 1n vivo blood glucose response to changes in insulin
delivery rate. The resulting constraint of Equation 328 imposes severe
limitations on device transport delays; it may thus be importan to
minimize such delays though careful design analysis if effective hybrid
artificial pancreas systems are to be realized in the future.
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C) Abnormalities of Diabetic Metabolism and Control
The Type I diabetic model employed for IMC design was obtained by
removing endogenous pancreatic insulin reslease from the physiologic model
of glucose metabolism originally formulated for normal man. This diabetic
model represents the ideal case of a well-controlled, metabolically-
normalized subject; the insulin-dependent diabetic for which all metabolism
is normal (with the exception of pancreatic insulin release) may be termed
a "controlled" Type I diabetic.
~
As discussed in Chapter Vs however s abnormalities such as insu0- -- --',)
resistance, insulin antibody binding, and impaired glucose CQunter-
regulation are commonly observed in Type I diabetics. The extent to which
these abnormalities appear to influence in vivo glucose regulation varies
over a wide range from patient to patient. Although the pathophysiologies
of these diabetes-related disorders are not well understood at present,
increasing clinical evidence suggests that the prevalence of these abnor-
malities is inversely related to the quality of therapy provided.
Furthermore, recent studies indicate reversi~ility of diabetic abnor-
malities upon provision of improved control. Because diabetic abnor-
malities are observed to a greater ~xtent in poorly controlled subjects,
the term "uncontrolled" Type I diabetic is often applied to the insulin-
dependent diabetic displaying such metabolic disorders. In Chapter V, an
uncontrolled Type- I diabetic model was formulated by introducing tissue
insulin resistance and insulin antibody binding into the controlled Type I
diabetic model. The resulting model may be assumed representative of the
uncontrolled Type I diabetic, as its use provided good predictions of 100g
OSTT response data for typical IDOM subjects during Biostator GCIIS therapy
(see Figure 104).
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Since the IMC system was designed using the controlled Type I diabetic
model, addition studies were performed to explore the effectiveness of this
system if applied to diabetics not initially in a metabolically-normalized
state. For these studies, the uncontrolled Type I diabetic model of
Chapter V was further modified to include the presence of inhibited glucose
counterreguldtory capacity. Patients with diabetes of long duration
treated by conventional injection therapies may not respond with any
increase above basal in circulating glucagon levels during hypoglycemia
(see Figure 93 from Bolli et al., 1983). Such impaired counterregulatory
response was modeled by setting M;rR equal to unity in Equation 155 such
that glucagon response would be fixed at basal sensitivity independent of
changes in arterial glucose concentration. For simulation studies coupling
the uncontrolled Type I diabetic model with IMC insulin delivery, a steady
state blood glucose concentration of 75 mg/dl required a basal insulin
infusion rate IRb of 390 ~U/kg·~in~ Due to the presence of insulin
resistance in the uncontrolled Type I diabetic model, the value of IRb here
is greater than that used previously for simulations with the controlled
Type I diabetic model (IRb=320 pU/kg~in).
For the IHe insulin d~livery system derived earlier in this chapter
(Equations 260 and 261), four design parameters influence performance.
Three of these parameters, namely Kp,Tps and 6p, resulted from charac-
terization of 1n vivo blood glucose response to changes in insulin delivery
rate. The fuurth parameter, fflmax' was imposed to limit plasma insulin
levels resulting from maximal controller action. For the controlled Type I
diabetic, fflmax was assigned a value of 905 ~U/kg.min such that the maximum
insulin delivery rate to the patient IRmax equaled 1225 ~U/kg~in; this
constraint limited plasma insulin concentration to 100 ~U/ml or less, the
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range obseved in normal subjects following oral glucose loading.
Because the controlled Type I diabetic model was employed for IMC
design and parameter selection t simulation studies were performed to
explore the effectiveness of this system if used to regulate blood glucose
in the Type I diabetic not initially in a metabolically-normalized state.
Simulation studies to assess the effects of IHe parameter selection on
blood gl~cose regulation in the uncontrolled Type I diabetic during the
100g OGTT are presented in Figure 131. Here, the IMC system was interfaced
with the uncontrolled Type I diabeti~ model while parameters Kp, Tp' ~,
and ffimax (via desig~ation of lRmax) were varied in the IMe internal model
(Equation 260) and controller (Equation 261). As shown in the upper panel
of Figure 131, use of the IHe parameter set originally derived for the
controlled Type I diabetic (denoted IMC1) resu1ted in peak hyperglycemia of
205 mg/dl, but IMC action did not induce hypoglycemia as blood glucose con-
centration remained modestly elevated 300 min after oral glucose administa-
tion. Included for comp~rison in Figure 131 are results presented earlier
(see Figure 109) from application of parameter set IHel to the controlled
Type I diabetic. As shown in the lower panel of Figure 131 t initial plasma
(free) insulin response to rising blood glucose concentration was much
slower in the uncontrol'led than in the controlled Type I diabetic using
parameter set IMCI. Such sluggishness of plasma free insulin response to
changes in insulin infusion rate result from the presence of circulating
insulin antibodies in the uncontrolled diahetic.
Because application of parameter set IMC~ to the uncontrolled Type I
diabetic resulted in significantly higher blood glucose than resulted by
IMCI application to the controlled Type I diabetic (see upper panel of
Figure 131), further work was undertaken to determine if improved IMC blood
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Des' gnat Ion Kplmg/d') (kg -ml n/ lJlj) Tptm' n) 6plmln) IPmax ( IAJlkg ."'. n)
"«:1 -0.2' 90 9 1225
UC2 -0.19 '50 22 1225
nC3 -0.21 90 9 24'0
I~ -0.19 150 22 24'0
Fig. 131 Simulation studies to assess the effects of IHe parameter selec-
tion on blood glucose control in the uncontrolled Type I diabetic
dur1 ng the 100g OGTT. Parameter va1ues for Kn. Tp. an. and "'max(via designation of IRmax> were var1ad in Equations 261 and 262 as
defined in the figure legend. Included for comparison is applica-
tion of parameter set IHel to regulation of the controlled 'Type I
diabetic_
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glucose control could be attained in the uncontrolled dabetic by changing
the IMC parameter values. Since parameters Kp, Tp' and op are selected on
the basis of characterization of in vivo blood glucose response to changes
in insulin infusion rate, a logical approach to improvement of contro1 was
to recharacterize this process using the uncontrolled Type I diabetic
model. For this purpose, an insulin infusion step change "experiment"
identical to that previously described for characterizing response in the
controlled diabetic (Figure 106) was repeated for the uncontrolled
diabetic; the resulting blood glucose response curve yielded the following
parameter values: Kp=-O.19 (mg/dl)(min.kg/lJU), "'p=150 min, and "p=22 min.
Changes in parameter values from those obtained for the control fed diabetic
are easily interpreted. For a step change in insulin delivery rate, the
presence of insulin antibodies does not affect the resulting steady state
plasma free insulin levels but does slow the dynamic transition between the
steady states. Thus, insulin antibody binding has no effect on the process
gain Kp, which solely reflects steady ~tate response, but increases the
process response time Tp and dead time Op, which reflect dynamic response.
In contrast, for a given pldsma insulin concentration, the presence of
tissue resistance to insulin action generally lowers the in vivo steady
state tissue glucose utilization rate. Therefore, tissue insulin
resistance decreases the magnitude of the process gain Kp, reflecting less
incremental blood glucose response to incremental insulin infusilJ.1 rate
changes, but does not effect values of dynamic response time Tp or dead
time Bp.
As shown 1n Figure 131, use of the above process characterization para-
meters in the IHe parameter set (denoted IMC2) only resulted in modest
improvement in blood glucose regulation of the uncontrolled Type I diabetic
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relative to that obtained by use of parameter set IMCI. In particular,
maximum hyperglycemia was almost identical in both cases as the speed of
initial plasma free insulin response was iiDt si~nificantly improved by use
of parameter set IMC2. Parameter set IMC2, however, did result in lowering
blood glucose at later times during the period of blood glucose recovery to
steady state.
Finally, the effects of varying the maximum allowed insulin delivery
rate IRmax was explored. Simulation studies were repeated using the pro-
cess characterization parameter values (Kp,TpsOp) obtained for the
controlled and uncontrolled diabetic cases, respectively, but the value of
IRmax was incr2ased twofold, from 1225 to 2450 ~U/kg.min. As shown in the
upper plot of Figure 131, increasing the value of IRmax significantly
reduced hyperglycemia during the 100g OGTT, but coupling higher IRmax with
process characterization parameters (Kp,Tp~Op) for the uncontrolled (IMC4)
versus th~ controlled (IMC3) diabetic state~ resulted in very modest impro-
vement in blood glucose regulation. As shown in the lower plot of Figure
131, increasing IRmax had two primary effects: 1) the speed of initial
dynamic plasma free insulin response to rising blood glucose concentration
became comparable to that attainable in the controlled diabetic, and 2) the
plasma free insulin levels essentially increased twofold as a result of
controller action during the 100g OGTT. In spite of higher plasma free
insulin concentration levels over the duration of the 100g OGTT, however,
blood gl~cose concentration peaked at 175 mg/dl, a value significantly
higher that that achievable for the controlled Type I diabetic (see upper
plot of Figure 131). Although not shown in Figure 131, use of even higher
values of IRmax did not significantly reduce hyperglycemia, but the
resulting increases in plasma insulin response levels became sufficient to
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induce hypoglycemic excursions below 60 mg/dl for values of IRmax>3000
~U/kg.min.
Results of th~ simulation studies presented in Figure 131 r" ise a
number of important issues. The controlled Type I diabetic represents the
idealized end state. The real issue thus lies in how application of
closed-loop insulin delivery can affect such a normalized metabolic state
if applied to diabetics initially in an uncontrolled metabolic state.
Insulin dosage may playa key role in the normalization process. The Type
I diabetic on conventional therapy typically exhibits some degree of insu-
lin resistance and, depending on the quantity and quality (primarily
purity) of daily exogenous insulin administation, significant titers of
circulating insulin antibodies. Insulin antibodies are the result of immu-
nogenic response to exogenous insulins, and antibody titers decreas in
patients changed from conventional to highly purified insulins. Use of
purified insulins together with low insulin dosages would thus favor reduc-
tion in insulin antibody interactions. As shown in Figure 131, doubling
the insulin levels in the uncontrolled Type I diabetic may not normalize
blood glucose levels during oral glucose loading if tissue insulin
resistance at high insulin levels is in evidence (post-receptor insulin
resistance). Clinical studies (Revers et al., 1984) have demonstated tnat
post-receptor insulin resistance 1n the poorly controlled Type I diabetic
on conventional injection therapy can be essentially reversed by 6 wks of
intensive injection therapy (i.e. home blood glucose monitoring 2-4 time
daily and frequent insulin dosage a~justmen~~j. It 1s highly likely that
the initial blood glucose control provided by parameter set IMCI would be
superior to control achieved by intensive injection therapy, and thus use
of this parameter set would be expected to affect insulin resistance rever-
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sal while gradually reducing hyperglycemia. Furthermore, restricting
plasma free insulin levels to normal ranges «100 ~U/ml) during the nor-
malization period could play an important role in preventing the develop-
ment of receptor type insulin resistance which presumably results from
insulin receptor down-regulation in response to prolonged exposure to high
iqsulin levels. Because increasing IRmax to affect initial improvement in
blood glucose regulation ,n the uncontrolled diabetic achieves such impro-
veme~t at the expense of high insulin dosages. which could enhance develop-
ment of insulin antibodies, and at the expense of conco~aitant inaucement of
abnormally high plasma insulin levels, which could induce receptor type
insulin resistance, the modest benefits to be gained by increasing initial
IMC insulin delivery capacity appear to be outweighed by the potential con-
sequences of such action. Future clinical experimentation, however, may
lead to better clarification of the factors affecting reversal of diabetic
abnormalities and could thus possibly allow for optimization of IMC para-
meter variation to more rapidly affect such normalization.
Finally, the notion of adjusting the process characterization parame-
ters (Kp,Tpt6p) to reflect states of initial m~tabolic control can be
extended to the concept of performing insulin infusion step change experi-
ments on diabetic patients and using the resulting blood glucose response
profiles to directly taylor the IMC parameters to the individual patient.
Blood glucose response to step changes in insulin infusion rate is reported
to be highly reproducible upon repetition in Type I diabetics (Bolli et
al •• 1984b). and such experiments would thus seem quite suitable for IMC
parameter determination. As suggested by the results af Figure 131,
although IMC gerformance improves with precise selection of the process
characterization parameters, such improvement may not be very dramatic.
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Adesirable feature of control systems is to achieve specified response
behavior which in turn is not extr€~~ly sensitive to the controller para-
meter values. Such systems display~ng such behavior are referred to as
robust in control terminology. Robustness is desirable because system per-
formance is not sensitive to errors in mvdel-derived control parameters
when such parameters are applied to control of real processes. Thus, in
the context of applying IMC to blood glucose regulation, a single reprl~sen­
tative parameter set may provide good control in spite of individual
variations in actual blood glucose sensitivity to changes in insulin
infusion delivery rate. Clinical experimentation will ultimately determine
if this is indeed the case; should individualized parameter adjustment be
deemed desirable, however, it should be feasible to determine parameter
values from analysis of individual experimental step response profiles.
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DEFINITION
TABLE DEFINING VARIABLES:
JOHN T 0 ScmENSEN
LAST REVISION JUNE 20, 1984
I«:JDEL OF GLUCOSE METABOLISM
IN NORMAL MAN
INVERSE TIME CONSTANT (MIN -1)
INVERSE TIME CONSTANT (MIN -1)
RATE OF lmAIN GLUCOSE UPTAKE (K;,lMIN)
EFFECT OF GLUCOSE ON HCP
EFFECT OF GLUCOSE ON HCU
EFFECT OF GLUCAGON ON HOP
INITIM. EFFECT OF GLUCACON ON RiP
EFFECT OF GLUCOSE ON PANCREATIC GLUCAOON RELEASE
EFFECT OF GLUCOSE ON PERIPHERAL GLUCOSE UPTAKE
EFF,CT OF INSULIN ON HOP
ASYMPTOTIC EFFECT OF INSULIN ON HCP
EFFECT OF INSULIN ON HGU
ASYMPTOTIC EFFECT OF INSULIN ON IG1
EFFECT OF INSULIN ON PAN~EATIC GLUCAGON RELEASE
EFFECT OF INSULIN ON PERIPHERAL GLUCOSE UPTAKE
FRACTION INSULIN CLEARANCE KIDNEY
FRACTION INSULIN CLEARANCE LIVER
INSULIN TRANSFER RATE (U/MIN)
GLUCAGON METABOLIC CLEARANCE RATE (L/MIN)
RATE OF GUT ORAL GLUCOSE ABSORPTION (f-C/MIN)
RATE OF GUT GLUCOSE UPTAKE (Ki/MIN)
RATE OF INTRAVENOUS GLUCOSE INFUSION (flC,lMIN)
INSULIN TRANSFER RATE CONSTANT (MIN -1)
HEPATIC GLUCOSE PRODUCTION RA.TE (K;JMIN)
FASTltJG HEPATIC GLUCOSE PRODUCTION RATE (t-C/MIN)
HEPATIC GLUCOSE UPTAKE RATE (ftC/MIN)
FASTING HEPATIC GLUCOSE UPTAKE RATE (K;jMIN)
RATE OF KIDNEY GLUCOSE EXaETION (K:/MIN)
KIDNEY INSULIN CLEARANCE (MU/MIN)
LIVER INSULI}~ CLEARANCE RATE (MU,lMIN)
RATE OF PANCREATIC INSULIN RELEASE (NORMALIZED)
RATE OF PERIPHERAL GLUCOSE UPTAKE (I«:/MIN)
FASTING RATE OF PERIPHERAL GLUCOSE UPTAKE (K::jMIN)
PERIPHERAL INSULIN CLEARANCE RATE (MU/MIN)
RATE OF INTRAVENOUS INSULIN INFUSICfi (MU/MIN)
PANCREATIC INSULIN RELEASE RATE (MUIMIN)
FASTING RATE OF PANCREATIC INSULIN RELEASE (MU/MIN)
INSULIN SECRETION RATE S (G) AT FASTING (u/MIlJ)
HEPATIC ARTERY GLUCOSE VASCULAR FLOW RATE . (DL/MIN)
BRAIN GLUCOSE VASCULAR FLOW RATE (DL/MIN)
CUT GLUCOSE VASct.JLMt FLCW RATE (DLjMIN)
HEART GLUCOSE VASCULAR FLOW RATE (DL/MIN)
KIDNEY GLUCOSE VASCULAR FLOW RATE (DLjMIN)
LIVER GLUCOSE VASCULAR FLOW RATE (DL/MIN)
A
B
BGU
EGHCP
EGHCU
EGNHGP
EGNHGPI
ECPGNR
EGPCU
EIHCP
EIHCPA
EIHGU
EIHCUA
EIPGNR
EIPCU
FICK
FICL
GAMMA
GNMC2
GCA
GClJ
CIN
H
HOP
HCPF
HCU
HGUF
KCE
XIC
LIe
PGNRN
PCt1
PCUF
PIC
Plla
PIR
PIRE
PIRREF
QVCA
QVCB
QVCC
QVCH
QVCK
QVCL
c-----------------------------------------------------------------
c
c
c
c
c
c
c
c
c-----------------------------------~-----------------------------
c
c
c
c
C CONSTANT
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
c.
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
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c QVCP PERIPHERAL GLUCOSE VASCULAR FLOW RATE (DLjMIN)
C gilA HEPATIC ARTERY INSULIN FLOW RATE (L/MIN)
C QVIB BRAIN INSULIN 'JASCULAR FLOW RATE (L/HIN)
C gvIC CUT INSULIN VASCULAR FLOW RATE (L/MIN)
C QVIH HEART IPISULIN VASCULAR FLOW RATE (L/MIN)
C QVIK KIDNEY INSU-r..IN VASCULAR FLOW RATE (L/MIN)
C QVIL LIVER INSULIN VASCULAR FLOW RATE (L,lMIN)
C QVIP PERIPHERAL INSULIN VASCULAR FLOW RATE (L/MIN)
C RBCU (HEART) RBC UPTAKE (ftC/MIN)
C TMCB BRAIN GLUCOSE TRANSMEMBRANE EQUIL TIME (MIN)
C 'I'K;P PERIPHERY CLUCOSE TRANSMEMBRANE ~QUIL TIME (MIN)
C TMIP PERIPHERAL INSULIN TRANSMEMBRANE £QUIL TIME (MIN)
C vee CUT GLUCOSE VOLUME (DL)
C VOl CUT INSULIN VOLUME (L)
C VGN GLUCAGON DISTRIBUTION VOLUME (L)
C VIS BRAIN INTERSTITIAL VOLUME (DL)
C VIP PERIPHERY INTERSTITIAL VOLUME (DL)
C VKC KIDNEY GLUCOSE VOLUME (DL)
C VLC LIVER GLUCOSE VOLUME (DL)
C VICI KIDNEY INSULIN VOLUME (L)
C VLI LIVER INSULIN VOLUME (L)
C WOB BRAIN GLUCOSE VASCULAR VOLUME (DL)
C WCH HEART GLUCOSE VASCULAR VOLUME (OL)
C wr:;p PERIPHERY GLUCOSE VASCULAR VOLUME (DL)
C WIS BRAIN INSULIN VASCULAR VOLUME (L)
C WIH HEART INSULIN VASCULAR VOLUME (L)
C WIP PERIPHERAL INSULIN VASCULAR VOLUME (L)
C Y20R LABILE INSULIN IN PANCREAS FOR C=O "C/DL (U)
C IMl INSULIN RELEASE CONSTANT (DIMENSIONLESS)
C XM2 INSULIN RELEASE CONSTANT (DIMENSIONLESS)
C
C
C
C
C INDEX DEFINITIONS:
C
C INDEX DERIVATIVE VARIABLES
C
C 1 BRAIN VASCULAR GLUCOSE CONC. (f-C/DL)
C 2 BRAIN INTERSTITIAL GLUCOSE CONe. (f«;/DL)
c 3 HEART VASCULAR GLUCOSE CONe.. (K;/DL)
c 4 KIDNEY GLUCOSE CONe. (Ki/DL)
c 5 LIVER CLUCOSE CONe. (ItC/DL)
c 6 PERIPHERY VASCULAR GLUCOSE CONe. (MeIDL)
c 7 PERIPHERY INTERSTITIAL CLUCOSE CONe. (MeIDL)
c 8 CUT GLUCOSE CONe. (MeIDL)
c 9 EFFECT OF INSULIN ON HCU (TIME DEPENDENT)
C 10 BRAIN VASCULAR INSULIN CONe. (MUlL)
c: 11 HEART VASCULAR INSULIN CONe. (MUlL)
c 12 KIDNEY INSULIN CONe. (MUlL)
c 13 LIVER INSULIN CONC. (MUlL)
C 14 PERIPHERAL VASCULAR INSULIN CONe. (MUlL)
c lS PERIPHERAL INTERSTITIAL INSULIN CONe. (MUlL)]
C 16 CUT INSULIN CONe. (MUlL)
c 17 EFFECT OF INSULIN ON HOP (TIME DEPENDENT)
C 18 PROVISIONARY FACTOR (DIMENSIONLESS)
C 19 INHIBITOR (DIMENSIONLESS)
C 20 LABILE INSULIN IN PANCREAS (U)
C 21 DECAYING EFFECT OF GLUCAGON ON HOP
C 22 NORMALI ZED PLASMA GLUCAGON CONe.
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NONDERIVATlVE VARIABLES
RUNGE KlJTTA INTEGRATION VARIABLES
NONLINEAR EFFECT OF GLUCOSE ON PIR (DIMENSIONLESS)
ASYMPTOTIC PROVISIONARY FACTOR VALUE (DIMENSIONLESS)
INSULIN SECRETION RATE S (0) BEFORE NORMALIZATION (UjMIN)
SIMULATION TIME (MIN)
TIME STEP (MIN)
NUMBER OF FIRST ORDER ODE'S
DERIVATIVE VARIABLES
TIME DERIVATIVE OF Yel)
NON-DERIVATIVE VARIABLES
-1 (FIRST INTEGRATION CALL)
o (INTERMEDIATE CALLS)
1 (FIRST CALL AT EACH NEW TIME STEP)
SIMULATION STARTING TIME (MIN)
SIMULATION ENDING TIME (MIN)
UNASSIGNED VARIABLES USED FOR INPtrr TO PROGRAM
THROUGH COMMON STATEMENT
T
DT
N
Y(l-N)
F (1)
Y(I,I>N)
NEWDT=
c
c
c------------------~---------------------------------------------
c
c
c
C 8G
C 87
C 85
CC _
C
C
C
C
C
C
C
C
C
C
C
C
C STlfJ1E
C FTlME
C CONSTANT (I)
C
C
C-----------------------------------------------------------~----------C
C
SUBROUTINE EQSIM
COMMON T ,DT,Y(98) ,F (98) ,STlME,FTlME,NEWDT,NEWRUN',N..
It IPR, I CD, lCN, TBREAK, PNEXT, TBACK, CONSTANT (30)
c
c
REAL KCE,KIC,LIC
c
C PARAMETERS - GLUCOSE MODEL
C
IF(NEWDT.EQ.-l) THEN
DATA QVGA,QVCB,QVCC,QVCH,QVGK/2.5,S.9,10.1,43.7,10.1/
DATA QVCL,QVGP/12.6,lS.1/
DATA VIB,VIP,VKG,VGG,VLG/4.S,63.,6.6,11.2,25.1/
DATA VVGB,VVGH,VVCP/3.S.13.8,lO.4/
DATA RBCU.GCU/IO.,20./
DATA BGU,HCUF,HCPF,PGUF/70.,20.,lSS •• 3S./
DATA TMCB,TMCP/2.1,S.O/
c
C PARAMETERS - INSULIN DISTRletrrION
C
DATA QVIA,QVIB,QVIC,QVIH.QVIK/.IB,.4S~.72.3.12,.72/
DATA QVIL,gVIP/.9,1.0S/
DATA VKI,VLI,VCI/.SOS,1.14,.945/
DATA VVIB,VVIH,VVIP/.265,.985,.735/
DATA FICK,FICL.FICP/.30,.40,.15/
DATA 'IMIP/20./
c
C PARAMETERS - I«mEL PANCREAS
t:
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DATA A.B,XN.H/.048229 •• 93141.1 •••0079378/
DATA Y20R,CAMMA/6.3294,.57493/
DA~ XMl,XM2/.007968,.106495/
c
C PARAMETERS - CLUCACCW KX>EL
C
CNMCR=O.910
VGN=VVl~VVIH+VVIP+VKI+VLl+VIp·O.l
c
ENDIF
c
C INITIALIZE GLUCOSE MODEL
IF(NEWDT.EQ.-l) tHEN
C··· INPUT FASTING PERIPHERAL VENOUS BLOOD GLUCOSE CONC. (t«i/DL)
Y(6)=CONSTANT(20)/O.S4
Y(3)=Y(6)+PCUF/QVCP
Y(4) =Y(3)
Y(1)=Y(3)-SCU/QYCB
Y(8)=Y(3)-GGU/QVCG
Y(S)=(1·/QVGL)·(QVGA*Y(3)~~*Y(8)+HCPF-HCUF)
Y(2)=Y(1)-(BGU*TMGB)/VIB
Y(7)=Y(6)-(PCUF*TMCP)/VIP
Y(9)=1.
Y(17)=1.
Y(21)=O.
C STORE BASAL VALUES FOR FUTURE Ca-!PUTATIONS
Y3F=Y(3)
YSF=Y(S)
Y7F=Y(7)
c
C INITIALIZE INSULIN MODEL
C*·· INPUT FASTING PERIPH£RAI.; VENOUS PLASMA INSULIN CONe. (MUlL)
Y(14)=CONSTANT(21)
Y(11)=Y(14)/(1.-FICP)
Y(lO)=Y(11)
Y(12)=Y(11)*(1.-FICK)
Y(13)=(1./QVIL)·(QVIH*Y(11)-QVIB*Y(lO)-QVIK*Y(12)-QVIP*Y(14»
Y(16)=Y(11)
Y(15) =Y (14) - ( (QVIP*TMIP) / (VIp· .1) ) • (Y (11) -Y (14) )
PIRF=(QVIL/(1.-FICL»*Y(13)-QVIG*Y(16)-QVIA*Y(11)
C STORE BASAL VALUES FOR FUTURE COMPUTATIONS
Y1IF=Y(11)
Y13F=Y(13)
Y1SF=Y(lS)
c
C INITIALIZE GLUCAGON MODEL
Y(22)=1.
c
c
C GLUCOSE MODEL PHYSIOLOGIC FUNCTI~S
C
IF (NEWDT.HE .0) THEN
C KIDNEY GLUCOSE EXCRETION RATE KGE
IF(Y(4).LT.460.) KCE=71.+71.*~(.011C(Y(4)-460.»
IF(Y(4).CE.460.) KCE=O.872*Y(4)-330.
C PERIPHERAL GLUCOSE UPTAKE
EOPCU=Y(7){rIF
EIPGU=7.03S+6.S1623*TANH(.33827*(Y(lS)/Y1SF-S.82113»
PCU=EGPCU·EIFCU*PCUF
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C LIVER GLUCOSE METABOLISM
C HEPATIC GLUCOSE UPTAKE
EIHGUA=2.*~(.549·(Y(13)/y13F»
EIHCU=Y(9)
ECHCU=5.6648+S.6S89*~(2.4375·(Y(5)/ySF-l.48»
HOU=EIHCU*£GHCU*HGUF
C HEPATIC CLUCOSE PRODUCTION
EIHCPA=1.2088-1.138*~(1.669*(Y(13)/y13F-.8885»
EIHCP=Y (17)
ECNHCPI=2.'*TANH(.38S*Y(22»
ECNHCP=ECNHCPI~Y(21)
EGHGP=1.425-1.406*TANH(.6199*(Y(S)/ySF-.4969»
HGP=ECNHCP"EIHCP*ECHCP*HCPF
c
ENDIF
c
C INPUTS FCR MODEL SIMULATION STUDIES
C
IF (NEWDT .HE .0) '!HEN
c
C INPUT Fat INTRAVENOUS GLUCOSE J:r.7USI01":
TlME1=-3.
TlME2=O.
IF (T.LT.TlME1) GIN=O.
IF(T.GE.TlME1.AND.T.LT.TlME2) GIN=CONSTANT(l)
IF(T.CE.TlME2) GIN=O.
c
C INPUT FOR HYPERGLYCEMIC CLAMP
C CALL HYCLAMP(Y(3).Y3F,Y\97),T,DT.NEWDT)
C
C INPUT FOR INTRAVENOUS INSULIN INFUSION
C PIIR=O.O
C IF (T.CT. TlME1.AND. T .I,T.TlME2) PI IR=CONSTANT (2)
C
C INPUT FOR EUCLYC£MIC INSULIN CLAMP
C CALL EUCLAMP(Y(3),Y3F,Y(97),PIIR,T,DT,NEWDT)
C
C INPUT FOR lODe ORAL GLUCOSE TOLERANCE TEST
C CALL XOCTT(CCA,PIR,PIRf,T,NEWDT)
C (NOTE: MODEL PANCREAS OUTPUT PIR MUST BE DISABLED FOR OGTT)
C
C
ENDIF
c
C CLUCOSE MODEL MASS BALANCE EQUATIONS
C
F(l)=(l./VVCB) * (QVCS* (Y(3)-Y(1»+(VIB/!MGB) * (1(2)-Y(1»)
F(2)=(1./VIB)* «VIB/!MGB) 6 (Y(1)-Y(2»-SCU)
F(3)=(1~/VVCH)·(QVCB*Y(1)+QYCL·Y(S)+QVGK*Y(4)+QVCP*Y(6)
• -QVCH*Y(3)-RBCU+GIN)
F(4)=(1./VKC)* (QVCK*(Y(3)-Y(4»-KCE)
F(S)=(l.jVLG) * (QVCC*Y(8)+QVQA*Y(3)-QYCL*Y(S)+HCP-HCU)
F(6)=(1./VVCP)* (QVCP*CY(3)-Y(6»+(VIP/TMCP)*(Y(7)-Y(6»)
F(7)=(1./VIP) * «VIPfTMGP) * (Y(6)-Y(7»-PCU)
F(8)=(1./VCG) * (QVCC*(Y(3)-Y(8»-OCU+CGA)
C TIME DEPENDENT LIVER GLUCOSE METABOLISM
F(9)=(1./2S.)*(£IHGUA-Y(9»
F(17)=(1./2S.)*(EIHCPA-Y(17)j
F(21)=(1·/6S.)*«ECNHGPI-l.)/2.-Y(21»
c
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cIF (NEWDT.NE .0) THEN
Y(88)=(Y(3)·*3.267)/(131.87*·3.267+5.932*Y(3)**3.024)
y (87) =y (88) **1.1141
C
C INITIALIZE MODEL PANCREAS TO FIRST PASS GLUCOSE
IF(NEWDT.EQ.-l) THEN
Y(18)=Y(87)
Y(19)=XN*Y(88)
Y(86)=Y(88)-Y(19)
IF(Y(B6).LT.0.) Y(S6)=O.
Y(20)=VK*Y20R+GAMMA*Y(18»/(XM1*Y(87)+XM2*Y(86)+EQ
PIRREF=(XM1*Y(87)+XM2*Y(86»*Y(20)
PIRF=(QVIL/(1.-FICL»*Y(13)-QVIC*Y(16)-QVIA*Y(11)
ENDIF
Y(86)=Y(88)-Y(19)
IF(Y(86).LT.O.) Y(86)=O.
Y(BS)=(XM1·Y(87)+XM2*Y(86»eY(20)
PIR=(XM1*Y(87)+XM2*Y(86»*Y(20) * (PIRF/pIRREF)
ENDIF
c
C MODEL PANCREAS DERIVATI'l~ EQUATIONS
F(18)=A*(Y(87)-Y(18»
F(19)=B*(XN*Y(SB)-Y(19»
F(20)=H*(Y20R-Y(20»+QAMMA*Y(18)-Y(8S)
c
c
C INSULIN MODEL PHYSIOLOGIC FUNCTIONS
C
IF (NEWDT.NE .0) THEN .
C KIDNEY INSULIN CLEARANCE
KIC=FICK*QVIK*Y(ll)
C LIVER INSULIN CLEARANCE
LIC=FICL*(QVIG*Y(16)+QVIA*Y(11)+PIR)
C PERIPHERAL INSULIN CLEARANCE
PIC=(l./«l.-FICP)/(FICP*QVIP)-(TMIP/(VIP*.l»»*Y(lS)
ENDIF
c
c
C INSULIN MASS BALANCE EQUATIONS
C
*
*
F(lO)=(l./VVIB) * (QVIB* (Y(11)-Y(10»)
F(11)=(1./VVIH) * (QVIB*Y(lO) +QVIL*Y(13) +QVIK*Y(12) +
QVIP*Y(14)-QVIH*Y(11)+PIIR)
F(12)=(1./YKI)*(QVIK*(Y(11)-Y(12»-KIC)
F(13)=(1./VLI) * (QVIA*Y(11)+QVIC*Y(16)-QVIL*Y(13)-LIC+PIR)
F(14)=(1./VVIP).(QVIP.(Y(11)-Y(14»+«VIP••1)~IP).
(Y (is) -Y (14) ) )
F(lS)=(1./(VIP*.1»*«(VIP·ol)~IP)·Ci(14)-Y(15»-PIC)
F(16)=(1./VCI) * (QVIG* (Y(11)-Y(16»)
c
c
C GLUCACON MODEL PHYSIOLOGIC FUNClOOS
IF (NEWDT.HE .0) THEN
EIPGNR=1.3102-0.61016*TANH(1.OS71*(Ci(11)/Yl1F)-O.46981»
EGPGNR=2.928S-2.09S~~(4.1B·«Y(3)/y3F)-a.61g1»
P~=EIPGNR*EGPCNR
ENDIF
535
c
C GLUCAGON MASS BALANCE EQUATION (DIMENSIONLESS)
C
c
C AUXILIARY OUTPUT VARIABLES
IF (NEWDT. NE .0) '!HEN
Y{SO)='f(6)·.S4
ENDIF
c
c
RETURN
END
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c---------------------------------------------------
c
C EUGLYCEMIC INSULIN CLAMP SUBROUTINE
C
C NOV 15, 1984
C
C----------------~----------------------------------
C
SUBROUTINE EUCLAMP(GIN,Y3F,GINFUSE,PIIR,T,DT.NEWDT)
GCLAMP=Y3F· .925
C INSULIN INF'JSION INPUT
IF(T.LE.O.+DT/2.) PIIR=O.
IF(T.GT.O.+DT/2.) PIIR=221.
IF(T.GT.l.+DT/2.) PIIR=197.
IF(T.CT.2.+DT/2.) ~IIR=17S.
IF(T.GT.3.+DT/2.) PIIR=lS6.
IF(T.CT.4.+0T/2.) PIIR=139.
IF(T.GT.5.+DT/2.) PIIR=124.
IF(T.GT.6.+DT/2.) PIIR=110.
IF(T.GT.7.+DT/2.) PIIR=98.
IF(T.GT.8.+DT/2.) PIIR=87.
IF(T.GT.9.+DT/2.) PIIR=78.
IF(T.GT.10.+0T/2.) PIIR=69.
IF(T.GT.120.+DT/2.) PIIR=O.
c
C GLUCOSE INFUSION ALCORI'I'HM
IF(NEWDT.EQ.-l) 112=0
IF(NEWDT.EQ.-l) 111=-1
IF(T.LT.O.+DT/2.) 00 TO 112
111=111+1
IF(Ill.EQ.50) ~
112=112+1
Q['EL=Ql
Ql=GIN·.925
SMDEL2=SMDELl
SMDEL1=SM
FMDEL1=FM
FM= (y3F t • 925) /Q1
IF(I12.EQ.2) SMDEL2=280.
IF(I12.£Q.3) SMD£L2=280.
SM=SMD£L2*FM*FMDELl
SI=8.8667*(GCLAMP-Ql)+SMDEL2*FMD£Ll*«Y3F*.925)/Ql)
111=0
ENDIF
IF(T.LT.4.+DT/2.) 51=0.
IF(T.G£.4.+DT/2 ••AND.T.LT.l0.+DT/2.) SI=140.
IF(T.GE.l0.+DT/2 ••AND.T.LT.15.+DT/2.) 51=175.
GINFUSE:=SI
GO TO 113
112 GINFUSE=O.
113 CONTINUE
RETURN
END
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c
c
c
c
c
c
c
c----------------------------------·----------------------------c
C KtPERGLYCEMIC CLAMP INFUSION ALCORI'mM
C
C DEC 27, 1984
C
C---------------------------------------------------------------
C
SUBROUTINE HYCLAMP(GIN,Y3F,GINFUSE,T,OT,NEWDT)
c
C CIN=ARTERIAL CLUCOSE CONe ~ (M:;/DL)
C GFAST=BASAL ARTERIAL GLUCOSE CONe. (M:;/DL)
C GINFUSE=CLUCOS£ INFUSION RATE (K;/MIN)
C
C
CFAST=Y3F* .925
CCLAMP=CFAST+12S.
IF(T.LE.O.+DT/2.) PDOS£=O.
IF(T.GT.O.+DT/2.) PDOS£=3QS9.
IF(T.GT.l.+DT/2.) PDOSE=2470.
IF(T.GT.2.+nT/2.) PDOSE=2000.
IF(T.GT.3.+DT/2.) PDOSE=lS8S.
IF(T.GT.4.+DT/2.) POOSE=13S3.
IF(T.GT.S.+DT/2.) PDOSE=1118.
IF(T.GT.6.+DT/2.) PDOSE=941.
IF(T.GT.7.+DT/2.) PDOS£=765.
IF(T.CT.8.+DT/2.) PDOSE=706.
IF(T.GT.9.+DT/2.) PDOS£=647.
C· *TEN MINUTE GLUCOSE VALUE USED TO ADJUST RATE
IF(T.CT.10.-DT/2.) PDOSE=O.
IF(T.CT.IO.+DT/2.) PDOSE=S88.
IF(T.CT.ll.+DT/2.) PDOSE=S29.
IF(T.GT.12.+DT/2.) PDOS£=471.
IF(T.CT.13.+DT/2.) PDOS£=412.
IF(T~GT.14.+DT/2.) PDOS£=412.
IF(T.GT.1S.+DT/2.) PDOSE=O.
IF(NEWDT.EQ.-l) 112=0
IF (NEWDT.EQ.-1) 111=-1
IF(T.LT.O.-OT/2.) co TO 112
111=111+1
IF(I11.EQ.SO~ THEN
1F(I12.EQ.1) tHEN
SM=412.
SMDEL1=412.
FM=1.00
ENDIF
112=112+1
QDEL1=Ql
Ql=GIN-.925
SMDEL2=SMDEL1
SMDEL1=SM
Ffo.mEL1=FM
FM=(CCLAMP-cFAST)/(Ql-cFAST)
SM=SMDEL2 ·FM*FMDELl
SI=8.8661*(CCL~-Ql)+SM
111=0
ENDIF
GINFUS£=PDOS£+SI
co TO 113
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112 CINFUSE=O.
113 CONTINUE
C
RETURN
END
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cc---------------------------------------------------------------
c
C 100 0 0Gn' SIMULATICW SUBROUTINE
C
C JUNE 1984
C
c-------------------------------------~-------------------------
c
SUBROUTINE XOCTT(CGA.PIR,PIRF,T.NEWDT)
DIMENSION CGAIN(3000),PIRIN(3000)
C
C R£AD IN CGA .AND PIR FROM EXTERNAL FJLES
IF(NEWDT.EQ.-l) THEN
OP£N(32.FIL~=·CGA·,STATUS=·OLD·)
OPEN(33.FILE='PIRIN',STATUS='OLD'}
DO 10 1=1.3000
R£AD(32,1) CGAIN(I)
R£AD(33.1) PIRIN(I)
t FORMAT(9X,F12.S)
lU CONTINUE
CLOSE (32,STATUS='SAVE')
CLOSE (33.STATUS='SAVE')
ENDIF
PIR=PIRF
IF(NEWDT.£Q.-l) lCOUNT=-l
IF (T .GT.O.) THEN
I COUNT=IC01JNT+l
CGA=GCAIN (ICOUNT)
PIR=PIRIN(ICOUNT)*PIRF+PIRF
ENDIF
RETURN
END
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APPENDIX B: Summary Overview of the Glucose Metabolism
Model of Guyton et al. (1978' Including the
Modifications of Hillman (1977) for OGTT
Simulation
In t~is section the mathematical model of Guyton et ale (1978) will
be overviewed. For purposes of mathematical documentation, the model is
presented in a tissue and organ compartmentalization format. A schematic
diagram of the glucose model is presented in Figure 81. The mass balance
equations for the glucose model were given by:
Glucose Model
Nervous System:
Cent ra1 Organs :
Periohery:
Liver:
Kidney.
where the mathematical nomenclature employed in Figure 81 and Equations 81-B8
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is defined as follows:
Variables: G = Glucose Concentration (mg/dl)
Q= Blood Flow Rate (dl/min)
V = Volume (dl)
T = Transcapillary Diffusion Time Constant (min)
r ~ Metabolic Source or Sink Rate (mg/min)
t =Time (min)
First Subscript
or Superscript: Physiologic Compartment
N = Central Nervous System
C = Central Organs (heart, lungs, major blood vessels, and
nonhepatic splanchnic organs)
P = Periphery (skeletal muscle and adipos tissue)
L = Liver
K= Kidney
G= Glucose Model
Second Subscript: Physiologic Subcompartment (if required)
B = Blood Spac~
I = Interstitial Fluid Space
Metabolic Rate
Subscripts: RSC = Red Blood Cell Glucose Uptake
CNS = Central Nervous System Glucose Uptake
CEN = Central Organs Glucose Uptake
PGU = Peripheral Glucose Uptake
GNG = Liver Gluconeogenesis
GBD = Liver Glycogen Breakdown
GSY = Liver Glycogen Synthesis
EXC =Kidney Glucose Excretion
Numarical values for the glucose model physiologic parameters were as follows:
543
In addition, glucose was taken up at a constant rate by the central nervous
system and central organ tissues:
Red blood cell uptake of glucose was assumed to occur at a total constant rate
of 10 mg/min, which was divided among the various organ and tissue blood volume
spaces according to their respective fractional contributions to the total
bloot! volume:
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TN = 0.2 m-in
T~ = 1.0 min
T~ = 5.0 min
QNB = 7.25 dl/min
QCB = 58.0 dl/min
QpB = 24.65 dl/min
QLB = 14.5 dl/min
QKB = 11.6 dl/min
VNB = 2 dl
V , = 2 dlN~
VCB = 22 dl
Vel = 35 dl
VpB = 24 dl
Vp1 = 70 dl
VL =20 dl
VK = 6 dl
r CNS = 100 mg/min (constant)
r CEN = 20 mg/min (constant)
r RBC =10.0 mg/min (constant)
r:Sc = 0.33 mg/min
r~C =3.67 mg/min
r:Oc = 4.00 mg/min
r~c =1.33 mg/min
r~c = 0.67 mg/min
The rate of liver glycogen synthesis was modeled
where
RrGSY = A x B x rGSV
r~SY = Reference Rate of Liver Glycogen Synthesis
= 100 mg/min
(89)
and non1 inear multipl iers "A': and JlB" are shown in Figure 82. The 1iver glycog~n
synthesis rate was mediated by liver glucose concentration (multiplier B), liver
interstitial insul in concentration (multipl ier- A), and changes in arterial
blood glucose concentration which was used to account for modification of
response during hypoglycemia. The rate of glycogen breakdown was given by
where
rGOD = C x 0 x r~o
r~o =Basal Rate of Liver Glycogen Breakdown
=100 mg/min
(810)
and multipliers lie" and 110" were given by the functions shown in Figure 83.
The rate of liver gluconeogenesis (rGNG) was mO~cled as a nonlinear function
of l;~er interstitial insulin concentration and arterial blood glucose
concentration as shown in Figure 84. Peripheral glucose uptake was mediated
by changes in the peripheral interstitial glucose and insulin concentrations,
modeled
where
r PGU =E x F x r~GU
r~GU =Basal Peripheral Glucose Uptake Rate
= 30 mg/min
(Bl1)
and multipliers IIE II and IIFII were computed from the nonlinear functions of
Figure 85. All of the above dynamic metabolic sources and sinks for glucose
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in the glucose model formulation were introduced via a three-minute time
delay representing the time required for regulatory mechanism activation.
Finally, the rate of. kidney glucose excretion as a function of the kidney
glucose concentration was given by
rEXC = I~.278{GK -180) GK~180 mg/dlGK~180 mg/dl (B12)
Initial conditions for the glucose model were as follows:
GNB = 67.54 mg/dl
GN1 = 57.54 mg/dl
GeB = 81.38 mg/dl
Gel =80.81 mg/dl
GpB = 80.00 mg/dl
GpI = 77.86 mg/dl
GL = 92.32 mg/dl
GK = 81.32 mg/dl
A schematic diagram of the insul~n model is presented in Figure 86.
The mass balance equations for the insulin model were given by:
dI Cp
Centra1 Organs : VCP Cit'
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Peri phery:
Liver:
Kidney:
dI pp
VppCft
dI pIVp1dt
dI LPVLPdt
dIll
VLI <It
dI KPVKPdt
dI K1VKIdt
(815)
(816)
(B17)
(B18)
(819)
(820)
where the mathematical nomenclature employed in Figu~ 86 and Equations 813-820
is defined as follows:
Variables: I = Insulin Concentration (mUll)
Q ~ Plasma Flow Rate (l/min)
V = VolLll1e (1)
T = Transcapillary Diffusion Time Constant (min)
r =Metabolic Source or Sink Rate (mU/min)
t = T"!me (min)
First Subscript
or Superscript: Physiologic Compartment
C = Central Organs (central nervous system, heart, lungs,
major blood vessels, nonhepatic splanchnic organs)
P = Periphery (skeletal muscle and adipose tissue)
L = Liver
K = kidney
I = Insulin Model
Second Subscript: Physiologic Subcompartment (if required)
P = Plasma Space
I = Interstitial Fluid Space
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Metabolic Rate
Subscripts: PID = Peripheral Insulin Degradation
KID = Kidney Insulin Degradation
LID = Liver Insulin Degradation
PIR = Pancreatic Insulin Release
Numerical values for the insulin model physiologic parameters were as follows:
VCP = 1.44 1
Vel = 3.7 1
Vpp = 1.44 1
VpI = 7.0 1
VLP = 0.48 1
VLI = 0.40 1
VKP = 0.24 1
VK1 = '0.20 1
QCP = 3.05 llmin .
Qpp = 1.48 1/min
QLP = 0.87 l/min
QKP = 0.70 l/min
T~ = 10 min
T~ =20 min
TL = 0.2 min
TK= 0.2 min
Insulin was degraded at a rate modeled as a linear function of the interstitial
insulin coricentrations in the liver, kidney, and periphery, respectively, given
by
Liver: B IIIr LlO = rUo(:a)
ILl
r~IO =Basal Liver Insulin Degradation Rate
:: 17. 6 mU/mi n
I~I =Basal Liver Interstitial Insulin Concentration
= 11.76 mUll
B IK1Kidney: rKIO = rKIO(-g-)IK1
(821)
(B22)
r~IO = Basal Kidney Insulin Degradation Rate
= 3.18 mU/min
I~I = Basal Kidney Interstitial Insulin Concentration
= 7.96 mUll
553
(823)Peri phery: B Ip1rpID = rpID{S)Ip1
r~ID = Basal Peripheral Insulin Degradation Rate
= 1.16 mU/min
I~I =Basal Perip~eral Interstitial Insulin Concentration
= 12.0 mUll
The heterogeneous fast pool model of pancreatic insulin release was used to
compute the rate of pancreatic insulin release (rpIR) as a function of
arterial blood glucose concentration (GCB ). The mathematical equations for
the heterogeneous fast pool pancreatic insulin release model, together with
parameter values and initial conditions, were reviewed in the pancreatic
insulin release section of the main text.
In order to simulate the 100g OGTT, Hillman (1977) modified the
heterogeneous fast pool model of pancreatic insulin release to account for
gut factor augmentation of insulin response to oral glucose. First, the rate
of insulin transfer from the slow pool to the fast pool (rISTF) was potentiated
through modification of the multiplying factor 'Ms in Equation 116 as shown
in Figure 87. Second, the distribution of fast pool sites (e) in Equation 122
was altered as shown in Figure 88. Finally, the rate of gut oral glucose
absorption (rGAGl for the 100g OGTT was modeled
0 t~3 min
800ISin[(,to -_ 33)1JI 3<tSl0 min
rGAG{mg/min) = 800 10<t:S30 min (824)
80011 Sin[(21o-_
3§o)!JI 30 < t S 240 min
0 240 min < t
where the glucose input appeared as a source term in the liver glucose
mass balance equation (B7).
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